NZ624231B2 - Assays and methods for selecting a treatment regimen for a subject with depression - Google Patents
Assays and methods for selecting a treatment regimen for a subject with depression Download PDFInfo
- Publication number
- NZ624231B2 NZ624231B2 NZ624231A NZ62423112A NZ624231B2 NZ 624231 B2 NZ624231 B2 NZ 624231B2 NZ 624231 A NZ624231 A NZ 624231A NZ 62423112 A NZ62423112 A NZ 62423112A NZ 624231 B2 NZ624231 B2 NZ 624231B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- allele
- snp
- nucleic acid
- acid sequence
- Prior art date
Links
- 238000004166 bioassay Methods 0.000 title claims abstract description 148
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 336
- 239000011724 folic acid Substances 0.000 claims abstract description 320
- 235000019152 folic acid Nutrition 0.000 claims abstract description 319
- 229940014144 Folate Drugs 0.000 claims abstract description 308
- 150000001875 compounds Chemical class 0.000 claims abstract description 211
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 205
- 241000282414 Homo sapiens Species 0.000 claims abstract description 176
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 152
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 144
- 102100002074 MTHFR Human genes 0.000 claims abstract description 73
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 claims abstract description 73
- 229940113082 Thymine Drugs 0.000 claims abstract description 72
- 102100008575 MTR Human genes 0.000 claims abstract description 63
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 50
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 47
- 239000002773 nucleotide Substances 0.000 claims abstract description 42
- 102200088972 MTHFR A222V Human genes 0.000 claims abstract description 22
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 claims abstract description 20
- 102200151471 MTR D919G Human genes 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 172
- 239000000935 antidepressant agent Substances 0.000 claims description 153
- 230000014509 gene expression Effects 0.000 claims description 118
- 230000001430 anti-depressive Effects 0.000 claims description 109
- 239000000090 biomarker Substances 0.000 claims description 90
- 210000002381 Plasma Anatomy 0.000 claims description 78
- 108020004707 nucleic acids Proteins 0.000 claims description 59
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 56
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 53
- 102100001875 MTRR Human genes 0.000 claims description 48
- 238000004458 analytical method Methods 0.000 claims description 47
- 235000004279 alanine Nutrition 0.000 claims description 44
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 43
- 210000004369 Blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- 201000003895 major depressive disease Diseases 0.000 claims description 42
- 102100014971 DRD2 Human genes 0.000 claims description 40
- 101700040453 DRD2 Proteins 0.000 claims description 40
- 102000002114 Reduced folate carrier Human genes 0.000 claims description 38
- 108050009454 Reduced folate carrier Proteins 0.000 claims description 38
- 108020002739 EC 2.1.1.6 Proteins 0.000 claims description 35
- 150000002500 ions Chemical class 0.000 claims description 35
- 102100018730 COMT Human genes 0.000 claims description 34
- 101700023114 MTRR Proteins 0.000 claims description 32
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 30
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 28
- 230000003321 amplification Effects 0.000 claims description 28
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 27
- 229940104302 Cytosine Drugs 0.000 claims description 23
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 206010012378 Depression Diseases 0.000 claims description 21
- 101700086161 GCH1 Proteins 0.000 claims description 21
- 102100010392 GCH1 Human genes 0.000 claims description 21
- 101700059829 folKE Proteins 0.000 claims description 21
- 102100003908 GCHFR Human genes 0.000 claims description 18
- 101710038589 GCHFR Proteins 0.000 claims description 18
- 102100008453 FOLH1 Human genes 0.000 claims description 17
- 101700036477 FOLH1 Proteins 0.000 claims description 16
- 102100007263 MTHFD1 Human genes 0.000 claims description 16
- 108010028485 methionine synthase reductase Proteins 0.000 claims description 16
- 102200124653 COMT V158M Human genes 0.000 claims description 14
- 101710038366 DNMT3B Proteins 0.000 claims description 13
- 102100015153 DNMT3B Human genes 0.000 claims description 13
- 208000008589 Obesity Diseases 0.000 claims description 13
- 230000001419 dependent Effects 0.000 claims description 13
- 229960003638 dopamine Drugs 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 102200088705 MTRR I22M Human genes 0.000 claims description 11
- 108060007762 SLC6A3 Proteins 0.000 claims description 11
- 102200088640 MTHFR R594Q Human genes 0.000 claims description 10
- 108010063808 Methylenetetrahydrofolate Dehydrogenase (NADP) Proteins 0.000 claims description 10
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims description 10
- 102200066104 MTHFD1 R653Q Human genes 0.000 claims description 9
- 102000005029 SLC6A3 Human genes 0.000 claims description 9
- 102100015024 FTCD Human genes 0.000 claims description 8
- 101700052624 FTCD Proteins 0.000 claims description 8
- 102000015436 Glutamate Formimidoyltransferase Human genes 0.000 claims description 8
- 108010064766 Glutamate Formimidoyltransferase Proteins 0.000 claims description 8
- 102100004926 CACNA1C Human genes 0.000 claims description 7
- 108060001067 CACNA1C Proteins 0.000 claims description 7
- 101710027940 PCYT1A Proteins 0.000 claims description 6
- 102100000438 PCYT1A Human genes 0.000 claims description 6
- 210000002700 Urine Anatomy 0.000 claims description 6
- 210000003296 Saliva Anatomy 0.000 claims description 5
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-Methylenetetrahydrofolate Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 claims description 4
- 102000003922 Calcium Channels Human genes 0.000 claims description 4
- 108090000312 Calcium Channels Proteins 0.000 claims description 4
- 239000002858 neurotransmitter agent Substances 0.000 claims description 4
- 102000037151 SLC-Transporter Human genes 0.000 claims description 3
- 108091006187 SLC-Transporter Proteins 0.000 claims description 3
- JVJFIQYAHPMBBX-FNORWQNLSA-N 4-HNE Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 claims 3
- 230000000052 comparative effect Effects 0.000 claims 2
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 claims 1
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 description 256
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine zwitterion Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 65
- 229940081973 S-Adenosylmethionine Drugs 0.000 description 62
- 229960001570 ademetionine Drugs 0.000 description 62
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 57
- JVJFIQYAHPMBBX-UHFFFAOYSA-N trans-4-hydroxy-2-nonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 57
- 230000035492 administration Effects 0.000 description 53
- 108090001123 antibodies Proteins 0.000 description 52
- 102000004965 antibodies Human genes 0.000 description 52
- 102000004190 Enzymes Human genes 0.000 description 49
- 108090000790 Enzymes Proteins 0.000 description 49
- 210000002966 Serum Anatomy 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 46
- 238000001514 detection method Methods 0.000 description 45
- 239000002609 media Substances 0.000 description 44
- 238000003752 polymerase chain reaction Methods 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 44
- 229940088598 Enzyme Drugs 0.000 description 41
- 230000035772 mutation Effects 0.000 description 38
- 239000000427 antigen Substances 0.000 description 37
- 102000038129 antigens Human genes 0.000 description 36
- 108091007172 antigens Proteins 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 238000003860 storage Methods 0.000 description 31
- 239000012472 biological sample Substances 0.000 description 30
- 238000000034 method Methods 0.000 description 30
- -1 lopram Chemical compound 0.000 description 29
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 24
- 229920000272 Oligonucleotide Polymers 0.000 description 24
- 230000000295 complement Effects 0.000 description 24
- 230000000875 corresponding Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- 239000002585 base Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 210000001772 Blood Platelets Anatomy 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 210000004027 cells Anatomy 0.000 description 16
- 239000000975 dye Substances 0.000 description 16
- 230000002068 genetic Effects 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 210000003743 Erythrocytes Anatomy 0.000 description 14
- 210000003324 RBC Anatomy 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 14
- 239000007850 fluorescent dye Substances 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000000994 depressed Effects 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 230000002459 sustained Effects 0.000 description 12
- 229960003208 Levomefolic Acid Drugs 0.000 description 11
- 108020004999 Messenger RNA Proteins 0.000 description 11
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N Tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 229920002106 messenger RNA Polymers 0.000 description 11
- 230000002093 peripheral Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000005460 tetrahydrofolate Substances 0.000 description 11
- ZNOVTXRBGFNYRX-STQMWFEESA-N 5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 10
- 101700080605 NUC1 Proteins 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 235000007635 levomefolic acid Nutrition 0.000 description 10
- 239000011578 levomefolic acid Substances 0.000 description 10
- 101700006494 nucA Proteins 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000004450 types of analysis Methods 0.000 description 10
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 9
- 229960002464 Fluoxetine Drugs 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 9
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 9
- 229960002073 Sertraline Drugs 0.000 description 9
- FNKQXYHWGSIFBK-RPDRRWSUSA-N Tetrahydrobiopterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 230000000240 adjuvant Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 238000010791 quenching Methods 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 102000025380 C-Reactive Protein Human genes 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 8
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 8
- 206010016880 Folate deficiency Diseases 0.000 description 8
- 229960000304 Folic Acid Drugs 0.000 description 8
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 229960001653 citalopram Drugs 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- 108091007521 restriction endonucleases Proteins 0.000 description 8
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 7
- 229920002676 Complementary DNA Polymers 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 229940064128 L-methylfolate Drugs 0.000 description 7
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 229960002296 paroxetine Drugs 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 101700011961 DPOM Proteins 0.000 description 6
- 206010012374 Depressed mood Diseases 0.000 description 6
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 6
- 229920001681 Heteroduplex Polymers 0.000 description 6
- 101710029649 MDV043 Proteins 0.000 description 6
- 101700061424 POLB Proteins 0.000 description 6
- VUVGYHUDAICLFK-UHFFFAOYSA-N Perosmic oxide Chemical compound O=[Os](=O)(=O)=O VUVGYHUDAICLFK-UHFFFAOYSA-N 0.000 description 6
- 101700054624 RF1 Proteins 0.000 description 6
- 229940053479 Selective serotonin reuptake inhibitors Drugs 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000000996 additive Effects 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000007894 caplet Substances 0.000 description 6
- 230000001809 detectable Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- 229960004341 escitalopram Drugs 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 230000003557 neuropsychological Effects 0.000 description 6
- 229920000023 polynucleotide Polymers 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 230000001502 supplementation Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 5
- 241000229754 Iva xanthiifolia Species 0.000 description 5
- 210000000265 Leukocytes Anatomy 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 229940076279 Serotonin Drugs 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 238000003795 desorption Methods 0.000 description 5
- 239000005546 dideoxynucleotide Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000003287 optical Effects 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 210000000579 Abdominal Fat Anatomy 0.000 description 4
- 210000000577 Adipose Tissue Anatomy 0.000 description 4
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 4
- 206010054089 Depressive symptom Diseases 0.000 description 4
- 206010022437 Insomnia Diseases 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108060001084 Luciferase family Proteins 0.000 description 4
- 210000004623 Platelet-Rich Plasma Anatomy 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 230000003001 depressive Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000008191 folinic acid Nutrition 0.000 description 4
- 239000011672 folinic acid Substances 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 229960001691 leucovorin Drugs 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000000171 quenching Effects 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 3
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 3
- 229920001405 Coding region Polymers 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 210000001624 Hip Anatomy 0.000 description 3
- 240000008526 Hypericum perforatum Species 0.000 description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- 206010057840 Major depression Diseases 0.000 description 3
- 206010061284 Mental disease Diseases 0.000 description 3
- 229960002748 Norepinephrine Drugs 0.000 description 3
- 229960001158 Nortriptyline Drugs 0.000 description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 235000002197 St. John’s wort Nutrition 0.000 description 3
- 229960003991 Trazodone Drugs 0.000 description 3
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000037348 biosynthesis Effects 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 108010041758 cleavase Proteins 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 150000002224 folic acids Chemical class 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 150000002302 glucosamines Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 201000010193 neural tube defect Diseases 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229950004354 phosphorylcholine Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229960004617 sapropterin Drugs 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- BGJXXVMOQCHQBO-QNTKWALQSA-N (2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid;calcium Chemical compound [Ca].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 BGJXXVMOQCHQBO-QNTKWALQSA-N 0.000 description 2
- OZRNSSUDZOLUSN-LBPRGKRZSA-M (4S)-4-[[4-[(2-amino-4-oxo-7,8-dihydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-M 0.000 description 2
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 2
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 2
- 229960000643 Adenine Drugs 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 229960000836 Amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960002519 Amoxapine Drugs 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N Amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- 206010002855 Anxiety Diseases 0.000 description 2
- 206010057666 Anxiety disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 229940116592 CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 206010057668 Cognitive disease Diseases 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 206010012401 Depressive disease Diseases 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 210000001198 Duodenum Anatomy 0.000 description 2
- 108030004409 EC 1.18.1.2 Proteins 0.000 description 2
- 108010010685 EC 3.5.4.9 Proteins 0.000 description 2
- 108010007730 EC 3.6.1.5 Proteins 0.000 description 2
- 102000007347 EC 3.6.1.5 Human genes 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100002309 FDXR Human genes 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 206010016256 Fatigue Diseases 0.000 description 2
- 229960004038 Fluvoxamine Drugs 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 108010023555 GTP Cyclohydrolase Proteins 0.000 description 2
- 102000036763 GTP Cyclohydrolase Human genes 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- QRMZSPFSDQBLIX-UHFFFAOYSA-N Homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- 108020004391 Introns Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 101710042577 MTHFD1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 229960000600 Milnacipran Drugs 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108020005203 Oxidases Proteins 0.000 description 2
- 229960003330 Pentetic Acid Drugs 0.000 description 2
- 229940023488 Pill Drugs 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 102100001821 SLC6A3 Human genes 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229960000278 Theophylline Drugs 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 229930003761 Vitamin B9 Natural products 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000002429 anti-coagulation Effects 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VWBBRFHSPXRJQD-ZEDZUCNESA-L calcium-L-methylfolate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 VWBBRFHSPXRJQD-ZEDZUCNESA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 2
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- 150000008275 galactosamines Chemical class 0.000 description 2
- 102000034448 gene-regulatory proteins Human genes 0.000 description 2
- 108091006088 gene-regulatory proteins Proteins 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 101710030587 ligN Proteins 0.000 description 2
- 101700077585 ligd Proteins 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 description 2
- 230000003340 mental Effects 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 201000008895 mood disease Diseases 0.000 description 2
- 239000005445 natural product Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000002474 noradrenergic Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002142 suicide Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960002431 trimipramine Drugs 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 235000019159 vitamin B9 Nutrition 0.000 description 2
- 239000011727 vitamin B9 Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- KYZWKYWGQFCRGN-RUCXOUQFSA-N (2S)-2-aminopentanedioic acid;(2S)-2-(methylamino)butanedioic acid Chemical compound CN[C@H](C(O)=O)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O KYZWKYWGQFCRGN-RUCXOUQFSA-N 0.000 description 1
- XNSAINXGIQZQOO-SDDRHHMPSA-N (2S)-N-[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound NC(=O)[C@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SDDRHHMPSA-N 0.000 description 1
- WIQRCHMSJFFONW-HNNXBMFYSA-N (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound O([C@@H](CCN)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-HNNXBMFYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- XFPJZGUGGRESHD-PHJLCXHGSA-N (6R,10bR)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;hydrobromide Chemical compound Br.ClC1=CC=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 XFPJZGUGGRESHD-PHJLCXHGSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- JCBQCKFFSPGEDY-UHFFFAOYSA-N 11-(1-azabicyclo[2.2.2]octan-3-yl)-5,6-dihydrobenzo[b][1]benzazepine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
- STDYWHYUOSSCBO-UHFFFAOYSA-N 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine Chemical compound C1C2=CC=CC=C2N=C(C)N(C)C1C1=CC=CC=C1 STDYWHYUOSSCBO-UHFFFAOYSA-N 0.000 description 1
- WETRBJOSGIDJHQ-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C2=CC=CC=C2CCC=1CC1=NCCN1 WETRBJOSGIDJHQ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGPDEAGGEXEMMM-UHFFFAOYSA-N 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1H-2,5-Benzoxazocine Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
- FWYRGHMKHZXXQX-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(CO)CC1=CC=C(Cl)C(Cl)=C1 FWYRGHMKHZXXQX-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- JOAQINSXLLMRCV-UHFFFAOYSA-N 4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoic acid Chemical compound C1=NC2=NC(N)=NC(O)=C2N=C1CNC1=CC=C(C(O)=O)C=C1 JOAQINSXLLMRCV-UHFFFAOYSA-N 0.000 description 1
- YCWUVLPMLLBDCU-UHFFFAOYSA-L 5-Formiminotetrahydrofolate Chemical compound N=CN1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 YCWUVLPMLLBDCU-UHFFFAOYSA-L 0.000 description 1
- ZNOVTXRBGFNYRX-ZGTCLIOFSA-N 5-Methyltetrahydrofolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ZGTCLIOFSA-N 0.000 description 1
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 description 1
- GGDBEAVVGFNWIA-UHFFFAOYSA-N 6-Nitroquipazine Chemical compound C1=CC2=CC([N+](=O)[O-])=CC=C2N=C1N1CCNCC1 GGDBEAVVGFNWIA-UHFFFAOYSA-N 0.000 description 1
- YQIFAMYNGGOTFB-XINAWCOVSA-N 7,8-dihydroneopterin Chemical compound N1CC([C@H](O)[C@H](O)CO)=NC2=C1N=C(N)NC2=O YQIFAMYNGGOTFB-XINAWCOVSA-N 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 101710039338 ATP2A2 Proteins 0.000 description 1
- 102100005631 ATP2A2 Human genes 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 229940022698 Acetylcholinesterase Drugs 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229960001456 Adenosine Triphosphate Drugs 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229960003225 Alaproclate Drugs 0.000 description 1
- FZSPJBYOKQPKCD-UHFFFAOYSA-N Alaproclate Chemical compound CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 240000000800 Allium ursinum Species 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ZPMKQFOGINQDAM-UHFFFAOYSA-N Amitriptylinoxide Chemical compound C1CC2=CC=CC=C2C(=CCC[N+](C)([O-])C)C2=CC=CC=C21 ZPMKQFOGINQDAM-UHFFFAOYSA-N 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 102100007283 BRCA2 Human genes 0.000 description 1
- 229950005683 Bazinaprine Drugs 0.000 description 1
- KRNDIPHOJLIHRI-UHFFFAOYSA-N Bazinaprine Chemical compound N#CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 KRNDIPHOJLIHRI-UHFFFAOYSA-N 0.000 description 1
- 229950000159 Befuraline Drugs 0.000 description 1
- SRIJFPBZWUFLFD-UHFFFAOYSA-N Befuraline Chemical compound C=1C2=CC=CC=C2OC=1C(=O)N(CC1)CCN1CC1=CC=CC=C1 SRIJFPBZWUFLFD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004938 Bipolar disease Diseases 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 229960001058 Bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 102100006339 CASP6 Human genes 0.000 description 1
- 101700059237 CASP6 Proteins 0.000 description 1
- 229940105657 CATALASE Drugs 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229950000303 Cericlamine Drugs 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 210000002987 Choroid Plexus Anatomy 0.000 description 1
- 229950002663 Clovoxamine Drugs 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N Dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 1
- 229950005551 Dazepinil Drugs 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N Deoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 229950007329 Diclofensine Drugs 0.000 description 1
- ZJDCGVDEEHWEIG-UHFFFAOYSA-N Diclofensine Chemical compound C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-UHFFFAOYSA-N 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N Dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000015554 Dopamine receptor family Human genes 0.000 description 1
- 108050004812 Dopamine receptor family Proteins 0.000 description 1
- 229940000011 Dothiepin Drugs 0.000 description 1
- 108020004461 Double-Stranded RNA Proteins 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 206010013982 Dysthymic disease Diseases 0.000 description 1
- 108010026217 EC 1.1.1.37 Proteins 0.000 description 1
- 102000013460 EC 1.1.1.37 Human genes 0.000 description 1
- 108010053835 EC 1.11.1.6 Proteins 0.000 description 1
- 102000016938 EC 1.11.1.6 Human genes 0.000 description 1
- 102000006378 EC 2.1.1.6 Human genes 0.000 description 1
- 102000020165 EC 2.1.1.71 Human genes 0.000 description 1
- 108010074253 EC 2.1.1.71 Proteins 0.000 description 1
- 102000007357 EC 2.5.1.6 Human genes 0.000 description 1
- 108010007784 EC 2.5.1.6 Proteins 0.000 description 1
- 102000005314 EC 3.5.4.16 Human genes 0.000 description 1
- 108020002645 EC 3.5.4.16 Proteins 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 229920002760 Expressed sequence tag Polymers 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N Femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- 210000004700 Fetal Blood Anatomy 0.000 description 1
- 229950000761 Fezolamine Drugs 0.000 description 1
- NELSQLPTEWCHQW-UHFFFAOYSA-N Fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N Fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 229940064302 Folacin Drugs 0.000 description 1
- 102000002686 Formate-Tetrahydrofolate Ligase Human genes 0.000 description 1
- 108010080982 Formate-Tetrahydrofolate Ligase Proteins 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 102000006602 Glyceraldehyde-3-Phosphate Dehydrogenases Human genes 0.000 description 1
- 108020004445 Glyceraldehyde-3-Phosphate Dehydrogenases Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 101710015954 HVA1 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000003532 Hypothyroidism Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 229950006314 Ifoxetine Drugs 0.000 description 1
- ZHFIAFNZGWCLHU-YPMHNXCESA-N Ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- SVFXPTLYMIXFRX-BBRMVZONSA-N Indatraline Chemical compound C1([C@@H]2C[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 SVFXPTLYMIXFRX-BBRMVZONSA-N 0.000 description 1
- 229950008889 Indatraline Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000001630 Jejunum Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine zwitterion Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 101700065814 LEA2 Proteins 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940040461 Lipase Drugs 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- MJJDYOLPMGIWND-UHFFFAOYSA-N Litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 1
- 229950004138 Litoxetine Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 102500000027 MTHFR C677T Human genes 0.000 description 1
- 101700006121 MTR Proteins 0.000 description 1
- 102200067132 MUTYH V22M Human genes 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 241001000161 Mago Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000570 Methylenetetrahydrofolate reductase deficiency Diseases 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 229960001785 Mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N Mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102100000560 NFATC3 Human genes 0.000 description 1
- 101710044742 NFATC3 Proteins 0.000 description 1
- 229950000323 Napamezole Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N Nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960000751 Nefopam Drugs 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 102000009493 Neurokinin receptors Human genes 0.000 description 1
- 108050000302 Neurokinin receptors Proteins 0.000 description 1
- 102000020283 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- CGYWLLGTCBIGSR-UHFFFAOYSA-N Nitroxazepine Chemical compound O=C1N(CCCN(C)C)C2=CC=CC=C2OC2=CC=C([N+]([O-])=O)C=C21 CGYWLLGTCBIGSR-UHFFFAOYSA-N 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- WKAJAKWUZNTYOH-XGONXTELSA-N OC(=O)[C@@H](N)CCC(O)=O.N1=C2C(=O)NC(N)=NC2=NC=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 Chemical compound OC(=O)[C@@H](N)CCC(O)=O.N1=C2C(=O)NC(N)=NC2=NC=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WKAJAKWUZNTYOH-XGONXTELSA-N 0.000 description 1
- 108009000359 One Carbon Metabolism Proteins 0.000 description 1
- FTKXWCQSVJPWPZ-VDWBQBBKSA-N Org 6906 Chemical compound Cl.C1C2=CC=CC=C2[C@H]2C=C[C@@H](N)[C@@H]1C2 FTKXWCQSVJPWPZ-VDWBQBBKSA-N 0.000 description 1
- AVVSOBGTJTTZKQ-RXVWUEJASA-N Org 6997 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@H]2C=C[C@@H](N)[C@@H]1C2 AVVSOBGTJTTZKQ-RXVWUEJASA-N 0.000 description 1
- LWRJZIPAGMGXQJ-DIJVWCDGSA-N Org-6582 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@@H]2[C@@H](N)[C@H]1C=CC2 LWRJZIPAGMGXQJ-DIJVWCDGSA-N 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 102100018844 PAPSS1 Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N Phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 229950007239 Pirandamine Drugs 0.000 description 1
- AMJPIGOYWBNJLP-UHFFFAOYSA-N Pirandamine Chemical compound C1C2=CC=CC=C2C2=C1C(CCN(C)C)(C)OCC2 AMJPIGOYWBNJLP-UHFFFAOYSA-N 0.000 description 1
- IWVRVEIKCBFZNF-UHFFFAOYSA-N Pirlindole Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
- 229950002220 Pirlindole Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 210000002442 Prefrontal Cortex Anatomy 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 229960000279 Quinupramine Drugs 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102100010735 RUBCN Human genes 0.000 description 1
- 101710029688 RUBCN Proteins 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N Reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102100001467 SLC18A2 Human genes 0.000 description 1
- 101710044968 SLC18A2 Proteins 0.000 description 1
- 102100010056 SLC19A1 Human genes 0.000 description 1
- 101710027453 SLC19A1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229950000319 Seproxetine Drugs 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HELHAJAZNSDZJO-UHFFFAOYSA-L Sodium tartrate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O HELHAJAZNSDZJO-UHFFFAOYSA-L 0.000 description 1
- 229960002167 Sodium tartrate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 108010022348 Sulfate Adenylyltransferase Proteins 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 108060008623 TRH Proteins 0.000 description 1
- 102100009392 TRH Human genes 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229940034199 Thyrotropin-Releasing Hormone Drugs 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 229940034208 Thyroxine Drugs 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N Tianeptine Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- 229950008817 Tiflucarbine Drugs 0.000 description 1
- BNKIWXODDDABSJ-UHFFFAOYSA-N Tiflucarbine Chemical compound N1C2=CC(F)=C3SC=C(C)C3=C2C2=C1CCN(CC)C2 BNKIWXODDDABSJ-UHFFFAOYSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940035722 Triiodothyronine Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000269386 Triturus Species 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229940045145 Uridine Drugs 0.000 description 1
- 229950006360 VIQUALINE Drugs 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- XFXANHWIBFMEOY-JKSUJKDBSA-N Viqualine Chemical compound C12=CC(OC)=CC=C2N=CC=C1CCC[C@@H]1CCNC[C@@H]1C=C XFXANHWIBFMEOY-JKSUJKDBSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- RQKBYNZCLOWPDE-UHFFFAOYSA-N [5-(2-amino-6-oxo-3H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] [3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)-4-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(2,4-d Chemical compound O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2COP(O)(O)=O)N2C3=C(C(N=C(N)N3)=O)N=C2)O)N2C(NC(=O)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)O1.O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2COP(O)(O)=O)N2C3=C(C(N=C(N)N3)=O)N=C2)O)N2C(NC(=O)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)O1 RQKBYNZCLOWPDE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical class C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 108060003434 alpha Proteins 0.000 description 1
- 229950010041 amitriptylinoxide Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229920002847 antisense RNA Polymers 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 1
- 238000004177 carbon cycle Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- BTGGPXGEUYGURY-FAXDREHLSA-M cobalt;[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,5Z,7S,10Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-1,2, Chemical compound [Co].N([C@@H]([C@]1(C)N=C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)\C(C)=C1/N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO BTGGPXGEUYGURY-FAXDREHLSA-M 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001149 cognitive Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920000407 conserved sequence Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 229960005217 dapoxetine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004189 ion pair high performance liquid chromatography Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229950004592 liothyronine Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 102000004882 lipase Human genes 0.000 description 1
- 108090001060 lipase Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 101700001016 mbhA Proteins 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 229950001527 nitroxazepine Drugs 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000803 paradoxical Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000014009 piper methysticum Nutrition 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 230000000506 psychotropic Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006485 reductive methylation reaction Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 229940121356 serotonin receptor antagonists Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Abstract
assay for selecting a treatment regimen for a human subject with depression, comprising (a) subjecting a test sample previously obtained from a human subject, who is diagnosed as having depression or having a risk for depression, to at least one genotyping assay adapted to determine the genotypes of at least two loci. The at least two loci are: i. position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133), where the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR) or ii.position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by rs1805087), where the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid sequence of methionine synthase (MTR). The assay furhter includes b) detecting from the genotypes of said at least two loci the presence of a single nucleotide polymorphism (SNP) selected from the following: i. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 comprising at least one thymine “T” allele; ii. a SNP2756 at position 2756 of SEQ ID NO.2 or position 27 of SEQ ID NO. 9 comprising at least one guanine “G” allele; and iii. a combination of at least one SNP677 T allele and at least one SNP2756 G allele; and if at least one of T allele at position SNP677 or at least one G allele at position SNP2756 or both at least one T allele at position SNP677 and at least one G allele at position SNP2756 is detected, then selecting a treatment regimen comprising an effective amount of a folate-containing compound. of at least two loci. The at least two loci are: i. position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133), where the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR) or ii.position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by rs1805087), where the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid sequence of methionine synthase (MTR). The assay furhter includes b) detecting from the genotypes of said at least two loci the presence of a single nucleotide polymorphism (SNP) selected from the following: i. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 comprising at least one thymine “T” allele; ii. a SNP2756 at position 2756 of SEQ ID NO.2 or position 27 of SEQ ID NO. 9 comprising at least one guanine “G” allele; and iii. a combination of at least one SNP677 T allele and at least one SNP2756 G allele; and if at least one of T allele at position SNP677 or at least one G allele at position SNP2756 or both at least one T allele at position SNP677 and at least one G allele at position SNP2756 is detected, then selecting a treatment regimen comprising an effective amount of a folate-containing compound.
Description
ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR
A SUBJECT WITH DEPRESSION
CROSS REFERENCE TO RELATED APPLICATIONS
This Application claims the benefit under 35 U.S.C §119(e) of U.S. Provisional
Application No. 61/559,541 filed November 14, 2011, the content of which is orated herein by
reference in its ty.
TECHNICAL FIELD OF THE DISCLOSURE
Embodiments of the inventions generally relate to assays, methods and systems for
selecting a ent regimen for a subject with depression, e.g., major depressive disorder. The
ions further relate to methods for treating a subject with depression, e.g., major depressive
BACKGROUND
Recent estimates te that more than 19 million Americans over the age of 18
years ence a depressive illness each year. It has been generally believed that there is some form
of association between folate-deficiency states and depression [1, 2 and 3], which in turn helps to
explain prior observations on the myriad neuropsychiatric presentations of megaloblastic anemia [4].
Recently, the relevance of folate in other medical conditions, in particular neural tube defects [5] and
cardiovascular disease, [6] and potential antidepressant efficacy of agents marketed as dietary
supplements or "nutraceuticals," [7 and 8] such as S-adenosyl-methionine , hypericum
perforatum (St. John’s wort), and 3-fatty acids, has been increasingly recognized. The field has
gradually moved toward researching the impact of folate deficiency, replacement, and
supplementation on the course and management of depressive disorders, in particular major
depressive disorder, [9] and putative roles of folate in central–nervous-system function. [10, 11 and
12]. While significant advances in the treatment of sion have been made in the past , as
many as 29% to 46% of patients with depression taking an anti-depressant are still partially or totally
resistant to the treatment. Those who suffer from treatment-resistant depression have almost no
alternatives. As not every ent regimen is effective for each individual, there is a strong need to
identify markers that can facilitate ion of an appropriate treatment regimen for a subject with
depression.
[0003a] Any discussion of the prior art throughout the specification should in no way be
considered as an admission that such prior art is widely known or forms part of common general
knowledge in the field.
[0003b] Unless the context clearly requires otherwise, throughout the description and the
claims, the words “comprise”, ising”, and the like are to be construed in an inclusive sense as
opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited
to”.
SUMMARY
A significant portion of patients with depression, such as major depressive disorders,
show only partial or no response to conventional antidepressant drugs, e.g., selective serotonin
ke inhibitors. Thus, there is a strong need to develop effective antidepressant therapies and/or to
stratify patients with sion such that they can receive appropriate antidepressant therapies.
Aspects of various embodiments described herein stem from the ery of single nucleotide
rphisms (SNPs), peripheral biomarkers and/or clinical features that are associated with an
efficacy response to the use of a folate-containing nd for treatment of depression, e. g., major
depressive disorders, as a monotherapy or as an adjunct to an antidepressant drug. In some
embodiments, the inventors have also shown that these markers or conditions described herein can
also be used to select a more effective treatment for subjects with treatment-resistant sion
(TRD), e. g., resistant to at least one selective serotonin reuptake inhibitor (SSRI).
Particularly, one or a combination of biomarkers that can be indicative of a patient
(e. g., with major depressive ers and/or TRD) suitable for a treatment regimen comprising a
-containing compound include, but are not limited to, at least one or more SNPs identified by rs
numbers as follows: rs1801133 t in methylenetetrahydrofolate reductase (MTHFR); rs2274976
present in MTHFR; rs1805087 present in methionine synthase (MTR); 394 present in
methionine synthase reductase (MTRR); 737 present in calcium channel, voltage-dependent, L-
type, alpha 1C subunit (CACNAlC); rs1883729 present in DNA (cytosine-5)-methyltransferase 3
beta (DNMT3B); rs7163862 t in GTP cyclohydrolase 1 feedback regulatory protein (GCHFR);
rs12659 present in reduced folate carrier protein ; rs202676 present in folate hydrolase
(prostate-specific membrane antigen) (FOLHl); 29l present in reduced folate carrier protein
(RCFl); rs1051266 t in reduced folate carrier protein 1 (RCFl); 267 present in GTP
cyclohydrolase l (GCHl); rs7639752 t in choline-phosphate cytidylytransferase A (PCYTlA);
rs6275present in dopamine receptor D2 (DRDZ); rs1079596 present in DRDZ; rs11240594 present in
DRDZ; rs4633 present in catechol-O-methyltransferase (COMT); rs4680 present in COMT; rs250682
present in dopamine active transporter (DAT, or SLC6A3); rs2277820 present in
formiminotransferase cyclodeaminase (FTCD); 225 present in methylenetetrahydrofolate
dehydrogenase (NADP+ dependent) l (MTHFDl); and any combinations thereof; and/or expression
of at least one of s-adenosyl methionine (SAM), s-adenosyl homocysteine (SAH), 4-hydroxynonenal
(4-HNE), high sensitivity c-reactive protein (hsCRP), and any combinations thereof. Additionally or
alternatively, determination of whether a human subject is obese or not (e. g., by measurement of a
BMI value) can also be used as a biomarker to select an appropriate treatment regimen (e.g.,
comprising a folate-containing compound or not) for a patient with depression or a risk for
depression. Any individual or combinations of such biomarkers disclosed herein can be used to
identify patients, who are diagnosed as having depression or having a risk for depression, for
receiving a treatment regimen sing a folate-containing compound. In some embodiments, a
-containing compound can be used in the e of an anti-depressant drug for treatment of
depression (e.g., major depressive disorders) in subjects selected for carrying at least one or more
biomarkers described herein. In alternative embodiments, a folate-containing compound can be used
alone or in combination (e.g., as an adjunct) with an anti-depressant drug for treatment of depression
(e. g., major sive disorders) in subjects selected for carrying at least one or more biomarkers
described herein. In one embodiment, the epressant drug can include a selective serotonin
ke inhibitor (SSRI). Examples of the SSRI include, but are not limited to, tine,
citalopram, paroxetine, lopram, sertraline, and any ations thereof.
Accordingly, provided herein generally relate to assays, methods, systems, and kits
for selecting a treatment regimen for a t with depression or a risk for depression, treating a
subject with depression or a risk for depression, and/or improving the effectiveness of a treatment
regimen recommended for or administered to a subject with depression or a risk for depression.
Provided herein also relate to folate-comprising compositions for use in treatment of sion in a
subject (e.g., a human subject) selected to carry at least one (e.g., at least two or more) or any
combinations of the biomarkers or ions described herein.
[0006a] In a first aspect of the invention there is provided an assay for ing a treatment
regimen for a human subject with depression, comprising:
(a) subjecting a test sample previously obtained from a human t, who is diagnosed
as having depression or having a risk for depression, to at least one genotyping assay
adapted to determine the genotypes of at least two loci, wherein said at least two loci are:
i. position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by
rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each
ndently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
ii.position 2756 of SEQ ID NO. 2 or on 27 of SEQ ID NO. 9 (identified
by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each
independently a portion of a genomic nucleic acid sequence of methionine
synthase (MTR); and
(b) detecting from the genotypes of said at least two loci the presence of a single
nucleotide polymorphism (SNP) selected from the following:
i. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
comprising at least one thymine “T” allele;
ii. a SNP2756 at position 2756 of SEQ ID NO.2 or position 27 of SEQ ID NO.
9 comprising at least one guanine “G” allele; and
iii. a combination of at least one SNP677 T allele and at least one SNP2756
G allele; and
if at least one of T allele at position SNP677 or at least one G allele at position
SNP2756 or both at least one T allele at position SNP677 and at least one G allele at
position SNP2756 is detected, then selecting a treatment regimen comprising an
effective amount of a folate-containing compound.
[0006b] In a second aspect of the invention there is provided an assay for selecting a treatment
n for a human subject having depression and currently taking an antidepressant, comprising:
(a) subjecting a test sample of the human subject, who is diagnosed as having depression
or having a risk for depression, to at least one analysis to determine ters of at least
two biomarkers from:
i. genotype of a SNP locus at position 677 of SEQ ID NO. 1 or position 27 of
SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1 and
SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase (MTHFR);
ii.genotype of a SNP locus at rs2274976 (position 1793 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO. 8
are each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
iii. genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of
SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and
SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase (MTR);
iv. genotype of a SNP locus at position 66 of SEQ ID NO. 3 or position 27 of
SEQ ID NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3 and
SEQ ID NO. 10 are each ndently a portion of a genomic nucleic acid
sequence of methionine synthase reductase (MTRR);
v. genotype of a SNP locus at rs1006737 (position 27 of SEQ ID NO. 11,
n the SEQ ID NO. 11 is a portion of a genomic c acid sequence
of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNA1C));
vi. genotype of a SNP locus at rs1883729 (position 27 of SEQ ID NO. 12,
wherein the SEQ ID NO. 12 is a n of a genomic nucleic acid sequence
of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B));
vii. genotype of a SNP locus at rs7163862 (position 27 of SEQ ID NO. 13,
n the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 ck regulatory protein (GCHFR)) ;
viii. genotype of a SNP locus at rs12659 ion 27 of SEQ ID NO. 14,
wherein the SEQ ID NO. 14 is a portion of a genomic c acid sequence
of reduced folate r protein (RCF2));
ix. genotype of a SNP locus at rs202676 ion 27 of SEQ ID NO. 15,
wherein the SEQ ID NO. 15 is a n of a c nucleic acid sequence
of folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1));
x. genotype of a SNP locus at 291 (position 27 of SEQ ID NO. 16,
wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence
of reduced folate carrier protein (RCF1));
xi.genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17,
n the SEQ ID NO. 17 is a portion of a genomic c acid sequence
of reduced folate carrier protein (RCF1));
xii. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO. 18,
wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid ce
of GTP cyclohydrolase 1 (GCH1));
xiii. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO. 19,
wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid sequence
of choline-phosphate cytidylyltransferase A A));
xiv. genotype of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20,
wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2));
xv. genotype of a SNP locus at rs1079596 (position 27 of SEQ ID NO. 21),
wherein the SEQ ID NO. 21 is a portion of a c nucleic acid sequence
of dopamine or D2 (DRD2);
xvi. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22),
wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
xvii. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23,
wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence
of catechol-O-methyltransferase (COMT));
xviii. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24),
wherein the SEQ ID NO. 24 is a n of a genomic nucleic acid sequence
of catechol-O-methyltransferase (COMT);
xix. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25,
wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence
of solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
(SLC6A3));
xx. genotype of a SNP locus at rs2277820 (position 27 of SEQ ID NO. 26,
n the SEQ ID NO. 26 is a portion of a c nucleic acid sequence
of formiminotransferase cyclodeaminase (FTCD)); and
xxi. genotype of a SNP locus at rs2236225 (position 27 of SEQ ID NO. 27,
wherein the SEQ ID NO. 27 is a portion of a genomic c acid sequence
of methylenetetrahydrofolate ogenase (NADP+ dependent) 1
(MTHFD1));
xxii. level of expression of SAM and SAH;
xxiii. level of expression of 4-HNE;
xxiv. level of expression of hsCRP; and any combinations thereof;
(b) detecting from the ters of said at least two biomarkers, the presence of at least
one ion selected from the following:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
comprising at least one thymine “T” allele;
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ
ID NO. 8) comprising at least one alanine “A” allele;
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele;
iv. a SNP at position 66 of SEQ ID NO. 3 or on 27 of SEQ ID NO. 10
comprising at least one guanine "G" allele;
v. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one
alanine “A” allele;
vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one
alanine “A” ;
vii. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least
one thymine “T” allele;
viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one
thymine “T” allele;
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one
guanine “G” allele;
x. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one
alanine “A” ;
xi. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one
alanine “A” allele;
xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least
one e “T” allele;
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19 ) comprising at least
one alanine “A” allele;
xiv. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one
thymine “T” allele;
xv. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least
one thymine “T” allele;
xvi. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least
one alanine “A” allele;
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) sing at least one
cytosine “C” allele;
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one
guanine “G” allele;
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one
cytosine “C” allele;
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least
one e “T” allele;
xxi. a SNP at 225 (position 1958 of SEQ ID NO. 27) comprising at least
one alanine “A” allele;
xxii. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or r);
xxiii. an expression level ratio of SAM to SAH smaller than a pre-determined
reference ratio;
xxiv. an expression level of 4-HNE greater than a termined reference
value;
xxv. an expression of hsCRP greater than about 2.3 mg per liter of plasma as
measured in a plasma sample; and any ations thereof, and
and if at least one of said conditions is detected, then ing a treatment regimen
comprising an effective amount of a folate-containing compound.
[0006c] In a third aspect of the invention there is provided use of a folate-comprising
composition in combination with an anti-depressant in the preparation of a medicament for use in
the treatment of depression in a human subject who carries at least the following single nucleotide
polymorphisms:
a. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
(identified by 133) comprising at least one thymine “T” allele; and
b. a SNP2756 at on 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele.
[0006d] In a fourth aspect of the invention there is provided use of a folate-comprising
composition in combination with an anti-depressant in the preparation of a medicament for use in
the treatment of depression in a human subject who carries at least two of the following conditions
or any combination f:
a. at least one thymine "T" allele at SNP locus at position 677 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each independently a portion of a c nucleic acid
ce of methylenetetrahydrofolate ase (MTHFR);
b. at least one alanine "A" allele at SNP locus at rs2274976 (position 1793 of SEQ ID
NO. 1 or on 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO.
8 are each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
c. at least one guanine "G" allele at SNP locus at position 2756 of SEQ ID NO.2 or
position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase (MTR);
d. at least one guanine "G" allele at SNP locus at position 66 of SEQ ID NO. 3 or
position 27 of SEQ ID NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3
and SEQ ID NO. 10 are each independently a portion of a c nucleic acid
sequence of methionine synthase reductase (MTRR);
e. at least one e "A" allele at SNP locus at rs1006737 (position 27 of SEQ ID NO.
11, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of
calcium channel, e-dependent, L type, alpha 1C subunit (CACNA1C));
f. at least one alanine "A" allele at SNP locus at rs1883729 (position 27 of SEQ ID NO.
12, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of
DNA (cytosine-5)-methyltransferase 3 beta B));
g. at least one thymine "T" allele at SNP locus at rs7163862 (position 27 of SEQ ID
NO. 13, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 ck regulatory protein (GCHFR));
h. at least one thymine "T" allele at SNP locus at rs12659 (position 27 of SEQ ID NO.
14, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF2));
i. at least one guanine "G" allele at SNP locus at rs202676 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of
folate ase (prostate-specific membrane n) 1 (FOLH1));
j. at least one alanine "A" allele at SNP locus at rs2297291 (position 27 of SEQ ID NO.
16, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF1));
k. at least one alanine "A" allele at SNP locus at rs1051266 (position 27 of SEQ ID NO.
17), wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF1);
l. at least one thymine "T" allele at SNP locus at rs8007267 (position 27 of SEQ ID
NO. 18, n the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 (GCH1));
m. at least one alanine "A" allele at SNP locus at rs7639752 ion 27 of SEQ ID NO.
19, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid sequence of
e-phosphate cytidylyltransferase A (PCYT1A));
n. at least one thymine "T" allele at SNP locus at rs6275 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence of
dopamine receptor D2 (DRD2));
o. at least one thymine "T" allele at SNP locus at rs1079596 (position 27 of SEQ ID
NO. 21), n the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
p. at least one e "A" allele at SNP locus at rs11240594 (position 27 of SEQ ID
NO. 22), wherein the SEQ ID NO. 22 is a n of a c nucleic acid sequence
of dopamine receptor D2 (DRD2);
q. at least one cytosine "C" allele at SNP locus at rs4633 (position 27 of SEQ ID NO.
23, n the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT));
r. at least one guanine "G" allele at SNP locus at rs4680 (position 27 of SEQ ID NO.
24), wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT);
s. at least one cytosine "C" allele at SNP locus at rs250682 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
(SLC6A3));
t. at least one thymine "T" allele at SNP locus at rs2277820 (position 27 of SEQ ID
NO. 26, wherein the SEQ ID NO. 26 is a n of a genomic c acid sequence
of inotransferase cyclodeaminase (FTCD)); and
u. at least one alanine "A" allele at SNP locus at rs2236225 (position 27 of SEQ ID NO.
27, wherein the SEQ ID NO. 27 is a n of a c nucleic acid sequence of
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1));
v. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or greater);
w. an expression level ratio of SAM to SAH smaller than a pre-determined reference
ratio;
x. an expression level of 4-HNE greater than a pre-determined reference value; and
y. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in a
plasma sample.
In a further aspect, provided herein is an assay for selecting a treatment regimen for a
human subject having depression or having a risk for depression. The assay comprises:
(a) subjecting a test sample of a human subject, who is diagnosed as having depression or
having a risk for depression, to at least one analysis to determine parameters of at least
two biomarkers from the following:
(i) genotype of a SNP locus at on 677 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are
each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
(ii) genotype of a SNP locus at position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8 (identified by rs2274976), wherein the SEQ ID NO. 1 and SEQ ID NO. 8 are
each independently a portion of a genomic nucleic acid ce of MTHFR;
(iii) genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are
each independently a n of a genomic nucleic acid sequence of methionine
synthase (MTR);
(iv) genotype of a SNP locus at on 66 of SEQ ID NO. 3 or position 27 of SEQ ID
NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3 and SEQ ID NO. 10
are each independently a portion of a genomic nucleic acid sequence of methionine
synthase reductase (MTRR);
(v) genotype of a SNP locus at position 27 of SEQ ID NO. 11 ified by rs1006737),
wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of
calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C);
(vi) pe of a SNP locus at position 27 of SEQ ID NO. 12 (identified by rs1883729),
wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of DNA
ine-5)-methyltransferase 3 beta (DNMT3B);
(Vii) pe of a SNP locus at position 27 of SEQ ID NO. 13 (identified by rs7163862),
wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence of GTP
ydrolase 1 feedback tory protein (GCHFR);
(viii) genotype of a SNP locus at position 27 of SEQ ID NO. 14 (identified by rs12659),
wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of reduced
folate carrier protein ;
(ix) genotype of a SNP locus at position 27 of SEQ ID NO. 15 (identified by rs202676),
wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of folate
hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
(x) genotype of a SNP locus at position 27 of SEQ ID NO. 16 (identified by rs2297291),
wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of d
folate carrier protein ;
(xi) genotype of a SNP locus at position 27 of SEQ ID NO. 17 (identified by rs1051266),
wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid sequence of reduced
folate carrier protein (RCFl);
(xii) genotype of a SNP locus at position 27 of SEQ ID NO. 18 (identified by rs8007267),
n the SEQ ID NO. 18 is a portion of a genomic c acid sequence of GTP
cyclohydrolase 1 (GCH1);
(xiii) genotype of a SNP locus at position 27 of SEQ ID NO. 19 (identified by rs7639752),
wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid sequence of choline-
phosphate cytidylyltransferase A (PCYTlA);
(xiv) genotype of a SNP locus at position 27 of SEQ ID NO. 20 (identified by rs6275),
wherein the SEQ ID NO. 20 is a portion of a genomic c acid sequence of dopamine
receptor D2 (DRD2);
(xv) genotype of a SNP locus at position 27 of SEQ ID NO. 21 (identified by rs1079596),
wherein the SEQ ID NO. 21 is a portion of a c nucleic acid sequence of dopamine
or D2 (DRD2);
(xvi) genotype of a SNP locus at position 27 of SEQ ID NO. 22 (identified by rs11240594),
wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
(xvii) genotype of a SNP locus at position 27 of SEQ ID NO. 23 ified by ),
wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of catechol-
O-methyltransferase (COMT);
(xviii) genotype of a SNP locus at position 27 of SEQ ID NO. 24 ified by rs4680),
wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-
O-methyltransferase (COMT);
2012/065084
(xix) genotype of a SNP locus at position 27 of SEQ ID NO. 25 (identified by rs250682),
n the SEQ ID NO. 25 is a portion of a genomic c acid sequence of solute
carrier family 6 (neurotransmitted transported, dopamine), member 3 (SLC6A3);
(xx) genotype of a SNP locus at position 27 of SEQ ID NO. 26 (identified by rs2277820),
wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of
formiminotransferase cyclodeaminase (FTCD);
(xxi) genotype of a SNP locus at position 27 of SEQ ID NO. 27 (identified by rs2236225),
wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) l 1));
(xxii) level of sion of SAM and SAH;
(xxiii) level of expression of 4-HNE;
(xxiv) level of expression of hsCRP; and any combinations thereof; and
(b) detecting, ally with a non-human e, from the determined ters of at least two
biomarkers, the ce of at least one condition selected from the following:
(A) a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by
rs1801133) comprising at least one thymine "T" allele;
(B) a SNP at position 1793 of SEQ ID NO. 1 or on 27 of SEQ ID NO. 8 (identified by
rs2274976) comprising at least one alanine "A" allele;
(C) a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by
rs1805087) comprising at least one guanine "G" allele;
(D) a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 (identified by
rs1801394) comprising at least one guanine "G" allele;
(E) a SNP at position 27 of SEQ ID NO. 11(identified by rs1006737) comprising at least one
alanine "A" allele;
(F) a SNP at position 27 of SEQ ID NO. 12 (identified by rs1883729) comprising at least one
alanine "A" allele;
(G) a SNP at position 27 of SEQ ID NO. 13(identified by rs7l63862) comprising at least one
thymine "T" allele;
(H) a SNP at position 27 of SEQ ID NO. 14 (identified by rsl2659) comprising at least one
thymine "T" allele;
(I) a SNP at position 27 of SEQ ID NO. ntified by rs202676) comprising at least one
guanine "G" allele;
(J) a SNP at position 27 of SEQ ID NO. 16 (identified by rs229729l) comprising at least one
e "A" allele;
(K) a SNP at position 27 of SEQ ID NO. 17 (identified by at rs1051266) comprising at least
one alanine "A" allele;
(L) a SNP at position 27 of SEQ ID NO. 18 (identified by rs8007267) comprising at least one
thymine "T" allele;
(M) a SNP at position 27 of SEQ ID NO. 19 (identified by 752) comprising at least one
alanine "A" allele;
(N) a SNP at position 27 of SEQ ID NO. 20 (identified by rs6275) comprising at least one
thymine "T" allele;
(0) a SNP at position 27 of SEQ ID NO. 21 (identified by 596) comprising at least one
thymine "T" allele;
(P) a SNP at position 27 of SEQ ID NO. 22 (identified by rsl 1240594) comprising at least
one alanine "A" allele;
(Q) a SNP at position 27 of SEQ ID NO. 23 (identified by rs4633) comprising at least one
ne "C" allele;
(R) a SNP at position 27 of SEQ ID NO. 24 ified by rs4680) comprising at least one
guanine "G" allele;
(S) a SNP at position 27 of SEQ ID NO. 25 ified by rs250682) comprising at least one
cytosine "C" allele;
(T) a SNP at position 27 of SEQ ID NO. 26 (identified by rs2277820) comprising at least one
thymine "T" allele;
(U) a SNP at position 1958 of SEQ ID NO. 27 (identified by rs2236225) comprising at least
one alanine "A" allele;
(V) an expression level ratio of SAM to SAH smaller than a termined reference ratio;
(W) an expression level of 4-HNE greater than a pre-determined nce value;
(X) an expression of hsCRP greater than about 2.3 mg per liter as measured in a plasma
sample; and any combinations thereof.
Based on the analysis results from step (b), if at least one of the conditions described
above is detected, the assay can further se selecting for the human t and optionally
stering to the human subject a treatment regimen comprising an effective amount of a folatecontaining
compound.
In some embodiments of this aspect and all other aspects described herein, any of the
SNPs described herein can comprise one or two folate-respsonive alleles. By way of example only, a
SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 ified by rs1801133) can
comprise one thymine "T" allele, or two thymine “T” alleles.
Any combinations of at least two biomarkers (i) to (xxiv) described herein can be
determined in a test sample for the assays bed herein. Exemplary combinations of at least two
biomarkers described herein can comprise genotypes of at least two SNP loci; or genotype of at least
one SNP loci and expression level of at least one indicated biomarker (e. g., 4-HNE); or expression
level of at least two indicated kers (e. g., SAM, SAH). Depending upon selected combinations
of at least two biomarkers described herein, the test sample can be subjected to one or more analyses,
e.g., including, but not limited to, genotyping assays, expression assays (e. g., protein and/or transcript
levels), or any combinations thereof.
ingly, in some embodiments, the assay can comprise subjecting a test sample
from a human subject, who is sed as having depression or having a risk for depression to at
least one genotyping assay adapted to ine genotypes of at least two loci, wherein said at least
two loci are: (i) position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by
rs1801133) and (ii) position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by
rs1805087). In such embodiment, ion of at least one SNP at either position 677 of SEQ ID NO.
1 (or position 27 of SEQ ID NO. 7) sing at least one thymine “T” allele or position 2756 of
SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9) comprising at least one guanine “G” allele, or
detection of both aforementioned SNPs indicates selection and optional administration of a treatment
regimen comprising an effective amount of a folate-containing compound to the human subject.
In some embodiments, the genotyping assay can comprise the step of amplifying the
test sample with a set of primers flanking any one of the SNPs described . In some
embodiments, at least two (e. g., at least three, at least four, at least five or more) sets of primers
amplifying at least two (e. g., at least three, at least four, at least five or more) of the SNPs can be used
in a lex amplification assay.
In some embodiments, the test sample can be subjected to determine parameters of at
least three, at least four, at least five or more biomarkers (i) to (xxiv) bed herein. For example,
in some embodiments, the assay can se: (a) subjecting a test sample of a subject to one or more
than one analyses (e. g., genotyping and/or expression analyses) to determine the presence or absence
of at least one of the following conditions:
i. an expression ratio of s-adenosyl methionine (SAM) to s-adenosyl homocysteine (SAH)
smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4-HNE) greater than a pre-determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID NO: 1 comprising at
least one thymine “T” allele, wherein the SEQ ID NO: 1 is a portion of a genomic nucleic
acid sequence of enetetrahydrofolate reductase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO: 2 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 2 is a n of a genomic c acid sequence of methionine
synthase (MTR); and
v. a SNP at position 66 of SEQ ID NO: 3 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 3 is a portion of a c nucleic acid sequence of methionine
synthase reductase (MTRR); and
if at least one of these conditions is determined to be present, the assay can r comprise selecting
for the human subject and optionally administering to the human subject a treatment regimen
comprising an effective amount of a folate-containing compound.
In some embodiments of this aspect and all other aspects described herein, when the
expression ratio of SAM to SAH is smaller than the pre-determined nce ratio, e.g., smaller than
3.0, or smaller than about 2.8 as ed in a plasma sample, the subject can be recommended for
and/or optionally administered with a treatment regimen comprising a folate-containing compound. In
one embodiment, the expression ratio of SAM to SAH being smaller than 2.71, as ed in a
plasma sample, is indicative of a subject recommended for and/or optionally administered with a
treatment regimen comprising a folate-containing compound. In some embodiments, if the expression
ratio of SAM to SAH is at least or greater than 2.71 as measured in a plasma sample, the subject is not
recommended for nor stered with a treatment n comprising a folate-containing
compound. Depending on the test sample , e.g., a blood sample vs. a buccal sample, the pre-
determined reference ratio for a blood plasma sample can be different from that for, e.g., a buccal
sample.
In some embodiments of this aspect and all other aspects described herein, when the
expression of 4-HNE is greater than the pre-determined reference value, e.g., greater than about 3 mg
per liter, or greater than about 3.2 mg per liter of plasma or higher as ed in a plasma sample,
the subject can be recommended for and/or optionally administered with a treatment regimen
sing a -containing compound. In one embodiment, if the expression of 4-HNE is at least
3.28 mg per liter of plasma as measured in a plasma sample or higher, a subject can be recommended
for and/or ally stered with a ent regimen comprising a folate-containing
compound. In some ments, if the expression of 4-HNE is less than 3.28 mg per liter of plasma
as measured in a plasma sample or lower, the subject is not recommended for nor administered with a
treatment regimen comprising a folate-containing compound. Depending on the test sample source,
e.g., a blood sample vs. a buccal sample, the pre-determined reference value for a plasma sample can
be different from that for, e.g., a buccal sample.
In some embodiments of this aspect and all other aspects described herein, the assay
can further comprise determining if the human subject is obese or not. If the human subject is
determined to be obese, then selecting for the human subject and ally administering to the
human subject a treatment regimen comprising an effective amount of a folate-containing compound.
Methods of determining y in a human subject are known in the art and can include, but are not
limited to, body mass index (BMI) measurement, measurement of abdominal fat (e.g., by waist
circumference or waist-hip ratio), measurement of body fat, skinfold thickess, underwater weighing
(densitometry), air-displacement plethysmography, computerized tomography (CT) and magnetic
resonance imaging (MRI), and dual energy X-ray absorptiometry (DEXA), and any combinations
thereof. For e, in one embodiment, the assay can further comprise measuring body mass index
(BMI) of the human subject to determine if the human subject is obese or not, and if the BMI value of
at least 30 kg/m2 or greater is measured in the subject, then selecting for the human subject and
optionally stering to the human subject a treatment regimen sing an effective amount of
a folate-containing compound. In some embodiments, if the human subject has a BMI value of less
than 30 kg/mz, it may not be ble to recommend or administer to the human t a treatment
n comprising a folate-containing compound.
In some embodiments, the assay can further comprise determining the presence or
absence of a SNP at position 1298 of the SEQ ID NO. 1 comprising at least one cytosine “C” allele,
wherein the presence of the SNP at position 1298 of the SEQ ID NO: 1 comprising at least one
cytosine “C” is indicative of the subject recommended for and optionally administered with a
treatment regimen comprising a folate-containing compound.
In some embodiments, the assay can further comprise determining expression of
high-sensitivity c-reactive protein (hsCRP), wherein the hsCRP expression greater than about 2.3 mg
per liter of plasma, as measured in a plasma , is indicative of the subject recommended for and
optionally administered with a treatment regimen comprising a folate-containing compound. In some
embodiments, if the expression of hsCRP is lower than 2.3 mg per liter of , as measured in a
plasma sample, then the subject is not ended for nor administered with a treatment regimen
comprising a folate-containing compound. Depending on the test sample source, e.g., a blood sample
vs. a buccal sample, the hsCRP expression a plasma sample can be different from that in, e.g., a
buccal .
While detection of the presence of at least one condition (A)-(X) described herein in a
test sample of a human subject with depression is generally sufficient to indicate the human t be
amenable to a treatment regimen comprising an effective amount of a folate-containing compound, in
some embodiments, it can be desirable to detect the presence of at least two conditions, three
ions, four conditions or more ponding to the selected kers in order to select for or
administer to the human subject a treatment regimen comprising an effective amount of a folate-
containing compound. In some ments, if none of these conditions (A) —(X) described herein
occurs in the human subject, the subject is not recommended for a treatment regimen comprising a
folate-containing compound.
Accordingly, in some embodiments of this aspect and all other aspects described
herein, the test sample can be analyzed to determine at least one or at least two, at least three, at least
four, at least five or six of the conditions (A)-(X) provided herein. For example, in some
embodiments, the test sample can be analyzed to determine if the subject has at least the SNPs located
at the positions 677 and 2756 of the MTHFR and MTR loci, tively. In some embodiments, the
test sample can be analyzed to determine if the subject is obese (e.g., whether the subject has at least
the BMI value of at least 30 kg/mz), and at least one or both of the SNPs located at the positions 2756
and 66 of the MTR and MTRR loci, respectively. In some embodiments, the test sample can be
analyzed to determine if the subject is obese (e. g., whether the subject has at least the BMI value of at
least 30 kg/mz), and at least one or both of the SNPs located at the positions 677 and 2756 of the
MTHFR and MTR loci, tively. In other embodiments, the test sample can be analyzed to
determine if the subject has at least the BMI value of at least 30 kg/m2 and the SNP located at the
position 2756 of the MTR locus. In some embodiments, the test sample can be analyzed to determine
if the subject has at least the SAM/SAH ratio smaller than the termined reference ratio and the
SNP located at the position 2756 of the MTR locus. In some embodiments, the test sample can be
analyzed to determine if the subject has at least the 4-HNE expression r than the pre-determined
standard and the SNPs located at the positions 2756 and 66 of the MTR and MTRR loci, respectively.
It is envisioned that any combinations of all the conditions (A)-(X) can be analyzed in the assay as
described herein.
In some embodiments, if at least one or at least two, including at least three or more,
of the conditions ) provided herein are determined to be present in the test sample, a treatment
regimen comprising a folate-containing compound is recommended or selected and optionally
administered to the human subject.
In some embodiments, if the human subject satisfies at least one, including at least
two, at least three or more, of the conditions (A)-(X) described herein (and an tor of a human
subject being obese, e.g., a BMI value of at least 30 kg/m2 or greater), the t can be administered
or prescribed with a folate-containing compound.
Some embodiments of the assays described herein can be included as part of a
treatment strategy, e. g., to select an appropriate treatment regimen for a human subject diagnosed as
having or having a risk for depression. Accordingly, another aspect provided herein relates to methods
of ng a human subject diagnosed as having, or having a risk, for depression. In some
embodiments, a method for treating a human t with depression can comprise ming one or
more embodiments of the assay provided herein. In some ments, if the subject satisfies at least
one of the conditions described in the assay provided herein, the treatment method can further
comprise administering or prescribing the subject with a treatment regimen comprising an effective
amount of a folate-containing compound.
Accordingly, in one embodiment, the method can comprise determining in a test
sample of a human subject parameters of at least two or more (including at least three, at least four, at
least five or more) biomarkers (i) to (xxiv) described herein; and administering to the human subject a
ent n comprising an effective amount of a folate-containing compound, if the presence
of at least one or more (including at least two, at least three, at least four, at least five or more), or any
combinations of the conditions ) bed herein is ed in the test sample.
In particular embodiments, the method can comprise determining in a test sample of a
human subject genotypes of at least two loci at position 677 of SEQ ID NO. 1 (or position 27 of SEQ
ID NO. 7) and at position 2756 of SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9); and
administering to the human subject a treatment regimen sing an effective amount of a folatecontaining
compound if either at least one or both of the following conditions is/are detected: (i) at
least one thymine “T” allele present at position 677 of SEQ ID NO. 1 (or on 27 of SEQ ID NO.
7); and (ii) at least one guanine “G” allele present at position 2756 of SEQ ID NO. 2 (or position 27 of
SEQ ID NO. 9). In these embodiments, the method can further se determining the presence or
absence of any of the conditions ) described herein.
In some embodiments, a method for treating a human subject with depression can
comprise administering a composition comprising an ive amount of a folate-containing
compound to the human subject, who is sed as having, or having a risk for, depression, and is
further determined to carry at least one or more (including at least two, at least three, at least four or
more), or any combinations of the conditions (A)-(X) described herein.
In certain embodiments, the method can se administering a composition
comprising an effective amount of a folate-containing compound to the human subject, who is
diagnosed as having, or having a risk for, depression, and is further determined to carry at least one of
the following SNPs or a combination thereof: (i) a SNP at position 677 of SEQ ID NO. 1 or position
27 of SEQ ID NO. 7 (identified by rs1801133) comprising at least one thymine "T" allele, and (ii) a
SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 sing at least one
guanine "G" allele. In these embodiments, the method can further comprise determining the presence
or absence of any of the conditions (A)-(X) described herein.
In some embodiments, the subject administered with a treatment regimen comprising
a folate-containing compound can be further determined to be obese (e. g., with a BMI value of at least
about 30 kg/m2 or higher).
In some embodiments of this aspect and all other aspects described herein, a folate-
containing nd can be administered in an amount effective to reduce at least one symptom
(e.g., but not limited to, low mood, insomnia, ion, anxiety and/or weight loss) ated with
depression, e.g., major depressive disorders. In some embodiments, the effective amount of a folate-
containing nd can provide at least about 0.1 to about 1 mg/kg body weight per day
administration to the human subject. In some embodiments, the effective amount of a folate-
containing compound can provide at least about 7.5 mg/day to about 50 mg/day administration to the
human subject. In one embodiment, the effective amount of a folate-containing compound can
provide at least about 15 mg/day of folate administration to the human subject.
The effective amount of the folate-containing nd can be administered to a
ed human subject as a single daily dose, or alternatively, in more than one divided doses per day
via any suitable administration route, e. g., oral administration.
The effective amount of folate administered to a ed human subject for ent
of depression as described herein is significantly higher than the typical amount taken as a dietary
supplement (between 50-600 ). In some embodiments, the effective amount of folate
administered to a selected human subject is at least about 2-fold, at least about 5-fold, at least about
-fold, at least about d, at least about 50-fold, at least about lOO-fold, at least about ld,
at least about 500-fold, at least about lOOO-fold or more than the typical amount taken as a dietary
supplement. Accordingly, in some embodiments, the -containing compound is desirable to be
formulated in slow-release or sustained release composition. For example, in one embodiment, the
composition comprising a folate-containing compound can be formulated to release the effective
amount of the folate-containing compound over a period between 3-6 hours or 4-5 hours post-
administration.
Any art-recognized folate-containing compound can be selected and/or optionally
administered to a human subject selected to carry at least one or more conditions (A)-(X) described
. In some embodiments, the folate-containing compound can comprise a L-methylfolate
compound. In one embodiment, the folate-containing nd can se -
methyltetrahydrofolate or a derivative thereof.
In some embodiments of this aspect and all other aspects described , the
treatment regimen can further comprise selecting and optionally administering an antidepressant drug.
In some embodiments, the anti-depressant drug can e a selective serotonin reuptake inhibitor,
including, but not limited to, fluoxetine, citalopram, paroxetine, escitalopram, sertraline, and any
combinations thereof.
In these embodiments, an antidepressant drug can be administered in the same
composition as the folate-containing compound. In alternative ments, the antidepressant drug
and the folate-containing compound can be administered in separate compositions at the same time
(e.g., concurrently) or sequentially (e. g., one after the other), or in any temporal administration
regimen, Where the nt effect of the -containing compound increases the efficacy of the
pressant drug as compared to the efficacy Without the folate-containing compound. In some
embodiments, the anti-depressant drug and/or the folate-containing nd can be administered in
a single dose or in divided doses. The number of dosages administered over a period of time (e.g., per
day) for the antidepressant drug and the -containing compound can be the same or different. The
antidepressant drug and the folate-containing compound can be administered via the same or different
routes.
In some embodiments of this aspect and all other aspects described herein, the
adjuvant effect of the folate-containing compound administered in combination with an antidepressant
drug can be additive.
In some ments of this aspect and all other aspects bed herein, the
adjuvant effect of the folate-containing compound administered in combination with an antidepressant
drug can be synergistic.
A further aspect provided herein is a method of determining and/or improving the
effectiveness of an anti-depressant drug administered to a human subject, e.g., by determining if the
human subject is amenable to folate or a derivative thereof as an nt, e. g., using the assay
described herein. In some ments of this aspect, the method can r comprise stering
or prescribing the subject with a compound containing an ive amount of folate as an nt to
the epressant drug, if the subject satisfies at least one of the conditions (A)-(X) provided herein.
An exemplary effective amount of folate is about 7.5 mg/day to about 50 my day, or in one
embodiment, the effective amount is at least about 15 mg/day. In one embodiment, the epressant
drug is a ive serotonin reuptake inhibitor, for example, without limitations, fluoxetine,
citalopram, paroxetine, escitalopram, sertraline, and any combinations thereof.
Yet another aspect provided herein is a method of improving the effectiveness or
efficacy of an anti-depressant drug taken by a subject, e.g., by identifying the subject with at least one
of the conditions as determined in the assay described herein. Accordingly, in some embodiments of
this aspect, the method can further comprise administering or prescribing the t with a compound
containing an effective amount of folate as an nt to the anti-depressant drug, if the subject
satisfies at least one of the conditions determined in the assay provided herein. An ary
effective amount of folate is at least about 15 mg/day. In one embodiment, the anti-depressant drug is
a selective serotonin reuptake inhibitor, for example, without limitations, fluoxetine, citalopram,
paroxetine, escitalopram, sertraline, and any ations thereof.
Computer systems for use in any aspects of the assays and/or methods described
herein are also provided. For e, one embodiment provided herein is a computer system for
ing data from at least one test sample obtained from at least one subject. The system comprises:
(a) a determination module configured to receive at least one test sample and perform at least one
analysis on at least one test sample to determine parameters of at least two biomarkers (i) to (xxiv)
described herein; (b) a storage device configured to store output data from the determination module;
(c) a computing module, e.g., a non-human machine, comprising specifically-programmed
instructions to determine from the output data the presence of at least one condition (A) to (X)
described ; and (d) a display module for displaying a content based in part on the data output
from the computing module, wherein the content comprises a signal indicative of the presence of at
least one condition (A) to (X) described herein, and optionally the absence of any one of the
conditions (A) to (X) described herein, or a signal indicative of the absence of all of the conditions
(A) to (X) described herein.
In some embodiments, the determination module can be configured to perform at
least one ping analysis on at least one test sample to determine the genotypes of at least two
loci comprising position 677 of SEQ ID NO. 1 (or position 27 of SEQ ID NO. 7) and position 2756 of
SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9). In these embodiments, the computing module can
be configured to determine the presence of at least one SNP located at position 677 of SEQ ID NO. 1
(or position 27 of SEQ ID NO. 7) comprising at least one thymine “T” allele, and/or at position 2756
of SEQ ID NO. 2 (or on 27 of SEQ ID NO. 9) comprising at least one guanine “G” allele.
In another embodiment, the determination module can be configured to perform at
least one analysis on at least one test sample to determine the presence or absence of at least one of
the following conditions:
i. an expression ratio of s-adenosyl methionine (SAM) to s-adenosyl homocysteine (SAH)
smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4-HNE) greater than a pre-determined reference value;
iii. a single tide polymorphism (SNP) at position 677 of SEQ ID NO. 1 (or at position
27 of SEQ ID NO. 7) comprising at least one thymine “T” allele, wherein the SEQ ID
NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate ase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO. 2 (or at position 27 of SEQ ID NO. 9) comprising
at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each
independently a portion of a genomic nucleic acid sequence of methionine se
(MTR); and
V. a SNP at position 66 of SEQ ID NO. 3 (or at position 27 of SEQ ID NO. 10) comprising
at least one e “G” allele, wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are each
independently a portion of a c nucleic acid sequence of methionine synthase
reductase (MTRR).
In these embodiments, the determination module can be further configured to
ine the ce or absence of at least one other condition (A)-(X) described herein. For
example, in some embodiments, the determination module can be further ured to determine
expression of high-sensitivity c-reactive protein (hsCRP). In some ments, the determination
module can be further configured to determine the ce or absence of a SNP at position 1298 of
the SEQ ID NO. 1 comprising at least one cytosine “C” allele.
In some embodiments, the ination module can be configured to analyze at least
one test sample to determine the presence or absence of at least two of the ions provided above.
In some embodiments, the determination module can further comprise a comparison
module adapted to compare the data output from the determination module with reference data stored
on the storage device.
In some embodiments, the storage device can be further configured to store physical
information of at least one subject, for example, comprising indicators of whether a test subject is
obese, e. g., BMI of at least one subject).
In some embodiments, the t yed on the y module can further
comprises the BMI value or a signal indicative of whether the BMI value is at least 30 kg/m2 or not.
In some embodiments, the content displayed on the display module can further comprise a signal
indicative of the subject recommended to receive a treatment regimen comprising a folate-containing
compound, or a signal tive of the subject recommended to receive an alternative treatment
regimen without a folate-containing compound.
A tangible and non-transitory (e.g., not transitory forms of signal transmission)
computer readable medium having computer readable instructions recorded thereon to define re
modules for implementing a method on a computer is also provided herein. In one embodiment, the
computer readable storage medium comprises: (a) instructions for comparing the data stored on a
storage device with reference data to provide a ison result, wherein the comparison identifies
the presence or absence of at least one condition (A)-(X) bed herein; and (b) instructions for
displaying a content based in part on the data output from the determination module, wherein the
content comprises a signal indicative of the presence of at least one of the conditions )
described herein, and optionally the absence of any one of these ions (A)-(X) described herein.
In other embodiments, the content can comprise a signal tive of the absence of all of the
ions (A)-(X) described herein.
In some embodiments, the instructions can be specifically programmed to perform a
comparison to identify the presence of at least one SNP located at position 677 of SEQ ID NO. 1 (or
position 27 of SEQ ID NO. 7) comprising at least one thymine “T” allele, and/or at position 2756 of
SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9) comprising at least one guanine “G” allele.
In other embodiments, the instructions can be specifically mmed to perform a
comparison to identify one of the following conditions:
i. an expression ratio of s-adenosyl methionine (SAM) to s-adenosyl homocysteine (SAH)
smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4-HNE) greater than a pre-determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID NO: 1 comprising at
least one thymine “T” allele, wherein the SEQ ID NO: 1 is a portion of a genomic nucleic
acid sequence of methylenetetrahydrofolate reductase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO: 2 comprising at least one e “G” allele,
wherein the SEQ ID NO: 2 is a portion of a genomic c acid sequence of methionine
synthase (MTR); and
v. a SNP at position 66 of SEQ ID NO: 3 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 3 is a n of a genomic nucleic acid sequence of methionine
synthase reductase (MTRR);
In these embodiments, the computer le medium can further comprise
instructions to identify the presence or e of at least one other condition (A)-(X) bed
herein. For example, in one embodiment, the computer readable medium can r comprise
ctions to identify the presence or absence of a SNP at position 1298 of the SEQ ID NO: 1
comprising at least one cytosine “C” . In some embodiments, the computer readable medium can
further comprise instructions to compare expression of high-sensitivity c-reactive protein (hsCRP)
with the reference data.
In some embodiments, the computer readable medium can further comprise
instructions to determine or calculate if the subject is obese (e.g., whether the subject has BMI of at
least 30 kg/m2 or not), based on input data of the subject’s physical features (e.g., weight and ).
In some embodiments, the er readable medium can further comprise
ctions to display a ement to determine whether a subject is obese (e.g., a BMI value) or a
signal indicative of whether the subject is obese (e.g., whether the BMI value is at least 30 kg/m2 or
not).
In some embodiments, the computer readable medium can further comprise
instructions to display a signal tive of the subject recommended to receive a treatment regimen
sing a folate-containing compound, or a signal indicative of the subject recommended to
receive an alternative treatment n without a folate-containing compound.
Based on the fication of SNPs and/or peripheral markers associated with a
response to the use of a folate-containing compound, one aspect described herein also provides for the
design and preparation of detection reagents needed to identify the SNPs and/or peripheral markers
disclosed herein in a test sample of a subject. For example, the detection reagents can be designed and
prepared to identify SNPs in MTHFR locus and MTR locus and optionally MTRR locus involved in
assays and methods described herein, and/or e expression levels of SAM, SAH and 4-HNE in a
test sample. Examples of detection ts that can be used to identify the sed SNPs in a test
sample can include a primer and a probe, wherein the probe can selectively hybridize the SNP-
containing nucleic acid molecules, as compared to a nucleic acid molecule which does not contain the
SNP at the same tide position. Examples of detection regents that can be used to measure
expression levels of serum or plasma proteins (e. g., SAM, SAH and/or 4-HNE) in a test sample can
include antibodies against such proteins, or a primer and a probe, wherein the probe specifically
hybridizes to a nucleic acid le corresponding to such proteins.
In one embodiment, a kit can comprise an oligonucleotide array affixed with a
plurality of oligonucleotide probes that ogate, e. g., no more than 30 SNPs, wherein the SNPs
comprise at least two or any combinations of the conditions ) described herein (e.g., but not
limited to, a combination of conditions (A) and (C)); and an optional container containing a detectable
label (e.g., comprising a cent molecule) to be conjugated to a nucleotide le derived from
a test sample of a human subject; and at least one reagent. Examples of a reagent that can be included
in the kit can include, without limitations, a restriction enzyme, a universal adaptor to be conjugated
to a nucleotide molecule, a primer complementary to the universal adaptor, a wash agent, and any
ations thereof.
In an alternative embodiment, a kit can comprise a plurality of oligonucleotide
primers that bind to at least one allele of no more than 30 SNPs, wherein each subset of
2012/065084
oligonucleotide primers that bind to a specific allele of a SNP is labeled with a distinct reporter, and
wherein said SNPs se at least two or any combinations of the SNP ions (A)-(U)
described herein (e. g., but not d to a combination of conditions (A) and (C)); and at least one
reagent, e.g., but not limited to, free nucleotide bases, a polymerase, or both.
In some embodiments, the kit can further comprise at least one reagent to determine
sion of at least one biomarker described herein (e.g., SAM, SAH, 4-HNE and hsCRP). For
example, in one embodiment, the kit can further comprise a solid substrate support affixed with at
least one protein-based binding moiety (e. g., an antibody) that ically binds to one or more of the
biomarkers described herein. Exemplary solid substrate support can include, but not limited to, a
microtiter plate for ELISA, a dipstick, a magnetic bead, or any combinations thereof. In another
embodiment, the kit can further comprise at least one primer designed to probe one or more
biomarkers described herein.
The assays, methods, systems and/or kits described herein can be performed and/or
used by a third-party service provider. For e, a third-party service er can provide and
charge for a service offered to determine the presence or absence of at least one ion (A)-(X) in a
test sample of a human subject, e.g., to facilitate selection of a treatment regimen for a human subject
with depression. Accordingly, methods for selecting a treatment regimen for a human subject are also
ed herein. For example, the method comprises (a) obtaining a test sample from a human subject
diagnosed as having, or having a risk, for sion; (b) subjecting the test sample to at least one
analysis to determine parameters of at least two biomarkers (i) —(xxiv) described herein (e. g., but not
limited to, a combination of biomarkers (i) and (iii)); (c) determining, from the parameters of the
selected biomarkers, the presence of at least one condition (A)-(X) (e.g., but not limited to, either one
or both of conditions (A) and (C)); and (d) providing a result output setting forth Whether at least one
of the conditions (A)-(X) is detected in the test sample. If at least one condition is present, the method
can further comprise selecting and ally administering a treatment regimen comprising an
ive amount of a folate-containing compound to the human subject.
In some ments, the step (b) of the method can further comprise ally
packing and shipping the test sample to a test facility, e. g., a third-party CLIA-certified service
provider.
In some ments, the step (d) of the method is performed by a non-human
machine.
The test sample for use in the assays, methods, s or kits described herein can
be derived from a biological sample of the subject, e.g., a blood sample or plasma or serum sample
from the subject. In some embodiments, the test sample can comprise a urine sample. In some
embodiments, the test sample can comprise a buccal sample. In some embodiments, the test sample
can comprise a saliva sample.
If the test sample is a nucleic acid , the test sample can be subjected to at least
one analysis selected from the group consisting of allele-specific probe hybridization, allele-specific
primer extension, allele-specific amplification, sequencing, 5’ nuclease ion, molecular beacon
assay, DNA chip analysis, oligonucleotide ligation assay, size analysis, single-stranded conformation
polymorphism, polymerase chain reaction (PCR), real-time quantitative PCR, and any combinations
thereof.
If the test sample is a protein sample, the test sample can be subjected to at least one
analysis selected from the group consisting of n blot, enzyme linked ance assay, mass
spectrometry, immunoassay, flow cytometry, immunohistochemical analysis, and any combinations
thereof.
A still further aspect provided herein relates to uses of a folate-comprising
composition in the ent of depression in a human subject who carries at least one of the
conditions ) described herein (e.g., but not limited to, either one or both ions (A) and
(C)). r aspect provided herein relates to a folate-comprising composition in combination with
an anti-depressant for use in the treatment of depression in a human subject who carries at least one of
the conditions (A)-(X) bed herein (e. g., but not limited to, either one or both conditions (A) and
(C)). In some embodiments of these aspects described herein, the folate-comprising composition can
se at least about 5 mg of folate (e. g., about 7.5 mg to about 50 mg of ). In some
embodiments, the folate-comprising composition can be formulated for a pre-determined release
profile (e.g., a sustained release). In some embodiments, the human subject is an adult.
Embodiments of s aspects described herein can be employed for use in a
human subject diagnosed as having, or having a risk for, any form of depression. In one embodiment,
various aspects described herein can be employed for use in a human subject diagnosed as having, or
having a risk for, a major depressive disorder. In some embodiments, the human subject can be further
determined to be resistant to at least one anti-depressant monotherapy. In some embodiments, the
human subject is an adult.
In some embodiments, various aspects described herein can be employed for use in a
human subject who is currently taking an antidepressant. In these embodiments, the human subject
who is determined to satisfy at least one (including, e.g., at least two, at least three or more) of the
conditions ) can be selected and/or administered with a ent regimen comprising a folate-
containing compound. In some embodiments, the treatment regimen does not include an
antidepressant. In some embodiments, the treatment regimen can include the same antidepressant that
the human subject is currently taking or a ent antidepressant.
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. lA-lB show schematic diagrams of exemplary study designs of analyzing the
efficacy of a -containing nd, e. g., as an adjunct to a selective serotonin reuptake inhibitor
(SSRI) for treating a t with depression or identifying biomarkers or conditions indicative of a
subject with sion recommended for a treatment regimen comprising a folate-containing
compound and an SSRI. Fig. 1A shows an exemplary study design, in which 7.5 mg/day L-
methylfolate (e. g., 6(S)methyltetrahydrofolate, abbreviated as 6(S)MTHF as bed herein) is
stered as an adjunct to an SSRI. Fig. 1B shows an exemplary study design, in which 15 mg/day
L-methylfolate (e.g., 6(S)MTHF) is administered as an adjunct to an SSRI.
Fig. 2 shows a tic diagram of an exemplary double-blind, placebo-controlled
study of 6(S)MTHF among SSRI-resistant outpatients with major depressive disorder (MDD)
using sequential parallel comparison. As an example, 10% t rate is assumed. The t
response and non-response rates provided in this figure are only meant to indicate the relative efficacy
effect, but do not mean to be construed as or limited by the absolute values of the ted
percentages.
Figs. 3A-3E show s of treating MDD patients with a folate-containing
nd, e.g., as an adjunct to an SSRI in Trial 2. Fig.3A shows the response rates of MDD patients
treated with either a folate-containing compound or a placebo, in conjunction with an SSRI, after 30-
day treatment. A responder is a MDD patient with at least 50% reduction in 7 after
treatment. Fig.3B shows the mean change in scores of various neuropsychological tests (e. g., HDAM-
17, QIDS-SR, and CGI-S) for MDD patients treated with either a folate-containing compound or a
placebo, in conjunction with an SSRI, after 30-day treatment. Fig. 3C shows percents of MDD
patients in remission, as measured by HDAM-l7, after treated with either a folate-containing
compound or a placebo, in conjunction with an SSRI, after 30-day treatment. Fig. 3D shows percents
of MDD patients in remission, as measured by QIDS-SR, after treated with either a folate-containing
compound or a placebo, in conjunction with an SSRI, after 30-day treatment. Figs. 3C—3D show that
remission rates after 30 days of adjuvant 15 mg/day L-methylfolate and an SSRI, compared to
placebo and the SSRI, was not significant in depressed patients who inadequately respond to SSRI
monotherapy. Fig. 3E shows percent of MDD patients discontinued from Trial 2, indicating no
significant difference in discontinuation rates due to overall adverse events.
Figs. 4A-4B show effects of a single genetic polymorphism (SNP) in the MTHFR
gene (MTHFR C677T) on the efficacy of the treatment comprising a folate-containing compound
(e. g., 6(S)MTHF) and ally an SSRI in a patient with depression. Fig. 4A shows cy
results as measured by 8 (28-item Hamilton Depression Rating Scale). Fig. 4B shows
efficacy results as measured by CGI-S (Clinical Global Impression-Severity).
Figs. 5A-5B show s of obesity (i.e., BMI is at least 30 kg/m2 or above) on the
efficacy of the treatment comprising a -containing compound (e. g., 6(S)MTHF) and
optionally an SSRI in a patient with sion. Fig. 5A shows efficacy results as measured by
HAMD-28 (28-item Hamilton Depression Rating Scale) with a chi-square of 3.94 for the treatment
WO 74676
effect. Fig. 4B shows efficacy s as measured by CGI-S (Clinical Global Impression-Severity)
with a chi-square of 10.03 for the treatment .
Fig. 6 is a block diagram showing an exemplary system for use in the s
described here, e.g., for selecting a treatment n for a subject with depression.
Fig. 7 is an exemplary set of instructions on a computer readable storage medium for
use with the systems described .
Figs. 8A-8B show mean changes in HAMD-28 in MDD patients ng at least one
rare variant on the indicated gene, as opposed to fully normal on the respective gene, when they were
treated with a folate-containing compound, e.g., as an t to an SSRI. Fig. 8A is a bar graph
showing the mean change in HAMD-28 with respect to various SNP biomarkers as indicated. Fig. 8B
is a table showing the results as shown in Fig. 8A and the corresponding loci in chromosomes. The
term “prevalence” as used in Fig. 8B refers to the total tage of MDD patients who carry the
SNP as indicated in this particular study.
Figs. 9A-9C are result tables g effects of the presence or absence of an
indicated condition, in MDD patients on the degree of depression, when the patients were treated with
a treatment regimen comprising a folate-containing compound. The degree of depression was
measured by Social Functioning Questionnaire (SFQ), Visual Analogue Scale (VAS), and Cognitive
and Physical Function Questionnaire (CPFQ). Fig. 9A shows analyses on all samples. Fig. 9B shows
analyses in biomarker subgroups. Fig. 9C shows analyses in genetic subgroups.
Figs. 10A-10E are result tables showing effects of the presence or absence of an
indicated ion, in MDD patients on the degree of sion, when the patients were treated with
a folate-containing compound (treatment group) or without a folate-containing compound (placebo
group). The degree of depression was measured by Maier or HAMD-7 le of HAMD. Fig. 10A
shows results of Maier SPCD. Fig. 10B shows Maier means. Fig. 10C shows HAMD-7 SPCD.
Fig. 10D shows HAMD-7 means. Fig. 10E shows a summary of the biomarker and genetic analyses
on Maier scale.
ED DESCRIPTION OF THE INVENTION
Recent estimates indicate that more than 19 million Americans over the age of 18
years experience a depressive illness each year. While significant advances in the treatment of
depression have been made in the past , as many as 29% to 46% of patients with depression
taking an anti-depressant are still partially or totally resistant to the treatment. Those who suffer from
treatment-resistant depression have almost no alternatives. As not every treatment regimen is effective
for each individual, there is a strong need to identify markers that can facilitate selection of an
appropriate treatment regimen for a human t with depression
In accordance with aspects of various embodiments described herein, at least 21
single nucleotide polymorphisms (SNPs) and 4 peripheral biomarker ters have been discovered
for predicting the effectiveness or efficacy of a treatment regimen comprising a folate-containing
compound. That is, these SNPs and serum/plasma biomarker parameters can be used to fy
subjects with depression that would t from or d to a treatment regimen comprising a
folate-containing compound, as compared to a treatment without a folate-containing compound. In
particular, these SNPs and serum/plasma biomarker parameters can be used to identify a subject with
treatment-resistant depression (e.g., a subject resistant to at least one selective serotonin reuptake
inhibitor (SSRI)) who would benefit from or respond to a treatment regimen comprising a folate-
containing compound, as compared to a treatment without the folate-containing compound. The
folate-containing compound can be stered in the absence of an anti-depressant drug, or it can
be provided as an adjuvant to an antidepressant drug. In some ments, the adjuvant effect of the
folate-containing compound administered in combination with an antidepressant drug can additive. In
other embodiments, the adjuvant effect of the folate-containing nd administered in
combination with an antidepressant drug can be synergistic.
Specifically, the SNPs that can predict efficacy of administering to a human subject a
folate-containing compound (e.g., alone or in a combination therapy to increase the efficacy of an
antidepressant) for treatment of depression include at least one or a combination of SNPs identified by
rs numbers as s: rs1801133 present in methylenetetrahydrofolate reductase (MTHFR);
976 present in MTHFR; rs1805087 present in methionine synthase (MTR); rs1801394 present
in methionine se reductase (MTRR); rs1006737 present in calcium channel, voltage-dependent,
L-type, alpha 1C subunit (CACNAIC); rs1883729 present in DNA (cytosine-5)-methyltransferase 3
beta (DNMT3B); rs7163862 present in GTP cyclohydrolase 1 feedback regulatory protein (GCHFR);
rsl2659 present in reduced folate carrier protein (RCF2); rs202676 present in folate ase
(prostate-specific membrane antigen) (FOLHl); rs229729l present in reduced folate carrier protein
(RCFl); rs1051266 present in reduced folate carrier protein 1 (RCFl); rs8007267 present in GTP
cyclohydrolase l (GCHl); rs7639752 present in choline-phosphate cytidylytransferase A (PCYTlA);
rs6275present in dopamine receptor D2 (DRD2); rs1079596 t in DRD2; rsl 1240594 present in
DRD2; rs4633 present in catechol-O-methyltransferase ; rs4680 present in COMT; rs250682
present in dopamine active orter (DAT, or SLC6A3); rs2277820 present in
inotransferase cyclodeaminase (FTCD); 225 present in methylenetetrahydrofolate
dehydrogenase (NADP+ dependent) l (MTHFDl); and any combinations thereof.
Further, peripheral biomarker ters that can predict cy of administering to
a human subject a folate-containing compound (e.g., alone or in a combination therapy to increase the
efficacy of an antidepressant) for treatment of depression include ve expression levels between s-
adenosyl nine (SAM) and s-adenosyl homocysteine (SAH), expression of 4-hydroxynonenal
(4-HNE), expression of high-sensitivity c-reactive protein (hsCRP), and any combinations thereof.
Additionally, obesity has also been discovered to be predicative of effectiveness of a treatment
regimen comprising a folate-containing compound (e.g., as a erapy or a ation therapy
with an antidepressant). These genetic polymorphisms, eral biomarkers and clinical features
2012/065084
have been assessed on a human cohort, who has major depressive disorder and has shown resistance
to anti-depressant monotherapies, e.g., has treatment-resistant depression (TRD), in ular,
selective serotonin reuptake inhibitor (SSRI)-resistant sion.
Accordingly, some embodiments described herein are generally related to assays,
methods, systems or kits for selecting a ent n for a subject with depression or identifying
a subject with depression amenable for, or responsive to a treatment comprising a folate-containing
compound. In some embodiments, the treatment can comprise a combination of a folate-containing
compound and an antidepressant drug. In one embodiment, the assays, methods, systems and kits are
directed to determining in a test sample from a human subject, e.g., a human subject sed as
having, or having a risk for sion (e.g., but not limited to, major sive er) the
presence or absence of at least one of single tide polymorphisms (SNPs) and/or peripheral
biomarker parameters to t the response of a subject to a treatment comprising a folate-
containing compound. If at least one of the conditions described herein is determined to be present in
the test sample from the human subject, a treatment regimen comprising a folate-containing
compound can be selected and optionally administered to the human subject. In some embodiments,
the treatment regimen can further comprise an anti-depressant drug (e.g., an SSRI) to be administered,
separately or concurrently, with a folate-containing compound.
Assaysfor selecting a treatment regimenfor a human subject with depression
Accordingly, provided herein generally relate to assays, methods, systems, and kits
for selecting a treatment n for a subject with depression or a risk for depression; for treating a
t with depression or a risk for depression, and/or for improving the effectiveness of a treatment
regimen recommended for and/or administered to a subject with sion or a risk for depression.
Provided herein also relate to folate-comprising compositions for use in treatment of depression in a
subject (e.g., a human subject) selected to carry at least one (e.g., at least two or more) or any
combinations of the biomarkers or conditions described herein.
One aspect described herein provides an assay for selecting a treatment regimen for a
subject with depression, by identifying in a test sample from the subject pes of at least one of
the SNPs and/or expression of at least one peripheral biomarker as described herein in order to
determine the responsiveness of the human subject to a treatment regimen comprising a folate-
containing compound. The assay comprises:
(a) subjecting a test sample of a human subject, who is diagnosed as having depression or having a
risk for depression, to at least one analysis to determine ters of at least two (including, e.g., at
least three, at least four, at least five or more) of the biomarkers (i) to (xxiv):
(i) genotype of a SNP locus at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
(identified by rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each
2012/065084
independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate
reductase (MTHFR);
(ii) genotype of a SNP locus at position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO.
8 (identified by rs2274976), wherein the SEQ ID NO. 1 and SEQ ID NO. 8 are each
independently a portion of a genomic nucleic acid sequence of MTHFR;
(iii) genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 (identified by 087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each
independently a portion of a genomic nucleic acid sequence of methionine synthase
(MTR);
(iV) pe of a SNP locus at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO.
(identified by rs1801394), wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are each
ndently a portion of a c nucleic acid sequence of methionine synthase
reductase (MTRR);
(V) genotype of a SNP locus at on 27 of SEQ ID NO. 11 (identified by rs1006737),
wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of calcium
channel, voltage-dependent, L type, alpha 1C subunit (CACNAlC);
(Vi) genotype of a SNP locus at position 27 of SEQ ID NO. 12 (identified by rs1883729),
wherein the SEQ ID NO. 12 is a portion of a genomic c acid sequence of DNA
(cytosine-5)-methyltransferase 3 beta (DNMT3B);
(Vii) genotype of a SNP locus at position 27 of SEQ ID NO. 13 (identified by rs7163862),
wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence of GTP
cyclohydrolase 1 feedback regulatory protein (GCHFR);
(Viii) genotype of a SNP locus at on 27 of SEQ ID NO. 14 (identified by rs12659),
wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of reduced
folate carrier protein ;
(ix) genotype of a SNP locus at position 27 of SEQ ID NO. 15 (identified by rs202676),
wherein the SEQ ID NO. 15 is a portion of a c nucleic acid sequence of folate
hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
(x) genotype of a SNP locus at position 27 of SEQ ID NO. 16 ified by 291),
wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of reduced
folate carrier protein (RCFl);
(xi) genotype of a SNP locus at position 27 of SEQ ID NO. 17 ified by rs1051266),
wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid sequence of reduced
folate carrier protein (RCFl);
(xii) genotype of a SNP locus at position 27 of SEQ ID NO. 18 (identified by rs8007267),
wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence of GTP
ydrolase 1 (GCH1);
(xiii) genotype of a SNP locus at position 27 of SEQ ID NO. 19 (identified by rs7639752),
wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid ce of choline-
phosphate cytidylyltransferase A (PCYT1A);
(xiv) pe of a SNP locus at position 27 of SEQ ID NO. 20 (identified by rs6275),
wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
(xv) genotype of a SNP locus at position 27 of SEQ ID NO. 21 (identified by rs1079596),
wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
(xvi) genotype of a SNP locus at position 27 of SEQ ID NO. 22 (identified by 0594),
wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
(xvii) genotype of a SNP locus at position 27 of SEQ ID NO. 23 (identified by rs4633),
wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of ol-
O-methyltransferase (COMT);
(xviii) genotype of a SNP locus at position 27 of SEQ ID NO. 24 (identified by rs4680),
wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-
yltransferase (COMT);
(xix) genotype of a SNP locus at position 27 of SEQ ID NO. 25 ified by rs250682),
n the SEQ ID NO. 25 is a portion of a c nucleic acid sequence of solute
carrier family 6 (neurotransmitted transported, dopamine), member 3 (SLC6A3);
(xx) genotype of a SNP locus at position 27 of SEQ ID NO. 26 (identified by rs2277820),
wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of
formiminotransferase cyclodeaminase (FTCD);
(xxi) genotype of a SNP locus at position 27 of SEQ ID NO. 27 (identified by rs2236225),
n the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
enetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1));
(xxii) level of expression of SAM and SAH;
(xxiii) level of expression of 4-HNE;
(xxiv) level of expression of hsCRP; and any combinations f; and
(b) detecting, optionally with a non-human machine, from the determined ters of at least two
biomarkers, the presence of at least one condition (including, e.g., at least two conditions, at least
three conditions, at least four conditions or more) ed from the ing conditions (A)-(X):
(A) a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by
rs1801133) sing at least one thymine "T" allele;
(B) a SNP at position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8 (identified by
rs2274976) comprising at least one alanine "A" allele;
(C) a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by
rs1805087) comprising at least one guanine "G" allele;
(D) a SNP at on 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 (identified by
rs1801394) comprising at least one e "G" allele;
(E) a SNP at position 27 of SEQ ID NO. 11 (identified by rs1006737) comprising at least one
alanine "A" allele;
(F) a SNP at position 27 of SEQ ID NO. 12 ified by 729) comprising at least one
alanine "A" allele;
(G) a SNP at position 27 of SEQ ID NO. 13 (identified by rs7163862) comprising at least one
thymine "T" allele;
(H) a SNP at position 27 of SEQ ID NO. 14 (identified by rs12659) comprising at least one
thymine "T" allele;
(I) a SNP at position 27 of SEQ ID NO. 15 (identified by rs202676) comprising at least one
guanine "G" allele;
(J) a SNP at position 27 of SEQ ID NO. 16 (identified by rs2297291) comprising at least one
alanine "A" ;
(K) a SNP at position 27 of SEQ ID NO. 17 (identified by at 266) comprising at least
one alanine "A" allele;
(L) a SNP at position 27 of SEQ ID NO. 18 (identified by rs8007267) comprising at least one
thymine "T" allele;
(M) a SNP at position 27 of SEQ ID NO. 19 (identified by rs7639752) comprising at least one
e "A" allele;
(N) a SNP at position 27 of SEQ ID NO. 20 (identified by rs6275) comprising at least one
thymine "T" allele;
(0) a SNP at position 27 of SEQ ID NO. 21 (identified by rs1079596) comprising at least one
thymine "T" allele;
(P) a SNP at position 27 of SEQ ID NO. 22 (identified by rs11240594) sing at least
one alanine "A" allele;
(Q) a SNP at position 27 of SEQ ID NO. 23 (identified by ) comprising at least one
cytosine "C" allele;
(R) a SNP at position 27 of SEQ ID NO. 24 (identified by ) comprising at least one
guanine "G" allele;
(S) a SNP at position 27 of SEQ ID NO. 25 (identified by rs250682) comprising at least one
cytosine "C" allele;
(T) a SNP at position 27 of SEQ ID NO. 26 (identified by rs2277820) comprising at least one
thymine "T" allele;
(U) a SNP at position 1958 of SEQ ID NO. 27 (identified by rs2236225) comprising at least
one alanine "A" allele;
(V) an expression level ratio of SAM to SAH smaller than a pre-determined reference ratio;
(W) an expression level of 4-HNE greater than a pre-determined reference value;
(X) an expression of hsCRP greater than about 2.3 mg per liter as measured in a plasma
sample; and any combinations f.
In some embodiments of this aspect and all other aspects described herein, any of the
SNPs described herein can comprise one or two folate-respsonive alleles. By way of example only, a
SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133) can
comprise one e "T" allele, or two thymine “T” alleles. Without wishing to be bound by theory,
a human subject determined to carry two folate-responsive alleles in a SNP locus described herein can
show greater se to a treatment regimen comprising a folate-containing compound than a human
subject with one folate-responsive allele in the same SNP locus.
ing on the design of primers and probes, the SNP conditions (A)-(U) can be
also represented by alleles complementary to the ponding folate-responsive alleles described
herein. For example, instead of detecting the presence of a SNP at on 677 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 7 (identified by rs1801133) comprising at least one thymine "T" allele,
one of skill in the art can readily design primers and/or probes for the complementary sequence of
SEQ ID NO. 7 to probe for a SNP at the same location comprising at least one “A” allele instead.
Accordingly, in some embodiments of this aspect and all other aspects described herein, the ce
of at least one condition (including, e. g., at least two conditions, at least three conditions, at least four
conditions or more) selected from the ions (A)-(U) can be indicated by detecting the presence of
the complementary allele of the folate-responsive allele as shown above and also in Table 42 below.
Based on the analysis results from step (b), if at least one of the conditions (A)-(X)
described above is detected, the assay can further comprise selecting for the human subject and
ally administering to the human subject a treatment regimen comprising an effective amount of
a folate-containing compound.
Any combinations of at least two kers (i) to (xxiv) described herein can be
determined in a test sample for the assays described herein. Exemplary combinations of at least two
biomarkers described herein can comprise genotypes of at least two SNP loci or more (e.g., including
at least three SNP loci, at least four SNP loci, at least five SNP loci or more); or genotype of at least
one SNP loci or more (e.g., including at least two SNP loci or more) and sion level of at least
one peripheral biomarker or more (e. g., 4-HNE, SAM, SAH); or sion level of at least two
peripheral biomarkers (e. g., 4-HNE, SAM, SAH). ing upon selected combinations of at least
two biomarkers described , the test sample can be subjected to one or more es, e. g.,
including, but not limited to, genotyping assays, sion assays (e. g., protein and/or transcript
levels), or any combinations thereof.
Accordingly, in some embodiments, the assay can comprise ting a test sample
from a human subject, who is diagnosed as having depression or having a risk for depression to at
least one genotyping assay adapted to determine genotypes of at least two loci, wherein said at least
two loci are: (i) position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by
133) and (ii) position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by
rs1805087). In such embodiment, detection of at least one SNP at either position 677 of SEQ ID NO.
1 (or position 27 of SEQ ID NO. 7) sing at least one thymine “T” allele or position 2756 of
SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9) comprising at least one guanine “G” allele, or
detection of both aforementioned SNPs indicates selection and optional administration of a treatment
regimen comprising an effective amount of a folate-containing compound to the human subject.
In some embodiments, the test sample can be subjected to at least one genotyping
assay adapted to determine genotypes of at least three loci, at least four loci, at least five loci, at least
six loci, at least seven loci, at least eight loci, at least nine loci, at least ten loci or more. The
onal loci to be interrogated can be selected from any combinations of the biomarkers (i)-(xxi).
In some embodiments, the ping assay can comprise the step of amplifying the
test sample with a set of primers flanking any one of the SNPs described herein. In some
embodiments, at least two (e. g., at least three, at least four, at least five or more) sets of primers
amplifying at least two (e. g., at least three, at least four, at least five or more) of the SNPs can be used
in a multiplex amplification assay.
In some embodiments, the test sample can be subjected to ine parameters of at
least three, at least four, at least five or more biomarkers (i) to (xxiv) described herein. For example,
in some embodiments, the assay can comprise: (a) subjecting a test sample of a subject to one or more
than one analyses (e. g., genotyping and/or expression analyses) to determine the presence or e
of at least one of the following conditions:
i. an expression ratio of osyl methionine (SAM) to s-adenosyl homocysteine (SAH)
smaller than a termined reference ratio;
ii. expression of 4-hydroxynonenal ) greater than a pre-determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID NO: 1 (or at position
27 of SEQ ID NO. 7) comprising at least one thymine “T” allele, wherein the SEQ ID
NO: 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase );
iv. a SNP at position 2756 of SEQ ID NO: 2 (or at position 27 of SEQ ID NO. 9) comprising
at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each
independently a portion of a genomic nucleic acid sequence of methionine synthase
(MTR); and
v. a SNP at position 66 of SEQ ID NO. 3 (or at position 27 of SEQ ID NO. 10) comprising
at least one guanine “G” , wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are each
independently a n of a genomic nucleic acid sequence of methionine synthase
reductase (MTRR).
In these ments, detection of the presence of at least one of these conditions is
indicative of the subject recommended for a ent regimen comprising a folate-containing
compound. In some embodiments, if none of the conditions described herein is present, the subject is
not recommended for a treatment regimen comprising a -containing compound.
In some ments of this aspect and all other aspects described herein, when the
expression ratio of SAM to SAH is smaller than the pre-determined reference ratio, e.g., r than
3.0, or smaller than about 2.8 as measured in a plasma sample, the subject can be recommended for
and optionally administered with a treatment regimen comprising a folate-containing compound. In
one embodiment, the expression ratio of SAM to SAH being smaller than 2.71 (as measured in a
plasma sample) is indicative of the subject recommended for and ally administered with a
treatment regimen comprising a folate-containing compound. In some embodiments, if the expression
ratio of SAM to SAH is at least or greater than 2.71 as measured in a plasma , the subject is not
recommended for nor stered with a treatment regimen comprising a folate-containing
compound. ing on the test sample source, e.g., a blood sample vs. a buccal sample, the pre-
determined reference ratio for a blood plasma sample can be different from that for, e.g., a buccal
sample.
In some embodiments of any aspects described herein, when the expression of 4-HNE
is greater than the pre-determined reference value, e.g., greater than about 3 mg/L, or greater than
about 3.2 mg per liter (as ed in a plasma sample), the subject can be recommended for and
optionally administered with a treatment regimen comprising a -containing compound. In one
embodiment, the expression of 4-HNE of at least 3.28 mg per liter or higher (as measured in a plasma
sample) is indicative of a subject recommended for and optionally administered with a treatment
regimen comprising a folate-containing compound. In some embodiments, if the expression of 4-HNE
is less than 3.28 mg per liter of plasma as measured in a plasma sample or lower, the subject is not
recommended for nor administered with a treatment regimen comprising a folate-containing
compound. Depending on the test sample source, e.g., a blood sample vs. a buccal sample, the pre-
determined reference value for a plasma sample can be different from that for, e.g., a buccal sample.
In some embodiments of this aspect and all other aspects bed herein, the assay
can further comprise ining if the human subject is obese or not. If the human t is
determined to be obese, then the human subject is selected for and optionally administered with a
treatment regimen comprising an effective amount of a folate-containing compound. Methods of
determining y in a human subject are known in the art and can include, but are not limited to,
body mass index (BMI) measurement, measurement of abdominal fat (e.g., by waist circumference or
waist-hip ratio), measurement of body fat, ld thickess, underwater weighing (densitometry), air-
displacement plethysmography, computerized tomography (CT) and magnetic resonance imaging
(MRI), and dual energy X-ray absorptiometry (DEXA), and any combinations thereof.
y can be defined clinically in different ways. For example, obsesity can be
defined by a body mass index (BMI) value of at least about 30 kg/m2 or higher. In another
embodiment, ty can be d by excessive abdominal fat (e.g., indicated by wasit
ference and/or waist-hip ratio). For example, excess abdominal fat can be clinically defined as
a waist circumference > 40 inches (>102 cm) in men and >35 inches (>88 cm) in women.
Alternatively, abdominal obesity can be defined as a waist—hip ratio above 0.95 for males and above
0.80 for females. In some embodiments, obesity can be defined by body fat percentage, e. g., obesity is
defined as a body fat tage of at least about 32% or more in women and at least about 25% or
more in men.
In one embodiment, measurement of BMI can be used to determine whether a human
t is obese. In such embodiment, the assay can further comprise ing body mass index
(BMI) of the human subject to determine if the human subject is obese or not, and if the BMI value of
at least 30 kg/m2 or greater is measured in the subject, then ing for the human subject and
optionally administering to the human subject a treatment regimen comprising an effective amount of
a folate-containing compound. In some embodiments, if the human subject has a BMI value of less
than 30 kg/mz, it may not be ble to recommend or administer to the human subject a treatment
regimen comprising a folate-containing compound.
In some embodiments, the assay can further comprise determining the presence or
absence of a SNP at position 1298 of the SEQ ID NO: 1 comprising at least one cytosine “C” ,
wherein the presence of the SNP at position 1298 of the SEQ ID NO: 1 comprising at least one
cytosine “C” is indicative of the subject recommended for and/or administered with a treatment
regimen comprising a folate-containing compound.
In some ments, the assay can further comprise determining expression of
ensitivity c-reactive protein (hsCRP), wherein the hsCRP expression greater than about 2.3 mg
per liter (as measured in a plasma sample) is indicative of the subject recommended for a treatment
regimen comprising an epressant drug and a folate-containing compound. In some
embodiments, if the expression of hsCRP is lower than 2.3 mg per liter of plasma, as ed in a
plasma sample, then the subject is not ended for nor administered with a treatment regimen
comprising a folate-containing compound. Depending on the test sample source, e. g., a blood sample
vs. a buccal sample, the hsCRP expression a plasma sample can be different from that in, e.g., a
buccal .
In some embodiments of the assay described herein, a test sample can be analyzed to
determine at least one or at least two, at least three, at least four, at least five, at least six of the
conditions provided herein. For example, in some embodiments, the test sample can be analyzed to
determine if the subject has at least the SNPs located at the positions 677 and 2756 of the MTHFR
and MTR loci, respectively. In some embodiments, the test sample can be analyzed to determine if the
subject is obese (e. g., whether the subject has at least the BMI value of at least 30 kg/mz), and the
SNPs located at the positions 2756 and 66 of the MTR and MTRR loci, respectively. In other
embodiments, the test sample can be analyzed to ine if the subject is obese (e.g., whether the
subject has at least the BMI value of at least 30 kg/mz) and the SNP located at the position 2756 of the
MTR locus. In some embodiments, the test sample can be analyzed to determine if the subject has at
least the SAM/SAH ratio smaller than the pre-determined reference ratio and the SNP located at the
position 2756 of the MTR locus. In some embodiments, the test sample can be analyzed to determine
if the subject has at least the 4-HNE sion greater than the pre-determined reference value and
the SNPs located at the positions 2756 and 66 of the MTR and MTRR loci, tively. As sed
previously, any combinations of one or more of the conditions (A)-(X) described herein can be
assayed at the same time or at different times.
] In some embodiments, if at least one or at least two, including at least three or more,
of the conditions provided herein are determined to be present in the test sample of a human subject, a
treatment regimen comprising a folate-containing compound is selected and optionally administered
to the human t.
In some embodiments, if the human subject ies at least one, including at least
two, at least three or more, of the conditions (A)-(X) described herein (and obesity, e.g., defined by a
BMI value of at least 30 kg/m2 or greater), the subject can be administered or prescribed with a
treatment regimen comprising a folate-containing nd.
In some embodiments, the treatment regimen can further se an anti-depressant
drug (e.g., an SSRI) to be administered in combination (e. g. rently or tely) with a folatecontaining
compound.
In some embodiments, the folate-containing compound can comprise a L-
methylfolate nd. In one embodiment, the folate-containing compound can comprise -
methyltetrahydrofolate or a derivative f.
The assays, methods, systems and/or kits described herein can be performed and/or
used by a third-party service provider. For example, a third-party service provider can provide and
charge for a service offered to determine the presence or absence of at least one condition (A)-(X) in a
test sample of a human subject, e.g., to facilitate selection of a treatment regimen for a human subject
with depression. Accordingly, methods for selecting a treatment regimen for a human subject are also
provided herein. For example, the method comprises (a) obtaining a test sample from a human subject
diagnosed as having, or having a risk, for sion; (b) subjecting the test sample to at least one
analysis to ine parameters of at least two biomarkers (i) —(xxiv) described herein (e.g., but not
limited to, a combination of biomarkers (i) and (iii)); (c) determining, from the parameters of the
selected biomarkers, the presence of at least one condition (A)-(X) (e.g., but not limited to, either one
or both of conditions (A) and (C)); and (d) providing a result output setting forth whether at least one
of the conditions (A)-(X) is detected in the test sample. If at least one ion is present, the method
can further comprise selecting and optionally administering a treatment n comprising an
effective amount of a folate-containing compound to the human t.
In some embodiments, the step (b) of the method can further comprise optionally
packing and shipping the test sample to a test facility, e.g., a third-party CLIA-certified service
provider.
In some embodiments, the step (d) of the method is performed by a non-human
machine.
Folate-Responsive Biomarkers (i)-(xxiv) and associated conditions (A)-(X) tive of a treatment
regimen comprising afolate-containing compound
Table 4lA-41B below indicates folate-responsive biomarkers (i)-(Xxiv) and
associated conditions (A)-(X), the presence of at least one of which in a test sample of a human
subject diagnosed as , or having a risk for, depression, indicates a treatment regimen
comprising a folate-containing nd be selected for and optionally administered to the human
subject.
Next page shows Table 41A: Folate-responsive biomarkers (i)-(xxi) used in assays,
methods, systems and kits described herein, and corresponding folate-responsive conditions (A)-(U).
The ces of human origin shown in Table 41A ding complementary sequences thereof)
can provide a basis for designing primers and probes for interrogation of the SNP biomarkers
bed herein.
WO 74676
«3 5 3:3me r:\V
.§ “mm
3me§3¥¢§3 EngEguwa Emma
fig?» wbmuasamfi Eu“
gawfiu 355mm
«5»:
,mfiuvm
nahxu 3.“ n”
.rv‘t31%.».
“fig“:
flak». {.Nsw.)3‘ .
umxofi‘muafia .mdwhw‘wmuflakum.» 3x
Ewfimafiwm (\ “Hawk“?
«Amman». naufin kmfififiw
UEN‘ wwuhhuxwwgufihut
fikfigb‘bn
.009
mummaaamgfiqmaw .wh .\
. UV
. “Nwmmuuuwmwfiwghnfiumfighuu ‘3.
V muvnxmm8&umfixm§uwwfituuww (hmimwo ‘hfiumwbfihfi m» ‘nfwtiwu.3 “.3.me {fiangufiwééufing Uuwwwfimfiwwgfiwwmfih&%flwwwfi§
36,3me Mr. ma ,
, .\
« ‘ «5%
fimamvwmxmuvflnwhfir .
‘$34. .
,. 1.1“,th
7:13. .1
3 uwxawnhum. u
no... “3% N. ‘
\ hfiufidmwmmfiwbfikfimufi Mngucwfi‘wmfifiuh. «brow 9t?1‘
figmhywfig <
xumi‘LSo : firm» :
r $3.
«tr Vfiwcwwefiwmhuuu
{U \...:,N.» Hamish kmfikmfindnfiufiwwfidhn‘mfiw fluxuuufiugfiuibfipufiufi w ‘gfixfiflfi
,6me
”Ema 3%:me
Table 41B: Folate-responsive biomarkers (xxii)-(xxiv) used in assays, methods,
s and kits described herein, and corresponding folate-responsive conditions ).
ker Peripheral Condition
_ ,_
, . . -respcnswe condition7
(dentmer biomarker_ ,identifier_ ‘
SAM, SAH expression ratio of SAM :0 BAH >5 3 prefleiarméned reference r3150
xxiii expression ievel of 4~HNE > a predetermined reference value
mm; hsCRP expresmm m" [KEG-2P :> 2“3 mgf‘L a2: measure-3‘ in a plasma sample
Table 42: Combinations of various folate-responsive biomarkers (i)-(xxv) used in
assays, methods, systems and kits described herein. See Tables 4lA-41B for additional information of
folate-responsive biomarkers (i)-(xxiv).
F0:RN<I(Q§QH$KUE . _ .: . . . . .
, a. , ,
l :4 :z. N v u: w mu 1: x u m aw) an: 11‘; w. mm. mm: XJX xx x.“ xxx:_ xx“.a
, . 4.. _
um am [99.“
bcwnsrksr «2(2an. _ _ .
3' I .\ I 4 .4 x x < x 4 .1 x :- .~, 3: .x .\ r. z 3 4 z. x a.
g, 1. ‘4 \ \ \‘ x y u x x x t. 7' x x /_ 'z' \ 3 .1 '\‘ .x , 3
iii < >: r: :r > z. 4 l 7 x :- x x -: :x’ a \- < :- :r x > x -. :6
iv 3 r. .\ I. I. x x .< x 4 A .\ :c r, x .\ .\ 4 4 3 .4 I, x <
v I. \' 7. \ V x y w: x \‘ x z 7 u: x x. 7' x .\ z ’x .\ l .\
'ri x z; x z 4 I. 1‘, x x I :v: x .x 3‘: x. x V I z x /_ :v' x 7,
vi: r \- x -c ( < x x x a : ;v :v a x .V :- q ..- .V x u 2- -
vit: ,4 x < > ,\ 3 .\ .x 7x, ,\ x x a x n 4 4 > x .4 .\ A a .\,
2E x z x z z y 1 x x 7 x x x x *x x \‘ 7 7 x 7. :v x '1’
) 3‘ K 3 f if < X X 'K i .1 '1 F 2 X )1 :- i K' F X E )- \'
.\:i x x \- x x r L» : :- x x u x u x- ‘- 3‘ x x l a: x .. >‘
xii .\ r, ,\ r: a .t. .-'. x .4 ;< 4 .\ 3a a ;< .\ .\ I. I. ,x ,1 I. x 3.
xiii 7. \' z w < x x x ‘\‘ x < c 7 z N z r »: x 2 x x I .\’
xiv < x c r m :< :~ : :- :1 3‘ x x x a s e r > .x ‘ x x K >
xv X r. X a a :1. .a. x 4 :4 A x .\’ x ;< x x A z x l x :v. \ 7.
mi 7 >4 y \‘ \‘ \‘ \- >‘ c x »: .4 *1 -, y < \’ 2 x w l \’
xvii V 7' \‘ :1 :1 y .4 v; v 2 :a x \- \’ x '1 \‘ :a 7 \- 7 ’x x 7'
map > -: > -< -< .4 .x‘ K x x < t: .w 3‘ x :v < -; , ac a: > a
x24 x x a x x .\‘ .V .V .x x ,\ x .1. 7. x x I. 7. .V .r. x x r x
x: x- y < :x :x v I x 7 2 > >: x < x 2 \- \~ > x , x \ >1
nxi )- .4 x -: >1 .4 x x < x 4 «a n s- : x .\ .k 4 -; 4 L: ) q
sxii .c x : m x .x , r :- :1 a x x -; x z w 4 r > x a, .x
viii \’ 2 x z x 2 I. m: t x a y x x 1-1 \’ V a a \ 1 x v
:23»; 7 a: > x x \’ x x \' x ‘: x : :-' 2 x 7 > ‘1 >4 ’\‘ v. <
3m (8m) \- y < :r >' a a r: 7 z > x \ < x ;~ \- \~ > >‘ \ y x
Embodiments of the various aspects described herein relate to determination of
appropriate parameters (e.g., genotypes or sion level) of at least two of the biomarkers (i) to
(xxiv) in a test sample of a human subject. In some embodiments, a physical biomarker (xxv) of
obesity tor (e.g., BMI), as shown in Table 42, can also be measured, wherein obesity (e.g.,
defined by a BMI value of at least about 30 kg/m2 or greater) indicates a treatment regimen
comprising a -containing compound be recommended for and/or administered to the human
subject. As shown in Table 42, any one of the folate-responsive biomarkers (selected from biomarker
(i) to (xxiv)) can be detected in ation with at least one other folate-responsive biomarker as
indicated by a “x” symbol in the table, including, e.g., at least two, at least three, at least four, at least
five, at least six, at least seven, at least eight, at least nine, at least ten, at least , at least twelve,
at least thirteen, at least en, at least fifteen, at least n, at least een, at least eighteen,
at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least
twenty-four other folate responsive biomarkers. By way of example only, considering column 1 of
Table 42, a folate responsive biomarker (i) (corresponding to a SNP at position 27 of SEQ ID NO. 7
or at position 677 of SEQ ID NO.1) can be detected with one or any combinations of other folate-
2012/065084
responsive biomarkers Xxv). For example, both folate-responsive biomarkers (i) and (iii) can be
selected for detection in the assays, methods, systems and kits described herein. In another
embodiment, a combination of three folate responsive biomarkers (i), (iii), and (xvii) can be selected
for detection in the assays, methods, systems and kits described herein. In another embodiment, a
ation of three folate responsive biomarkers (i), (iii), and (XXV) can be ed for detection in
the , methods, systems and kits described herein.
] Methylenetetrahydrofolate reductase ). Methylenetetrahydrofolate
reductase (MTHFR) is an enzyme that in humans is encoded by the MTHFR gene. SEQ ID NO: 1
corresponds to a portion of the genomic nucleic acid ce of human wild-type or normal MTHFR
gene obtained from NCBI database (NCBI Reference Sequence: NM_005957.4), wherein the
tide at position 677 and 1298 of SEQ ID NO: 1 are normal (e. g., wild-type) “C” allele and “A”
allele, respectively. Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation
to methionine. Genetic variation in this gene has been previously shown to influence susceptibility to
occlusive vascular disease, neural tube defects, colon cancer, acute leukemia, Alzheimer’s or vascular
dementia, and mutations in this gene are associated with methylenetetrahydrofolate reductase
deficiency.
The mutation of the MTHFR tide at position 677 of SEQ ID NO: 1 from “C”
allele to “T” allele (C677T) results in a change of amino acid residue from alanine to valine at
position 222 of the corresponding amino acid sequence (SEQ ID NO: 4). Such amino acid substitution
encodes a thermolabile enzyme with reduced activity. People with the thermolabile form of such
enzyme generally have increased levels of homocysteine in their blood. Accordingly, in some
embodiments, ion of an increase in levels of steine in a blood sample of a subject with
patient can be an indicative of a SNP at position 677 (e.g., C677T) of the MTHFR gene (or SEQ ID
NO: 1). In some embodiments, detection of valine at position 222 (e. g., A222V) of the corresponding
amino acid sequence (SEQ ID NO: 4), e.g., by mass spectrometry, can indicate a SNP at position 677
(e. g., C677T) of the MTHFR gene (or SEQ ID NO: 1).
At nucleotide 1298 of the MTHFR, there are generally two ilities: “A” or “C”.
MTHFR 1298A (leading to a Glu at amino acid residue 429) is the most common while 1298C
(leading to an Ala substitution at amino acid 429) is less common. In some embodiments, detection of
alanine at position 429 ) of the corresponding amino acid sequence (SEQ ID NO: 4) can
indicate a SNP at position 1298 of the MTHFR gene (or SEQ ID NO: l).Without wishing to be bound
by theory, previous studies on human recombinant MTHFR have ed that the protein encoded by
1298C cannot be distinguished from 1298A in terms of activity, thermolability, FAD release, or the
protective effect of 5-methyl-THF. (See, e.g.,Yamada K. et al. (2001). Proc. Natl. Acad. Sci. USA.
98 (26): 14853—8). It is believed that the C mutation (e.g., A1298C) does not appear to affect the
MTHFR protein or result in thermolabile MTHFR, or affect steine levels.
Methods for detecting the SNPs of the MTHFR gene, e. g., C677T, A1298C, or
G1793A are well known in the art, for examples, including the methods and primers used in US. Pat.
No.: US 6,833,243, which is incorporated herein by reference.
Methionine se (MTR). Methionine synthase also known as MS, MeSe, MetH
is an enzyme that in humans is encoded by the MTR gene (5-methyltetrahydrofolate-homocysteine
methyltransferase). SEQ ID NO: 2 corresponds to a portion of the genomic nucleic acid sequence of
human wild-type or normal MTR gene obtained from NCBI database (NCBI Reference Sequence:
NM_000254.2), wherein the nucleotide at position 2756 of SEQ ID NO: 2 is normal (e. g., ype)
“A” allele. This enzyme is responsible for the regeneration of methionine from homocysteine.
Methionine synthase forms part of the osylmethionine (SAM) biosynthesis and regeneration
cycle. A polymorphism in the MTR gene, an A-to-G transition at position 2756 (e.g., A2756G) of
SEQ ID NO: 2 causes an amino acid substitution from aspartic acid to glycine at codon 919 (D919G)
of the corresponding amino acid sequence (SEQ ID NO: 5). Accordingly, in some embodiments,
detection of glycine at position 919 (e.g., D919G) of the corresponding amino acid sequence (SEQ ID
NO: 5), e.g., by mass spectrometry, can te a SNP at position 2756 (e.g., A2756G) of the MTR
gene (or SEQ ID NO: 2).
Methionine synthase reductase (MTRR). Methionine synthase reductase, also known
as MSR, is an enzyme that in humans is encoded by the MTRR gene. SEQ ID NO: 3 ponds to a
portion of the genomic nucleic acid ce of human wild-type or normal MTRR gene obtained
from NCBI database (NCBI Reference Sequence: NM_002454.2), wherein the tide at position
66 of SEQ ID NO: 3 is normal (e. g., wild-type) “A” allele. Methionine is an essential amino acid
required for protein synthesis and one-carbon metabolism. Its synthesis is catalyzed by the enzyme
methionine synthase. Methionine se eventually becomes inactive due to the ion of its
cob(I)alamin cofactor. Methionine synthase reductase regenerates a functional methionine se
via reductive methylation, and is a member of the ferredoxin-NADP(+) reductase (FNR) family of
electron transferases. MTRR rphism, an adenine-to-guanine mutation at position 66 (e.g.,
A66G) of SEQ ID NO: 3 converts an isoleucine to a methionine amino acid (I22M) at on 22 of
the corresponding amino acid sequence (SEQ ID NO: 6). Accordingly, in some embodiments,
ion of nine at position 22 (e. g., I22M) of the corresponding amino acid sequence (SEQ
ID NO: 6), e. g., by mass spectrometry, can indicate a SNP at on 66 (e.g., A66G) of the MTRR
gene (or SEQ ID NO: 3).
Catecholmethyltransferase (COMT). ol-O-methyltransferase is an enzyme
responsible for the breakdown of dopamine and norepinephrine, e. g., in the prefrontal cortex.
Met/Met are more rapid metabolizers than Val/Val subjects in which are associated with cognitive
dysfunction and disease pathology. In some embodiments, a hypometholated state has led to an
pression of COMT and greater executive dysfunction. COMT polymorphism (identified by
rs4680: SEQ ID NO. 24), an adenine-to-guanine mutation at position 27 of SEQ ID NO. 24 converts a
valine (Val) to a methionine (Met) amino acid (Va1158Met) at the corresponding position of the
amino acid sequence. Accordingly, in some embodiments, detection of methionine at position 158
(e. g., V22M) of the corresponding amino acid sequence (SEQ ID NO. 28), e.g., by mass
ometry, can indicate a SNP at position 27 of SEQ ID NO. 24.
Reducedfolate carrier 1 &2 (RCFI and RCFZ). Reduced folate r 1 and 2 (at
1) are receptors that transport S-MTHF across various membranes including the choroid
plexus and blood brain barrier.
Dopamine receptor D2 (DRD2). Taq1B and H313H are dopamine receptor
polymorphisms that effect dopamine transmission, receptor density, and antipsychotic response.
DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B). DNA (cytosine-5)-
transferase 3 beta is s gene encoding a DNA methyltransferase which is believed to function in
de novo methylation, rather than maintenance methylation.
e-phosphate Cytidylytransferase A A). Choline-phosphate
Cytidylytransferase A (PCYTlA) is an enzyme that aids in the transformation of phosphatidylcholine
to choline.
GTP cyclohydrolase I (GCH1). GTP ydrolase I is part of the folate and
biopterin biosynthesis pathways. It is responsible for the ysis of guanosine triphosphate (GTP)
to form 7,8-dihydroneopterin phosphate. GTPCH is encoded by the gene GCH1 and is the rate-
ng enzyme in tetrahydrobiopterin (THB, BH4) thesis. GCH1 is an essential or in
monamine synthesis and NO production.
Folate hydrolase (prostate-specific membrane n) (FOLH1). FOLH1 is also
known as glutamate carboxypeptidase II, which is an enzyme that in humans is encoded by the
FOLH1 (folate hydrolase 1) gene. GCPII is a class 11 membrane glycoprotein. It catalyzes the
hydrolysis of N-acetylaspartylglutamate (NAAG) to ate and N-acetylaspartate (NAA).
Dopmaine active transporter (DA T). The dopamine transporter (also dopamine
active transporter, DAT, SLC6A3) is a membrane-spanning protein that pumps the neurotransmitter
dopamine out of the synapse back into cytosol, from which other transporters sequester DA and NE
into vesicles for later storage and release.
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR). GTP cyclohydrolase
1 feedback regulatory protein is an enzyme that in humans is encoded by the GCHFR gene. GTP
cyclohydrolase 1 feedback regulatory protein binds to and mediates tetrahydrobiopterin inhibition of
GTP cyclohydrolase 1 which aids in the production of de novo BH4 production.
Calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNAIC). Gene
CACNA1C encodes an alpha-1 t of a voltage-dependent calcium channel. Calcium channels
mediate the influx of calcium ions into the cell upon membrane polarization.
Formiminotransferase cyclodeaminase (FTCD). Formiminotransferase
cyclodeaminase is an enzyme that catalyzes the sion of inoglutamate and
tetrahydrofolate into formiminotetrahydrofolate and ate.
Methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1 (MTHFD 1).
Methylenetetrahydrofolate dehydrogenase (NADP+dependent) l is a tri-allelic gene that encodes a
protein that ses three distinct enzymatic activities, methylenetetrahydrofolate dehydrogenase,
methenyltetrahydrofolate cyclohydrolase and formate—tetrahydrofolate ligase. Each of these activities
catalyzes one of three sequential reactions in the interconversion of l-carbon derivatives of
tetrahydrofolate, which are ates for methionine, ylate, and de novo purine syntheses. A
common single nucleotide polymorphism (SNP) at nucleotide 1958 of the MTHFDl gene (or at
position 27 of SEQ ID 27) causes a “G” to “A” transition, which results in an arginine to glutamate
substitution at amino acid position 653 in the synthetase domain of the enzyme ( See, e.g., Hol et al.,
(1998) “Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD
(methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase,
tetrahydrofolate synthetase) in patients with neural tube defects.” Clin Genet 53: 119-25).
S-adenosyl methionine (SAM) and S-adenosyl homocysteine (SAH). S-adenosyl
methionine, commonly known as SAM, or SAM-e, or AdoMet, is a natural compound found in all
living cells. It is one of the most used enzymatic substrates in biochemical reactions, second only to
the universal energy storage and transfer molecule, adenosyl triphosphate (ATP).
S-Adenosyl methionine is a common cosubstrate involved in methyl group ers.
It is made from adenosine triphosphate (ATP) and nine by methionine adenosyltransferase.
Transmethylation, transsulfuration, and ropylation are the metabolic ys that use SAM.
SAH is formed by the demethylation of S-adenosyl-L-methionine (SAM). Further s about SAM
and SAH, including immunoassays for determining SAM, SAH and/or ratios thereof are described in
US. Pat. App. No.: US 2009/0263879, which is incorporated herein by reference.
4-hydroxynonenal (4-HNE). 4-Hydroxynonenal, or 4-hydroxynonenal or 4-HNE
or HNE, 02), is an 0., B-unsaturated hydroxyalkenal which is produced by lipid peroxidation in
cells. 4-HNE is the primary 0., B-unsaturated hydroxyalkenal formed in this s. It is found
throughout animal tissue, and in higher quantities during oxidative stress due to the increase in the
lipid peroxidation chain reaction, due to the increase in stress . 4-HNE has been believed to
play a key role in cell signal transduction, in a variety of pathways from cell cycle events to cellular
adhesion. 4-HNE is also considered as possible causal agents of numerous diseases, such as chronic
inflammation, neurodegenerative diseases, adult respiratory distress syndrome, atherogenesis,
diabetes and different types of cancer.
Protein residues known to react with 4HNE via 1,4-addition are Cys, His, and Lys.
Thus, in some embodiments, sion levels of 4-HNE can be determined by measuring expression
levels of 4-HNE s, e.g., 4-HNE-His. Commercial ELISA kits for measuring 4-HNE adducts,
e.g., OxiSelectTM HNE-His Adduct ELISA Kit are available, e.g., from CellBioLabs.
Test sample and collection and preparation thereof
Collections of test samples for at least one analysis performed in the assays and/or
methods described herein are well known to those skilled in the art. In some embodiments, a test
sample subjected to analysis performed in the assays and/or methods described herein are derived
from a biological sample of a subject. The term “biological sample” as used herein denotes a sample
taken or isolated from a biological organism, e.g., cell lysate, a homogenate of a tissue sample from a
subject or a fluid sample from a subject. The term “biological sample” also includes untreated or pre-
d (or pre-processed) biological samples. In some embodiments, the biological sample can be a
biological fluid, including, but not limited to, blood (including whole blood, plasma, cord blood and
serum), lactation products (e.g., milk), amniotic fluids, sputum, saliva, urine, semen, cerebrospinal
fluid, bronchial aspirate, perspiration, mucus, liquefied feces, synovial fluid, lymphatic fluid, tears,
tracheal aspirate, and fractions thereof. In other embodiments, the biological sample can include cell
lysate and fractions f. For e, cells (such as red blood cells, ets, white blood cells
and any cells circulating in the ical fluid described herein) can be ted and lysed to obtain
a cell lysate. In some embodiments, a test sample or a biological sample is a blood sample. In some
embodiments, a test sample or a biological sample is a plasma sample. In some embodiments, a test
sample or a biological sample is a saliva sample. In some embodiments, a test sample or a biological
sample is a buccal sample. In some embodiments, a test sample or a biological sample is a urine
sample.
A “biological sample” can contain cells from subject, but the term can also refer to
non-cellular biological material, such as non-cellular fractions of blood, saliva, or urine, that can be
used to e plasma/serum biomarker expression levels or determine SNPs. In some
embodiments, the sample is from a resection, biopsy, or core needle biopsy. In addition, fine needle
aspirate samples can be used. Samples can be either in-embedded or frozen tissue.
The sample can be ed by removing a sample of cells from a subject, but can
also be accomplished by using previously isolated cells (e. g. isolated by r person). In addition,
the biological sample can be freshly collected or a previously collected sample.
] In some embodiments, the test sample or the biological sample can be a frozen
biological sample, e.g., a frozen tissue or fluid sample such as urine, blood, serum or plasma. The
frozen sample can be thawed before employing methods, assays and systems described . After
thawing, a frozen sample can be centrifuged before being subjected to methods, assays and systems
described herein.
In some embodiments, a test sample or a biological sample can be a c acid
product amplified after polymerase chain reaction (PCR). The nucleic acid product can include DNA,
RNA and mRNA and can be isolated from a particular ical sample using any of a number of
procedures, which are well-known in the art, the particular isolation procedure chosen being
appropriate for the particular biological sample. s of isolating and analyzing nucleic acid
variants as bed above are well known to one skilled in the art and can be found, for example in
the Molecular Cloning: A Laboratory Manual, 3rd Ed., Sambrook and , Cold Spring Harbor
Laboratory Press, 2001.
In some embodiments, the test sample or the biological sample can be treated with a
chemical and/or biological reagent. Chemical and/or biological reagents can be employed to protect
and/or maintain the stability of the , including biomolecules (e. g., c acid and protein)
therein, during processing. One exemplary reagent is a protease inhibitor, which is generally used to
protect or maintain the stability of protein during processing. In addition, or alternatively, chemical
and/or biological reagents can be employed to release nucleic acid or n from the sample.
The skilled artisan is well aware of methods and processes appropriate for pre-
sing of test or biological samples, e. g., blood, required for determination of SNPs or expression
levels of serum/plasma biomarkers as bed herein.
In some embodiments, the test sample or biological sample is a blood sample, e.g.,
whole blood, plasma, and serum. In some embodiments, the test sample or biological sample is a
whole blood sample. In some embodiments, the test sample or biological sample is a serum sample. In
some embodiments, the test sample or biological sample is a plasma sample. In some ments,
the blood sample can be allowed to dry at room temperature from about 1 hour to overnight, or in the
refrigerator (low humidity) for up to several months before subjected to analysis, e. g., SNP analysis.
See, for example, Ulvik A. and Ueland RM. (2001) Clinical Chemistry 47: 2050, for methods of SNP
genotyping in unprocessed whole blood and serum by real-time PCR.
To collect a blood , by way of e only, the t’s blood can be drawn
by trained l personnel directly into anti-coagulants such as citrate, EDTA PGE, and
theophylline. The whole blood can be separated into the plasma portion, the cells, and platelets
portion by refrigerated centrifugation at 3500 g for 2 minutes. After centrifugation, the supernatant is
the plasma and the pellet is RBC. Since platelets have a tendency to adhere to glass, it is preferred that
the collection tube be siliconized. Another method of isolating red blood cells (RBCs) is described in
Best, CA et al., 2003, J. Lipid Research, 44:612-620.
Alternatively, serum can be collected from the whole blood. By way of example,
about 15 mL of whole blood can be drawn for about 6 mL of serum. The blood can be collected in a
hard plastic or glass tube; blood will not clot in soft plastic. The whole blood is allowed to stand at
room temperature for 30 minutes to 2 hours until a clot has formed. Then, clot can be carefully
separated from the sides of the container using a glass rod or wooden applicator stick and the rest of
the sample can be left overnight at 4°C. After which, the sample can be centrifuged, and the serum
can be transferred into a clean tube. The serum can be clarified by centrifugation at 1000 g for 10
minutes at 4°C. The serum can be stored at —80°C before analysis. In such embodiments, carotenoids
may not be stable for long s of time. Detailed described of ing serum using collection
tubes can be found in U. S. Patent No. 3,837,376 and is incorporated by reference. Blood collection
tubes can also be sed from BD Diagnostic s, Greiner Bio-One, and Kendall Company.
The whole blood can be first separated into platelet-rich plasma and cells (white and
red blood cells). Platelet rich plasma (PRP) can be isolated from the blood centrifugation of citrated
whole blood at 200 g for 20 minutes. The et rich plasma is then transferred to a fresh
polyethylene tube. This PRP is then centrifuged at 800 g to pellet the platelets and the supernatant
(platelet poor plasma [PPP]) can be saved for analysis, e. g., by ELISA, at a later stage. Platelets can
be then gently re-suspended in a buffer such as Tyrodes buffer containing lU/ml PGE2 and ed
by centrifugation again. The wash can be repeated twice in this manner before removing the
membrane fraction of platelets by centrifugation with Triton X, and lysing the pellet of et for
platelet-derived PF4 analyses. Platelets can be lysed using 50 mM Tris HCL, 100-120 mM NaCl, 5
mM EDTA, 1% Igepal and Protease Inhibitor Tablet (complete TM mixture, Boehringer Manheim,
Indianopolis, IN).
] In one embodiment, platelets are separated from whole blood and the SNPs or hsCRP
transcripts can be ined rom. When whole blood is centrifuged as described herein to
separate the blood cells from the plasma, a pellet is formed at the end of the centrifugation, with the
plasma above it. Centrifugation separates out the blood components (RBC, WBC, and platelets) by
their various densities. The RBCs are denser and will be the first to move to the bottom of the
collection/centrifugation tube, followed by the smaller white blood cells, and finally the platelets. The
plasma fraction is the least dense and is found on top of the pellet. The “buffy coat” which contains
the majority of platelets will be sandwiched between the plasma and above the RBCs. Centrifugation
of whole blood (with anti-coagulant, PGE and theophylline) can produce an ed platelet rich
"buffy coat" that lies just above the buoy. The buffy coat contains the concentrated ets and white
blood cells.
In another embodiment, ets can be separated from blood according to methods
described in United States Patent No. 4,656,035 using lectin to agglutinate the ets in whole
blood. Alternatively, the methods and apparatus described in U. S. Patent No. 7,223,346 can be used
involving a platelet collection device comprising a centrifugal eparator container with a cavity
having a longitudinal inner surface in order to collect the “buffy coat” enriched with platelets after
centrifugation. As another alternative, the methods and apparatus as described in WO/2001/066l72
can be used. Each of these references is incorporated by nce herein.
In another embodiment, platelets can be isolated by the two methods described in A.
L. Copley and R. B. Houlihan, Blood, 1947, 2: 170-181, which is incorporated by reference herein.
Both methods are based on the principle that the platelet layer can be obtained by repeated fractional
centrifugation.
In some ments, apparatus and related s are used to obtain the sample,
for example, machines described in U.S. Pat. No. 4,120,448, 5,879,280 and 7,241,281, which are
incorporated herein by reference.
Methods for collecting different types of a test sample are known in the art and can be
employed to prepare a test sample for the assays and methods described herein.
SNPs. Polymorphisms and Alleles
The genomes of all sms undergo spontaneous mutation in the course of their
uing evolution, generating variant forms of progenitor genetic sequences (Gusella, Ann. Rev.
Biochem. 55, 831-854 ). The tence of multiple forms of a genetic sequence gives rise to
genetic polymorphisms, including SNPs.
Approximately 90% of all polymorphisms in the human genome are SNPs. SNPs are
single base positions in DNA at which different alleles, or alternative nucleotides, exist in a
tion. The SNP position (interchangeably ed to herein as SNP, SNP site, SNP allele or
SNP locus) is y preceded by and followed by highly conserved sequences of the allele (e.g.,
sequences that vary in less than 1/100 or 1/1000 members of the populations). An individual can be
homozygous or heterozygous for an allele at each SNP position. A SNP can, in some instances, be
referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP is an amino acid
coding sequence.
A SNP can arise from a substitution of one nucleotide for another at the polymorphic
site. Substitutions can be transitions or transversions. A transition is the replacement of one purine
nucleotide by another purine tide, or one dine by another pyrimidine. A transversion is
the replacement of a purine by a pyrimidine, or vice versa. A SNP can also be a single base insertion
or deletion variant referred to as an "in/del" (Weber et al., "Human diallelic insertion/deletion
polymorphisms", Am J Hum Genet r 2002;71(4):854-62).
A synonymous codon change, or silent mutation/SNP (the terms "SNP" and
"mutation" are used herein interchangeably), is one that does not result in a change of amino acid due
to the degeneracy of the genetic code. A substitution that changes a codon coding for one amino acid
to a codon coding for a different amino acid (i.e., a non-synonymous codon change) is referred to as a
missense mutation. A nonsense mutation results in a type of non-synonymous codon change in which
a stop codon is formed, thereby g to premature termination of a polypeptide chain and a
truncated protein. A read-through mutation is r type of non-synonymous codon change that
causes the destruction of a stop codon, thereby ing in an extended polypeptide product. While
SNPs can be bi-, tri-, or tetra-allelic, the vast majority of the SNPs are bi-allelic, and are thus often
referred to as "bi-allelic markers", or "di-allelic markers".
] A major database of human SNPs is maintained at NCBI as dbSNP, and it contains
data for unique human SNPs consisting of 1.78 x 108 submitted SNP (identified by an “ss” number)
and 5.2 x 107 reference SNP ified by an “rs” number), as of Build History 135: human_9606
based on NCBI human genome build 37.3. The rs numbers are unique, do not change and allow
analysis of the particularly identified SNP in any genetic sample. Throughout the specification, the
SNPs described herein can also be identified by an “rs” . For example, the SNP at position 677
of SEQ ID NO: 1 can be identified by rs 1801133; the SNP at position 1298 of SEQ ID NO: 1 can be
identified by rs 1801131; the SNP at position 2756 of SEQ ID NO: 2 can be identified by rs 1805087;
The SNP at position 66 of SEQ ID NO: 2 can be identified by rs 1801394. With the “rs” numbers
known for each SNP, one of skill in the art will be able to determine the position of a specific SNP
within a respective chromosome.
While a SNP could conceivably have three or four alleles, nearly all SNPs have only
two alleles. Analysis of the SNPs identified herein generally relies on the two alleles that are listed in
connection with each SNP. For example, the SNPs at the MTHFR locus described herein are each
indicated to have two alleles, “C” or “T” at the position 677 of SEQ ID NO. 1, and “A” or “C” at the
position 1298 of SEQ ID NO. 1, wherein SEQ ID NO. 1 is a n of a genomic nucleic acid
sequence of MTHFR. The presence of at least one allele “T” at position 677 of SEQ ID NO. 1 and/or
at least one allele “C” at position 1298 of SEQ ID NO. 1 indicates that a subject with depression is
recommended for a treatment n comprising a folate-containing compound. The SNP at the
MTR locus described herein is indicated to have two alleles, “A” or “G”. The presence of at least one
allele “G” at position 2756 of SEQ ID NO. 2, wherein SEQ ID NO: 2 is a portion of a genomic
nucleic acid ce of methionine synthase (MTR), indicates the subject ended for a
treatment regimen comprising a folate-containing nd. The SNP at the MTRR locus described
herein is indicated to have two s, “A” or “G”. The presence of at least one allele “G” at position
66 of SEQ ID NO. 3, n SEQ ID NO. 3 is a portion of a genomic nucleic acid sequence of
methionine synthase reductase (MTRR), indicates the subject recommended for a treatment regimen
comprising a folate-containing nd.
Those skilled in the art will readily recognize that nucleic acid molecules can be
double-stranded molecules and that reference to a ular site on one strand refers, as well, to the
corresponding site on a complementary strand. In defining a SNP position, SNP allele, or nucleotide
sequence, reference to an adenine “A”, a thymine “T” ne “U”), a cytosine “C”, or a guanine “G”
at a particular site on one strand of a nucleic acid molecule also defines the thymine “T” (uridine
“U”), adenine “A”, e “G”, or cytosine “C” (respectively) at the corresponding site on a
complementary strand of the nucleic acid molecule. Thus, reference can be made to either strand in
order to refer to a particular SNP position, SNP allele, or nucleotide sequence. Probes and primers can
be designed to ize to either strand and SNP genotyping methods disclosed herein can generally
target either strand.
ingly, the claims are intended to cover analysis of the te strand as well.
For the opposite-strand analysis, the SNPs at the MTHFR locus is allele “A” at position 677 or allele
“G” at position 1298 of the complementary sequence of SEQ ID NO. 1, wherein SEQ ID NO. 1 is a
portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR); while
the SNP at the MTR locus is allele “C” at position 2756 of the mentary sequence of SEQ ID
NO. 2, wherein SEQ ID NO. 2 is a portion of a c c acid sequence of methionine synthase
(MTR); and the SNP at the MTRR locus is allele “C” at on 66 of the complementary sequence
of SEQ ID NO. 3, wherein SEQ ID NO. 3 is a portion of a c c acid sequence of
methionine synthase reductase (MTRR).
Identification method of SNPs can be of either a positive-type (inclusion of an )
or a negative-type (exclusion of an allele). Positive-type methods determine the identity of a
nucleotide ned in a rphic site, whereas negative-type methods determine the identity of a
nucleotide not present in a polymorphic site. Thus, a wild-type site can be identified either as wild-
type or not mutant. For example, at a biallelic polymorphic site where the wild-type allele contains
thymine and the mutant allele contains cytosine, a site can be positively determined to be either
thymine or cytosine or negatively determined to be not thymine (and thus cytosine) or not cytosine
(and thus thymine).
Methodsfor detecting the SNPS disclosed herein
According to one aspect described herein, a method for determining whether a t
is homozygous for a polymorphism, heterozygous for a polymorphism, or lacking the polymorphism
altogether (i.e. homozygous wildtype) is encompassed. As an exemplary embodiment only, a method
to detect the C>T variance at position 677 of SEQ ID NO: 1, a method for determining the allele,
heterozygous for the C— and T-alleles, or homozygous for the C—allele or the T-allele at the SNP loci
are provided. Substantially any method of detecting any allele of the SNPs described herein, such as
restriction enzyme digestion, allele-specific probe hybridization, allele-specific primer extension,
allele specific amplification, sequencing, 5’ nuclease digestion, molecular beacon assay,
oligonucleotide ligation assay, size analysis, and single-stranded conformational rphism, can
be used.
] In one embodiment, an allelic discrimination method for fying the pes of
SNPs of a human described herein can be used. Such a method may involve the use of distinct
oligonucleotide probes, for example one complementary to a sequence having a major allele and
another complementary to a sequence having a minor allele. The allelic discrimination method also
involves use of at least one, and preferably a pair of amplification primers for amplifying a nce
region of the MTHFR, MTR or MTRR locus of a subject. The reference region includes at least a
portion of the human MTHFR, MTR or MTRR locus.
] For full-length genes and entire protein-coding sequences, a SNP flanking sequence
can be, for example, up to about 10 Kb, 9 Kb, 8 Kb, 7 Kb, 6Kb, 5 Kb, 4 Kb, 3 Kb, 2 Kb, 1 Kb on
either side of the SNP. Furthermore, in such instances, the isolated nucleic acid molecule comprises
exonic sequences (including protein-coding and/or non-coding exonic sequences), but may also
include intronic sequences. Thus, any protein coding sequence may be either contiguous or separated
by introns. The ant point is that the nucleic acid is isolated from remote and rtant
flanking sequences and is of appropriate length such that it can be subjected to the specific
manipulations or uses described herein such as recombinant protein expression, preparation of probes
and primers for assaying the SNP position.
The probe is ably a DNA oligonucleotide haVing a length in the range from
about 20 to about 40 nucleotide residues, preferably from about 20 to about 30 nucleotide residues,
and more preferably haVing a length of about 25 nucleotide residues. In one embodiment, the probe is
rendered incapable of extension by a talyzing enzyme such as Taq polymerase, for example by
haVing a fluorescent probe attached at one or both ends thereof. Although non-labeled ucleotide
probes can be used in the kits and methods described herein, the probes are preferably detectably
labeled. Exemplary labels include radionuclides, light-absorbing chemical moieties (e. g. dyes),
fluorescent moieties, and the like. Preferably, the label is a fluorescent moiety, such as 6-
yfluorescein (FAM), 6-carboxy-4,7,2',7'-tetrachlorofluoroscein (TET), rhodamine, JOE (2,7-
oxy-4,5-dichlorocarboxyfluorescein), HEX (hexachlorocarboxyfluorescein), or VIC.
In some embodiments, the probe can comprise both a cent label and a
fluorescence-quenching moiety such as 6-carboxy-N,N,N',N'-tetramethylrhodamine (TAMRA), or 4-
(4'-dimethlyaminophenylazo)benzoic acid (DABCYL). When the fluorescent label and the
fluorescence-quenching moiety are ed to the same oligonucleotide and separated by no more
than about 40 nucleotide residues, and preferably by no more than about 30 nucleotide es, the
fluorescent intensity of the fluorescent label is diminished. When one or both of the fluorescent label
and the fluorescence-quenching moiety are separated from the oligonucleotide, the intensity of the
fluorescent label is no longer diminished. Preferably, the probe for use in the assays, methods,
systems and kits described herein can have a fluorescent label ed at or near (i.e. within about 10
nucleotide residues of) one end of the probe and a fluorescence-quenching moiety attached at or near
the other end. Degradation of the probe by a PCR-catalyzing enzyme releases at least one of the
fluorescent label and the fluorescence-quenching moiety from the probe, y discontinuing
fluorescence ing and increasing the detectable intensity of the fluorescent . Thus,
cleavage of the probe (which, as discussed above, is correlated with complete complementarity of the
probe with the target portion) can be detected as an increase in fluorescence of the assay e.
If detectably different labels are used, more than one labeled probe can be used. For
e, the assay mixture can contain a first probe which is completely complementary to the target
portion of the polymorphism of the MTHFR, MTR, or MTRR gene and to which a first label is
attached, and a second probe which is completely mentary to the target portion of the wildtype
or major allele. In some embodiments, by way of example only, the assay mixture can contain a first
probe which is completely complementary to the target portion of the polymorphism of the MTHFR
gene and to which a first label is attached, and a second probe which is completely complementary to
the target portion of another gene, e.g., MTR or MTRR. When two probes are used, the probes are
detectably different from each other, , for example, detectably ent size, absorbance,
excitation, or emission spectra, radiative on properties, or the like. For example, a first probe
can be completely complementary to the target portion of the polymorphism and have FAM and
TAMRA attached at or near opposite ends thereof. The first probe can be used in the methods, ,
systems and kits bed herein together with a second probe which is completely complementary to
the target n of the wildtype allele and has TET and TAMRA attached at or near te ends
thereof. Fluorescent enhancement of FAM (i.e. effected by cessation of fluorescence quenching upon
degradation of the first probe by Taq polymerase) can be detected at one wavelength (e.g. 518
nanometers), and fluorescent enhancement of TET (i.e. effected by cessation of fluorescence
quenching upon ation of the second probe by Taq polymerase) can be detected at a ent
wavelength (e. g. 582 nanometers).
Any approach that detects mutations or polymorphisms in a gene can be used to
detect the presence or absence of SNP kers described herein, including but not limited to
single-strand conformational polymorphism (SSCP) analysis (Orita et al. (1989) Proc. Natl. Acad. Sci.
USA 86:2766-2770), heteroduplex analysis (Prior et al. (1995) Hum. Mutat. 5:263-268),
oligonucleotide ligation (Nickerson et al. (1990) Proc. Natl. Acad. Sci. USA 87:8923-8927) and
hybridization assays (Conner et al. (1983) Proc. Natl. Acad. Sci. USA 80:278-282). Traditional Taq
polymerase PCR-based strategies, such as PCR-RFLP, allele-specific amplification (ASA) (Ruano
and Kidd (1989) Nucleic Acids Res. 17:8392), single-molecule dilution (SMD) (Ruano et al. (1990)
Proc. Natl. Acad. Sci. USA 87:6296-6300), and coupled amplification and cing (CAS) (Ruano
and Kidd (1991) Nucleic Acids Res. 19:6877—68 82), are easily performed and highly sensitive
methods to determine ypes (Michalatos-Beloin et al. (1996) Nucleic Acids Res. 24:4841-4843;
Barnes (1994) Proc. Natl. Acad. Sci. USA 91:5695-5699; Ruano and Kidd (1991) Nucleic Acids Res.
19:6877-6882).
Restriction Fragment Length Polymorphism Analysis
In some embodiments, restriction enzymes can be utilized to identify ces or a
polymorphic site using “restriction fragment length polymorphism” (RFLP) is (Lentes et al. ,
Nucleic Acids Res. 16:2359 ; and CK. McQuitty et al., Hum. Genet. 93:225 (1994)). In RFLP,
at least one target polynucleotide is digested with at least one ction enzyme and the resulting
restriction fragments are separated based on mobility in a gel. Typically, smaller fragments migrate
faster than larger fragments. Consequently, a target polynucleotide that contains a particular
restriction enzyme recognition site will be digested into two or more smaller fragments, which will
migrate faster than a larger fragment lacking the ction enzyme site. Knowledge of the nucleotide
sequence of the target polynucleotide, the nature of the polymorphic site, and knowledge of restriction
enzyme recognition sequences guide the design of such assays. In another embodiment, restriction site
analysis of ular nucleotide sequence to fy a nucleotide at a polymorphic site is determined
by the presence or e of a restriction enzyme site. A large number of restriction enzymes are
known in the art and, taken er, they are capable of recognizing at least one allele of many
polymorphisms. However, such single nucleotide polymorphisms (SNPs) rarely result in changes in a
restriction endonuclease site. Thus, SNPs are rarely detectable by restriction fragment length analysis.
Ligation Based Assays (e.g., Oligonucleotide Ligation Assay)
A number of approaches use DNA ligase, an enzyme that can join two nt
ucleotides hybridized to a DNA template. In Oligonucleotide Ligaton Assay (OLA) the
sequence surrounding the mutation site is first amplified and one strand serves as a template for three
ligation probes, two of these are ASO (allele-specific oligonucleotides) and a third common probe.
Numerous approaches cane be used for the detection of the ligated products, for example the ASOs
with differentially labeled with fluorescent of hapten labels and ligated products ed by
fluorogenic of colorimetric enzyme-linked immunosorbent assays (Tobe et al, Nucleic Acid Res,
l996;24;3728-32). For electrophorosis-based systems, use of a morbidity modifier taqgs or variation
in probe length coupled with fluorescence detection enables the multiplex genotyping of l
single nucleotide substitutions in a single tube (Baron et al, 1997; Clinical Chem., 43;l984-6). When
used on arrays, ASOs can be spotted at specific locations or addresses on a chip, PCR amplified DNA
can then be added and ligation to d oligonucleotides at specific addresses on the array measured
(Zhong et al, Proc Natl Acad Sci 2003; 100;11559-64).
Single-Base Extension
Single base-extension or minisequencing involves annealing an oligonucleotide
primer to the single strand of a PCR product and the addition of a single dideoxynucleotide by thermal
DNA polymerase. The oligonucleotide is designed to be one base short of the mutation site. The
dideoxynucleotide orated is complementary to the base at the mutation site. Approaches can use
different fluorescent tags or haptens for each of the four different dideoxynucleotides (Pastinen et al,
Clin Chem 1996, 42;l39l-7). The dideoxynucleotide differ in molecular weight and this is the basis
for single-base extension methods utilizing mass-spectrometry, and genotyping based on the mass of
the ed oligonucleotide primer, can be used, for example matrix-assisted laser adsorption/
tion time-of flight mass spectrometry or MALDI-TOF (Li et al, Electrophorosis, 1999,20;1258-
65), which is quantitative and can be used to calculate the relative allele abundance making the
ch suitable for other applications such as gene dosage studies (for example for estimation of
allele frequencies on pooled DNA samples).
Minisequencing or equencing by TOF can be performed by means
known by persons skilled in the art. In a variation of the MALDI-TOF technique, some embodiments
can use the om’s Mass Array Technology (www.sequenom.com) (Sauser et al, Nucleic Acid
Res, 2000, 28;E13 and Sauser et al, Nucleic Acid Res 2000, 28: E100). and also the GOOD Assay
(Sauer S et al, Nucleic Acid Res, 2000; 28, E13 and Sauer et al, Nucleic Acid Res, 2000;28:E100).
In some embodiments, variations of MALDI-TOF can be performed for analysis of
variances in the genes associated with SNPs described herein. For example, MALDI and ospray
ioinization (ESI) (Sauer S. Clin Chem Acta, 2006; 363; 93-105) can also be used in various aspects
described herein.
Hybridization Based Genotyping (e.g., Allele-Specific Amplification (ASA))
Allele-specific Amplification is also known as amplification refectory mutation
system (ARMS) uses allele specific oligonucleotides (ASO) PCR primers and is an well established
and known PCR based method for genotyping (Newton et al, J Med Genet, 1991 ;28;248-51).
Typically, one of the two oligonucleotide primers used for the PCR binds to the mutation site, and
amplification only takes place if the tide of the mutation is present, with a mismatch being
refractory to amplification. The resulting PCR Products can be analyzed by any means known to
persons skilled in the art. In a ion of the approach, termed mutagenically separated PCR (MS-
PCR) the two ARMS primer of different lengths, one specific for the normal gene and one for the
mutation are used, to yield PCR procures of different lengths for the normal and mutant alleles (Rust
et al, Nucl Acids Res, 1993; 21 ;3623-9). Subsequent gel ophoresis, for example will show at
least one of the two allelic products, with normal, mutant or both (heterozygote) genes. A further
ion of this forms the basis of the Masscode SystemTM (www.bioserve.com) which uses small
molecular weight tags covalently attached through a photo-cleavable linker to the ARMS primers,
with each ARMS primers labeled with a tag of differing weight (Kokoris et al, 2000, 5;329-40). A
catalogue of numerous tags allows simultaneous amplification/genotyping (multiplexing) of 24
different targets in a single PCR reaction. For any one mutation, genotyping is based on comparison
of the relative abundance of the two relevant mass tags by mass spectrometry.
Normal or mutant alleles can be ped by ing the binding of allele-
specific oligonucleotides (ASO) hybridization probes. In such embodiments, two ASO probes, one
complementary to the normal allele and the other to the mutant allele are hybridized to PCR-amplified
DNA ng the mutation site. In some embodiments, the amplified ts can be immobilized
on a solid surface and hybridization to radiolabelled oligonucleotides such as known as a ‘dot-blot’
assay. In alternative embodiments, the binding of the PCR ts containing a fiable label
(e.g., biotin or fluorescent labels) to a solid phase allele-specific ucleotide can be measured.
Alternatively, for a reverse hybridization assay, or “reverse ot” the binding of PCR ts
ning a quantifiable label (for example but not limited to biotin or fluorescent labels) to a solid
phase allele-specific oligonucleotide can be measured. In some embodiments, the use of microarrays
comprising hundreds of ASO immobilized onto a solid support surfaces to form an array of ASO can
also be used for large scale genotyping of multiple single polymorphisms simultaneously, for example
Affymetrix GENECHIP® Mapping 10K Array, which can easily be performed by persons skilled in
the art.
nous assays
Homogenous assays, also called “closed tube” arrays, genomic DNA and all the
ts required for the ication and genotyping are added simultaneously. Genotyping can be
achieved without any post-amplification processing. In some embodiments, one such nous
assay is the 5’flurogenic nuclease assay, also known as the TAQMAN® Assay (Livak et al, Genet
Anal, 1999; 14: 143-9) and in alternative embodiments Melting curve analyses of FRET probes are
used. Such methods are carried out using “real-time” thermocyclers, and e two dual-labeled ASO
hybridization probes complementary to normal and mutant alleles, where the two probes have
different reported labels but a common quencher dye. In such ments, the changes in
fluorescence characteristics of the probes upon binding to PCR products of target genes during
ication enables “real-time” monitoring of PCR amplification and differences in affinity of the
fluorogenic probes for the PCR products of normal and mutant genes s differentiation of
genotypes. The approach uses two dual-labeled ASO hybridization probes complementary to the
mutant and normal s. The two probes have different fluorescent reported dyes but a common
quencher dye. When intact, the probes do not fluoresces due to the proximity of the reporter and
quencher dyes. During ing phase of PCR, two probes compete for hybridization to their target
sequences, downstream of the primer sites and are subsequently cleaved by 5’ nuclease activity of
Thermophilis aquaticus (Taq) polymerase as the primer is extended, resulting in the separation of the
er dyes from the quencher. Genotyping is determined by measurement of the fluorescent
intensity of the two reporter dyes after PCR amplification. Thus, when intact the probes do not
fluoresce due to the proximity of the quencher dyes, whereas during the annealing phase of the PCR
the probes e for hybridization of the target sequences and the separation of one of the probes
from the er which can be detected.
Melting-carve ofFRET hybridization
Melting-curve analysis of FRET hybridization is another approach that can be used to
detect the presence or absence of SNP biomarkers described herein. Briefly, the reaction includes two
oligonucleotide probes which when in close proximity forms a fluorescent complex, where one probe
often termed the “mutant ” probe is designed to specifically hybridize across the mutation site
and the other probe (often referred to as the “anchor probe”) hybridizes to an nt site.
scent light is emitted by the “donor” excites the “acceptor” fluorophore creasing a unique
fluorogenic complex, which only forms when the probes bind to adjacent sites on the amplified DNA.
The “sensor” probe is complementary to either the normal or the mutant allele. Once PCR is
complete, heating of the sample through the melting temperatures of the probe yields a fluorescent
temperature curve which differs for the mutant and normal allele.
A variation of the FRET hybridization method is the LCGREENTM method, which
obviates the requirement for fluorescent d probes ther. LCGREENTM is a sensitive highly
fluorogenic double-stranded DNA (dsDNA) binding dye that is used to detect the dissociation of
unlabelled probes (Liew et al, Clin Chem, 2004; 50;l 156-64 and Zhou et al, Clin Chem, 2005;
5l;l76l 2). The method uses unlabeled allele-specific oligonucleotides probes that are perfectly
complementary either to the mutant or normal allele, and the mismatch of the ASO/template double
strand DNA complex results in a lower melting temperature and an earlier reduction in fluorescent
signal form the dsDNA binding dye with increasing temperature.
The OLA can also be performed by the use of FRET probes (Chen et al, Genome Res,
l998;8: 549-56). In such an embodiment, the PCR/ligation mix contains PCR primers, a thermostable
DNA polymerase t 5’ exonuclease activity (to t the cleavage of ligation probes during
the ligation phase), a thermostable DNA ligase as well as the oligonucleotides for the ligation
reaction. The ligation of the ASO each have a different acceptor fluorophore and the third ligation
oligonucleotide which binds adj acently to the ASO has a donor fluorophore. The three ligation
oligonucleotides are designed to have a lower melting temperature than the annealing temperature for
the PCR primers in order to prevent their interference in PCR amplification. Following PCR, the
temperature is lowered to allow ligation to proceed. Ligation results in FRET between donor and
acceptor dyes, and alleles can be discerned by comparing the fluorescence emission of the two dyes.
Molecular Beacon Assays
Further, variations of the homogenous PCR- and hybridization based techniques to
detect polymorphisms can also be used to detect the presence or absence of SNP biomarkers described
. For example, the use of Molecular Beacons (Tyagi et al, Nat Biotech 1998; 16; 49-53) and
SCORPION® Probes (Thelwell et al, Nucleic Acid Res 2000;28;3752-6l). Molecular Beacons are
sed of oligonucleotides that have fluorescent reporter and dyes at their 5’ and 3’ ends, with the
central n of the ucleotide hybridizing across the target sequence, but the 5’ and 3’
flanking regions are complementary to each other. When not hybridized to their target ce, the
’ and 3’ flanking regions hybridize to form a stem-loop structure, and there is little cence
e of the ity of the reported and the quencher dyes. However, upon hybridization to their
target sequence, the dyes are separated and there is a large increase in the fluorescence. Mismatched
probe-target hybrids dissociate at substantially lower atures than exactly matched
complementary hybrids. There are a number of ions of the “molecular Beacon” approach. In
some ments, such a variation includes use of SCORPION® Probes which are similar but
incorporate a PCR primer sequence as part of the probe ell et al, Nucleic Acid Res
2000;28;3752 61). In another variation, x’ format gives a better fluorescent signal (Solinas et al,
Nucleic Acid Res, 2001, 29; E96).
In another embodiment, rphisms can be detected by genotyping using a
homogenous or real-time analysis on whole blood samples, without the need for DNA extraction or
real-time PCR. Such a method is compatible with FRET and TAQMAN® (Castley et al, Clin Chem,
2005;51; 0) enabling extremely rapid ing for the particular polymorphism of interest.
Fluorescent Polarization (FP)
In FP, the degree to which the emitted light remains polarized in a particular plane is
proportional to the speed at which the molecules rotate and tumble in on. Under nt
pressure, temperature and viscosity, FP is ly related to the molecular weight of a fluorescent
species. Therefore, when a small fluorescent molecule is incorporated into a larger molecule, there is
an increase in PP. PP can be used in for genotyping of polymorphisms of interest (Chen et al,
Genome Res, 1999; 9: 492-8 and Latif et al, Genome Res, 2001; 11;436-40). FP can be utilized in 5’
nuclease assay (as described above), where the oligonucleotide probe is digested to a lower molecule
weight species, for example is amenable to is by FP, but with the added benefit of not requiring
a quencher. For example, Perkin-Elmers AcycloPrimeTM-FP SNP Detection Kit can be used as a PP
minisequencing method. Following PCR amplification, unicoportated primers and nucleotides are
degraded enzymatically, the enzymes heat inactivated and a minisequencing reaction using DNA
polymerase and fluorescent-labeled dideoxynucleotides performed. FP is then measured, typically in
a 96- to 386-well plate format on a FP-plate reader.
Pyrosequencing
In some embodiments, the primer extension reaction and analysis is performed using
PYROSEQUENCINGTM (Uppsala, Sweden) which essentially is sequencing by synthesis. A
cing primer, designed directly next to the nucleic acid differing between the disease-causing
mutation and the normal allele or the different SNP s is first hybridized to a single stranded,
PCR amplified DNA template from the individual, and incubated with the enzymes, DNA
polymerase, ATP sulfurylase, luciferase and apyrase, and the substrates, adenosine 5/ phosphosulfate
(APS) and rin. One of four deoxynucleotide triphosphates (dNTP), for example, corresponding
to the nucleotide t in the mutation or polymorphism, is then added to the reaction. DNA
polymerase catalyzes the incorporation of the dNTP into the standard DNA strand. Each
incorporation event is accompanied by release of osphate (PPi) in a quantity lar to the
amount of incorporated tide. Consequently, ATP ylase converts PPi to ATP in the
presence of adenosine 5/ phosphosulfate. This ATP drives the rase-mediated conversion of
luciferin to oxyluciferin that generates visible light in amounts that are proportional to the amount of
ATP. The light produced in the luciferase-catalyzed reaction is detected by a charge coupled device
(CCD) camera and seen as a peak in a PYROGRAMTM. Each light signal is proportional to the
number of nucleotides incorporated and allows a clear ination of the presence or absence of, for
e, the mutation or polymorphism. Thereafter, apyrase, a nucleotide degrading enzyme,
continuously degrades unincorporated dNTPs and excess ATP. When degradation is complete,
another dNTP is added which corresponds to the dNTP present in for example the selected SNP.
Addition of dNTPs is performed one at a time. Deoxyadenosine alfa-thio triphosphate (dATPS) is
used as a substitute for the natural deoxyadenosine triphosphate (dATP) since it is efficiently used by
the DNA polymerase, but not recognized by the luciferase. For detailed information about reaction
conditions for the PYROSEQUENCING, see, e.g. U.S. Patent No. 6,210,891, which is incorporated
herein by reference.
INVADER® Assay
Alternatively, an INVADER® assay can be used (Third Wave Technologies, Inc
(Madison, WI)). This assay is generally based upon a structure-specific nuclease activity of a variety
of enzymes, which are used to cleave a -dependent cleavage structure, y indicating the
presence of ic nucleic acid ces or specific variations thereof in a sample (see, e.g. U.S.
Patent No. 6,458,535). For example, an INVADER® operating system (OS), provides a method for
detecting and quantifying DNA and RNA. The INVADER® OS is based on a "perfect match"
enzyme-substrate reaction. The INVADER® OS uses proprietary CLEAVASE® enzymes (Third
Wave Technologies, Inc (Madison, WI)), which recognize and cut only the ic structure formed
during the INVADER® process which structure differs between the different alleles selected for
detection, i.e. the e-causing allele and the normal allele as well as between the different selected
SNPs. Unlike the PCR-based methods, the INVADER® OS relies on linear amplification of the signal
generated by the INVADER® process, rather than on exponential ication of the target.
In the INVADER® process, two short DNA probes hybridize to the target to form a
structure ized by the CLEAVASE® enzyme. The enzyme then cuts one of the probes to release
a short DNA "flap." Each released flap binds to a fluorescently-labeled probe and forms another
cleavage structure. When the CLEAVASE® enzyme cuts the labeled probe, the probe emits a
able fluorescence signal.
Mutations or polymorphisms can also be detected using allele-specific hybridization
followed by a MALDI-TOF-MS detection of the different ization products. In the preferred
embodiment, the detection of the enhanced or amplified nucleic acids representing the ent alleles
is med using matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) mass
spectrometric (MS) analysis described in the Examples below. This method differentiates the alleles
based on their different mass and can be applied to analyze the products from the various above-
described -extension methods or the INVADER® process.
Gel Migration-Based Methods (e. g., Single Stranded Conformation Polymorphism)
In other embodiments, alterations in electrophoretic mobility are used to identify the
particular allelic variant. For example, single strand mation polymorphism (SSCP) can be used
to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et
al. (1989) Proc Natl. Acad. Sol USA ; Cotton (1993) Mutat. Res. 285:125-144 and Hayashi
(1992) Genet Anal Tech Appl 9:73-79). Single-stranded DNA fragments of sample and control
nucleic acids are denatured and allowed to renature. The secondary structure of single-stranded
nucleic acids varies according to the sequence, the resulting alteration in electrophoretic mobility
enables the detection of even a single base change. Alterations in the mobility of the resultant
products are thus tive of a base change. Suitable controls and knowledge of the "normal"
migration patterns of the ype alleles can be used to identify polymorphic variants. The DNA
fragments can be d or ed with labeled probes. The sensitivity of the assay can be enhanced
by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in
ce. In another preferred embodiment, the subject method utilizes heteroduplex analysis to
separate double ed heteroduplex molecules on the basis of changes in electrophoretic mobility
(Keen et al. (1991) Trends Genet. 7:5).
In yet another embodiment, the identity of the allelic variant is obtained by analyzing
the movement of a nucleic acid comprising the rphic region in polyacrylamide gels containing
a gradient of denaturant, which is assayed using denaturing gradient gel electrophoresis (DGGE)
(Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be
ed to insure that it does not completely denature, for, example by adding a GC clamp of
approximately 40 bp of high-melting GC rich DNA by PCR. In a further embodiment, a temperature
gradient is used in place of a denaturing agent gradient to identify differences in the mobility of
control and sample DNA (Rosenbaum and Reissner (1987) s Chem 265: 1275).
Other Assays
Other methods for genetic ing can be used to detect the presence or absence of
any of the SNP biomarkers described herein, for example, to detect mutations in c DNA,
cDNA and/or RNA s. Methods commonly used, or newly developed or methods yet unknown
are encompassed for use in detection of the presence or e of any of the SNP biomarkers
bed herein. Examples of newly discovered methods e for e, but are not limited to;
SNP mapping (Davis et al, Methods Mol y, 2006; 351;75-92); Nanogen Nano Chip, (keen-Kim
et al, 2006; Expert Rev Mol Diagnostic, 6;287-294); Rolling circle amplification (RCA) combined
with circularable oligonucleotide probes (c-probes) for the detection of nucleic acids (Zhang et al,
2006: 363;61-70), luminex XMAP system for detecting multiple SNPs in a single reaction vessel
(Dunbar SA, Clin Chim Acta, 2006; 363;71-82; Dunbar et al, Methods Mol Med, 2005;114:147-1471)
and enzymatic mutation detection methods (Yeung et al, Biotechniques, 2005; 38;749-75 8).
WO 74676
In one embodiment, one method of screening for point mutations is based on RNase
cleavage of base pair ches in RNA/DNA or RNA/RNA heteroduplexes. As used herein, the
term "mismatch" is defined as a region of one or more unpaired or mispaired nucleotides in a double-
stranded RNA/RNA, RNA/DNA or DNA/DNA le. This definition thus includes mismatches
due to insertion/deletion ons, as well as single or multiple base point mutations.
In such embodiments, protection from cleavage agents (such as a nuclease,
hydroxylamine or osmium tetroxide and with dine) can be used to detect mismatched bases in
RNA/RNA DNA/DNA, or RNA/DNA heteroduplexes (see, e.g., Myers et al. (1985) Science
230:1242). In general, the technique of "mismatch cleavage" starts by providing heteroduplexes
formed by hybridizing a control nucleic acid, which is optionally labeled, e. g., RNA or DNA,
comprising a tide sequence of the allelic variant of the gene of interest with a sample nucleic
acid, e. g., RNA or DNA, obtained from a tissue sample. The double-stranded duplexes are treated
with an agent which cleaves -stranded regions of the duplex such as duplexes formed based on
ir mismatches between the control and sample strands. For instance, A duplexes can
be treated with RNase and A hybrids treated with S1 nuclease to enzymatically digest the
mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated
with ylamine or osmium tetroxide and with piperidine in order to digest mismatched regions.
After digestion of the mismatched s, the resulting material is then ted by size on
denaturing polyacrylamide gels to determine r the control and sample nucleic acids have an
identical nucleotide sequence or in which nucleotides they are different. See, for example, U. S.
Patent No. 6,455,249, Cotton et al. (1988) Proc. Natl. Acad. Sci. USA 85:4397; Saleeba et al. (1992)
Methods Enzy. 217:286-295. In another embodiment, the control or sample nucleic acid is labeled for
detection.
US. Patent 4,946,773 describes an RNaseA ch ge assay that involves
ing single-stranded DNA or RNA test s to an RNA probe, and subsequent treatment of
the nucleic acid duplexes with RNaseA. For the detection of mismatches, the single-stranded products
of the RNaseA treatment, electrophoretically ted according to size, are compared to similarly
treated control es. Samples containing smaller fragments (cleavage products) not seen in the
control duplex are scored as positive. The use of RNaseI for mismatch detection is also described in
literature from Promega Biotech. Promega markets a kit containing RNaseI that is reported to cleave
three out of four known mismatches.
In one embodiment, a long-range PCR (LR-PCR) is used to detect mutations or
polymorphisms. LR-PCR products are genotyped for mutations or polymorphisms using any
genotyping methods known to one skilled in the art, and haplotypes inferred using mathematical
approaches (e.g., Clark's algorithm (Clark (1990) Mol. Biol. Evol. 7:111-122).
For example, methods including complementary DNA (cDNA) arrays (Shalon et al.,
Genome Research 6(7):639-45, 1996; Bernard et al., Nucleic Acids Research 24(8):l435-42, 1996),
solid-phase mini-sequencing technique (U.S. Patent No. 6,013,431, Suomalainen et al. M01.
Biotechnol. Jun; 15(2):123-31, 2000), ion-pair high-performance liquid chromatography (Doris et al.
J. togr. A can 8; 806(1):47-60, 1998), and 5' nuclease assay or real-time RT-PCR (Holland et
al. Proc Natl Acad Sci USA 88: 7276—7280, 1991), or primer extension methods described in the U.S.
Patent No. 6,355,433, can be used.
Another method to detect mutations or polymorphisms is by using cence
tagged dNTP/ddNTPs. In addition to use of the fluorescent label in the solid phase mini-sequencing
method, a standard nucleic acid sequencing gel can be used to detect the fluorescent label
incorporated into the PCR amplification product. A sequencing primer is designed to anneal next to
the base differentiating the e-causing and normal allele or the selected SNP alleles. A primer
extension reaction is performed using chain terminating dideoxyribonucleoside triphosphates
(ddNTPs) labeled with a fluorescent dye, one label attached to the ddNTP to be added to the standard
nucleic acid and another to the ddNTP to be added to the target c acid.
Others have described using the MutS protein or other DNA-repair enzymes for
detection of single-base ches. Alternative methods for detection of on, insertion or
substitution mutations that can be used in the practice of various aspects described herein are
disclosed in U.S. Patents 5,849,483, 5,851,770, 5,866,337, 525 and 870, each of which is
orated herein by reference.
In another embodiment, multiplex PCR procedures using allele-specific primers can
be used to simultaneously y multiple regions of a target nucleic acid (PCT Application
W089/10414), enabling amplification only if a ular allele is present in a sample. Other
embodiments using alternative primer-guided nucleotide incorporation procedures for assaying
polymorphic sites in DNA can be used, and have been described (Komher, J. S. et al., Nucl. Acids.
Res. 17:7779-7784 (1989); v, B. P., Nucl. Acids Res. 18:3671 (1990); Syvanen, A.-C., et al.,
Genomics 8:684-692 (1990); Kuppuswamy, M.N. et al., Proc. Nad. Acad. Sci. ) 88:1143-1147
(1991); Bajaj et al. (U.S. Patent No. 5,846,710); Prezant, T.R. et al., Hum Mutat. 1: 159-164 (1992);
Ugozzoli, L. et al., GATA 112 47 (1992); Nyr6n, P. et al., Anal. Biochem. 208:171-175
( 1993)).
Other known nucleic acid ication procedures include transcription- based
amplification systems (Malek, L.T. et al., U.S. Patent 238; Davey, C. et al., European Patent
Application 329,822; Schuster et al.) U.S. Patent 5,169, 766; , H.I. et al., PCT cation
W089/06700; Kwoh, D. et al., Proc. Natl. Acad Sci. (U.S.A) 86:1173 Zl989); Gingeras, T.R. et al.,
PCT Application W08 8/10315)), or isothermal amplification methods (Walker, G.T. et al., Proc. Natl.
4cad Sci. (U.S.A) 89:392-396 (1992)) can also be used.
Another method to determine genetic variation is using “gene chips”. The use of
microarrays comprising a multiplicity of sequences is becoming increasingly common in the art.
Accordingly, a microarray having at least one oligonucleotide probe, as described above, appended
thereon, can be used for SNP genotyping to interrogate the presence or absence of at least one SNP
described herein and/or additional alleles ated with responsiveness to a folate-containing
compound.
Probes can be affixed to surfaces for use as " gene chips." Such gene chips can be
used to detect genetic variations by a number of techniques known to one of skill in the art. In one
technique, oligonucleotides are arrayed on a gene chip for determining the DNA sequence of a by the
sequencing by hybridization approach, such as that outlined in US. Patent Nos. 6,025,136 and
6,018,041. The probes can also be used for fluorescent ion of a genetic sequence. Such
techniques have been described, for e, in US. Patent Nos. 5,968,740 and 5,858,659. A probe
also can be affixed to an electrode surface for the electrochemical detection of nucleic acid sequences
such as described by Kayyem et al. US. Patent No. 5,952,172 and by , SC. et al. (1999)
Nucleic Acids Res. 27:4830-4837.
Examples of identifying polymorphisms and applying that information in a way that
yields useful information regarding patients can be found, for example, in US. Patent No. 6,472,157;
US. Patent Application Publications 20020016293, 20030099960, 20040203034; WO 0180896, all of
which are hereby incorporated by reference.
Determination of expression levels ofserqulasma biomarkers (e. g., SAM, SAH, 4-HNE, hsCRP)
At least one of serum/plasma biomarkers as described herein (e.g., SAM, SAH, 4-
HNE, and/or hsCRP) can be measured ing to methods to one skilled in the art. In some
embodiments, sion levels of serum/plasma biomarkers (e.g., SAM, SAH, 4-HNE and/or
hsCRP) can be determined by measuring protein levels. In some embodiments, sion levels of
serum/plasma biomarkers (e.g., hsCRP) can be determined by measuring mRNA levels.
Determining sion level by measuring protein: By way of example only, the
levels of serum/plasma kers (e.g., SAM, SAH, 4-HNE and/or hsCRP) can be measured by
contacting a test sample with an antibody-based binding moiety that specifically binds to at least one
of the plasma kers described herein, or to a fragment thereof. Formation of the
antibody- protein complex is then detected by a variety of methods known in the art.
The term "antibody-based binding " or “antibody” can include
immunoglobulin molecules and immunologically active determinants of immunoglobulin molecules,
e.g., molecules that contain an antigen binding site which specifically binds (immunoreacts with) to
the serum/plasma ns (e.g., SAM, SAH, 4-HNE and/or hsCRP). The term ody-based
binding moiety” is intended to include whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE,
etc), and includes fragments thereof which are also specifically reactive with the serum/plasma
proteins (e.g., SAM, SAH, 4-HNE and/or hsCRP). Antibodies can be fragmented using conventional
techniques. Thus, the term es segments of proteolytically-cleaved or recombinantly-prepared
ns of an antibody molecule that are e of selectively reacting with a certain protein. Non-
WO 74676
limiting examples of such lytic and/or recombinant fragments include Fab, F(ab’)2, Fab’ , Fv,
dAbs and single chain antibodies (scFv) containing a VL and VH domain joined by a peptide linker.
The scFv’s can be covalently or non-covalently linked to form antibodies having two or more binding
sites. Thus, "antibody-base binding moiety" includes polyclonal, monoclonal, or other purified
preparations of antibodies and recombinant antibodies. The term "antibody-base binding moiety" is
further intended to include humanized dies, bispecific antibodies, and chimeric molecules
having at least one n binding determinant derived from an antibody molecule. In some
embodiments, the dy-based g moiety can be detectably labeled.
"Labeled antibody", as used herein, includes antibodies that are labeled by a
detectable means and include, but are not limited to, antibodies that are enzymatically, radioactively,
fluorescently, and chemiluminescently labeled. Antibodies can also be labeled with a detectable tag,
such as c-Myc, HA, VSV-G, HSV, FLAG, V5, or HIS. The detection and quantification of the
serum/plasma proteins (e. g., SAM, SAH, 4-HNE and/or hsCRP) in test samples correlate to the
intensity of the signal emitted from the detectably d antibody.
In some embodiments, the dy-based binding moiety can be detectably labeled
by linking the antibody to an . The enzyme, in turn, when exposed to its substrate, will react
with the substrate in such a manner as to produce a chemical moiety which can be detected, for
example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used to
detectably label the antibodies against the serum/plasma proteins (e. g., SAM, SAH, 4-HNE and/or
hsCRP) can include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-V-
steroid isomerase, yeast l dehydrogenase, alpha-glycerophosphate dehydrogenase, triose
phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, e oxidase,
alactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate ogenase,
glucoamylase and acetylcholinesterase.
Detection can also be accomplished using any of a y of other immunoassays.
For e, by radioactively labeling an antibody, it is possible to detect the antibody through the
use of radioimmune assays. The radioactive isotope can be detected by such means as the use of a
gamma r or a scintillation counter or by autoradiography. Isotopes which are particularly useful
for the purpose of detection are 3H, 131I, 35S, 14C, and 125I.
It is also possible to label an antibody with a cent compound. When the
fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can then be
detected due to fluorescence. Examples of the most commonly used fluorescent labeling compounds
include, but not d to, CYE dyes, fluorescein isothiocyanate, rhodamine, phycoerytherin,
phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
An antibody can also be detectably labeled using fluorescence emitting metals such as
152Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal
chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid
(EDTA).
An antibody also can be detectably labeled by coupling it to a chemiluminescent
compound. The presence of the chemiluminescent-antibody is then determined by detecting the
presence of luminescence that arises during the course of a chemical reaction. Examples of
chemiluminescent labeling compounds can include, but not limited to, luminol, luciferin, inol,
theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
Without limitations, levels of the serum/plasma ns (e.g., SAM, SAH, 4-HNE
and/or hsCRP) can be detected by immunoassays, such as enzyme linked immunoabsorbant assay
), radioimmunoassay (RIA), Immunoradiometric assay (IRMA), Western blotting,
immunocytochemistry or immunohistochemistry, each of which are described in more detail below.
In some embodiments, immunoassays such as ELISA or RIA can be used for determining expression
levels of the serum/plasma proteins (e.g., SAM, SAH, 4-HNE and/or hsCRP). Antibody arrays or
protein chips can also be employed, see for e US. Patent Application Nos: 2003/0013208A1;
2002/0155493A1; 017515 and US. Patent Nos: 6,329,209; 6,365,418, which are herein
incorporated by reference. Commercially ble antibodies and/or immunoassays (such as ELISA)
for detecting the serum/plasma proteins (e.g., SAM, SAH, 4-HNE and/or hsCRP), e.g., from Cell
BioLabs, Abcam, Novus Biologicals, and Thermo Scientific Pierce Antibodies, can be used in the
assays and/or methods described herein.
Immunoassays: The most common enzyme immunoassay is the "Enzyme-Linked
Immunosorbent Assay (ELISA)." ELISA is a technique for ing and measuring the
concentration of an antigen using a labeled (e. g. enzyme ) form of the antibody. There are
different forms of ELISA, which are well known to those skilled in the art. The standard techniques
known in the art for ELISA are described in ds in Immunodiagnosis", 2nd Edition, Rose and
Bigazzi, eds. John Wiley & Sons, 1980; Campbell et al., "Methods and Immunology", W. A.
Benjamin, Inc., 1964; and Oellerich, M. 1984, J. Clin. Chem. Clin. Biochem., 22:895-904.
In a "sandwich ELISA", an antibody (e.g. anti-enzyme) is linked to a solid phase (i.e.
a microtiter plate) and exposed to a biological sample containing antigen (e. g. enzyme). The solid
phase is then washed to remove unbound antigen. A labeled antibody (e.g. enzyme linked) is then
bound to the bound-antigen (if t) forming an antibody-antigen-antibody sandwich. Examples of
enzymes that can be linked to the antibody are alkaline phosphatase, adish peroxidase,
luciferase, urease, and B-galactosidase. The enzyme linked antibody reacts with a substrate to
generate a colored on product that can be measured.
In a "competitive ELISA", antibody is incubated with a sample ning antigen
(i.e. enzyme). The antigen-antibody mixture is then contacted with a solid phase (e. g. a microtiter
plate) that is coated with n (i.e., enzyme). The more antigen present in the sample, the less free
antibody that will be available to bind to the solid phase. A labeled (e.g., enzyme linked) secondary
2012/065084
antibody is then added to the solid phase to determine the amount of primary antibody bound to the
solid phase.
In an "immunohistochemistry assay" a test sample is tested for specific proteins by
ng the test sample to antibodies that are specific for the n that is being assayed. The
antibodies are then ized by any of a number of methods to determine the presence and amount
of the protein present. Examples of methods used to visualize antibodies are, for example, through
enzymes linked to the antibodies (e.g., luciferase, alkaline phosphatase, horseradish peroxidase, or
beta-galactosidase), or chemical methods (e.g., DAB/Substrate chromagen). The sample is then
analysed microscopically, for example, by light microscopy of a sample stained with a stain that is
detected in the visible um, using any of a y of such staining methods and reagents known
to those skilled in the art.
] Alternatively, "Radioimmunoassays" can be employed. A radioimmunoassay is a
technique for detecting and measuring the concentration of an antigen using a labeled (e.g..
radioactively or fluorescently d) form of the antigen. Examples of radioactive labels for
antigens include 3H, 14C, and 125I. The concentration of antigen enzyme in a test sample or a
ical sample can be measured by having the antigen in the biological sample compete with the
labeled (e. g. radioactively) antigen for binding to an antibody to the antigen. To ensure competitive
binding between the labeled antigen and the unlabeled antigen, the labeled antigen is present in a
concentration ient to saturate the binding sites of the antibody. The higher the concentration of
antigen in the sample, the lower the concentration of labeled antigen that will bind to the antibody.
In a radioimmunoassay, to determine the concentration of labeled antigen bound to
antibody, the antigen-antibody complex must be ted from the free antigen. One method for
separating the antigen-antibody complex from the free antigen is by precipitating the antigen-antibody
complex with an anti-isotype antiserum. Another method for separating the antigen-antibody complex
from the free antigen is by performing a "solid-phase radioimmunoassay" where the antibody is linked
(e.g., covalently) to Sepharose beads, polystyrene wells, polyvinylchloride wells, or microtiter wells.
By comparing the concentration of labeled n bound to antibody to a standard curve based on
samples having a known concentration of antigen, the tration of antigen in the biological
sample can be determined.
An "Immunoradiometric assay" (IRMA) is an immunoassay in which the antibody
reagent is radioactively labeled. An IRMA requires the production of a multivalent antigen conjugate,
by techniques such as conjugation to a protein e. g., rabbit serum n (RSA). The multivalent
n conjugate must have at least 2 antigen residues per molecule and the antigen residues must be
of sufficient ce apart to allow binding by at least two dies to the antigen. For e, in
an IRMA the multivalent antigen conjugate can be attached to a solid surface such as a plastic sphere.
Unlabeled "sample" antigen and antibody to antigen which is radioactively d are added to a test
tube containing the multivalent antigen ate coated sphere. The antigen in the sample competes
with the multivalent antigen conjugate for antigen antibody binding sites. After an appropriate
incubation period, the unbound reactants are removed by washing and the amount of radioactivity on
the solid phase is determined. The amount of bound radioactive antibody is inversely proportional to
the concentration of antigen in the sample.
In some embodiments, Western ng (Towbin et at., Proc. Nat. Acad. Sci. 76:4350
(1979)) can be used to measure sion levels of the serum/plasma ns (e.g., SAM, SAH, 4-
HNE and/or hsCRP, n a ly treated sample is run on an SDS-PAGE gel before being
transferred to a solid support, such as a nitrocellulose filter. Detectably labeled anti- enzyme
antibodies can then be used to assess enzyme levels, where the intensity of the signal from the
detectable label ponds to the amount of enzyme present. Levels can be quantified, for example
by densitometry.
In addition to assays, the expression level of at least one of the plasma
biomarkers can be determined by mass spectrometry such as MALDI/TOF (time-of-flight),
SELDI/TOF, liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass
spectrometry ), high performance liquid chromatography-mass spectrometry (HPLC-MS),
capillary electrophoresis-mass spectrometry, r magnetic resonance spectrometry, or tandem
mass spectrometry (e. g., MS/MS, MS/MS/MS, ESI-MS/MS, etc.). See for example, U.S. Patent
Application Nos: 20030199001, 20030134304, 20030077616, which are herein incorporated by
reference. Mass spectrometry methods are well known in the art and have been used to quantify
and/or identify molecules (see, e. g., Li et al. (2000) Tibtech 18:151-160; Rowley et al. (2000)
s 20: 383-397; and Kuster and Mann (1998) Curr. Opin. Structural Biol. 8: 393-400).
In certain embodiments, a gas phase ion spectrophotometer is used. In other
embodiments, laser-desorption/ionization mass spectrometry is used to analyze the sample. Modern
laser desorption/ionization mass spectrometry ("LDI-MS") can be practiced in two main variations:
matrix assisted laser desorption/ionization ("MALDI") mass spectrometry and surface-enhanced laser
desorption/ionization ("SELDI"). In MALDI, the analyte is mixed with a solution containing a
matrix, and a drop of the liquid is placed on the surface of a substrate. The matrix solution then co-
crystallizes with the ical molecules. The substrate is inserted into the mass spectrometer. Laser
energy is directed to the substrate surface where it desorbs and ionizes the biological les
without significantly fragmenting them. See, e. g., U.S. Pat. No. 5,118,937 (Hillenkamp et al.), and
U.S. Pat. No. 5,045,694 (Beavis & Chait).
In SELDI, the substrate surface is modified so that it is an active participant in the
desorption process. In one variant, the surface is tized with adsorbent and/or e reagents
that selectively bind the protein of interest. In another variant, the surface is derivatized with energy
absorbing molecules that are not ed when struck with the laser. In another variant, the surface
is derivatized with les that bind the protein of interest and that contain a photolytic bond that is
broken upon application of the laser. In each of these methods, the derivatizing agent generally is
localized to a ic location on the substrate surface where the sample is applied. See, e.g., US.
Pat. No. 060 and WO 98/59361. The two methods can be combined by, for example, using a
SELDI affinity surface to capture an analyte and adding matrix-containing liquid to the captured
analyte to provide the energy absorbing material.
For additional information regarding mass spectrometers, see, e.g., Principles of
Instrumental Analysis, 3rd edition., Skoog, rs College Publishing, Philadelphia, 1985; and
Kirk-Othmer Encyclopedia of Chemical Technology, 4.sup.th ed. Vol. 15 (John Wiley & Sons, New
York 1995), pp. 1071-1094. Software programs such as the Biomarker Wizard program (Ciphergen
Biosystems, Inc., Fremont, Calif.) can be used to aid in analyzing mass spectra, e.g., comparing the
signal strength of peak values from a of a test subject sample and a control sample (e.g., a
normal healthy person). The mass spectrometers and their techniques are well known to those of skill
in the art.
Determining expression level of a gene or protein by measuring mRNA: Real
time PCR is an amplification technique that can be used to ine expression levels of mRNA
corresponding to a protein of interest (e.g., hsCRP). (See, e.g., Gibson et al., Genome Research 6:995-
1001, 1996; Heid et al., Genome Research 6:986-994, 1996). Real-time PCR tes the level of
PCR product accumulation during amplification. This technique permits quantitative evaluation of
mRNA levels in multiple samples. For mRNA levels, mRNA can be extracted from a biological
sample, e.g. a blood sample (such as white blood cells and/or platelets) and cDNA is prepared using
standard techniques. ime PCR can be performed, for example, using a Perkin Elmer/Applied
Biosystems (Foster City, Calif.) 7700 Prism instrument. Matching primers and fluorescent probes can
be ed for genes of interest using, for example, the primer express program provided by Perkin
Elmer/Applied Biosystems (Foster City, Calif.). Optimal concentrations of primers and probes can be
initially determined by those of ordinary skill in the art, and control (for example, beta-actin) primers
and probes can be obtained commercially from, for example, Perkin Elmer/Applied Biosystems
(Foster City, Calif.). To quantitate the amount of the specific c acid of st in a , a
standard curve is generated using a control. Standard curves can be generated using the Ct values
determined in the real-time PCR, which are related to the initial concentration of the nucleic acid of
interest used in the assay. Standard dilutions g from 101-106 copies of the gene of interest are
generally sufficient. In on, a standard curve is generated for the control sequence. This permits
standardization of initial content of the c acid of interest in a test sample to the amount of
control for comparison purposes.
Methods of ime tative PCR using TaqMan probes are well known in the
art. Detailed protocols for real-time tative PCR are provided, for example, for RNA in: Gibson
et al., 1996, A novel method for real time quantitative RT-PCR. Genome Res., 10995-1001; and for
DNA in: Heid et al., 1996, Real time quantitative PCR. Genome Res., 10:986-994.
2012/065084
The TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5'
fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be
extended due to a blocking agent at the 3' end. When the PCR product is ied in subsequent
, the 5' nuclease activity of the polymerase, for example, AmpliTaq, results in the cleavage of
the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby
resulting in an increase in fluorescence as a function of amplification (see, for example, Perkin-
Elmer).
In another embodiment, detection of RNA transcripts can be achieved by Northern
blotting, wherein a preparation of RNA is run on a denaturing agarose gel, and transferred to a
suitable support, such as activated cellulose, nitrocellulose or glass or nylon membranes. Labeled
(e. g., radiolabeled) cDNA or RNA is then hybridized to the preparation, washed and analyzed by
methods such as autoradiography.
Detection of RNA transcripts can further be accomplished using known amplification
methods. For example, mRNA can be reverse-transcribed into cDNA followed by polymerase chain
reaction (RT-PCR); or, to use a single enzyme for both steps as bed in U.S. Pat. No. 5,322,770,
or reverse transcribe mRNA into cDNA ed by symmetric gap lipase chain reaction (RT-
AGLCR) as described by R. L. Marshall, et al., PCR s and Applications 4: 80-84 . One
suitable method for detecting enzyme mRNA transcripts is bed in reference Pabic et. al.
Hepatology, 37(5): 1056-1066, 2003, which is herein incorporated by reference.
In situ ization visualization can also be employed, n a radioactively
labeled antisense RNA probe is hybridized with target biomarkers in a test sample, washed, d
with RNase and exposed to a sensitive emulsion for autoradiography. The samples can be stained with
haematoxylin to demonstrate the histological composition of the , and dark field imaging with
a suitable light filter shows the developed emulsion. Non-radioactive labels such as digoxigenin can
also be used.
Alternatively, mRNA expression can be detected on a DNA array, chip or a
microarray. Oligonucleotides corresponding to enzyme are immobilized on a chip which is then
hybridized with labeled nucleic acids of a test sample obtained from a patient. Positive hybridization
signal is obtained with the sample ning ker transcripts. Methods of preparing DNA
arrays and their use are well known in the art. (See, for example U.S. Patent Nos: 6,618,6796;
6,379,897; 377; 6,451,536; 548,257; U.S. 20030157485 and Schena et al. 1995 Science 20:467-
470; Gerhold et al. 1999 Trends in Biochem. Sci. 24, 168-173; and Lennon et al. 2000 Drug discovery
Today 5: 59-65, which are herein incorporated by reference). Serial Analysis of Gene Expression
(SAGE) can also be med (See for e U.S. Patent Application 20030215858).
Methodsfor treating a human subject with depression
] In accordance with various aspects bed herein, if a subject with depression is
detected to have the presence of at least one of the conditions (A)-(X) determined in the assay
described herein, the subject is recommended for and/or administered with a treatment regimen
comprising a folate-containing compound. In such embodiments, the subject can be further
administered or prescribed with a treatment n comprising an anti-depressant drug and a folate-
ning compound. Accordingly, ed herein are also methods for treating a subject with
depression. In some embodiments, the method comprises performing any embodiments of the assay
for selecting a treatment regimen for a subject with depression described herein. In some
embodiments, the method can further comprise ibing and/or administering a treatment regimen
comprising a folate-containing compound to the selected human subject.
In some embodiments, a method for treating a human subject with depression can
comprise administering a composition comprising an effective amount of a folate-containing
compound to the human subject, who is diagnosed as having, or having a risk for, depression, and is
further determined to carry at least one or more ding at least two, at least three, at least four or
more), or any combinations of the conditions (A)-(X) described .
In certain embodiments, the method can comprise administering a composition
comprising an effective amount of a folate-containing compound to the human subject, who is
diagnosed as having, or having a risk for, sion, and is further determined to carry at least one of
the following SNPs or a combination thereof: (i) a SNP at position 677 of SEQ ID NO. 1 or position
27 of SEQ ID NO. 7 (identified by rs1801133) comprising at least one thymine "T" allele, and (ii) a
SNP at position 2756 of SEQ ID NO. 2 or on 27 of SEQ ID NO. 9 comprising at least one
guanine "G" allele. In these embodiments, the method can further comprise determining the presence
or absence of any of the conditions (A)-(X) bed .
In some embodiments, the subject administered with a ent regimen comprising
a folate-containing compound can be further ined to be obese (e.g., with a BMI value of at least
about 30 kg/m2 or higher).
The terms “treatment” and “treating” as used herein, with respect to treatment of a
disease, means preventing the progression of the e, or altering the course of the disorder (for
example, but are not limited to, slowing the progression of the er), or reversing a symptom of
the disorder or reducing one or more symptoms and/or one or more mical markers in a t,
preventing one or more symptoms from worsening or progressing, promoting recovery or improving
prognosis. For example, in the case of treating depression, therapeutic treatment refers to alleviation
of at least one symptom associated with depression. Measurable lessening includes any statistically
significant decline in a measurable marker or symptom, such as measuring markers for depression in
the blood as described later or assessing the degree of depression, e.g., using the criteria listed in
DSM-IV or the efficacy measures as described in the Examples, e.g., HAMD-l7, 8, CGI,
Maier or HAMD-7, after treatment. In one embodiment, at least one symptom of depression is
2012/065084
alleviated by at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least
about 40%, or at least about 50%. In another embodiment, at least one symptom is alleviated by more
than 50%, e. g., at least about 60%, or at least about 70%. In one embodiment, at least one symptom is
alleviated by at least about 80%, at least about 90% or greater, as compared to a control (e.g., a
subject having the same or similar degree of sion as the treated subject is administered without
a folate-containing compound, or a subject who has met none of the conditions described herein is
administered with treatment regimen comprising a folate-containing nd). In some
embodiments, at least one neuropsychological test is improved (e. g., HAMD-17 rating is decreased)
by at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%,
or at least about 50%. In another ment, at least one neuropsychological test is improved (e.g.,
HAMD-17 rating is decreased) by more than 50%, e.g., at least about 60%, or at least about 70%. In
one embodiment, at least one neuropsychological test is improved (e.g., HAMD-17 rating is
decreased) by at least about 80%, at least about 90% or greater, as compared to a control (e.g., a
subject having the same or similar degree of depression as the treated subject is administered without
a -containing compound, or a subject who has met none of the conditions described herein is
administered with treatment n comprising a folate-containing compound). In some
embodiments, at least one symptom of depression can be alleviated by at least about 10%, at least
about 15%, at least about 20%, at least about 30%, at least about 40%, or at least about 50% or higher
within a period of at least about 10 days, including, e.g., at least about 20 days, at least about 30 days,
at least about 40 days, or longer. In some embodiments, at least one neuropsychological test is
improved (e. g., HAMD-17 rating is decreased) by at least about 10%, at least about 15%, at least
about 20%, at least about 30%, at least about 40%, or at least about 50% or higher within a period of
at least about 10 days, including, e.g., at least about 20 days, at least about 30 days, at least about 40
days, or longer.
In some embodiments of this aspect and all other aspects described herein, a folate-
containing nd can be administered in an amount effective to reduce at least one m
(e.g., but not limited to, low mood, anhedonia, low energy, insomnia, agitation, anxiety and/or weight
loss) associated with depression, e. g., major depressive disorders. In some embodiments, the effective
amount of a folate-containing nd can provide at least about 0.1 to about 1 mg/kg body weight
per day administration to the human subject. In some embodiments, the effective amount of a folate-
containing compound can provide at least about 7.5 mg/day to about 50 mg/day administration to the
human t. In one embodiment, the effective amount of a folate-containing compound can
provide at least about 15 mg/day of folate administration to the human t.
] The effective amount of the folate-containing compound can be administered to a
selected human subject as a single daily dose, or alternatively, in more than one d doses per day
via any suitable administration route, e. g., oral administration.
2012/065084
In some embodiments of this aspect and all other aspects described herein, the
treatment regimen can r comprise selecting and optionally administering an antidepressant drug.
In some embodiments, the anti-depressant drug can include a selective serotonin reuptake inhibitor,
including, but not limited to, fluoxetine, citalopram, paroxetine, escitalopram, sertraline, and any
ations f.
The subject with depression being treated with the methods described herein can be a
t currently taking an antidepressant. Accordingly, the methods of treating a human subject with
depression described herein can also be used to select a human subject to be treated with the
ation of a folate-containing nd and an antidepressant to improve the effectiveness of an
anti-depressant drug tly taken by a subject accordingly. Accordingly, if the human t
currently taking an antidepressant is determined to have at least one (including, e.g., at least two, at
least three or more) of the conditions (A)-(X) bed herein, the subject can be further administered
or prescribed with a folate-containing compound as an adjuvant to the anti-depressant he/she is
currently taking.
In other embodiments, if the subject currently taking an antidepressant is determined
to have at least one (including, e.g., at least two, at least three or more) of the conditions (A)-(X)
described herein, the subject can be administered to a ent regimen comprising a folate-
containing compound without the antidepressant.
] In some embodiments, the methods described herein can be used to treat at least one
or more core symptoms of depression (e.g., but not limited to low or depressed mood, anhedonia (e.g.,
loss of interest or pleasure in nearly all activities), low energy levels) in a subject who is determined
to have at least one (including, e.g., at least two, at least three or more) of the conditions (A)-(X)
described herein.
Treatment regimen comprising afolate-eontaining compound
A -containing compound included in a treatment regimen can be administered
can be administered together via a single dosage form or by separate administration. In certain
ments, the folate-containing compound can be administered in a single dosage form. For
example, the single dosage form can be administered as a single tablet, pill, capsule for oral
stration or a solution for parenteral administration. Alternatively, the folate-containing
compound can be administered as separate itions, e.g., as separate tablets or solutions. The
length of time between administration of a sub-dose of a folate-containing compound can be adjusted
to achieve the d therapeutic effect.
In some embodiments, a treatment regimen comprising a folate-containing compound
further comprise at least one anti-depressant (e.g., l, 2, 3 or more antidepressants). A treatment
regimen comprising a folate-containing compound and at least one epressant can be
administered together via a single dosage form or by separate administration. In certain embodiments,
the antidepressant and the -containing compound are administered together in a single dosage
form. For e, the single dosage form can be administered as a single tablet, pill, e for oral
administration or a solution for eral administration. Alternatively, the antidepressant and the
folate-containing compound can be administered as separate compositions, e.g., as separate tablets or
solutions. The antidepressant can be administered at the same time as the folate-containing compound,
or the antidepressant can be administered intermittently with the folate-containing compound. The
length of time between administration of the antidepressant and the folate-containing compound can
be adjusted to achieve the desired therapeutic effect. In particular, the folate-containing compound can
be administered at any frequency or administration protocol to e the efficacy of the
antidepressant drug, as compared to efficacy of the antidepressant drug alone (e. g., in the absence of
the folate-containing compound).
] In some embodiments, the folate-containing compound can be administered only a
few minutes (e. g., l, 2, 5, 10, 30, or 60 min) before or after administration of the antidepressant.
Alternatively, the folate-containing compound can be administered several hours (e.g., 2, 4, 6, 10, 12,
24, or 36 hr) before or after administration of the antidepressant. Depending on the half-lives of the
antidepressant and the folate-containing compound, in certain embodiments, it can be advantageous to
administer more than one dosage of the folate-containing compound between strations of the
antidepressant. For example, the folate-containing compound can be administered at 3 hours and then
again at 6 hours following administration of the pressant. Alternatively, it can be advantageous
to administer more than one dosage of the antidepressant between administrations of the folate-
ning nd. Importantly, in some embodiments, the eutic effect of each
antidepressant and -containing compound can overlap for at least a portion of the duration of
each therapeutic agent so that the overall therapeutic effect of the combination therapy is attributable
in part to the combined of the combination therapy. In some embodiments, the folate-containing
compound and the pressant can be administered in a pulse administration. In other
embodiments, they can be administered as a pulse-chase administration, e. g., where a folate-
containing compound is administered for a brief period of time (pulse), followed by administration of
the antidepressant for a longer period of time (e.g., chase).
In some ments where the antidepressant and the folate-containing compound
are administered in separate compositions, the antidepressant and the folate-containing compound can
be administrated by the same or different routes. For example, the antidepressant can be administered
by intravenous injection while the folate-containing compound can be administered orally, or vice
versa. Alternatively, for example, both the antidepressant and -containing nd can be
administered together by intravenous injection or by oral administration.
In any embodiments of the s described herein, the adjuvant effect of the
folate-containing compound administered in combination with an antidepressant can be additive. The
term “additive" as used herein in the context of one agent has an additive effect on a second agent,
refers to an increase in effectiveness of a first agent in the presence of a second agent as compared to
the use of the first agent alone. Stated in another way, the second agent can function as an agent which
enhances the physiological response of an organ or organism to the presence of a first agent. Thus, a
second agent will increase the effectiveness of the first agent by increasing an individual’s response to
the presence of the first agent.
] In any embodiments of the methods described herein, the nt effect of the
folate-containing compound administered in combination with an antidepressant can be istic.
The term “synergy" or “synergistic" as used herein refers to the interaction of two or more agents so
that their combined effect is greater than each of their individual effects at the same dose alone.
In some embodiments, the treatment regimen can further comprise life-style advice,
including, e.g., prescribing an se regime, dietary , and/or administering another
ceutical agent effective in ent of depression.
Folate orfolate-wntaining compounds
Any art-recognized folate-containing compound can be selected and/or optionally
administered to a human t selected to carry at least one or more conditions (A)-(X) described
herein. The term “folate-containing compound” as used herein refers to a nd containing an
effective amount of at least one folate for use in the methods described herein. Folate is a form of the
soluble vitamin B9. The term “folate” as used herein encompasses the naturally-occurring form
of folate, folic acid (also known as vitamin B9 or folacin) and metabolites or derivatives thereof such
as methylfolate, tetrahydrofolate, and methyltetrahydrofolate. The term "folate" as used herein can
also refer to both pteroic acid monoglutamate (folic acid) and reduced forms such as dihydrofolates
and ydrofolates, e. g. yltetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5,10-
methylenetetrahydrofolic acid, 5,l0-methenyltetrahydrofolic acid, lO-formyltetrahydrofolic acid and
tetrahydrofolic acid, polyglutamates thereof, optical isomers thereof (e. g., lly pure natural
isomers thereof, and also mixtures of optical isomers such as racemic mixtures), derivatives thereof,
pharmaceutically acceptable salts and esters thereof, glucosamine salts thereof, and galactosamine
salts thereof.
As used herein, the term "pharmaceutically acceptable salts and esters” refers to
pharmacologically acceptable and pharmaceutically acceptable salts and esters. Pharmacologically
and pharmaceutically acceptable salts can include, but are not limited to, alkali metal or alkaline earth
metal salts, e.g., sodium, potassium, magnesium or calcium salts. Pharmacologically and
pharmaceutically acceptable esters can e, but are not limited to, C1-C4 alkyl, C5 cycloalkyl
oder C6 cycloalkyl, phenyl, Cl-C4 alkylphenyl, benzyl or Cl-C4-alkylbenzyl esters. The esters can
be ters or diesters. Diesters can be homogeneous or heterogeneous. In some embodiments,
pharmacologically and pharmaceutically acceptable esters can be homogeneous diesters such as C1-
C4 dialkylesters, for example dimethyl- or diethylesters.
In some embodiments, the folate-containing compound can include at least one
(including at least two, at least three or more) alkaline metal or alkaline earth metal salt of folate, e. g.,
but not d to, a calcium salt of folate.
In some embodiments, the folate-containing compound can include at least one
(including at least two, at least three or more) amine salt and/or galactosamine salt of folate
(including, e. g., folic acid and d folate, e. g., but not limited to, tetrahydrofolate, and derivatives
thereof). Examples of glucosamine-folate and/or galactosamine-folate and derivatives there of, e.g.,
disclosed in US. Pat. US 7,947,662, can be administered to a human subject in the methods or
ed in the compositions bed herein. In one embodiment, QUATREFOLIC® (Gnosis S.p.A,
Milan, IT) or N-[4-[[[(6S)amino-l,4,5,6,7,8-hexahydromethyloxo
pteridinyl]methyl]amino]benzoyl]-L-glutamic acid, glucosamine salt can be administered to a human
subject in the methods or included in the compositions described herein.
Folic acid, folate and their metabolites or reduced folates, e.g., methylfolate, are
substances that are characterized as vitamins, essential nutrients available in small amounts in leafy
vegetables and other foods. Folic acid is itself not biologically active, but it can be biologically
converted to tetrahydrofolate and other tives after its conversion to dihydrofolic acid in the liver
in the ce of appropriate enzymes.
In the form of a series of tetrahydrofolate (THF) compounds, folate derivatives are
substrates in a number of single-carbon-transfer reactions and also are ed in the synthesis of
dTMP (2'—deoxythymidine-5'-phosphate) from dUMP (2'—deoxyuridine-5'-phosphate).
] The pathway leading to the formation of methylfolate such as tetrahydrofolate (THF)
begins when folic acid (F), as folate, is reduced to dihydrofolate (DHF), which is then reduced to
tetrahydrofolate (THF). The enzyme dihydrofolate reductase catalyses the last step. Accordingly, in
some embodiments, for a subject with depression who is deficient in the enzyme dihydrofolate
reductase, methyl folate, also known as Me-THF, N5-Methyl-THF, MTHF, 5-MTHF, L-methylfolate,
and Levomefolic acid, or a pharmaceutically acceptable salt thereof (e. g., sodium salt, potassium salt,
ium salt, calcium salt, glucosamine salt, or galactosamine salt), is more desirable for use as a
-containing compound. For example, methyl folate calcium salt is available by prescription in
the United States as DEPLIN® (L-methylfolate calcium salt). Methyl folate calcium salt is also
available outside of the United States as METAFOLIN®, BODYFOLIN®, and NUTRIFOLIN®.
Additional examples of folates or folate-containing nds that can be
administered to a subject in the methods or ed in the compositions described herein can include,
but not limited to, the ones described in the US. Pat. Nos.: US 185; US 6,921,754; and US
7,947,662; and US. Pat. App. No.: US 2008/0064702, the contents of which are incorporated herein
by reference.
Biological effects of folate on the central nervous : The role of folate in
central—nervous-system function has been previously discussed, including the essential role of folate
in the one-carbon cycle that furnishes SAMe, the principal methyl donor for a broad range of
reactions involving the sis of neuroactive substances, the formation of membrane
phospholipids, and the metabolism of nucleic acids [10]. When administered in parenteral and certain
oral forms, SAM has been reported in European studies to have antidepressant efficacy greater than
placebo and comparable to that of tricyclic antidepressants [41]. Folate also appears to influence the
rate of synthesis of tetrahydrobiopterin [21], a cofactor in the hydroxylation of phenylalanine and
tryptophan, rate-limiting steps in the biosynthesis of dopamine, norepinephrine, and serotonin,
neurotransmitters postulated to play a role in the pathogenesis of depression. In addition, MTHF has
been shown to bind to aptic glutamate receptors [42], where it may potentially modulate the
release of other neurotransmitters, including the monoamines. Elevated levels of steine,
resulting from folate deficiency, can play a role in mediating some of its neuropsychiatric
complications by both generating elevated levels of S-adenosyl-homocysteine, which broadly inhibits
methylation ons [43], and also possibly ng direct excitoxic effects via activity at the N-
methyl-aspartate glutamate receptors [44].
] Low cerebrospinal fluid levels of the serotonin metabolite 5-hydroxyindole acetic
acid and the dopamine metabolite homovanillic acid have been detected, though not always [45],
among folate-deficient patients with sy [46], other neuropsychiatric disorders [47], and
congenital folate-deficiency states [48]. Whether folate supplementation actually enhances
monoamine sis or release or furnishes additional SAMe has not yet been ished. Human
studies examining the impact of supraphysiologic doses of folate on cerebrospinal-fluid metabolites
are lacking. Indeed, a previous study in rats yielded the paradoxical finding that folate
supplementation and folate deficiency d brain serotonin. [47], which can in turn indicate the
ility of a similarly complex pattern in humans.
Folate and depression: Neuropsychiatric and depressive symptoms, including
apathy, fatigue, insomnia, irritability, and impaired concentration, have been discussed in clinical
descriptions of folate-deficiency states ated with orption,[13] nvulsant-treated
sy, [14, 15] megaloblastic anemia, [16] and dietary folate restriction [1]. Previous s have
reported that as many as one-third of patients among psychiatric cohorts, mainly from the United
Kingdom, exhibited low or deficient serum folate values, with generally comparable findings in the
few studies that have assessed red blood cell (RBC) folate as a more accurate reflection of tissue
folate stores [12, 17, 18]. In the subset of the studies in which depressed patients were ed with
psychiatric or non-psychiatric control subjects, depressed patients were reported to have serum folate
[2,19], RBC folate [21], or serum methyltetrahydrofolate (MTHF) [22] levels that were lower than
levels in all other groups except for patients with alcoholism who had a r prevalence of low
folate [20]. Furthermore, low serum or RBC folate and serum MTHF were often associated with
greater symptom severity among sed patients [22, 23, 24, 25]. Among studies that failed to
demonstrate such relationship between low folate and depression severity, an inverse relationship
between folate and the duration of the depressive episode [26] or the length of alization [27]
was observed.
Folate levels and response to antidepressant treatment: The ors have
previously assessed serum folate and response to the selective serotonin reuptake inhibitor
antidepressant, fluoxetine, among 213 adults with major depression [28]. Among those depressed, but
otherwise healthy, outpatients, the prevalence of actual folate deficiency (defined as <1.5 ng/mL) was
low (2%), whereas borderline low values (1.5- 2.5 ng/mL) were more common (17%). Individuals
with low or deficient serum folate ted a 35% rate of sponse to an adequate course of
fluoxetine compared with a 20% rate of sponse among those with serum folate levels in the
normal range. A similar result was reported among 22 depressed patients older than 60 years old
treated with nortriptyline or sertraline for whom there was an inverse relationship between RBC folate
and antidepressant response [29]. Consistent with this finding, in an earlier study of 101 sed
inpatients receiving a variety of treatments, including electroconvulsive therapy, antidepressants, or
tryptophan, outcome was significantly poorer for patients with low serum folate [24]. r, for a
small number of patients undergoing electroconvulsive therapy, serum MTHF did not appear to
ate with response [22]. Thus, accurate and sensitive predictors of refractoriness to antidepressant
treatment have remained elusive [30].
Folate and MTHF supplementation/augmentation: Godfrey et al.[31]
administered MTHF (15 mg), an oral form of folate actively transported across the brain
barrier, to 24 patients with major depression and low or deficient folate (RBC folate <200 [Lg/L). In
this h, randomized, double-blind trial, those 13 depressed patients who received methylfolate
were rated globally as having superior symptom improvement and social adjustment at 3 and 6
months when ed with the 11 ts who were assigned to placebo. However, this report was
inconclusive, based on the relatively small sample and need for replication, stematic
concomitant treatments (e.g., antidepressants, lithium, or no medications), symptom improvement on
some but not all measures, and similar, gh somewhat less dramatic, response to MTHF among
comparably d patients with schizophrenia, indicating that the positive effects of MTHF may not
have been specific to depression. The prior reports extended previous work on folate replacement,
reporting improved long-term neuropsychiatric outcome among folate-deficient patients with
psychiatric [32] and gastrointestinal [13] disorders and in some, although not all, studies on
nvulsant-treated patients with epilepsy [14].
The actual clinical nce of these previous studies, however, is likely to be
increasingly limited. Recent work has reported that the ence of folate deficiency or borderline
low values is lower among contemporary psychiatric cohorts than originally believed [28] and also
that Western estimates may not be comparable to other parts of the world including Asia [33].
Moreover, most of the studies on folate and depression are based on data gathered before
implementation of folic-acid—fortification programs and the widespread public awareness about the
2012/065084
possible health benefits of folate. In the United States, the Food and Drug Administration mandate
requiring folic-acid fortification of all enriched grain products by 1998 appears to have exerted a rapid
and ntial impact on the prevalence of low and deficient folate in the community, nearly
eradicating low serum-folate values (<3 ng/mL) among 350 middle-aged and older adults in the
Framingham Offspring Study Cohort [34].
A comparable study is needed on the prevalence of low folate among carefully
diagnosed depressed cohorts in this postfortification era, ularly because the extent to which
dietary intake butes to low folate among depressed duals is not well established [2, 24, 25,
28, 35, 36]. heless, the prevalence of low folate among depressed sample subjects is believed to
be reduced well below the estimates prior to implementation of the folic-acid fortification programs.
If so, the more compelling clinical focus for clinicians who treat sion shifts from folate
replacement to folate supplementation and to the question of whether supraphysiologic doses of
folate, as monotherapy or augmentation of conventional agents, may confer antidepressant benefit
among depressed, normofolatemic patients.
Despite tremendous advances in the development of safe and effective
antidepressants, as many as 30—40% of depressed patients continue to be symptomatic and
functionally impaired despite an adequate course of antidepressant therapy [30]. Thus, the
development of novel treatment strategies has considerable public-health significance.
Correlational analyses had reported that, among individuals with major mood
disorders, higher folate values predicted better acute [25] and long-term outcome [37]. In the latter
study, duals with unipolar-depression or bipolar-disorder folate levels were boosted with daily
low-dose folate supplementation (200 ug) together with pharmacologic prophylaxis of affective
symptoms. r demonstration of the ial antidepressant t of folate comes from a
double-blind study of 96 non—folate-deficient patients with senile dementia and depressive symptoms
in which significant improvement of sion was reported among patients ized to MTHF
(50 mg), similar to that observed on the active antidepressant comparator, trazodone (100 mg/d) [38].
Among 16 elderly non-demented subjects with major depression, an open trial of MTHF (50 mg) also
resulted in ntial improvement in depressive symptoms, even among the 14 subjects who had
normal baseline serum folate [39].
] The inventors have also previously assessed the efficacy of methylfolate as an
adjunctive treatment among adults with MDD and inadequate response to an SSRI [40]. -two
adults (59% female; mean age 45.2 +/- 11.0 years) with DSM-IV MDD, partial or nonresponse to an
SSRI after at least 4 weeks of ent, and a 17—item Hamilton Depression Rating Scale (HAM-D-
17) score greater than or equal to 12 were enrolled in this 8-week prospective open trial. Exclusion
criteria included current use of anticonvulsants or psychotropics other than an SSRI, or B12
deficiency. Folinic acid was selected as an oral, synthetic, highly bioavailable form of folate that is
metabolized to MTHF after absorption and, unlike MTHF, is available for prescription in the United
States. Thus, folinic acid was added to SSRIs at 15-30 mg/day. Folate levels rose from 28 +/- 19
ng/mL to 301 +/- 203 ng/mL (p < 0.001). HAM-D-17 scores among the 16 completers decreased from
19.1 +/— 3.9 to 12.8 +/- 7.0 (p < 0.01). 31% of completers and 27% of the intent-to-treat (ITT) sample
achieved response (with at least 50% reduction in 17 scores), and 19% of completers and
18% of the ITT sample achieved remission (HAM-D-17 no r than 7). In this report, folinic acid
appeared to be only modestly effective as an adjunct in SSRI-refractory depressed individuals with
normal folate levels, and surprisingly a significant portion of depressed individuals still did not
respond to the folinic acid as an adjunct to an antidepressant. Thus, folate augmentation in treatment-
resistant depression does not produce an effective response in all individuals [49], and in particular, as
many as 29% to 46% of MDD patients show only partial or non-response to an te course of an
antidepressant [50]. In particular, these reports did not identify in which patients the folate
argumentation was effective or those ts where the antidepressant drug efficacy was not
enhanced by folate. In fact, none of these reports identify biomarkers or a screen method to identify
those subjects in where folate can e the efficacy of the pressant drug.
The assays and/or methods described herein can be used as a screen to identify and
select for particular patients with depression, where a treatment regimen sing an antidepressant
and a -containing compound will be beneficial to enhance the therapeutic effect of the
antidepressant drug.
In accordance with the assays and/or methods described , subjects with
sion who have been ined to have the presence of at least one of the ions described
herein (e.g., SNPs and/or plasma/serum biomarkers described herein) can benefit from the eutic
effect of an antidepressant administered in combination with an effective amount of a folate-
containing compound. In some embodiments, the folate-containing compound can comprise L-
methylfolate. In some ments, the folate-containing compound can comprise 6(S)
methyltetrahydrofolate (also known as 6(S)MTHF) or DEPLIN®.
] The effective amount of folate for use in the treatment methods described herein can
vary, depending upon the types and/or dosage of the antidepressant (if any), types of , severity
of depression, physical conditions of a subject (e.g., ages, genders, weights). The term “effective
amount” as used herein generally refers to an amount of folate or a folate-containing compound that,
when administered to a selected subject, can reduce at least one symptom associated with depression
as described later, e.g., by at least about 5%, at least about 10%, at least about 20%, at least about
%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about
80%, at least about 90% or more, as compared to the treatment in the absence of a folate-containing
compound.
In some embodiments, the term “effective ” as used herein refers to an amount
of folate or a folate-containing compound, when administered to a selected subject in combination
with an antidepressant, can increase the effect (e.g., efficacy or therapeutic effect) of the
antidepressant, e. g., by at least about 5%, at least about 10%, at least about 20%, at least about 30%,
at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at
least about 90% or more, as compared to the treatment with antidepressant alone. Stated another way,
the term tive amount” as used herein refers to an amount of folate or a folate-containing
compound, when administered to a ed subject in combination with an antidepressant, can reduce
at least one symptom associated with depression as described later, e.g., by at least about 5%, at least
about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least
about 60%, at least about 70%, at least about 80%, at least about 90% or more, as compared to the
treatment with antidepressant alone.
In some embodiments, the effective amount of folate in the treatment regimen as
described herein can range from about 1 mg/day to about 70 mg/day, from about 1 mg/day to about 50
mg/day, from about 2.5 mg/day to about 40 mg/day, from about 5 mg/day to about 40 , from
about 5 mg/day to about 30 mg/day or from about 7 mg/day to about 15 mg/day. In some
embodiments, the effective amount of folate in the treatment regimen as described herein can range
from about 7.5 mg/day to about 50 mg/day. In some embodiments, the effective amount of folate in
the ent regimen as described herein can range from about 7.5 mg/day to about 40 mg/day. In
some embodiments, the effective amount of folate in a ent regimen can be about 15 .
Antidepressants
As used herein, unless otherwise noted, the term "antidepressant" or “anti-depressant”
or “antidepressant drug” refers to any pharmaceutical agent which treats depression. In some
embodiments, the anti-depressant drug administered to the subject in accordance with the methods
described herein can be any conventional pharmaceutical agent which is commonly ted for
treating depression. Examples of antidepressants or antidepressant drugs can include, but are not
limited to, mine oxidase inhibitors such as phenelzine, tranylcypromine, and moclobemide;
tricyclics such as imipramine, amitriptyline, desipramine, nortriptyline, doxepin, protriptyline,
trimipramine, chlomipramine, and amoxapine; tetracyclics such as maprotiline; non-cyclics such as
nsine; triazolopyridines such as trazodone; serotonin reuptake inhibitors such as fluoxetine,
sertraline, paroxetine, citalopram, and fluvoxamine; serotonin receptor antagonists such as
done; serotonin noradrenergic reuptake inhibitors such as venlafaxine, and milnacipran;
noradrenergic and specific serotonergic agents such as mirtazapine; noradrenaline ke tors
such as reboxetine. Additional antidepressants that can be used in the methods described herein can
include, but are not limited to, bupropion; natural products such as Kava-Kava, and St. John's Wort;
dietary supplements such as osylmethionine; neuropeptides such as thyrotropin-releasing
hormone; compounds targeting neuropeptide receptors such as neurokinin receptor antagonists; and
hormones such as triiodothyronine.
2012/065084
In some ments, the antidepressant or the antidepressant drug can be a
serotonin reuptake inhibitor (SR1) or selective serotonin reuptake inhibitor (SSRI). Examples of SRIs
and/or SSRIs include, without limitations, citalopram, escitalopram, fluoxetine, R-fluoxetine,
sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, mine,
mine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine,
femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY
27866, imeldine, ifoxetine, tiflucarbine, viqualine, milnacipran, bazinaprine, YM 922, S 33005, F
98214TA, OPC 14523, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin,
amoxapine, nitroxazepine, McN 5652, McN 5707, 01 77, Org 6582, Org 6997, Org 6906,
amitriptyline, amitriptyline N-oxide, nortriptyline, CL 255. 663, pirlindole, indatraline, LY 113.821,
LY 214.281, CGP 6085 A, RU 25.591, napamezole, diclofensine, trazodone, EMD 68.843, BMY
42.569, NS 2389, remine, nitroquipazine, ademethionine, sibutramine and clovoxamine. The
SRIs can be used in the form of the base or a pharmaceutically acceptable acid addition salt thereof.
In some embodiments, other eutic compounds that can cause an elevation in the
extracellular level of 5-HT in the synatic cleft, e.g., tianeptine, can be used as an antidepressant in the
methods described herein.
In some embodiments, the pressant or the antidepressant drug can be a selective
serotonin reuptake inhibitor (SSRI). The term “selective serotonin reuptake inhibitor (SSRI)” as used
herein, refers to an inhibitor of the monoamine transporters, which has stronger inhibitory effect at the
serotonin transporter than the dopamine and the noradrenaline transporters. Examples of selective
serotonin reuptake inhibitors (SSRIs) can include, t limitations, fluoxetine, citalopram,
tine, escitalopram, sertraline, and any combinations thereof.
onal SRIs and/or SSRIs that can be administered to a t with depression in
combination with a folate-containing compound can include, for example, the ones described in the
US. Pat. App. No.: US 2005/0054688, and US 2008/0138411; and US. Pat. Nos.: 6,720,003;
6,787,560; 7,893,261; and 7148238.
One d in the art would be able to readily determine recommended dosage levels
for known and/or marketed antidepressant drugs by consulting appropriate references such as drug
package s, FDA guidelines, and the ian's Desk Reference. In some embodiments, the
antidepressant drug dose can range from 0.1 mg/day to about 1000 mg/day, from about 0.5 mg/day to
about 500 , from about 1 mg/day to about 400 mg/day, from about 5 mg/day to about 300
mg/day, or from about 10 mg/day to about 200 mg/day. One of skill in the art can readily adjust
dosage for each different antidepressant drug, ing on a number of factors such as types and/or
potency of antidepressants, severity of depression, physical condition of a t (e.g., ages, genders,
and weights), administration routes, other medications taken by a subject, and any combinations
thereof.
Pharmaceutical compositionsfor treatment of depression
For in viva stration to subjects who have met at least one (e.g., at least two, at
least three or more) of the conditions (A)-(X) determined in the assays described herein, provided
herein are pharmaceutical itions comprising a eutically effective amount of a folate-
containing compound, and a pharmaceutically acceptable carrier.
In various embodiments, the therapeutically effective amount of a folate-containing
compound or folate, optionally administered with an antidepressant or a pharmaceutically salt thereof,
is sufficient to se the degree of improvement in at least one neuropsychological test, e. g., as
ed by HAMD-17, HAMD-28 or other efficacy measures as described in the Examples, by at
least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least
about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, as
ed to the degree of improvement obtained in the absence of the folate-containing compound
(e. g., with or without the antidepressant monotherapy). In some embodiments, the therapeutically
effective amount of a folate-containing compound or folate, optionally administered with an
antidepressant or a pharmaceutically salt thereof, is sufficient to increase the degree of improvement
in at least one neuropsychological test, e.g., as measured by HAMD-17, 8 or other cy
es as described in the es, by at least about 1-fold, at least about 2-fold, at least about 3-
fold, at least about 4-fold, at least about 5-fold or more, as compared to the degree of improvement
ed in the absence of the folate-containing nd (e.g., with or without the antidepressant
monotherapy).
In some embodiments, a dose of a folate-containing nd or folate for
administration to a human can be in the range of about 0.01 to about 50 mg per am body weight
of the recipient per day, in the range of about 0.05 to about 5 mg per kilogram body weight per day, or
in the range of about 0.1 to about 1 mg per kilogram body weight per day. In certain embodiments,
the desired dose can be presented as one single unit dosage form, e. g., containing about 0.5 mg to
about 500 mg, about 5 mg to about 250 mg, about 10 mg to about 100 mg, or about 10 mg to about 50
mg. In some embodiments, one single unit dosage form can provide about 1 mg to about 70 mg
folate, about 5 mg to about 60 mg folate, or from about 7 mg to about 50 mg folate. In some
embodiments, one single unit dosage form can provide about 7.5 mg to about 50 mg folate. In other
embodiments, the desired dose can be presented in two, three, four, five or more sub-doses
administered at appropriate intervals throughout the day. These sub-doses can be administered in unit
dosage forms, for example, containing about 0.1 mg to about 250 mg, about 1 mg to about 100 mg,
about 2 mg to about 20 mg, or about 2 mg to about 10 mg.
In some embodiments, the pharmaceutical composition can further comprise at least
one antidepressant. In general, a dose of an antidepressant or a pharmaceutically acceptable salt
thereof suitable for administration to a human is in the range of about 0.01 to 50 mg per kilogram
body weight of the recipient per day, or in the range of 0.1 to 5 mg per kilogram body weight per day..
In certain embodiments, the desired dose can be presented as one single unit dosage form, e.g.,
containing about 1 mg to about 500 mg, or about 5 mg to about 300 mg. In other embodiments, the
desired dose can be presented in two, three, four, five or more sub-doses administered at appropriate
intervals throughout the day. These sub-doses can be administered in unit dosage forms, for example,
containing about 0.1 mg to about 100 mg or about 1 mg to about 50 mg.
As used herein, the term “pharmaceutically acceptable” refers to those compounds,
materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment,
le for use in contact with the tissues of human beings and animals without excessive toxicity,
irritation, allergic response, or other problem or complication, surate with a reasonable
t/risk ratio.
As used herein, the term “pharmaceutically acceptable carrier” means a
pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent,
ent, manufacturing aid (e. g., lubricant, talc magnesium, calcium or Zinc te, or steric acid),
or solvent encapsulating material, involved in carrying or transporting the subject compound from one
organ, or portion of the body, to another organ, or portion of the body. Each carrier must be
“acceptable” in the sense of being compatible with the other ingredients of the formulation and not
injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable
carriers include: (i) sugars, such as lactose, glucose and sucrose; (ii) starches, such as corn starch and
potato starch; (iii) cellulose, and its derivatives, such as sodium carboxymethyl cellulose,
methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (iv) powdered
tragacanth; (v) malt; (vi) gelatin; (vii) lubricating agents, such as magnesium te, sodium lauryl
sulfate and talc; (viii) excipients, such as cocoa butter and suppository waxes; (ix) oils, such as peanut
oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and n oil; (x) glycols, such as
propylene glycol; (xi) polyols, such as in, sorbitol, mannitol and polyethylene glycol (PEG);
(xii) esters, such as ethyl oleate and ethyl laurate; (xiii) agar; (xiv) ing agents, such as
magnesium hydroxide and aluminum hydroxide; (xv) alginic acid; (xvi) pyrogen-free water; (xvii)
ic saline; (xviii) Ringer's solution; (xix) ethyl alcohol; (xx) pH buffered solutions; (xxi)
polyesters, rbonates and/or polyanhydrides; (xxii) bulking agents, such as ptides and
amino acids (xxiii) serum component, such as serum albumin, HDL and LDL; (xxiv) C2-C12 alchols,
such as ethanol; and (xxv) other non-toxic compatible substances employed in pharmaceutical
ations. Wetting agents, coloring agents, e agents, coating agents, ning agents,
flavoring agents, ing agents, preservative and antioxidants can also be present in the
formulation.
Pharmaceutically acceptable carriers can vary in a composition described herein,
ing on the administration route and formulation. For example, the pharmaceutically able
composition described herein can be delivered via injection. These routes for administration (delivery)
include, but are not limited to, subcutaneous or parenteral including intravenous, intraarterial,
intramuscular, intraperitoneal, yocardial, and infusion techniques. In one embodiment, the
pharmaceutical acceptable composition is in a form that is suitable for injection. In another
ment, the pharmaceutical composition is formulated for ry by a catheter.
When administering a ceutical composition parenterally, it can be generally
formulated in a unit dosage injectable form (solution, suspension, emulsion). The pharmaceutical
formulations suitable for injection include sterile aqueous solutions or dispersions. The carrier can be
a solvent or dispersing medium containing, for example, water, cell culture medium, buffers (e.g.,
phosphate buffered ), polyol (for example, glycerol, propylene glycol, liquid polyethylene
glycol, and the like), suitable mixtures thereof. In some embodiments, the pharmaceutical carrier can
be a buffered solution (e.g. PB S).
In some embodiments, the pharmaceutical composition can be formulated in an
emulsion or a gel.
In some embodiments, the pharmaceutical compositions described herein can be
formulated for oral administration or for inhalation. For oral administration, suitable dosage forms can
include tablets, troches, cachets, caplets, and capsules, including hard and soft gelatin capsules.
In some embodiments, both an antidepressant and a folate-containing compound can
be formulated in a single pharmaceutical composition. For example, both an antidepressant and a
folate-containing compound can be formulated in a single tablet for oral administration.
In some ments where the antidepressant and folate-containing nd are
ated in a single composition, they can be released from the composition at the same time or at
different times. By way of example only, if the -containing compound is formulated in an outer
layer of a composition (e.g., a tablet or drug-delivery particle) while the pressant is formulated
in an inner layer of the composition, the folate-containing compound could be ed from the
composition first with a faster rate, while the antidepressant could be released from the composition
later with a slower rate. On the other hand, if the antidepressant and the folate-containing compound
are mixed nously within the composition, both can be released simultaneously from the
composition.
In other embodiments, an antidepressant and a folate-containing compound can be
formulated in separate pharmaceutical compositions for the same or different routes of administration
during a therapy . For example, an pressant can be formulated for inhalation
administration while a folate-containing compound can be formulated for oral administration. In other
embodiments, both the antidepressant and folate-containing nd can be formulated for oral
stration, e.g., in separate tablets.
The effective amount of folate administered to a selected human subject for treatment
of depression as described herein is icantly higher than the typical amount taken as a y
supplement (between 50-600 ug/day). In some embodiments, the effective amount of folate
administered to a selected human t is at least about 2-fold, at least about 5-fold, at least about
-fold, at least about 25-fold, at least about 50-fold, at least about ld, at least about 250-fold,
at least about 500-fold, at least about 1000-fold or more than the typical amount taken as a dietary
supplement. Accordingly, in some embodiments, the folate-containing compound is desirable to be
formulated in slow-release or sustained release composition.
Accordingly, in some embodiments, the pharmaceutical compositions comprising a
folate-containing compound (with or without an anti-depressant) can be formulated for sustained
release or ned ry. In some embodiments, the pharmaceutical compositions can be
formulated in controlled-release drug-delivery systems, e. g., to provide sustained release of a -
containing compound (and optionally an anti-depressant). As used herein, the term "sustained release”
or “sustained delivery" refers to continual delivery of a therapeutic agent in vivo over a period of time
following administration. For example, sustained release can occur over a period of at least about 1
hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at
least about 6 hours, at least about 9 hours, at least about 12 hours, at least about 16 hours, at least
about 24 hours following administration. In some embodiments, sustained release can occur over a
period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least
about 5 days, at least about 6 days, at least about 7 days following stration. In some
embodiments, the release of a folate-containing compound from a drug-delivery system can be steady
state (zero-order kinetics) with at least about 30% (e. g., ing at least about 40%, at least about
50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about
95% or more) of the folate-containing compound (and optionally an anti-depressant) released between
about 3-6 hours post administration, or between about 4-5 hours post administration. In one
embodiment, the release of a folate-containing compound (and ally an anti-depressant) from a
drug-delivery system can be steady state (zero-order kinetics) with substantially full release (e.g.,
~100%) of the folate-containing compound ed between about 3-6 hours post administration, or
between about 4-5 hours post administration. In some embodiments, the folate-containing compound
can be released from a drug-delivery system at a rate that is slow enough not to overload the intestinal
absorption capacity of a patient’s duodenum (first 1/3 of the small ines where ~90% of the
tion occurs for a folate-containing compound, e.g., L-MTHF). In some embodiments, the
folate-containing compound and an epressant (if any) can be released from a drug-delivery
system rently or separately, with the same or a different release rate.
Any drug delivery system (e.g., but not limited to polymer-based) that es a
sustained release of a folate-containing nd (and optionally an anti-depressant) over a pre-
determined period of time can be used for administration of a folate-containing compound (and
optionally an anti-depressant). In one embodiment, the drug-delivery system can be a caplet design
large enough to be blocked by a pyloric valve between the stomach and the duodenum, thus allowing
the caplet to slowly and lly dissolve over a desirable period of time, e. g., over a period of about
2-3 hours, during which the folate-containing compound is steadily released from the caplet. As the
caplet dissolves to a size that can get through the pyloric valve at which time it completes its steady
state release (e.g., an additional period of time, e.g., an additional 2 hours), the caplet can continue to
travel into the jejunum (the second third of the small intestines) where tion is minimal.
In some ments, a drug delivery system can use a blend of hydrophilic and
hobic polymers to l release of a folate-containing compound (and optionally an anti-
depressant) via diffusion through, and erosion of, a polymer matrix.
In some ments, a drug delivery system can comprise a folate-containing
compound (and ally an anti-depressant) encapsulated in polymer-based particles. These folatecontaining
r-based particles can be filled into capsules or single-dose sachets for additional
control of release.
] Controlled-release (e.g., sustained release) drug ry systems for different
administration methods (e.g., oral administration, injection, implantation, inhalation) are known in the
art and can be adopted to deliver a folate-containing compound (and optionally an antidepressant) for
the treatment methods described herein. See, e.g., International Pat. App. Nos. WO 2012/ l l 1961 (oral
formulation), (injectable formulation); US. Pat. App. Nos. US 2012/0258161
(implantable formulation), US 2001/0038854, US 2001/0033866; and US. Pat. No. 8268347
(inhalation formulation), the t of which are incorporated herein by reference, for various types
of drug-delivery systems to deliver an active agent via various administration routes.
Additionally, various additives which enhance the stability, sterility, and isotonicity
of the compositions, including antimicrobial preservatives, antioxidants, ing agents, and buffers,
can be added. tion of the action of microorganisms can be ensured by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. In many
cases, it may be desirable to include isotonic agents, for example, sugars, sodium chloride, and the
like.
The compositions can also contain auxiliary substances such as g or
emulsifying agents, pH buffering , g or viscosity enhancing additives, preservatives,
colors, binders, and the like, depending upon the route of administration and the preparation desired.
Standard texts, such as “REMINGTON‘S PHARMACEUTICAL SCIENCE”, 17th edition, 1985,
incorporated herein by reference, may be consulted to prepare suitable preparations, without undue
experimentation. With respect to compositions described herein, r, any vehicle, diluent, or
additive used should have to be biocompatible with the antidepressant or a pharmaceutically
acceptable salt f and/or a -containing compound.
The pharmaceutical compositions can be isotonic, i.e., they can have the same
osmotic pressure as blood and lacrimal fluid. The desired isotonicity of the compositions of the
composition described herein can be accomplished using sodium chloride, or other pharmaceutically
acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other nic or
organic solutes. In one embodiment, sodium chloride is used in buffers containing sodium ions.
] Viscosity of the compositions can be maintained at the selected level using a
pharmaceutically acceptable thickening agent. In one embodiment, methylcellulose is used because it
is y and economically available and is easy to work with. Other suitable thickening agents
include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and
the like. The preferred concentration of the thickener will depend upon the agent selected. The
important point is to use an amount which will achieve the selected viscosity. Viscous itions
are normally prepared from solutions by the addition of such thickening agents.
Typically, any additives (in addition to the pressant and/or folate-containing
compound) can be present in an amount of 0.001 to 50 wt % solution in phosphate buffered saline,
and the active ingredient is present in the order of micrograms to rams to grams, such as about
0.0001 to about 5 wt %, about 0.0001 to about 1 wt %, about 0.0001 to about 0.05 wt % or about
0.001 to about 20 wt %, about 0.01 to about 10 wt %, and about 0.05 to about 5 wt %. For any
therapeutic ition to be administered to a subject with ssion, and for any particular
method of stration, it is preferred to ine toxicity, such as by determining the lethal dose
(LD) and LD50 in a suitable animal model e. g., rodent such as mouse; and, the dosage of the
composition(s), concentration of components therein and timing of administering the composition(s),
which elicit a suitable response. Such determinations do not require undue experimentation from the
knowledge of the skilled artisan.
Those skilled in the art will recognize that the components of the compositions should
be selected to be biocompatible with respect to the active agent, e. g., the antidepressant and/or folate-
containing compound. This will present no problem to those skilled in chemical and pharmaceutical
principles, or problems can be readily d by reference to standard texts or by simple experiments
(not involving undue experimentation).
The compositions described herein can be prepared by mixing the ingredients
following generally-accepted procedures. For example, the ingredients can be mixed in an appropriate
pharmaceutically acceptable carrier and the mixture can be ed to the final concentration and
viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an
additional solute to l tonicity. lly the pH can vary from about 3 to about 7.5. In some
embodiments, the pH of the composition can be about 6.5 to about 7.5. Compositions can be
administered in dosages and by techniques well known to those skilled in the medical and veterinary
arts taking into consideration such factors as the age, sex, weight, and condition of the particular
t, and the composition form used for administration (e.g., liquid). Dosages for humans or other
mammals can be determined without undue experimentation by a skilled n.
] A still further aspect provided herein relates to uses of a folate-comprising
composition in the treatment of depression in a human subject who carries at least one of the
conditions (A)-(X) described herein (e.g., but not limited to, either one or both conditions (A) and
(C)). Another aspect provided herein relates to a folate-comprising composition in combination with
an anti-depressant for use in the treatment of depression in a human subject who carries at least one of
the ions (A)-(X) described herein (e. g., but not limited to, either one or both conditions (A) and
(C)). In some embodiments of these s described herein, the folate-comprising composition can
comprise at least about 5 mg of folate (e. g., about 7.5 mg to about 50 mg of folate). In some
embodiments, the folate-comprising composition can be formulated for a termined release
profile (e.g., a sustained release). In some embodiments, the human subject is an adult.
Selection of subjects with depression
In some embodiments, ts amenable to assays, methods and compositions
described herein can be subjects that have been diagnosed with or suspected of having or developing
depression. Accordingly, in some ments, subjects that have been diagnosed or suspected of
having or developing with depression are selected prior to subjecting them to the assays, methods
and/or itions bed herein. In some embodiments, a subject is selected for a treatment
regimen comprising a folate-containing nd is being treated for depression. In some
embodiments, the subject is specifically administered with a folate-containing nd to enhance
(or as an adjuvant) the effect of the antidepressant drug, and not for r . For example, a
female with depression wishing to become pregnant, or who is pregnant, or is lactating may take
prenatal supplements containing folic acid in combination with an antidepressant drug. In such
instance, a human subject amenable to the assays, methods and/or compositions described herein is
ically selected for depression before performing the assays and/or methods described herein
and/or administering the itions described herein.
In some embodiments, the subject is specifically administered with a -
containing nd for treatment of depression, and not for another reason. For example, a human
t diagnosed as having, or have a risk for, depression may take an effective amount of a folate-
containing compound (with or without an anti-depressant). In such instance, a human subject
amenable to the assays, methods, and/or compositions described herein is specifically selected for
depression before performing the assays and/or methods bed herein and/or administering the
compositions bed herein.
The phrase “having a risk for depression” or "suspected of having or developing
depression" or “suspected of having or developing major depressive disorder” refers to a subject that
presents one or more symptoms indicative of a depression including major depressive disorder (e.g.,
ained insomnia, fatigue, irritability, etc.) or is being screened for depression including major
depressive disorder (e. g., during a routine physical), for example, in accordance with the criteria listed
in DSM-IV or ICD-lO as discussed below.
As used , the term "depression" generally refers to a mental state of depressed
mood characterized by feelings of sadness, despair and discouragement. In some embodiments,
depression is a al m, and can include, but not d to, major depressive disorder
(including single episode and recurrent), ar depression, treatment-refractory depression,
resistant depression, anxious depression and dysthymia (also referred to as dysthymic er).
Further, the term "depression" can encompass any major depressive disorder, dysthymic er,
mood disorders due to medical conditions with depressive features, mood ers due to medical
conditions with major depressive-like es, substance-induced mood ers with depressive
features and depressive disorder not otherwise specific as defined by their diagnostic criteria, as listed
in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition (DSM-IV) or any later edition thereof, or the World Health Organization's International
Statistical Classification of Diseases and Related Health Problems (ICD-lO). In one embodiment,
depression is major depressive disorder.
The DSM-IV and ICD-lO provides a common language and standard criteria for the
classification of mental disorders, and have been ly used by a suitably trained general
practitioner, or by a psychiatrist or psychologist for diagnosis of depression including major
depressive disorders. Symptoms of depression can include, but are not limited to, problems
concentrating, remembering, and/or making decisions, changes in eating and/or sleeping , a loss
of interest in ble activities, difficulty going to work or taking care of daily responsibilities,
feelings of guilt and/or hopelessness, slowed thoughts and/or speech, and preoccupation with thoughts
of death or suicide. One of skill in the art can determine the score or rating of depression based on
DSM-IV or ICD-lO.
Other scales or criteria for classification of mental disorders known in the art, e. g.,
Maier or HAMD-7 scale, or social functioning questionnaire (SFQ), visual analogue scale (VAS),
and/or cognitive and physical function questionnaire (CPFQ) can also be used to determine the degree
of depression.
During diagnosis for depression, the practitioner can also assess the patient’s medical
history, discuss the subject’s current ways of regulating their mood (healthy or otherwise) such as
l and drug use, and/or perform a mental state examination, which is an assessment of the
person's t mood and thought content, in particular the presence of themes of hopelessness or
pessimism, self-harm or suicide, and an absence of positive thoughts or plans. Additionally, a
practitioner can generally perform a medical examination to rule out other non-cognitive causes of
depressive symptoms. For e, blood tests measuring TSH and thyroxine can be used to exclude
hypothyroidism; basic electrolytes and serum calcium to rule out a metabolic disturbance; and a full
blood count including ESR to rule out a systemic infection or chronic disease. Testosterone levels can
also be evaluated to se hypogonadism, a cause of depression in men.
Any c or biomarker methods known in the art can also be used for diagnosis of
depression. For example, US. Pat. App. No. US 273153 describes that the presence of TG7AT
haplotype can be indicative of predisposition to major depressive disorder. Additional marker gene for
depression such as ATP2A2, SCYAS, STIPl, , GRBlO, CASP6, TSSCl, RAB9, NFATC3,
TPR, and any others listed in, for example, US. Pat. App. No. US 2005/0239110 can also be used for
diagnosing depression.
] In some embodiments, subjects amenable to assays, methods and compositions
bed herein are subjects that have been diagnosed with or suspected of having or developing
major depressive disorder. A major depressive episode is characterized by the ce of a severely
depressed mood that persists for at least two weeks. Episodes can be ed or recurrent and can be
categorized by a skilled practitioner as mild (few symptoms in excess of minimum criteria), moderate,
or severe (marked impact on social or occupational functioning).
In some embodiments, subjects amenable to assays, methods and compositions
described herein are subjects that have been diagnosed with major depressive disorder (MDD) and are
resistant to antidepressant monotherapy, i.e., a treatment for depression with a single antidepressant
only. The phrase “resistant to pressant monotherapy” is used herein in nce to a subject
with depression being resistant to at least one antidepressant in one or more classes. This includes
subjects with depression that are resistant to at least two, at least three, at least four or more
antidepressants in one or more classes. In some embodiments, subjects amenable to assays, methods
and compositions described herein are subjects that have been diagnosed with major depressive
disorder (MDD) and are resistant to at least one serotonin reuptake tors (SRI), including at least
one, at least two, at least three, at least four or more SRIs. In some embodiments, subjects amenable to
assays, methods and compositions described herein are subjects that have been diagnosed with major
depressive disorder (MDD) and are resistant to at least one ive serotonin reuptake inhibitor
(SSRI), including at least two, at least three, at least four or SSRIs.
In some embodiments, the t selected for the , methods and compositions
described herein have been in remission from depression and is now diagnosed with a relapse or a
predisposition to a relapse. In other embodiments, the t ed for the assays, methods and
compositions bed herein have been diagnosed with depression and is currently taking at least an
antidepressant.
As used herein, a “subject” can mean a human or an . Examples of subjects
include primates (e.g., humans, and monkeys). Generally, the animal is a vertebrate such as a primate,
rodent, domestic animal or game . Primates include chimpanzees, cynomologous monkeys,
spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits
and hamsters. A patient or a subject includes any subset of the foregoing, e.g., all of the above, or
includes one or more groups or species such as humans, primates or rodents. In certain embodiments
of the aspects described herein, the subject is a mammal, e.g., a primate, e.g., a human. The terms,
“patient9, cs
, dual”, and “subject” are used interchangeably herein. A subject can be male or
female. In some embodiments, the subjects le to the assays, methods and/or compositions
described herein can be female subjects.
In certain embodiments, the subject is a human subject. Human subjects can come
from any ethnicity or race, e.g., including, but not limited to, Caucasian, African American, Asian and
Hispanic, n Indian and Alaska Native, Native Hawaiian and other Pacific Islander. In some
embodiments, the human subjects amenable to the assays, s and/or itions described
herein can be Caucasian subjects. As used herein, the term "Caucasian" refers to a member of the
white race consisting of individuals of European, north African, or southwest Asian ry. In some
embodiments, the human subjects amenable to the assays, methods and/or compositions described
herein can be African an subjects. In some embodiments, the human subjects le to the
assays, methods and/or compositions described herein can be Asian subjects. In some embodiments,
the human subjects amenable to the assays, methods and/or compositions described herein can be
Hispanic subjects.
In some embodiments, the human subjects amenable to the assays, methods and
compositions described herein can be of any age. In some ments, the human ts amenable
to the assays, methods and/or compositions described can be at an age of at least 18 years old. In other
embodiments, human ts below 18 years can also be subjected to the assays, methods and/or
compositions described .
Systems and computer readable mediafor use in the assays and/0r methods described herein
Embodiments of a further aspect also provide for systems (and computer readable
media for causing er systems) to perform an assay for selecting a treatment regimen for a
subject with depression based on at least sequence information of the SNP biomarkers (i)-(xxi)
described herein and/or expression levels of the peripheral biomarkers (xxii)-(xxiv).
A er system for obtaining data from at least one test sample obtained from at
least one subject is ed. The system comprises: (a) a determination module configured to
receive at least one test sample and perform at least one is on at least one test sample to
determine parameters of at least two biomarkers (i) to (xxiv) described herein; (b) a storage device
configured to store output data from the determination module; (c) a computing module, e.g., a non-
human machine, sing specifically-programmed instructions to determine from the output data
the presence of at least one condition (A) to (X) described herein; and (d) a display module for
displaying a content based in part on the data output from the computing module, wherein the t
comprises a signal indicative of the presence of at least one condition (A) to (X) described herein, and
optionally the absence of any one of the conditions (A) to (X) described herein, or a signal indicative
of the absence of all of the conditions (A) to (X) described herein.
2012/065084
In some embodiments, the ination module can be configured to m at
least one genotyping analysis on at least one test sample to determine the genotypes of at least two
loci sing position 677 of SEQ ID NO. 1 (or position 27 of SEQ ID NO. 7) and position 2756 of
SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9). In these embodiments, the computing module can
be configured to determine the presence of at least one SNP located at position 677 of SEQ ID NO. 1
(or position 27 of SEQ ID NO. 7) comprising at least one thymine “T” allele, and/or at position 2756
of SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9) comprising at least one guanine “G” allele.
In another embodiment, the determination module can be configured to perform at
least one analysis on at least one test sample to determine the presence or absence of at least one of
the following conditions:
i. an expression ratio of s-adenosyl methionine (SAM) to s-adenosyl homocysteine (SAH)
smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4-HNE) greater than a pre-determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID NO: 1 comprising at
least one thymine “T” allele, n the SEQ ID NO: 1 is a portion of a genomic nucleic
acid sequence of methylenetetrahydrofolate reductase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO: 2 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 2 is a portion of a genomic nucleic acid sequence of methionine
synthase (MTR); and
V. a SNP at position 66 of SEQ ID NO: 3 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 3 is a portion of a genomic nucleic acid sequence of methionine
se reductase (MTRR).
] In these embodiments, the determination module can be r configured to
determine the presence or absence of at least one other condition (A)-(X) described herein. For
example, in some embodiments, the determination module can be further configured to determine
sion of high-sensitivity c-reactive protein (hsCRP). In some embodiments, the determination
module can be further configured to determine the presence or e of a SNP at position 1298 of
the SEQ ID NO. 1 comprising at least one cytosine "C" allele.
In some embodiments, the determination module of the computer system can be
ured to analyze at least one test sample to ine the presence or absence of at least two of
the conditions (i) — (V) bed above and expression of hsCRP.
In some embodiments, the determination module of the computer system can further
comprise a ison module adapted to compare the data output from the determination module
with reference data stored on the storage device. In some embodiments, the reference data can
include, but not limited to, major and/or rare ts of alleles corresponding to the SNPs described
herein, a pre-determined reference value of 4-HNE (e.g., at least 3.2 mg/L or above as ed in a
plasma sample), a termined reference value of hsCRP (e.g., greater than 2.3 mg/L as measured
in a plasma sample), a pre-determined reference ratio of SAM/SAH (e. g., less than 2.8 as measured in
a plasma sample), and any combinations thereof.
Embodiments of the computer system described herein also comprises a storage
device configured to store data output from the determination module; and a display module for
displaying a content based in part on the data output from the ination module, wherein the
content comprises a signal indicative of the presence of at least one of the conditions (i)-(v) described
above, or a signal indicative of the absence of at least one of these conditions. In some embodiments,
the content displayed on the display module can further comprise a signal indicative of the subject
recommended to receive a treatment regimen comprising a folate-containing compound, or a signal
tive of the subject ended to receive an alternative treatment regimen.
] In some embodiments, the storage device of the computer system can be further
configured to store physical information of at least one subject to be . Examples of the physical
information can include obesity tor (e.g., BMI) and/or gender of at least one tested subject. In
such ments, the content yed on the display module of the er system can further
comprise the obsesity indicator (e.g., the BMI value) or a signal indicative of whether the human
subject is obese or not (e. g., whether the BMI value is at least 30 kg/m2 or not).
A le and non-transitory (e.g., no tory forms of signal transmission)
computer readable medium having computer readable instructions recorded thereon to define software
modules for implementing a method on a computer is also provided herein. In one embodiment, the
computer readable storage medium comprises: (a) instructions for comparing the data stored on a
storage device with reference data to provide a comparison result, wherein the comparison identifies
the presence or absence of at least one condition (A)-(X) described herein; and (b) instructions for
displaying a content based in part on the data output from the determination module, wherein the
content comprises a signal indicative of the presence of at least one of the conditions (A)-(X)
described herein, and optionally the absence of any one of these conditions (A)-(X) bed herein.
In other embodiments, the content can se a signal tive of the absence of all of the
conditions (A)-(X) bed herein.
In some embodiments, the instructions can be specifically programmed to perform a
comparison to identify the presence of at least one SNP located at position 677 of SEQ ID NO. 1 (or
position 27 of SEQ ID NO. 7) comprising at least one thymine “T” allele, and/or at position 2756 of
SEQ ID NO. 2 (or position 27 of SEQ ID NO. 9) sing at least one guanine “G” allele.
In other embodiments, the instructions can be specifically mmed to perform a
comparison to identify one of the following conditions:
i. an expression ratio of s-adenosyl nine (SAM) to s-adenosyl steine (SAH)
smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4 HNE) greater than a pre-determined reference value;
iii. a single nucleotide polymorphism (SNP) at on 677 of SEQ ID NO: 1 comprising at
least one thymine “T” , wherein the SEQ ID NO: 1 is a portion of a genomic nucleic
acid sequence of methylenetetrahydrofolate reductase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO: 2 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 2 is a portion of a genomic nucleic acid sequence of methionine
synthase (MTR); and
V. a SNP at position 66 of SEQ ID NO: 3 comprising at least one guanine “G” allele,
wherein the SEQ ID NO: 3 is a portion of a genomic nucleic acid sequence of methionine
se reductase (MTRR);
In these embodiments, the computer readable medium can further comprise
instructions to identify the presence or absence of at least one other condition (A)-(X) described
herein. For example, in one embodiment, the computer readable medium can further se
instructions to fy the presence or absence of a SNP at position 1298 of the SEQ ID NO: 1
comprising at least one ne “C” allele. In some embodiments, the er readable medium can
further comprise instructions to compare expression of high-sensitivity c-reactive protein (hsCRP)
with the reference data, e.g., pre-determined reference value of hsCRP expression level r than
2.3 mg/L as ed in a plasma sample.
Embodiments of the display module of the computer readable medium described
herein also comprise instructions for ying a content based in part on the data output from the
comparison module, wherein the content comprises a signal indicative of the presence of at least one
of the conditions, or a signal indicative of the absence of at least one of the ions. In some
embodiments, the display module can further comprises instructions to display a signal indicative of
the subject recommended to receive a treatment regimen comprising a folate-containing compound, or
a signal tive of the subject recommended to receive an alternative treatment regimen.
In some embodiments, the comparison module of the computer readable medium can
further comprise instructions to determine if a human t is obese (e.g., if BMI of at least one
subject is at least 30 kg/m2 or not). In such embodiments, the display module can further comprise
instructions to display the obesity tor (e. g., the BMI value) or a signal indicative of whether the
subject is obese (e. g., whether the BMI value is at least 30 kg/m2 or not).
ments of the s described herein have been described through
functional s, which are defined by computer executable instructions ed on computer
readable media and which cause a er to perform method steps when executed. The modules
have been segregated by function for the sake of clarity. However, it should be understood that the
modules need not correspond to discrete blocks of code and the described functions can be carried out
by the execution of various code portions stored on various media and executed at various times.
Furthermore, it should be appreciated that the modules may perform other functions, thus the modules
are not limited to having any particular functions or set of functions.
The er readable media can be any available tangible media that can be
accessed by a computer. Computer readable media includes volatile and nonvolatile, removable and
non-removable tangible media ented in any method or technology for storage of information
such as computer readable instructions, data structures, program modules or other data. Computer
readable media includes, but is not limited to, RAM m access memory), ROM (read only
memory), EPROM (eraseable programmable read only memory), EEPROM (electrically eraseable
programmable read only memory), flash memory or other memory technology, CD-ROM (compact
disc read only memory), DVDs al versatile disks) or other optical storage media, magnetic
cassettes, magnetic tape, magnetic disk storage or other magnetic storage media, other types of
volatile and non-volatile memory, and any other tangible medium which can be used to store the
desired information and which can accessed by a computer ing and any suitable combination of
the foregoing.
In some embodiments, the computer readable storage media 700 can e the
“cloud” , in which a user can store data on a remote server, and later access the data or perform
further analysis of the data from the remote server.
Computer-readable data embodied on one or more computer-readable media, or
computer readable medium 700, may define instructions, for example, as part of one or more
programs, that, as a result of being executed by a er, ct the computer to perform one or
more of the functions described herein (e.g., in relation to system 600, or computer readable medium
700), and/or various embodiments, variations and combinations thereof. Such instructions may be
written in any of a plurality of programming languages, for example, Java, J#, Visual Basic, C, C#,
C++, Fortran, Pascal, Eiffel, Basic, COBOL assembly language, and the like, or any of a y of
combinations thereof. The computer-readable media on which such instructions are embodied may
reside on one or more of the components of either of system 600, or computer readable medium 700
described herein, may be distributed across one or more of such components, and may be in transition
there between.
The computer-readable media can be transportable such that the instructions stored
thereon can be loaded onto any computer resource to implement the assays and/or methods described
herein. In addition, it should be appreciated that the instructions stored on the computer readable
media, or computer-readable medium 200, described above, are not limited to instructions embodied
as part of an application program running on a host computer. Rather, the ctions may be
embodied as any type of computer code (e.g., software or microcode) that can be employed to
m a computer to implement the assays and/or methods described herein. The computer
able instructions may be written in a suitable er language or combination of several
languages. Basic computational y s are known to those of ordinary skill in the art and
are described in, for example, Setubal and is et al., Introduction to Computational Biology
Methods (PWS Publishing Company, Boston, 1997); Salzberg, s, Kasif, (Ed.), Computational
Methods in Molecular Biology, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, Bioinformatics
: Application in Biological Science and Medicine (CRC Press, London, 2000) and Ouelette and
Bzevanis Bioinformatics: A Practical Guide for Analysis of Gene and Proteins (Wiley & Sons, Inc.,
2nd ed., 2001).
The functional modules of certain embodiments of the system described herein can
include a determination module, a storage device, and a display module. In some embodiments, the
system can further include a comparison module. The functional s can be executed on one, or
multiple, computers, or by using one, or le, computer networks. The determination module 602
has computer executable instructions to e sequence information in computer readable form. As
used herein, "sequence information" refers to any nucleotide and/or amino acid sequence, including
but not limited to full-length nucleotide and/or amino acid ces, partial nucleotide and/or amino
acid sequences, or mutated sequences. Moreover, information "related to" the sequence information
includes detection of the presence or absence of a ce (e.g., detection of a mutation or deletion),
determination of the concentration of a sequence in the sample (e.g., amino acid ce expression
levels, or nucleotide (RNA or DNA) expression levels), and the like. The term “sequence
information” is ed to include the presence or absence of post-translational modifications (e.g.
orylation, glycosylation, summylation, farnesylation, and the like).
As an example, determination modules 602 for ining sequence ation
may include known s for ted sequence analysis including but not limited to i
FMBIO® and Hitachi FMBIO® II Fluorescent Scanners (available from Hitachi Genetic Systems,
Alameda, California); Spectrumedix® SCE 9610 Fully Automated 96-Capillary Electrophoresis
c Analysis Systems (available from uMedix LLC, State e, Pennsylvania); ABI
PRISM® 377 DNA Sequencer, ABI® 373 DNA Sequencer, ABI PRISM® 310 Genetic Analyzer,
ABI PRISM® 3100 Genetic Analyzer, and ABI PRISM® 3700 DNA Analyzer (available from
Applied Biosystems, Foster City, California); Molecular Dynamics FluorImagerTM 575, SI
Fluorescent Scanners, and Molecular Dynamics FluorImagerTM 595 Fluorescent Scanners (available
from Amersham ences UK Limited, Little Chalfont, Buckinghamshire, England);
GenomnyCTM DNA Sequencing System (available from Genomyx Corporation r City,
California); and Pharmacia ALFTM DNA Sequencer and Pharmacia ALFexpressTM (available from
Amersham Biosciences UK Limited, Little Chalfont, Buckinghamshire, England).
Alternative methods for determining sequence ation, i.e. determination
modules 602, include systems for protein and DNA analysis. For example, mass spectrometry systems
including Matrix Assisted Laser Desorption Ionization — Time of Flight (MALDI-TOF) systems and
TOF-MS ProteinChip array profiling systems; systems for analyzing gene expression data
(see, for example, published US. Patent Applicaion, Pub. No. US. 2003/0194711); systems for array
based expression analysis: e.g., HT array systems and cartridge array systems such as GeneChip®
AutoLoader, Complete GeneChip® Instrument System, ip® Fluidics Station 450, GeneChip®
Hybridization Oven 645, GeneChip® QC Toolbox Software Kit , GeneChip® Scanner 3000 7G plus
Targeted Genotyping System, GeneChip® Scanner 3000 7G Whole-Genome ation System,
GeneTitanTM Instrument and GeneChip® Array Station (each available from Affymetrix, Santa
Clara, California); automated ELISA systems (e.g., DSX® or DS2® able from Dynax,
Chantilly, VA) or the Triturus® (available from Grifols USA, Los Angeles, California), The Mago®
Plus (available from Diamedix Corporation, Miami, Florida) ; Densitometers (e. g. X-Rite
Spectro Densitometer® (available from RP ImagingTM, Tucson, Arizona), The HYRYSTM 2 HIT
densitometer (available from Sebia Electrophoresis, Norcross, Georgia); automated Fluorescence
insitu hybridization s (see for e, United States Patent 6,136,540); 2D gel imaging
s coupled with 2-D imaging re; microplate s; Fluorescence activated cell sorters
(FACS) (e.g. Flow Cytometer FACSVantage SE, (available from Becton Dickinson, Franklin Lakes,
New Jersey); and radio isotope analyzers (e.g. scintillation counters).
The sequence information of SNPs and/or expression level information of
/serum biomarkers determined in the determination module can be read by the storage device
604. As used herein the “storage device” 604 is intended to include any suitable computing or
processing apparatus or other device configured or adapted for storing data or information. Examples
of electronic apparatus suitable for use with the system described herein can include stand-alone
computing apparatus, data telecommunications networks, including local area networks (LAN), wide
area networks (WAN), Internet, et, and et, and local and distributed computer processing
systems. Storage devices 604 also include, but are not limited to: magnetic storage media, such as
floppy discs, hard disc storage media, magnetic tape, optical storage media such as CD-ROM, DVD,
electronic storage media such as RAM, ROM, EPROM, EEPROM and the like, l hard disks
and hybrids of these categories such as ic/optical storage media. The storage device 604 is
adapted or configured for having recorded thereon ce information or expression level
information. Such information may be provided in digital form that can be itted and read
electronically, e. g., via the Internet, on diskette, via USB (universal serial bus) or via any other
suitable mode of communication, e. g., the “cloud”.
As used herein, "expression level information" refers to any nucleotide and/or amino
acid expression level information, including but not limited to ength nucleotide and/or amino
acid sequences, partial tide and/or amino acid sequences, or mutated sequences. Moreover,
information "related to" the expression level information includes detection of the ce or absence
of a sequence (e. g., presence or e of an amino acid sequence, nucleotide sequence, or post
translational modification), determination of the concentration of a sequence in the sample (e. g.,
amino acid sequence levels, or nucleotide (RNA or DNA) expression , or level of post
translational modification), and the like. In some embodiments, the expression level information also
includes arithmetic manipulation of sion levels of at least two or more biomarkers (e. g.,
expression ratio of SAM to SAH).
As used herein, "stored" refers to a process for encoding information on the storage
device 604. Those skilled in the art can readily adopt any of the tly known methods for
recording information on known media to te manufactures comprising the ce
information or expression level information.
A variety of software programs and formats can be used to store the sequence
information or expression level information on the e device. Any number of data sor
structuring formats (e.g., text file or database) can be employed to obtain or create a medium having
recorded thereon the sequence information or expression level information.
By providing sequence information and/or expression level information in computer-
readable form, one can use the sequence information and/or expression level ation in readable
form in the comparison module 606 to compare a specific ce or expression profile with the
reference data within the storage device 604. For example, search programs can be used to identify
fragments or regions of the sequences that match a particular sequence (reference data, e.g., sequence
information of major or rare alleles corresponding to the SNPs described herein) or direct comparison
of the determined expression level can be compared to the reference data expression level (e.g.,
median expression level information obtained from a population of subjects). The comparison made
in computer-readable form provides a er readable comparison result which can be processed
by a variety of means. t 608 based on the comparison result can be retrieved from the
determination module 600 or the comparison module 606 to indicate the presence or e of at
least one SNP and serum/plasma biomarkers described herein.
In one embodiment the reference data stored in the storage device 604 to be read by
the determination module 600 or the ison module 606 is sequence information data obtained
from a l biological sample of the same type as the biological sample to be tested. Alternatively,
the reference data are a database, e.g., a part of the entire genome sequence of an organism, or a
protein family of sequences, or an expression level profile (RNA, protein or e). In one
embodiment, the reference data are sequence information and/or sion level profiles that are
used to facilitate determining whether a subject with depression should be recommended for a
treatment regimen comprising a folate-containing compound.
In one embodiment, the reference data are one or more reference polynucleotide, or
polypeptide sequences. In some embodiments, the reference polynucleotide ces can be derived
from nucleotide sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ
ID NO: 3, and a portion there of comprising the tide at the corresponding SNP location, and
ments f. In some embodiments, the reference polypeptide sequences can be derived from
amino acid sequences selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID
NO: 6, and a portion thereof comprising an amino acid residue at the corresponding mutation location.
In one embodiment, the reference data are electronically or digitally ed and
annotated from databases including, but not limited to GenBank (NCBI) protein and DNA databases
such as genome, ESTs, SNPS, Traces, Celara, Ventor Reads, Watson reads, HGTS, and the like;
Swiss Institute of Bioinformatics ses, such as ENZYME, PROSITE, 2DPAGE, Swiss-
Prot and TrEMBL databases; the Melanie software package or the ExPASy WWW server, and the
like; the SWISS-MODEL, Swiss-Shop and other network-based computational tools; the
Comprehensive Microbial Resource database (available from The Institute of Genomic Research).
The resulting information can be stored in a relational data base that may be employed to determine
homologies between the nce data or genes or proteins within and among s.
The “comparison module” 606 can use a variety of available software programs and
formats for the comparison operative to compare sequence ation determined in the
determination module 602 to nce data. In one embodiment, the ison module 606 is
configured to use pattern recognition ques to compare sequence ation from one or more
entries to one or more reference data patterns. The comparison module 606 may be ured using
existing commercially-available or freely-available software for comparing patterns, and may be
optimized for particular data isons that are conducted. The ison module 606 provides
computer readable information related to the sequence information that can include, for example,
detection of the presence or absence of a sequence (e.g., detection of a mutation or on (protein or
DNA), information regarding distinct alleles, detection of post-translational modification, or omission
or repetition of sequences); determination of the concentration of a sequence in the sample (e. g.,
amino acid sequence/protein expression levels, or nucleotide (RNA or DNA) expression levels, or
levels of post-translational modification), or determination of an expression profile.
In one embodiment, the comparison module 606 permits the prediction of protein
sequences from polynucleotide sequences, s tion of open reading frames (ORF), or
permits prediction of homologous sequence information in comparison to reference data, i.e.,
homologous protein domains, homologous DNA or RNA sequences, or homologous exons and/or
introns.
In one embodiment, the comparison module 606 uses sequence information
alignment programs such as BLAST (Basic Local Alignment Search Tool) or FAST (using the Smith-
Waterman algorithm) may be employed individually or in combination. These algorithms determine
the alignment between similar regions of ces and a percent identity between sequences. For
example, alignment may be calculated by matching, bases-by-base or amino acid-by amino-acid.
The comparison module 606, or any other module of the system described herein,
may include an operating system (e.g., UNIX) on which runs a relational database management
system, a World Wide Web application, and a World Wide Web . World Wide Web application
includes the executable code necessary for generation of se language statements (e.g.,
Structured Query Language (SQL) statements). Generally, the executables will e embedded
SQL statements. In addition, the World Wide Web application may include a configuration file which
contains pointers and addresses to the various software entities that comprise the server as well as the
various external and internal databases which must be accessed to service user requests. The
Configuration file also directs requests for server resources to the appropriate hardware--as may be
ary should the server be distributed over two or more separate computers. In one embodiment,
the World Wide Web server supports a TCP/IP protocol. Local networks such as this are mes
referred to as "Intranets." An advantage of such Intranets is that they allow easy communication with
public domain databases residing on the World Wide Web (e.g., the GenBank or Swiss Pro World
Wide Web site). Thus, in a particular ment, users can directly access data (via Hypertext links
for example) residing on Internet databases using a HTML interface provided by Web rs and
Web s. In another embodiment, users can directly access data residing on the “cloud” provided
by the cloud computing service providers.
In one embodiment, the comparison module 606 performs comparisons with mass-
spectrometry spectra, for example comparisons of peptide fragment sequence information can be
carried out using spectra processed in MATLAB with script called “chalign” (see for example
WO2007/022248, herein incorporated by nce) and s” (Spectrum Square Associates,
Ithaca, NY), or Ciphergen Peaks 2.1TM software. The processed spectra can then be aligned using
alignment algorithms that align sample data to the control data using minimum entropy algorithm by
taking baseline corrected data (see for example WIPO Publication WO2007/022248, herein
incorporated by reference). The comparison result can be further processed by calculating ratios.
Protein expression profiles can be discerned.
In one embodiment, computational algorithms are used in the comparison module 606
such as expectation-maximization (EM), subtraction and PHASE are used in methods for statistical
tion of haplotypes (see, e.g., Clark, A.G. Mol Biol Evol 7:111-22 (1990); Stephens, M., Smith,
N.J. & ly, P. AmJ Hum Genet 68:978-89 ; Templeton, A.R., Sing, C.F., Kessling, A. &
Humphries, Genetics 120:1145-54 (1988)).
] Various algorithms are available which are useful for comparing data and identifying
the predictive gene signatures. For example, algorithms such as those fied in Xu et al., Physiol.
Genomics 11:11-20 (2002). There are numerous software available for detection of SNPs and
polymorphisms that can be used in the comparison module, including, but not limited to:
HaploSNPer, a web-based m for detecting SNPs and alleles in user-specified input sequences
from both diploid and polyploid species (available on the world-wide web at
bioinformatics.nl/tools/haplosnper/; see also Tang et al., BMC Genetics 9:23 (2008)); Polybayes, a
tool for SNP discovery in redundant DNA ces , GT., et al., Nature Genetics 23(4):452-6
(1999); SSAHA-SNP, a polymorphism detection tool that uses the SSAHA alignment algorithm
(available from Wellcome Trust Sanger Institute, Cambridge, United Kingdom, see also Ning 2., et
al., Genome ch 11(10): 1725-9 ); red, A SNP discovery package built on phred,
phrap, and consed tools (available on the world-wide web, see Nickerson, DA et al., Nucleic Acids
ch 25(14):2745-51 (1997)); NovoSNP, a graphical Java-based program (PC/Mac/Linux) to
identify SNPs and indels (available on the world-wide web, see Weckx, S. et al., Genome Research
436-442 ); SNPdetectorTM, for automated identification of SNPs and mutations in
fluorescence-based resequencing reads (available from Affymetrix, Santa Clara, California), see also
Zhang et al. PLoS Comput Biol (5):e53 (2005). SNPdetector runs on inux platform and is
available publicly; Affymetrix (Santa Clara, California) has multiple data analysis software that can
be used, for example Genotyping ConsoleTM Software, GeneChip® Sequence Analysis re
(GSEQ), GeneChip® Targeted Genotyping Analysis Software (GTGS) and Expression ConsoleTM
Software.
In one embodiment, the comparison module 606 compares gene expression profiles.
For example, detection of gene expression profiles can be determined using Affymetrix Microarray
Suite software n 5.0 (MAS 5.0) (available from Affymetrix, Santa Clara, California) to analyze
the relative abundance of a gene or genes on the basis of the intensity of the signal from probe sets,
and the MAS 5.0 data files can be transferred into a database and analyzed with Microsoft Excel and
GeneSpring 6.0 software (available from Agilent Technologies, Santa Clara, California). The
detection algorithm of MAS 5.0 re can be used to obtain a comprehensive overview of how
many transcripts are detected in given samples and allow a comparative analysis of two or more
microarray data sets.
In one embodiment, the comparison module 606 compares protein sion
profiles. Any available comparison software can be used, including but not limited to, the Ciphergen
Express (CE) and Biomarker Patterns Software (BPS) package (available from Ciphergen
Biosystems, Inc., Freemont, California). Comparative analysis can be done with protein chip system
software (e.g., The Proteinchip Suite (available from Bio-Rad Laboratories, Hercules, California).
thms for fying sion profiles can include the use of optimization algorithms such as
the mean variance algorithm (e. g. IMP Genomics algorithm available from JMP re Cary, North
Carolina).
In one ment, pattern ison software can be used to determine whether
patterns of expression or mutations are indicative of the presence or the absence of the ions
detected in a test sample of a subject.
The comparison module 606 provides computer readable comparison result that can
be processed in computer readable form by predefined criteria, or ia defined by a user, to provide
a content based in part on the comparison result that may be stored and output as requested by a user
using a y module 610. The display module 610 enables display of a content 608 based in part on
the comparison result for the user, wherein the content 608 is a signal tive of the presence of at
least one of the conditions bed herein or a signal indicative of the e of at least one of the
conditions described herein. Such signal, can be for example, a display of content 608 indicative of
the presence or absence of at least one of the conditions on a computer monitor, a printed page of
t 608 indicating the presence or absence of at least one of the ions from a printer, or a
light or sound indicative of the presence or absence of at least one of the conditions.
In various embodiments of the er system described herein, the comparison
module 606 can be integrated into the determination module 602.
The content 608 based on the ison result can also include an expression profile
of one or more plasma/serum biomarkers described herein. In one embodiment, the content 608 based
on the comparison includes a sequence of a particular gene or protein and a determination of the
ce of one or more ons, or specific post-translational modification. In one embodiment,
the content 608 based on the comparison result is merely a signal indicative of the presence or
absence of at least one of the conditions bed herein. In some ments, the content 608 can
be a signal indicative of an obesity indicator (e.g., a BMI value) or a signal indicative of whether the
subject is obese (e. g., whether the BMI value is at least 30 kg/m2 or not). In some embodiments, the
content 608 can be a signal indicative of the subject recommended to receive a treatment regimen
comprising a folate-containing compound, or a signal indicative of the subject recommended to
receive an alternative treatment regimen.
In one embodiment, the content 608 based on the comparison result is displayed a on
a computer monitor. In one embodiment, the content 608 based on the comparison result is displayed
through printable media. The display module 610 can be any suitable device configured to e
from a computer and display er readable information to a user. Non-limiting examples
include, for example, general-purpose computers such as those based on Intel PENTIUM-type
processor, la PowerPC, Sun UltraSPARC, Hewlett-Packard PA-RISC processors, any of a
variety of processors available from Advanced Micro Devices (AMD) of Sunnyvale, California, or
any other type of processor, visual display devices such as flat panel displays, cathode ray tubes and
the like, as well as computer rs of various types.
In one embodiment, a World Wide Web browser is used for providing a user interface
for display of the content 608 based on the comparison result. It should be understood that other
modules of the system described herein can be adapted to have a web browser interface. h the
Web browser, a user may construct requests for retrieving data from the comparison module. Thus,
the user will typically point and click to user interface elements such as buttons, pull down menus,
scroll bars and the like conventionally employed in graphical user interfaces. The requests so
formulated with the user's Web browser are transmitted to a Web application which formats them to
produce a query that can be employed to extract the pertinent information related to the sequence
information, e. g., display of an indication of the presence or absence of mutation or deletion (DNA or
protein); display of sion levels of an amino acid sequence in); display of nucleotide (RNA
or DNA) expression ; y of sion, SNP, or on profiles, or haplotypes, or display
of information based thereon. In one embodiment, the sequence information of the reference sample
data is also displayed.
In any ments, the comparison module can be executed by a computer
ented software as discussed earlier. In such embodiments, a result from the comparison
module can be displayed on an electronic y. The result can be yed by graphs, numbers,
characters or words. In additional ments, the s from the comparison module can be
transmitted from one location to at least one other location. For example, the comparison results can
be transmitted via any electronic media, e.g., internet, fax, phone, a “cloud” system, and any
combinations thereof. Using the “cloud” system, users can store and access personal files and data or
perform r analysis on a remote server rather than physically carrying around a storage medium
such as a DVD or thumb drive.
The system 600, and computer readable medium 700, is merely illustrative
embodiments for performing assays for selecting a treatment regimen for a subject with depression,
based on expression level information or sequence information, and is not intended to limit the scope
of the inventions described herein. Variations of system 600, and computer readable medium 700, are
possible and are intended to fall within the scope of the inventions described herein.
] The modules of the machine, or used in the computer readable medium, may assume
numerous configurations. For example, function may be provided on a single machine or distributed
over multiple machines.
Kits
Based on the identification of SNPs and/or peripheral markers associated with a
se to the use of a folate-containing compound, one aspect described herein also provides for the
design and preparation of detection reagents needed to identify the SNPs and/or peripheral markers
sed herein in a test sample of a subject. For example, the detection reagents can be ed and
prepared to fy SNPs in MTHFR locus and MTR locus and optionally MTRR locus involved in
assays and methods described , and/or measure expression levels of SAM, SAH and 4-HNE in a
test sample. Examples of detection reagents that can be used to identify the disclosed SNPs in a test
sample can include a primer and a probe, wherein the probe can selectively hybridize the SNP-
containing nucleic acid molecules, as compared to a nucleic acid molecule which does not contain the
SNP at the same nucleotide on. Examples of detection regents that can be used to measure
expression levels of peripheral proteins (e. g., SAM, SAH and/or 4-HNE) in a test sample can include
antibodies against such proteins, or a primer and a probe, wherein the probe specifically hybridizes to
a nucleic acid molecule corresponding to such proteins.
Accordingly, ed herein include kits for selecting a treatment regimen for a
subject with depression. In some embodiments, the kits can be used for monitoring the efficacy
response of a subject treated with a combination y comprising a folate-containing compound,
for example as shown in Example 5. The kits can include at least one reagent specific for detecting for
the presence or absence of SNP s (i)-(xxi) described herein (e. g., MTHFR C677T, MTR
A2756G, and/or MTRR A66G) and/or antibodies specific for detecting peripheral biomarkers (xxii) —
(xxiv) (e.g., SAM, SAH, and 4-HNE), and instructions for determining that the subject is
recommended for a treatment n comprising a folate-containing compound if the presence of at
least one of the conditions bed herein is detected in a test sample (e.g., a blood sample, a saliva
sample, or a buccal ) of the subject, for example, the procedures as shown in Example 5. The
kit can optionally include a nucleic acid for detection of the gene of interest.
In one embodiment, a kit can comprise an oligonucleotide array affixed with a
plurality of oligonucleotide probes that interrogate no more than 30 SNPs (including no more than 25
SNPs, no more than 20 SNPs, no more than 15 SNPs, no more than 10 SNPs, no more than 5 SNPs or
less), wherein the SNPs comprise at least two or any combinations of the conditions (A)-(U)
described herein (e.g., but not limited to, a combination of conditions (A) and (C)); and an optional
container containing a detectable label (e.g., comprising a cent molecule) to be ated to a
nucleotide molecule derived from a test sample of a human subject; and at least one reagent.
es of a reagent that can be included in the kit can e, without limitations, a restriction
enzyme, a universal adaptor to be conjugated to a nucleotide molecule, a primer complementary to the
universal adaptor, a wash agent, and any combinations thereof.
In some embodiments, the plurality of oligonucleotide probes affixed to an
oligonucleotide array can interrogate about 2-30 SNPs, e.g., about 3-25 SNPs, about 3-20 SNPs, about
3-10 SNPs, or about 3-5 SNPs, wherein the SNPs comprise at least two or any combinations of the
conditions (A)-(U) described herein (e.g., but not limited to, a combination of conditions (A) and (C)).
In an alternative embodiment, a kit can comprise a plurality of oligonucleotide
primers that bind to at least one allele of no more than 30 SNPs (including no more than 25 SNPs, no
more than 20 SNPs, no more than 15 SNPs, no more than 10 SNPs, no more than 5 SNPs or less),
wherein each subset of ucleotide s that bind to a ic allele of a SNP is labeled with a
ct reporter, and wherein said SNPs comprise at least two or any combinations of the SNP
conditions (A)-(U) described herein (e.g., but not limited to a combination of ions (A) and (C));
and at least one t, e.g., but not limited to, free tide bases, a polymerase, or both.
In some embodiments, the plurality of oligonucleotide primers can bind to at least one
allele of about 2-30 SNPs, e.g., about 3-25 SNPs, about 3-20 SNPs, about 3-10 SNPs, or about 3-5
SNPs, wherein the SNPs comprise at least two or any combinations of the conditions (A)-(U)
described herein (e.g., but not limited to, a combination of conditions (A) and (C)).
Additional reagents included in the kit can vary with the selection of a ping
assay, e.g., but not limited to, allele-specific probe hybridization, allele-specific primer extension,
allele-specific ication, sequencing, 5’ nuclease digestion, molecular beacon assay, DNA chip
analysis, oligonucleotide ligation assay, size analysis, -stranded conformation polymorphism,
polymerase chain reaction (PCR), real-time quantitative PCR, and any combinations thereof.
In some embodiments, the kit can further comprise at least one reagent to determine
sion of at least one biomarker described herein (e.g., SAM, SAH, 4-HNE and . For
example, in one embodiment, the kit can further comprise a solid substrate support affixed with at
least one protein-based binding moiety (e. g., an antibody) that specifically binds to one or more of the
biomarkers described herein. Exemplary solid substrate support can include, but not limited to, a
microtiter plate for ELISA, a dipstick, a ic bead, or any combinations thereof. Different solid
substrate supports can be selected based on various types of expression assays, e.g., but not d to,
western blot, enzyme linked absorbance assay, mass spectrometry, immunoassay, flow cytometry,
immunohistochemical analysis, and any combinations f.
In another embodiment, the kit can further comprise at least one primer designed to
probe one or more biomarkers described herein.
Embodiments of the various aspects described herein can also be bed by any
one of the following numbered paragraphs.
1. An assay for selecting a treatment regimen for a human subject with depression, comprising:
(a) subjecting a test sample from a human subject, who is sed as haVing depression
or haVing a risk for depression, to at least one genotyping assay adapted to determine the
genotypes of at least two loci, wherein said at least two loci are:
i. on 677 of SEQ ID NO. 1 or on 27 of SEQ ID NO. 7
(identified by 133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are
each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
ii. position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
(identified by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are
each ndently a portion of a genomic nucleic acid sequence of
methionine synthase (MTR); and
(b) ing from the genotypes of said at least two loci the presence of a single
nucleotide polymorphism (SNP) selected from the following:
i. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO.
7 comprising at least one thymine “T” ;
ii. a SNP2756 at position 2756 of SEQ ID NO.2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine “G” allele; and
iii. a combination of at least one SNP677 T allele and at least one SNP2756
G allele; and
if at least one of T allele at position SNP677 or at least one G allele at position
SNP2756 or both at least one T allele at position SNP677 and at least one G allele at
position SNP2756 is detected, then selecting, and optionally administering, a
treatment regimen comprising an effective amount of a folate-containing compound.
2. The assay of paragraph 1, wherein if r SNP677 T allele nor SNP2756 G allele is
detected then selecting a treatment regimen without a folate-containing compound.
3. An assay for selecting a ent regimen for a human subject haVing depression,
sing:
subjecting a test sample of the human subject, who is diagnosed as haVing depression or
haVing a risk for depression, to at least one assay to detect the ce or absence of at
least one of the following conditions:
i. an expression ratio of s-adenosyl methionine (SAM) to s-adenosyl
homocysteine (SAH) smaller than a pre-determined nce ratio;
ii. expression of 4-hydroxynonenal (4-HNE) greater than a pre-
determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID
NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133) comprising
at least one thymine “T” allele, wherein the SEQ ID NO. 1 and SEQ ID
NO. 7 are each independently a portion of a genomic nucleic acid sequence
of enetetrahydrofolate reductase (MTHFR);
iV. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine “G” , wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase (MTR); and
V. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO.
comprising at least one guanine “G” allele, wherein the SEQ ID NO. 3 and
SEQ ID NO. 10 are each ndently a portion of a genomic nucleic acid
sequence of methionine synthase reductase (MTRR);
and if at least one of said ions is detected to be present then recommending that
a treatment regimen comprising a folate-containing compound be selected; and if
none of these conditions is determined to be present then recommending a ent
regimen t a folate-containing compound.
2012/065084
4. The assay of any one of the preceding paragraphs, further comprising ining a
parameter of at least one biomarker from the following:
i. genotype of a SNP locus at position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8 ified by rs2274976), wherein SEQ ID NO. 1 and SEQ ID NO. 8 are
each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR) ;
ii. genotype of a SNP locus at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID
NO. 10 (identified by rs1801394), n the SEQ ID NO. 3 and SEQ ID NO.
are each independently a portion of a genomic nucleic acid ce of
nine synthase reductase (MTRR);
iii. pe of a SNP locus at 737 (position 27 of SEQ ID NO. 11), wherein the
SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of calcium
channel, voltage-dependent, L type, alpha 1C subunit (CACNAlC);
iV. genotype of a SNP locus at rs1883729 (position 27 of SEQ ID NO. 12), wherein the
SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of DNA
(cytosine-5)-methyltransferase 3 beta B);
. genotype of a SNP locus at rs7163862 (position 27 of SEQ ID NO. 13), wherein the
SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence of GTP
cyclohydrolase 1 feedback regulatory protein (GCHFR);
Vi. genotype of a SNP locus at rs12659 (position 27 of SEQ ID NO. 14), wherein the
SEQ ID NO. 14 is a n of a genomic nucleic acid sequence of reduced folate
carrier protein (RCFZ);
Vii. genotype of a SNP locus at rs202676 (position 27 of SEQ ID NO. 15), wherein the
SEQ ID NO. 15 is a portion of a c nucleic acid sequence of folate
hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
Viii. genotype of a SNP locus at rs2297291 (position 27 of SEQ ID NO. 16), wherein the
SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of reduced folate
carrier protein (RCF 1 );
ix. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17 ), wherein the
SEQ ID NO. 17 is a portion of a genomic nucleic acid ce of reduced folate
carrier protein (RCF 1 );
2012/065084
X. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO. 18), wherein the
SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence of GTP
cyclohydrolase 1 (GCH1);
xi. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO. 19), wherein the
SEQ ID NO. 19 is a portion of a c nucleic acid sequence of choline-
phosphate cytidylyltransferase A (PCYTlA);
xii. genotype of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20), wherein the SEQ
ID NO. 20 is a portion of a genomic c acid sequence of dopamine receptor
D2 (DRD2);
xiii. genotype of a SNP locus at rs1079596 (position 27 of SEQ ID NO. 21), wherein the
SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
xiV. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22), wherein the
SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
XV. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23), wherein the SEQ
ID NO. 23 is a portion of a genomic nucleic acid sequence of catechol-O-
methyltransferase (COMT);
xvi. genotype of a SNP locus at rs4680 ion 27 of SEQ ID NO. 24), wherein the SEQ
ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-O-
methyltransferase (COMT);
xvii. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25, n the
SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of solute carrier
family 6 transmitted transported, dopamine), member 3 3);
xviii. genotype of a SNP locus at rs2277820 (position 27 of SEQ ID NO. 26), wherein the
SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of
formiminotransferase cyclodeaminase ;
xix. genotype of a SNP locus at 225 (position 27 of SEQ ID NO. 27), wherein the
SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFDl);
XX. an obesity indicator (e.g., a BMI value);
xxi. expressions of SAM and SAH;
xxii. expression of 4-HNE;
xxiii. expression of hsCRP; and any ations thereof.
. The assay of paragraph 4, r comprising determining, from the determined parameter of
said at least one biomarker, the presence of at least one condition from the following:
i. a SNP at position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8 comprising
at least one alanine “A” allele;
ii. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising at
least one guanine "G" allele;
iii. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) sing at least one alanine
“A” allele;
iV. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele;
V. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele;
Vi. a SNP at rs12659 ion 27 of SEQ ID NO. 14) sing at least one thymine “T”
allele;
Vii. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele;
Viii. a SNP at rs2297291 ion 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele;
ix. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele;
x. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele;
xi. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele;
xii. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele;
xiii. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele;
xiV. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele;
xv. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele;
xvi. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
allele;
xvii. a SNP at 82 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele;
xviii. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele; and
xix. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) sing at least one alanine
“A” allele;
xx. obesity (e.g., defined by a BMI value of 30 kg/m2 or greater);
xxi. an expression ratio of SAM to SAH smaller than a pre-determined reference ratio;
xxii. an expression of 4-HNE greater than a pre-determined reference value;
xxiii. an expression of hsCRP greater than about 2.3 mg per liter as measured in a plasma
sample; and any ations f; and
if at least one of the condition is detected, then selecting, and optionally administering, a
treatment n comprising an effective amount of a folate-containing compound.
6. An assay for selecting a treatment n for a human subject having depression,
comprising:
(a) subjecting a test sample of the human subject, who is sed as having depression
or having a risk for depression, to at least one analysis to determine parameters of at least
two biomarkers from:
i. genotype of a SNP locus at position 677 of SEQ ID NO. 1 or position
27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each independently a portion of a genomic nucleic
acid ce of methylenetetrahydrofolate reductase (MTHFR);
ii. genotype of a SNP locus at rs2274976 (position 1793 of SEQ ID NO.
1 or position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID
NO. 8 are each independently a portion of a genomic c acid sequence
of methylenetetrahydrofolate reductase (MTHFR);
iii. genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or
position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID
NO. 2 and SEQ ID NO. 9 are each independently a portion of a genomic
nucleic acid sequence of nine synthase (MTR);
iV. genotype of a SNP locus at position 66 of SEQ ID NO. 3 or position
27 of SEQ ID NO. 10 ified by rs1801394), wherein the SEQ ID NO. 3
and SEQ ID NO. 10 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase reductase (MTRR);
V. genotype of a SNP locus at rs1006737 (position 27 of SEQ ID NO.
11, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid
sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNAlC));
Vi. pe of a SNP locus at rs1883729 (position 27 of SEQ ID NO.
12, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid
sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B));
Vii. genotype of a SNP locus at rs7163862 (position 27 of SEQ ID NO.
13, wherein the SEQ ID NO. 13 is a portion of a c nucleic acid
sequence of GTP cyclohydrolase 1 feedback regulatory protein )) ;
Viii. genotype of a SNP locus at rs12659 (position 27 of SEQ ID NO. 14,
wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence
of reduced folate carrier n (RCF2));
ix. genotype of a SNP locus at rs202676 ion 27 of SEQ ID NO. 15,
wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence
of folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1));
X. genotype of a SNP locus at 291 (position 27 of SEQ ID NO.
16, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCF1)) ;
xi. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO.
17, wherein the SEQ ID NO. 17 is a n of a genomic c acid
sequence of reduced folate carrier protein (RCF1));
xii. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO.
18, n the SEQ ID NO. 18 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 (GCH1));
xiii. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO.
19, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid
sequence of choline-phosphate cytidylyltransferase A (PCYT1A));
xiv. genotype of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20,
wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2));
xv. genotype of a SNP locus at 596 (position 27 of SEQ ID NO.
21), wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvi. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO.
22), wherein the SEQ ID NO. 22 is a portion of a genomic c acid
sequence of dopamine receptor D2 (DRD2);
xvii. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23,
n the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence
of catechol-O-methyltransferase (COMT));
xviii. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24),
n the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence
of catechol-O-methyltransferase (COMT);
xix. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25,
wherein the SEQ ID NO. 25 is a n of a genomic nucleic acid sequence
of solute carrier family 6 (neurotransmitted transported, dopamine), member
3 (SLC6A3));
xx. genotype of a SNP locus at rs2277820 (position 27 of SEQ ID NO.
26, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid
sequence of formiminotransferase eaminase (FTCD)); and
xxi. pe of a SNP locus at 225 (position 27 of SEQ ID NO.
27, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid
ce of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1
(MTHFD1));
xxii. an obesity indicator (e. g., a BMI value);
xxiii. level of expression of SAM and SAH;
xxiv. level of expression of 4-HNE;
xxv. level of expression of hsCRP; and any combinations thereof;
(b) detecting, optionally with a non-human machine, from the ters of said at least
two biomarkers, the presence of at least one ion selected from the following:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
comprising at least one thymine “T” allele;
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ
ID NO. 8) comprising at least one alanine “A” allele;
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele;
iV. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10
comprising at least one guanine "G" allele;
. a SNP at 737 (position 27 of SEQ ID NO. 11) comprising at least
one alanine “A” allele;
Vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least
one alanine “A” allele;
Vii. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least
one thymine “T” allele;
Viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one
e “T” allele;
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one
guanine “G” allele;
. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least
one alanine “A” allele;
xi. a SNP at 266 (position 27 of SEQ ID NO. 17) comprising at least
one alanine “A” allele;
xii. a SNP at rs8007267 ion 27 of SEQ ID NO. 18) sing at least
one thymine “T” allele;
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19 ) comprising at least
one alanine “A” allele;
xiV. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one
thymine “T” allele;
XV. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least
one e “T” allele;
xvi a SNP at rsl 1240594 (position 27 of SEQ ID NO. 22) comprising at least
one alanine “A” allele;
xvii. a SNP at rs4633 ion 27 of SEQ ID NO. 23) comprising at least one
ne “C” allele;
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one
guanine “G” allele;
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one
cytosine “C” allele;
XX. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least
one thymine “T” allele;
xxi. a SNP at rs2236225 ion 1958 of SEQ ID NO. 27) comprising at least
one alanine “A” allele;
xxii. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or greater);
xxiii. an sion level ratio of SAM to SAH smaller than a termined
reference ratio;
xxiv. an expression level of 4-HNE greater than a pre-determined nce
value;
XXV. an expression of hsCRP greater than about 2.3 mg per liter of plasma as
ed in a plasma ; and any combinations thereof, and
and if at least one of said conditions is detected, then selecting and optionally
administering a treatment n comprising an effective amount of a folate-
containing compound.
7. The assay of any of the preceding paragraphs, wherein the pre-determined reference ratio is
about 2.8 if measured in a plasma sample.
8. The assay of any of the preceding paragraphs, wherein the pre-determined reference ratio is
about 3.0 if measured in a plasma sample.
9. The assay of any of the preceding paragraphs, wherein the predetermined reference value is
about 3.0 mg per liter of plasma if measured in a plasma sample.
. The assay of any of the preceding paragraphs, wherein the predetermined reference value is
about 3.2 mg per liter of plasma as measured in a plasma sample.
11. The assay of any of the preceding paragraphs, wherein the test sample is analyzed to
determine at least two of the conditions.
12. The assay of any of the preceding paragraphs, wherein the test sample is analyzed to
determine at least three of the ions.
13. The assay of any of the preceding paragraphs, wherein the test sample comprises a blood
sample.
14. The assay of any of the preceding paragraphs, wherein the test sample comprises a urine
sample.
. The assay of any of the preceding paragraphs, wherein the test sample comprises a buccal
sample.
16. The assay of any of the preceding paragraphs, wherein the test sample comprises a saliva
sample.
17. The assay of any of the preceding paragraphs, wherein the genotyping comprises the step of
amplifying the test sample with a set of primers flanking any one of the SNPs.
18. The assay of paragraph 17, n at least two sets of s ying at least two of the
SNPs are used in a multiplex ication assay.
19. The assay of any of the preceding paragraphs, wherein the test sample comprises a protein
sample, and the test sample comprising a protein sample is subjected to at least one analysis selected
from the group consisting of n blot, enzyme linked absorbance assay, mass spectrometry,
immunoassay, flow cytometry, immunohistochemical analysis, and any combinations thereof.
. The assay of any of the preceding paragraphs, n the treatment regimen further
comprises selecting and optionally administering an antidepressant drug.
21. The assay of paragraph 20, wherein the anti-depressant drug comprises a selective serotonin
reuptake inhibitor.
22. The assay of any of the preceding paragraphs, n the depression is major depressive
disorder.
23. A method for treating a human subject with depression, comprising administering a
composition sing an effective amount of a folate-containing compound to a human t,
who is diagnosed to have depression or have a risk for sion, and is further determined to carry
at least one of the following single nucleotide polymorphisms (SNPs) or a combination thereof:
i. a SNP at on 677 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 7 (identified by rs1801133) comprising at least one thymine “T” allele,
wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a
portion of a genomic nucleic acid sequence of methylenetetrahydrofolate
reductase (MTHFR); and
ii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine “G” allele, n the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase (MTR).
24. A method for treating a human subject with depression, comprising
a. determining the genotypes of at least two loci in a biological sample of a
subject, who is diagnosed as having depression or having a risk for depression,
wherein said at least two loci are:
i. SNP677, wherein the SNP677 is position 677 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 7 (identified by rs1801133), n the SEQ ID
NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic
nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR); and
ii. SNP2756, wherein the SNP2756 is position 2756 of SEQ ID N02 or
position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID
NO. 2 and SEQ ID NO. 9 are each ndently a n of a genomic
c acid sequence of methionine synthase (MTR); and
b. administering a treatment regimen comprising a composition comprising an
effective amount of a folate-containing compound to the subject if at least one of the
ing conditions is detected:
i. at least one thymine “T” allele at SNP677;
ii. at least one e “G” allele at SNP2756; or
iii. at least one thymine “T” allele at SNP677 and at least one guanine
“G” allele at SNP2756.
. A method of ing the effectiveness of an anti-depressant drug administered to a human
subject, comprising administering a composition comprising an effective amount of a folate-
containing compound, in combination with the anti-depressant drug, to the human subject if the
human subject is determined to carry any one of the ing single nucleotide polymorphisms
(SNPs) or a combination thereof:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 7 (identified by rs1801133) comprising at least one thymine "T" allele,
wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a
n of a genomic nucleic acid sequence of enetetrahydrofolate
reductase (MTHFR); and
ii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine "G" allele, n the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase (MTR).
26. The method of any of the preceding paragraphs, wherein the subject is further determined to
carry at least one of the following conditions or any combinations thereof:
i. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8) comprising at least one alanine “A” allele;
ii. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising
at least one e "G" allele, wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are
each independently a n of a genomic c acid sequence of methionine
se reductase (MTRR);
iii. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid
sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
iV. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one e
“A” allele, n the SEQ ID NO. 12 is a portion of a genomic c acid
sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
. a SNP at rs7l63862 (position 27 of SEQ ID NO. 13) sing at least one thymine
“T” allele, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR);
Vi. a SNP at rsl2659 (position 27 of SEQ ID NO. 14) sing at least one thymine
“T” allele, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCF2);
Vii. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” , wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid
sequence of folate hydrolase (prostate-specific membrane n) 1 (FOLHl);
Viii. a SNP at rs229729l (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 16 is a portion of a c nucleic acid
sequence of reduced folate carrier protein (RCFl);
2012/065084
ix. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) sing at least one alanine
“A” allele, wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFl);
. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid
ce of GTP cyclohydrolase 1 (GCHl);
xi. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele, n the SEQ ID NO. 19 is a portion of a genomic nucleic acid
sequence of choline-phosphate cytidylyltransferase A (PCYT1A);
xii. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele), wherein the SEQ ID NO. 20 is a portion of a genomic c acid sequence
of dopamine receptor D2 (DRD2);
xiii. a SNP at 596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele ), wherein the SEQ ID NO. 21 is a n of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xiV. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” , ), wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
XV. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele, wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase ;
xvi. a SNP at rs4680 (position 27 of SEQ ID NO. 24) sing at least one guanine “G”
allele, wherein the SEQ ID NO. 24 is a portion of a genomic c acid sequence of
catechol-O-methyltransferase (COMT);
xvii. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid
sequence of solute r family 6 (neurotransmitted transported, dopamine),
member 3 (SLC6A3);;
xviii. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid
sequence of formiminotransferase eaminase (FTCD); and
xix. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) l
(MTHFDl);
XX. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or r);
xxi. an expression ratio of SAM to SAH smaller than a pre-determined ratio;
xxii. an expression of 4-HNE greater than a pre-determined standard; and
xxiii. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in
a plasma sample.
27. A method for treating a human subject with depression, sing stering a
composition comprising an effective amount of a folate-containing compound to the human subject
haVing been diagnosed with depression or with a risk for sion, and is further determined to
carry at least one of the following conditions or any ations f:
1. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified
by rs1801133) comprising at least one thymine “T” allele, wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate ase (MTHFR);
ii. a SNP at rs2274976 ion 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8) comprising at least one alanine “A” allele, wherein the SEQ ID NO. 1 and
SEQ ID NO. 8 are each independently a portion of a genomic nucleic acid sequence
of methylenetetrahydrofolate reductase (MTHFR);
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 comprising
at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are
each independently a portion of a genomic nucleic acid sequence of methionine
synthase (MTR);
iV. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising
at least one guanine "G" allele, wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are
each independently a portion of a genomic nucleic acid sequence of methionine
synthase reductase (MTRR);
. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 11 is a portion of a c nucleic acid
sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
2012/065084
Vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid
sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
Vii. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 13 is a n of a genomic nucleic acid
ce of GTP ydrolase 1 feedback regulatory protein (GCHFR);
Viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCF2);
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one e
“G” allele, wherein the SEQ ID NO. 15 is a portion of a c nucleic acid
sequence of folate hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
. a SNP at 291 (position 27 of SEQ ID NO. 16) sing at least one alanine
“A” allele, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFl);
xi. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 17 is a n of a genomic c acid
sequence of reduced folate carrier protein (RCFl);
xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid
ce of GTP cyclohydrolase 1 (GCH1);
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 19 is a portion of a genomic c acid
sequence of choline-phosphate cytidylyltransferase A (PCYT1A);
xiV. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele), wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence
of ne receptor D2 (DRD2);
XV. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele, ), wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvi. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele, ), wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele, wherein the SEQ ID NO. 23 is a portion of a genomic c acid ce of
catechol-O-methyltransferase (COMT);
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
, wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT);
xix. a SNPat rs250682 (position 27 of SEQ ID NO. 25) comprising at least one ne
“C” allele, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid
sequence of solute r family 6 (neurotransmitted transported, dopamine),
member 3 (SLC6A3);;
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid
sequence of formiminotransferase cyclodeaminase (FTCD); and
xxi. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) l
(MTHFDl);
xxii. obesity (e.g., d by a BMI value of at least 30 kg/m2 or greater);
xxiii. an expression ratio of SAM to SAH smaller than a pre-determined ratio;
xxiv. an expression of 4-HNE greater than a pre-determined standard; and
xxv. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in
a plasma sample.
28. A method of treating depression in a human subject comprising detecting at least one of the
following conditions in a biological sample from the human subject and if any one of them is
present then stering to the human subject a treatment regimen comprising an effective amount
of a folate-containing compound, wherein said at least one of the conditions is selected from the
ing:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified
by 133) comprising at least one thymine “T” allele;
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8) comprising at least one alanine “A” allele;
iii. a SNP at position 2756 of SEQ ID N02 or on 27 of SEQ ID NO. 9 sing
at least one guanine “G” allele;
iV. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising
at least one guanine "G" allele;
. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele;
Vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one e
“A” allele;
Vii. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele;
Viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one thymine
“T” allele;
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele;
. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele;
xi. a SNP at 266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele;
xii. a SNP at rs8007267 ion 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele;
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19 ) sing at least one alanine
“A” allele;
xiV. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele;
XV. a SNP at 596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele;
xvi. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele;
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele;
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
allele;
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one ne
“C” allele;
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele;
xxi. a SNP at rs2236225 (position 1958 of SEQ ID NO. 27) comprising at least one
alanine “A” allele;
xxii. obesity (e. g., defined by a BMI value of at least 30 kg/m2 or greater);
xxiii. an expression level ratio of SAM to SAH smaller than a pre-determined reference
ratio;
xxiv. an expression level of 4-HNE greater than a pre-determined reference value;
xxv. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in
a plasma sample; and any combinations thereof.
29. The method of any of the preceding paragraphs, wherein the subject is further ined to
carry at least two of the conditions or more.
. The method of any of the preceding paragraphs, n the effective amount of the folate-
containing compound ranges from about 0.1 to about 1 mg/kg body weight per day.
31. The method of any of the preceding paragraphs, wherein the effective amount of the folate-
containing compound is about 7.5 mg/day to about 50 mg/day.
32. The method of any of the preceding paragraphs, wherein the effective amount of the folate-
ning compound is about 15 mg/day.
33. The method of any of the preceding paragraphs, wherein the effective amount of the folate-
containing compound is administered as a single daily dose.
34. The method of any of the preceding paragraphs, wherein the effective amount of the folate-
containing compound is administered in more than one divided doses per day.
. The method of any of the preceding paragraphs, wherein the administration is oral.
36. The method of any of the preceding paragraphs, wherein the composition is formulated to
release at least a n of the folate-containing compound over a period of at least about 3-6 hours,
upon the administration of the composition, wherein the release is ally a steady-state release.
37. The method of any of the ing paragraphs, further comprising selecting and ally
administering an epressant drug in ation with the -containing compound.
38. The method of paragraph 37, wherein the anti-depressant drug ses a selective serotonin
reuptake inhibitor.
39. The method of paragraph 38, wherein the selective serotonin reuptake tor is selected
from the group consisting of fluoxetine, pram, paroxetine, lopram, sertraline, and any
combinations thereof.
40. The method of any of the preceding paragraphs, wherein the subject who is diagnosed as
having depression is resistant to at least one pressant monotherapy.
41. The method of any of the preceding paragraphs, wherein the depression is major depressive
42. The method of any of the ing paragraphs, wherein the test sample comprises a buccal
sample.
43. The method of any of the preceding paragraphs, wherein the test sample comprises a saliva
sample.
44. The method of any of the preceding paragraphs, wherein the test sample comprises a blood
sample.
45. The method of any of the preceding paragraphs, wherein the test sample comprises a urine
sample.
46. A computer system for obtaining data from at least one test sample obtained from at least one
subject, the system comprising:
(a) at least one determination module ured to receive said at least one test
sample and perform at least one analysis on said at least one test sample to determine
the presence or absence of at least one of the following conditions or any
combinations thereof:
i. an expression ratio of s-adenosyl methionine (SAM) to s-adenosyl
homocysteine (SAH) smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4-HNE) r than a pre-
determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID
NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133) comprising
at least one thymine “T” , wherein the SEQ ID NO. 1 and SEQ ID NO.
7 are each ndently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine “G” allele, wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase (MTR); and
V. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO.
sing at least one guanine “G” allele, wherein the SEQ ID NO. 3 and
SEQ ID NO. 10 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase reductase (MTRR);
(b) at least one storage device configured to store data output from said ination
module; and
(d) at least one display module for displaying a content based in part on the data
output from said determination module, wherein the content comprises a signal
indicative of the presence of at least one of these ions, and optionally the
absence of any one of these ions, or a signal indicative of the e of all of
these conditions.
47. The computer system of paragraph 46, wherein said ination module is configured to
e said at least one test sample to ine the presence or e of at least two of the
conditions.
48. The er system of paragraph 46 or 47, wherein said determination module further
comprises a comparison module adapted to compare said data output from said determination
module with reference data stored on said storage device.
49. A computer system for obtaining data from at least one test sample obtained from at least one
subject, the system comprising:
(a) a determination module configured to receive said at least one test sample and
perform at least one genotyping analysis on said at least one test sample to determine
the genotypes of at least two loci, wherein said at least two loci se:
(i) position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified
by rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently
a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase
(MTHFR);
(ii) position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
(identified by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each
independently a portion of a genomic nucleic acid sequence of methionine synthase
(MTR); and
(iii) optionally, position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO.
(identified by rs1801394), wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are
2012/065084
each independently a portion of a genomic nucleic acid sequence of methionine
se reductase (MTRR);
(b) a storage deVice configured to store output data from said determination module;
(c) a computing module comprising specifically-programmed instructions to
determine from the output data the presence of at least one single nucleotide
polyphormism (SNP) from the following:
i. a SNP at position 677 of SEQ ID NO. 1 or on 27 of SEQ ID
NO. 7 comprising at least one e “T” allele;
ii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine “G” allele; and
iii. optionally a SNP at the position 66 of SEQ ID NO. 3 or position 27
of SEQ ID NO. 10 comprising at least one guanine “G” allele.
(d) a y module for displaying a content based in part on the data output from
said computing module, wherein the content comprises a signal indicative of the
presence of at least one of these SNPs, and optionally the absence of any one of these
SNPs, or a signal indicative of the absence of all of these SNPs.
50. The computer system of any one of the preceding paragraphs, wherein said determination
module is further determine a parameter of at least one of the following biomarkers or any
combinations thereof:
i. pe of a SNP locus at rs2274976 (position 1793 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO. 8 are
each ndently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
ii. genotype of a SNP locus at rs1006737 (position 27 of SEQ ID NO. 11,
wherein the SEQ ID NO. 11 is a n of a genomic nucleic acid sequence of
calcium channel, e-dependent, L type, alpha 1C subunit (CACNAlC));
iii. genotype of a SNP locus at rs1883729 (position 27 of SEQ ID NO. 12,
wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of DNA
(cytosine-5)-methyltransferase 3 beta B));
iV. genotype of a SNP locus at rs7l63862 (position 27 of SEQ ID NO. 13,
wherein the SEQ ID NO. 13 is a portion of a genomic c acid sequence of GTP
cyclohydrolase 1 feedback regulatory protein (GCHFR)) ;
V. genotype of a SNP locus at rs12659 (position 27 of SEQ ID NO. 14, wherein
the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of reduced folate
carrier protein (RCF2));
Vi. genotype of a SNP locus at rs202676 (position 27 of SEQ ID NO. 20,
wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of folate
hydrolase (prostate-specific ne antigen) 1 (FOLH1));
Vii. genotype of a SNP locus at 291 (position 27 of SEQ ID NO. 16,
wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF1)) ;
Viii. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17,
wherein the SEQ ID NO. 17 is a portion of a genomic c acid sequence of
reduced folate carrier protein (RCF1));
ix. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO. 18,
n the SEQ ID NO. 18 is a n of a genomic nucleic acid ce of GTP
cyclohydrolase 1 (GCH1));
x. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO. 19,
n the SEQ ID NO. 19 is a portion of a genomic c acid sequence of
choline-phosphate cytidylyltransferase A (PCYT1A));
xi. genotype of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20, wherein
the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence of dopamine
or D2 (DRD2));
xii. genotype of a SNP locus at 596 (position 27 of SEQ ID NO. 21),
wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence of
dopamine receptor D2 (DRD2);
xiii. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22),
wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence of
dopamine receptor D2 (DRD2);
xiV. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23, wherein
the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of catechol-O-
methyltransferase (COMT));
xv. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24), n
the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-O-
methyltransferase (COMT);
WO 74676
xvi. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25,
wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of solute
carrier family 6 (neurotransmitted transported, dopamine), member 3 (SLC6A3));
xvii. genotype of a SNP locus at rs2277820 (position 27 of SEQ ID NO. 26,
wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of
formiminotransferase eaminase ); and
xviii. genotype of a SNP locus at rs2236225 (position 27 of SEQ ID NO. 27,
wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
enetetrahydrofolate dehydrogenase (NADP+ dependent) l (MTHFD1));
xix. an obesity indicator (e. g., a BMI value);
xx. level of expression of SAM and SAH;
xxi. level of expression of 4-HNE;
xxii. level of expression of hsCRP.
51. The computer system of paragraph 50, wherein said computing module is further adapted to
determine the presence of at least one of the following conditions or any combinations thereof:
i. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO.
8) comprising at least one e “A” allele;
ii. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele;
iii. a SNP at rs1883729 ion 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele;
iv. a SNP at rs7l63862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele;
v. a SNP at rsl2659 ion 27 of SEQ ID NO. 14) comprising at least one thymine
“T” allele;
vi. a SNP at 76 (position 27 of SEQ ID NO. 15) comprising at least one e
“G” allele;
vii. a SNP at rs229729l (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele;
viii. a SNP at rs105l266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele;
2012/065084
ix. a SNP at 267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele;
. a SNP at rs7639752 (position 27 of SEQ ID NO. 19 ) comprising at least one alanine
“A” allele;
xi. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele;
xii. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele;
xiii. a SNP at rsl 1240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele;
xiv. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele;
XV. a SNP at rs4680 ion 27 of SEQ ID NO. 24) comprising at least one guanine “G”
allele;
xvi. a SNP at rs250682 ion 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele;
xvii. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” ;
xviii. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) sing at least one alanine
“A” allele;
xix. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or greater);
XX. an expression level ratio of SAM to SAH smaller than a pre-determined reference
ratio;
xxi. an expression level of 4-HNE greater than a pre-determined reference value;
xxii. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in
a plasma sample.
52. A computer system for obtaining data from at least one test sample obtained from at least one
subject, the system comprising:
(a) a determination module configured to receive said at least one test sample and
perform at least one analysis on said at least one test sample to determine parameters
of at least two biomarkers, wherein the ters of said at least two kers are
selected from the following:
. genotype of a single tide rphism (SNP) locus at position 677 of
SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133),
wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a
portion of a genomic nucleic acid sequence of methylenetetrahydrofolate
reductase (MTHFR);
ii. genotype of a SNP locus at rs2274976 (position 1793 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 8), n the SEQ ID NO. 1 and SEQ ID
NO. 8 are each independently a portion of a genomic nucleic acid ce
of methylenetetrahydrofolate reductase );
iii. genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of
SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and
SEQ ID NO. 9 are each independently a portion of a genomic c acid
sequence of methionine synthase (MTR);
iV. genotype of a SNP locus at position 66 of SEQ ID NO. 3 or position 27 of SEQ
ID NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3 and SEQ
ID NO. 10 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase reductase (MTRR);
. pe of a SNP locus at rs1006737 (position 27 of SEQ ID NO. 11),
n the SEQ ID NO. 11 is a portion of a genomic nucleic acid
sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
Vi. genotype of a SNP locus at rs1883729 (position 27 of SEQ ID NO. 12),
wherein the SEQ ID NO. 12 is a portion of a c nucleic acid
sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
Vii. genotype of a SNP locus at rs7163862 (position 27 of SEQ ID NO. 13),
wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 feedback regulatory n (GCHFR);
Viii. genotype of a SNP locus at rs12659 (position 27 of SEQ ID NO. 14), wherein
the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of
d folate carrier protein (RCF2);
ix. genotype of a SNP locus at rs202676 (position 27 of SEQ ID NO. 15), wherein
the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of
folate hydrolase ate-specific membrane antigen) 1 (FOLHl);
. genotype of a SNP locus at rs2297291 (position 27 of SEQ ID NO. 16),
wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFl);
xi. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17),
wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid
sequence of reduced folate r protein (RCFl);
xii. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO. 18),
wherein the SEQ ID NO. 18 is a n of a genomic nucleic acid
sequence of GTP ydrolase 1 (GCHl);
xiii. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO. 19),
wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid
sequence of choline-phosphate lyltransferase A (PCYTlA);
xiV. genotype of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20), wherein
the SEQ ID NO. 20 is a portion of a genomic c acid sequence of
dopamine or D2 (DRD2);
XV. genotype of a SNP locus at 596 (position 27 of SEQ ID NO. 21),
n the SEQ ID NO. 21 is a n of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvi. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22),
wherein the SEQ ID NO. 22 is a portion of a c nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvii. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23), wherein
the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT);
xviii. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24), wherein
the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of
ol-O-methyltransferase (COMT);
xix. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25), wherein
the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of
solute carrier family 6 (neurotransmitted transported, dopamine), member 3
(SLC6A3);;
xx. genotype of a SNP locus at rs2277820 ion 27 of SEQ ID NO. 26),
wherein the SEQ ID NO. 26 is a portion of a c nucleic acid
sequence of formiminotransferase cyclodeaminase (FTCD);
xxi. genotype of a SNP locus at rs2236225 (position 27 of SEQ ID NO. 27),
wherein the SEQ ID NO. 27 is a portion of a genomic c acid
sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
1 (MTHFDl);
xxii. sions of SAM and SAH;
xxiii. expression of 4-HNE;
xxiV. expression of hsCRP; and any combinations thereof.
(b) a storage deVice configured to store output data from said determination ;
(c) a computing module comprising specifically-programmed instructions to
determine from the output data the presence of at least one condition from the
following:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
comprising at least one thymine “T” allele;
ii. a SNP at rs2274976 ion 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8) sing at least one alanine “A” allele;
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele;
iV. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10
comprising at least one guanine "G" allele;
V. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one
alanine “A” allele;
Vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) sing at least one
alanine “A” allele;
Vii. a SNP at rs7l63862 (position 27 of SEQ ID NO. 13) comprising at least one
thymine “T” allele;
Viii. a SNP at rsl2659 (position 27 of SEQ ID NO. 14) comprising at least one
thymine “T” allele;
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one
guanine “G” allele;
. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one
alanine “A” allele;
xi. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one
alanine “A” allele;
xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one
thymine “T” allele;
xiii. a SNP at 752 (position 27 of SEQ ID NO. 19) comprising at least one
alanine “A” allele;
xiV. a SNP at rs6275 ion 27 of SEQ ID NO. 20) comprising at least one
thymine “T” allele;
XV. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one
thymine “T” allele;
xvi. a SNP at 0594 (position 27 of SEQ ID NO. 22) comprising at least one
alanine “A” allele;
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one
cytosine “C” allele;
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one
guanine “G” allele;
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) sing at least one
cytosine “C” allele;
XX. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one
thymine “T” allele; and
xxi. a SNP at rs2236225 ion 27 of SEQ ID NO. 27) comprising at least one
alanine “A” allele;
xxii. an expression ratio of SAM to SAH smaller than a termined reference
ratio;
xxiii. an expression of 4-HNE r than a pre-determined reference value;
xxiV. an expression of hsCRP greater than about 2.3 mg per liter of plasma as
measured in a plasma sample; and any combinations thereof.
(d) a display module for displaying a content based in part on the data output from
said computing module, wherein the content ses a signal indicative of the
2012/065084
presence of at least one of the conditions, and optionally the absence of any one of the
conditions, or a signal indicative of the absence of all of the conditions.
53. The computer system of any of the preceding paragraphs, wherein the pre-determined
reference ratio is about 3.0 as measured in a plasma sample.
54. The computer system of any of the preceding aphs, wherein the pre-determined
reference ratio is about 2.8 as measured in a plasma sample.
55. The computer system of any of the preceding paragraphs, wherein the predetermined
reference value is about 3.0 mg per liter as ed in a plasma sample.
56. The computer system of any of the preceding paragraphs, n the predetermined
nce value is about 3.2 mg per liter as ed in a plasma sample.
57. The er system of any of the preceding paragraphs, wherein the determination module
is configured to determine parameters of at least three kers or more.
58. The computer system of any of the preceding paragraphs, wherein the computing module is
configured to determine the presence of at least two conditions or more.
59. The computer system of any of the preceding paragraphs, wherein said computing module
further comprises a comparison module adapted to compare said output data from said
determination module with reference data stored on said storage device.
60. The computer system of any of the preceding paragraphs, wherein the storage device is
further configured to store physical information of said at least one subject.
61. The er system of paragraph 60, wherein the physical information comprises an obesity
indicator (e.g., BMI) of said at least one subject.
62. The computer system of any of the preceding aphs, wherein the content displayed on
said display module further comprises the obesity indicator (e.g., the BMI value) or a signal
indicative of whether the subject is obese (e.g., whether the BMI value is at least 30 kg/m2 or not).
63. The computer system of any of the ing aphs, wherein the content displayed on
said display module further comprises a signal indicative of the subject recommended to receive a
treatment regimen sing a folate-containing compound, or a signal indicative of the subject
recommended to receive an alternative treatment regimen without a folate-containing compound.
64. The computer system of any of the preceding paragraphs, wherein the depression is major
depressive disorder.
65. A computer readable medium having computer le instructions recorded thereon to
define software modules for implementing a method on a er, said computer readable storage
medium comprising:
(a) instructions for comparing the data stored on a storage device with reference data to
provide a comparison result, n the comparison identifies the presence or absence
of at least one of the following conditions or any ations thereof:
i. an expression ratio of s-adenosyl nine (SAM) to s-adenosyl
homocysteine (SAH) smaller than a pre-determined reference ratio;
ii. expression of 4-hydroxynonenal (4-HNE) greater than a pre-
determined reference value;
iii. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID
NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133) comprising
at least one thymine “T” allele, n the SEQ ID NO. 1 and SEQ ID NO.
7 are each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
iv. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 comprising at least one guanine “G” allele, wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase (MTR); and
v. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO.
comprising at least one guanine “G” allele, n the SEQ ID NO. 3 and
SEQ ID NO. 10 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase reductase (MTRR);
(b) ctions for displaying a content based in part on the data output from said
determination module, wherein the t comprises a signal indicative of the
presence of at least one of the conditions, and optionally the absence of any one of the
conditions, or a signal indicative of the absence of all of the conditions.
66. A computer readable medium having computer readable instructions recorded thereon to
define software s for implementing a method on a computer, said er readable storage
medium comprising:
(a) instructions for comparing the data stored on a storage device with reference data to
provide a comparison result, wherein the ison identifies the presence or absence
of at least one of the following conditions:
i. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID
NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133) sing
at least one thymine “T” allele, wherein the SEQ ID NO. 1 and SEQ ID NO.
7 are each independently a portion of a genomic nucleic acid sequence of
enetetrahydrofolate ase (MTHFR);
ii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID
NO. 9 sing at least one guanine “G” allele, wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic
acid sequence of methionine synthase (MTR); and
(b) instructions for ying a content based in part on the data output from said
determination module, wherein the content ses a signal indicative of the
presence of at least one of the conditions, and ally the absence of any one of the
conditions, or a signal indicative of the e of all of the conditions.
67. The computer readable medium of any of the preceding paragraphs, further comprising
instructions to identify the presence or absence of at least one of the following conditions or any
combinations thereof:
i. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8) comprising at least one alanine “A” allele, wherein the SEQ ID NO. 1 and
SEQ ID NO. 8 are each independently a portion of a genomic nucleic acid sequence
of methylenetetrahydrofolate reductase (MTHFR);
ii. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 sing
at least one guanine "G" allele, wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are
each independently a portion of a genomic nucleic acid sequence of methionine
synthase reductase (MTRR);
iii. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid
sequence of calcium l, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
iV. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid
sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
V. a SNP at 862 ion 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR);
Vi. a SNP at rsl2659 (position 27 of SEQ ID NO. 14) comprising at least one thymine
“T” , wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
ce of d folate carrier protein (RCF2);
vii. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid
ce of folate hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
viii. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 16 is a n of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFl);
ix. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFl);
x. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 (GCH1);
xi. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid
sequence of choline-phosphate cytidylyltransferase A (PCYT1A);
xii. a SNP at rs6275 ion 27 of SEQ ID NO. 20) comprising at least one thymine “T”
, wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
xiii. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one e
“T” , wherein the SEQ ID NO. 21 is a portion of a c nucleic acid
sequence of dopamine receptor D2 ;
xiv. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xv. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele, wherein the SEQ ID NO. 23 is a portion of a genomic c acid ce
of catechol-O-methyltransferase (COMT);
xvi. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
, wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence
of ol-O-methyltransferase (COMT);
xvii. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele, wherein the SEQ ID NO. 25 is a n of a genomic nucleic acid
sequence of solute carrier family 6 (neurotransmitted transported, dopamine),
member 3 (SLC6A3);
xviii. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele, n the SEQ ID NO. 26 is a portion of a genomic nucleic acid
sequence of formiminotransferase cyclodeaminase (FTCD); and
xix. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) sing at least one alanine
“A” allele, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) l
(MTHFDl);
xx. obesity (e. g., defined by a BMI value of at least 30 kg/m2 or r);
xxi. an expression ratio of SAM to SAH r than a pre-determined ratio;
xxii. an sion of 4-HNE greater than a pre-determined standard; and
xxiii. an expression of hsCRP r than about 2.3 mg per liter of plasma as measured in
a plasma .
68. A computer readable medium haVing computer readable instructions recorded thereon to
define software modules for implementing a method on a computer, said computer readable storage
medium comprising:
(a) instructions for comparing the data stored on a storage deVice with reference data to
provide a comparison result, wherein the comparison identifies the presence or absence
of at least one of the following ions:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified
by rs1801133) comprising at least one thymine “T” allele, wherein the SEQ ID
NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic
acid sequence of methylenetetrahydrofolate reductase (MTHFR);
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID
NO. 8) comprising at least one alanine “A” allele, wherein the SEQ ID NO. 1 and
SEQ ID NO. 8 are each independently a portion of a genomic c acid
ce of methylenetetrahydrofolate reductase (MTHFR);
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 comprising
at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are
each ndently a portion of a genomic nucleic acid sequence of methionine
synthase (MTR);
iV. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising
at least one guanine "G" allele, wherein the SEQ ID NO. 3 and SEQ ID NO. 10
are each independently a portion of a genomic nucleic acid sequence of
nine synthase reductase (MTRR);
V. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” , wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid
sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNA1C);
Vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid
sequence of DNA (cytosine-5)-methyltransferase 3 beta B);
Vii. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR);
Viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFZ);
ix. a SNP at rs202676 ion 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid
sequence of folate hydrolase ate-specific ne antigen) 1 (FOLHl);
x. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 16 is a portion of a genomic c acid
sequence of reduced folate carrier protein (RCFl);
xi. a SNP at rs1051266 ion 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid
sequence of reduced folate r protein (RCFl);
xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 (GCH1);
xiii. a SNP at rs7639752 ion 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid
sequence of choline-phosphate lyltransferase A (PCYT1A);
xiv. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele, wherein the SEQ ID NO. 20 is a portion of a genomic c acid
sequence of dopamine receptor D2 (DRD2);
xv. a SNP at rs1079596 ion 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvi. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 22 is a portion of a genomic c acid
sequence of dopamine receptor D2 (DRD2);
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
, wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid
sequence of catechol-O-methyltransferase (COMT);
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
allele, wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid
sequence of catechol-O-methyltransferase (COMT);
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele, wherein the SEQ ID NO. 25 is a portion of a genomic c acid
sequence of solute carrier family 6 (neurotransmitted transported, dopamine),
member 3 (SLC6A3);
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele, n the SEQ ID NO. 26 is a portion of a genomic nucleic acid
sequence of formiminotransferase cyclodeaminase ; and
xxi. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate ogenase (NADP+ dependent) 1
(MTHFD1);
xxii. obesity (e. g., defined by a BMI value of at least 30 kg/m2 or greater);
xxiii. an expression ratio of SAM to SAH r than a pre-determined ratio;
xxiv. an expression of 4-HNE greater than a termined standard;
xxv. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in
a plasma sample; and any combinations thereof; and
(b) instructions for displaying a t based in part on the data output from said
determination module, wherein the content comprises a signal indicative of the
2012/065084
presence of at least one of the conditions, and optionally the absence of any one of the
conditions, or a signal indicative of the absence of all of the conditions.
69. The computer readable medium of paragraph 68, r comprising instructions to display a
signal indicative of the subject recommended to receive a treatment regimen comprising a folate-
containing compound, or a signal indicative of the subject recommended to receive an alternative
treatment regimen without a folate-containing compound.
70. The computer readable medium of any of the preceding aphs, wherein the sion is
major depressive disorder.
71. A kit comprising:
an oligonucleotide array affixed with a plurality of oligonucleotide probes that interrogate no
more than 30 single nucleotide polymorphisms (SNPs), wherein said SNPs comprise at least
two of the following SNPs or any combinations thereof:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified
by rs1801133) comprising at least one thymine “T” allele, wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate ase (MTHFR);
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO.
8) comprising at least one alanine “A” allele, wherein the SEQ ID NO. 1 and SEQ
ID NO. 8 are each ndently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
iii. a SNP at position 2756 of SEQ ID NO. 2 or on 27 of SEQ ID NO. 9 comprising
at least one e “G” allele, wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are
each independently a n of a genomic nucleic acid sequence of methionine
synthase (MTR);
iv. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising
at least one guanine "G" allele, wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are
each independently a portion of a genomic nucleic acid ce of methionine
synthase reductase (MTRR);
a SNP at 737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 11 is a n of a genomic nucleic acid
sequence of calcium l, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
Vi. a SNP at rs1883729 ion 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid
ce of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
Vii. a SNP at rs7163862 (position 27 of SEQ ID NO. 13) comprising at least one e
“T” allele, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 ck tory protein (GCHFR);
Viii. a SNP at 9 (position 27 of SEQ ID NO. 14) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein ;
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid
sequence of folate hydrolase (prostate-specific membrane n) 1 (FOLHl);
a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid
ce of reduced folate carrier protein (RCFl);
xi. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCFl);
xii. a SNP at rs8007267 ion 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid
sequence of GTP cyclohydrolase 1 ;
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 19 is a portion of a c nucleic acid
sequence of e-phosphate cytidylyltransferase A (PCYT1A);
xiV. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele, wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence
of dopamine or D2 (DRD2);
XV. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvi. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele, wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid
sequence of dopamine receptor D2 (DRD2);
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele, wherein the SEQ ID NO. 23 is a portion of a genomic c acid sequence
of catechol-O-methyltransferase (COMT);
xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
allele, wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence
of catechol-O-methyltransferase (COMT);
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) sing at least one cytosine
“C” , wherein the SEQ ID NO. 25 is a portion of a c nucleic acid
sequence of solute r family 6 transmitted transported, ne),
member 3 (SLC6A3);
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid
sequence of formiminotransferase cyclodeaminase (FTCD); and
xxi. a SNP at rs2236225 ion 27 of SEQ ID NO. 27) comprising at least one alanine
“A” , wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) l
(MTHFDl); and
an optional container containing a detectable label to be conjugated to a nucleotide molecule
derived from a test sample of a subject; and
at least one reagent.
72. A kit comprising:
an oligonucleotide array affixed with a ity of oligonucleotide probes that interrogate no
more than 5 single nucleotide rphisms (SNPs), said SNPs comprising:
(i) a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by
rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion
of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR);
(ii) a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 ified by
rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a portion
of a genomic nucleic acid sequence of methionine synthase (MTR);
an optional container containing a detectable label to be conjugated to a nucleotide molecule
derived from a test sample of a subject; and
at least one reagent.
73. The kit of paragraph 71 or 72, wherein the at least one reagent is selected from the group
consisting of a restriction , a universal r to be conjugated to a nucleotide molecule, a
primer complementary to the universal adaptor, a wash agent, and any combinations thereof.
74. The kit of any of paragraphs 71-73, wherein the detectable label comprises a fluorescent
molecule.
75. A kit comprising:
a plurality of ucleotide primers that bind to at least one allele of no more than 30 single
nucleotide polymorphisms , wherein each subset of oligonucleotide s that bind
to a ic allele of a SNP is labeled with a distinct reporter, and wherein said SNPs
comprise at least two of the following SNPs or any combinations thereof:
i. a single nucleotide rphism (SNP) at position 677 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 7 ified by rs1801133) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each
independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO.
8) comprising at least one alanine “A” allele, wherein the SEQ ID NO. 1 and
SEQ ID NO. 8 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase (MTHFR);
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ
ID NO. 9 are each independently a n of a c nucleic acid sequence of
methionine synthase (MTR);
iV. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10
comprising at least one guanine "G" allele, wherein the SEQ ID NO. 3 and SEQ
ID NO. 10 are each independently a portion of a genomic nucleic acid sequence
of methionine synthase reductase (MTRR);
a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one
e “A” allele, wherein the SEQ ID NO. 11 is a portion of a genomic c
acid sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
Vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one
alanine “A” , wherein the SEQ ID NO. 12 is a portion of a genomic nucleic
acid sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
vii. a SNP at 862 (position 27 of SEQ ID NO. 13) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 13 is a n of a genomic c
acid sequence of GTP cyclohydrolase 1 ck regulatory protein (GCHFR);
viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) sing at least one thymine
“T” allele, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
sequence of d folate carrier protein (RCF2);
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid
sequence of folate hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
x. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) sing at least one
alanine “A” allele, wherein the SEQ ID NO. 16 is a n of a genomic nucleic
acid sequence of reduced folate carrier protein (RCFl);
xi. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 17 is a portion of a genomic nucleic
acid sequence of reduced folate carrier protein ;
xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 18 is a portion of a c nucleic
acid sequence of GTP cyclohydrolase 1 (GCH1);
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic
acid sequence of choline-phosphate cytidylyltransferase A (PCYT1A);
xiv. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one e
“T” allele, wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid
sequence of ne receptor D2 (DRD2);
xv. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 21 is a portion of a genomic nucleic
acid sequence of dopamine or D2 (DRD2);
xvi. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 22 is a portion of a genomic nucleic
acid sequence of dopamine receptor D2 (DRD2);
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine
“C” , wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid
sequence of catechol-O-methyltransferase (COMT);
XViii. a SNP at rs4680 ion 27 of SEQ ID NO. 24) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid
sequence of catechol-O-methyltransferase (COMT);
xix. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one ne
“C” allele, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid
sequence of solute carrier family 6 (neurotransmitted transported, dopamine),
member 3 (SLC6A3);
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) sing at least one
thymine “T” allele, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic
acid sequence of formiminotransferase cyclodeaminase (FTCD); and
xxi. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic
acid sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
l (MTHFDl); and
at least one t.
76. A kit comprising:
a plurality of oligonucleotide primers that bind to at least one allele of no more than 5 single
nucleotide rphisms (SNPs), wherein each subset of ucleotide primers that bind
to a specific allele of a SNP is d with a distinct reporter, and wherein said SNPs
se the following SNPs:
(i) a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified
by rs1801133) comprising at least one thymine “T” allele, wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid ce
of methylenetetrahydrofolate reductase (MTHFR);
(ii) a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 comprising
at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each
ndently a portion of a genomic nucleic acid sequence of methionine synthase
(MTR); and
at least one reagent.
77. The kit of any of paragraphs 75-76, wherein said at least one reagent comprises free
nucleotide bases, a rase, or both.
78. A kit for selecting a treatment regimen for a subject with depression, comprising
at least one reagent for ining in a test sample of a human t diagnosed as haVing
depression or haVing a risk for depression, the ce or e of the following SNPs :
i. a single nucleotide polymorphism (SNP) at position 677 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 7 (identified by rs1801133) comprising at least one
thymine “T” , wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each
independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR); and
ii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele, wherein the SEQ ID NO. 2 and SEQ ID
NO. 9 are each independently a portion of a genomic nucleic acid sequence of
methionine se (MTR); and
instructions for use in the assay of any of paragraphs 1-69, in the method of any of
paragraphs 70-129, or in the system of any of paragraphs 130-171, or any
combinations thereof.
79. The kit of paragraph 78, wherein said SNPs further comprises one or any combination of the
ing:
i. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO.
8) comprising at least one alanine “A” allele, wherein the SEQ ID NO. 1 and
SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase (MTHFR);
ii. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10
comprising at least one guanine "G" allele, wherein the SEQ ID NO. 3 and SEQ
ID NO. 10 are each independently a portion of a genomic nucleic acid sequence
of methionine synthase reductase (MTRR);
iii. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one
e “A” allele, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic
acid ce of calcium l, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
iV. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic
acid sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
V. a SNP at rs7l63862 (position 27 of SEQ ID NO. 13) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic
acid sequence of GTP cyclohydrolase 1 ck regulatory protein (GCHFR);
Vi. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one e
“T” allele, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid
sequence of reduced folate carrier protein (RCF2);
Vii. a SNP at rs202676 ion 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 15 is a portion of a genomic c acid
sequence of folate hydrolase (prostate-specific ne antigen) 1 (FOLHl);
Viii. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic
acid sequence of reduced folate carrier protein (RCFl);
ix. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one
alanine “A” , wherein the SEQ ID NO. 17 is a portion of a genomic nucleic
acid ce of reduced folate carrier protein (RCFl);
x. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic
acid sequence of GTP cyclohydrolase 1 (GCH1);
xi. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one
e “A” allele, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic
acid sequence of choline-phosphate cytidylyltransferase A (PCYT1A);
xii. a SNP at rs6275 (position 27 of SEQ ID NO. 20) sing at least one thymine
“T” allele, wherein the SEQ ID NO. 20 is a n of a c nucleic acid
ce of dopamine receptor D2 (DRD2);
xiii. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one
thymine “T” allele, wherein the SEQ ID NO. 21 is a portion of a genomic nucleic
acid sequence of dopamine receptor D2 (DRD2);
xiV. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 22 is a portion of a genomic c
acid sequence of dopamine receptor D2 (DRD2);
xv. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine
“C” , wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid
sequence of catechol-O-methyltransferase (COMT);
xvi. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine
“G” allele, wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid
sequence of catechol-O-methyltransferase (COMT);
xvii. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” , wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid
sequence of solute carrier family 6 (neurotransmitted orted, dopamine),
member 3 (SLC6A3);
xviii. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) sing at least one
thymine “T” allele, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic
acid sequence of formiminotransferase cyclodeaminase (FTCD); and
xix. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one
alanine “A” allele, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic
acid sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
1 (MTHFDl).
80. The kit of any of the preceding paragraphs, further comprising a solid substrate support
d with at least one protein-based binding moiety that specifically binds to a biomarker selected
from the group consisting of SAM, SAH, 4-HNE and hsCRP.
81. The kit of paragraph 80, n the protein-based binding moiety comprises an antibody.
82. The kit of paragraph 80 or 81, wherein the solid substrate support is a microtiter plate for
ELISA.
83. The kit of paragraph 80 or 81, wherein the solid substrate support is a dipstick.
84. The kit of paragraph 80 or 81, wherein the solid substrate support comprises a magnetic bead.
85. The kit of any of the preceding paragraphs, further comprising at least one primer designed to
probe a biomarker selected from the group consisting of SAM, SAH, 4-HNE, and hsCRP.
86. The kit of any of the preceding paragraphs, wherein the depression is major depressive
disorder.
87. A method for selecting a ent regimen for a human subject with depression, comprising:
a. obtaining a test sample from the human subject sed as haVing depression;
b. subjecting the test sample to at least one analysis to determine parameters of at least two
biomarkers, wherein the parameters of said at least two kers are selected from the
following:
i. pe of a SNP locus at position 677 of SEQ ID NO. 1 or position 27 of
SEQ ID NO. 7 (identified by 133), wherein the SEQ ID NO. 1 and
SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid
ce of methylenetetrahydrofolate ase (MTHFR);
ii. genotype of a SNP locus at rs2274976 (position 1793 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO. 8
are each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
iii. genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of
SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and
SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase (MTR);
iV. genotype of a SNP locus at on 66 of SEQ ID NO. 3 or position 27 of SEQ
ID NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3 and SEQ ID
NO. 10 are each independently a portion of a genomic nucleic acid sequence
of methionine synthase reductase (MTRR);
. genotype of a SNP locus at rs1006737 ion 27 of SEQ ID NO. 11),
wherein the SEQ ID NO. 11 is a n of a genomic nucleic acid sequence
of calcium channel, voltage-dependent, L type, alpha 1C subunit
(CACNAlC);
Vi. pe of a SNP locus at rs1883729 (position 27 of SEQ ID NO. 12),
wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence
of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B);
Vii. pe of a SNP locus at rs7163862 (position 27 of SEQ ID NO. 13),
n the SEQ ID NO. 13 is a n of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 feedback regulatory protein );
Viii. genotype of a SNP locus at rs12659 (position 27 of SEQ ID NO. 14), wherein
the SEQ ID NO. 14 is a portion of a c nucleic acid sequence of
reduced folate carrier protein (RCF2);
ix. genotype of a SNP locus at rs202676 (position 27 of SEQ ID NO. 15), wherein
the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of folate
hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
. genotype of a SNP locus at rs2297291 (position 27 of SEQ ID NO. 16),
n the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence
of reduced folate carrier protein (RCFl);
xi. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17, wherein
the SEQ ID NO. 17 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF1));
xii. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO. 18),
wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 (GCH1);
xiii. genotype of a SNP locus at 752 (position 27 of SEQ ID NO. 19),
wherein the SEQ ID NO. 19 is a portion of a c nucleic acid ce
of choline-phosphate cytidylyltransferase A (PCYTlA);
xiV. genotype of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20), wherein
the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence of
dopamine receptor D2 (DRD2);
XV. genotype of a SNP locus at rs1079596 (position 27 of SEQ ID NO. 21),
wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
xvi. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22),
wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
xvii. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23), wherein
the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT);
xviii. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24), wherein
the SEQ ID NO. 24 is a portion of a c nucleic acid sequence of
catechol-O-methyltransferase (COMT);
xix. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 250, wherein
the SEQ ID NO. 25 is a n of a genomic nucleic acid ce of solute
carrier family 6 (neurotransmitted transported, ne), member 3
(SLC6A3);
XX. genotype of a SNP locus at rs2277820 (position 27 of SEQ ID NO. 26),
wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence
of inotransferase cyclodeaminase (FTCD);
xxi. genotype of a SNP locus at rs2236225 (position 27 of SEQ ID NO. 27),
wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence
of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1
(MTHFDl);
xxii. expressions of SAM and SAH;
2012/065084
xxiii. sion of 4-HNE;
xxiV. expression of hsCRP; and any combinations thereof; and
c. determining, from the parameters of said at least two biomarkers, the presence of at least
one condition selected from the following:
i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 comprising at
least one thymine “T” allele;
ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8)
comprising at least one alanine “A” allele;
iii. a SNP at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 comprising at
least one guanine “G” allele;
iV. a SNP at on 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising at
least one guanine "G" allele;
V. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine
“A” allele;
Vi. a SNP at rs1883729 ion 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele;
Vii. a SNP at rs7l63862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele;
Viii. a SNP at 9 (position 27 of SEQ ID NO. 14) comprising at least one thymine “T”
allele;
ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele;
x. a SNP at rs229729l (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” ;
xi. a SNP at 266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele;
xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) sing at least one thymine
“T” allele;
xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele;
xiV. a SNP at rs6275 (position 27 of SEQ ID NO. 20) comprising at least one thymine “T”
allele;
xv. a SNP at 596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” allele;
xvi. a SNP at rsl 1240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele;
xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele;
xviii. a SNP at rs4680 ion 27 of SEQ ID NO. 24) sing at least one guanine “G”
allele;
xix. a SNP at 82 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele;
xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele; and
xxi. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one alanine
“A” allele;
xxii. an sion ratio of SAM to SAH smaller than a pre-determined reference ratio;
xxiii. an expression of 4-HNE greater than a pre-determined reference value;
xxiv. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in a
plasma sample; and any combinations thereof;
d. providing a result output setting forth whether at least one of said condition is detected
from the test sample and if at least one condition is detected, then selecting and optionally
administering a treatment n comprising an effective amount of a folate-containing compound
to the human subject.
88. A method for selecting a ent regimen for a subject with depression, comprising:
a. obtaining a test sample from the human subject diagnosed as having depression;
b. subjecting the test sample to at least one analysis to determine parameters of at least two
biomarkers, wherein the parameters of said at least two biomarkers comprise the following:
i. pe of a SNP locus at position 677 of SEQ ID NO. 1 or position 27 of
SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1 and
SEQ ID NO. 7 are each independently a n of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase (MTHFR);
ii. pe of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of
SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and
SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase (MTR);
c. determining, from the determined parameters of said at least two biomarkers, the presence
of at least one condition of the following or a combination thereof :
i. a SNP at position 677 of SEQ ID NO. 1 comprising at least one thymine “T” allele;
ii. a SNP at position 2756 of SEQ ID NO. 2 sing at least one e “G” allele;
d. providing a result output setting forth whether at least one of said condition is detected
from the test sample and if at least one condition or both is detected, then selecting and optionally
administering a ent regimen sing an effective amount of a folate-containing compound
to the human t.
89. The method of aph 88, wherein the test sample is r subjected to determine a
parameter of at least one of the following biomarkers or any combinations thereof:
i. genotype of a SNP locus at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27
of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO. 8 are each
independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
ii. genotype of a SNP locus at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID
NO. 10 (identified by 394), wherein the SEQ ID NO. 3 and SEQ ID NO.
are each independently a portion of a genomic nucleic acid sequence of
methionine synthase reductase (MTRR);
iii. genotype of a SNP locus at rs1006737 (position 27 of SEQ ID NO. 11), wherein the
SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of calcium
channel, voltage-dependent, L type, alpha 1C t (CACNAIC);
iV. genotype of a SNP locus at rsl883729 (position 27 of SEQ ID NO. 12), wherein the
SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of DNA
(cytosine-5)-methyltransferase 3 beta (DNMT3B);
V. genotype of a SNP locus at rs7l63862 (position 27 of SEQ ID NO. 13), n the
SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence of GTP
cyclohydrolase 1 feedback regulatory protein (GCHFR);
Vi. genotype of a SNP locus at rsl2659 (position 27 of SEQ ID NO. 14), wherein the
SEQ ID NO. 14 is a portion of a genomic nucleic acid ce of reduced folate
carrier protein (RCF2);
2012/065084
Vii. genotype of a SNP locus at rs202676 (position 27 of SEQ ID NO. 15), wherein the
SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of folate
hydrolase (prostate-specific membrane antigen) 1 (FOLHl);
Viii. genotype of a SNP locus at rs2297291 (position 27 of SEQ ID NO. 16), wherein the
SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of reduced folate
carrier protein (RCF 1 );
ix. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17, wherein the
SEQ ID NO. 17 is a n of a c nucleic acid sequence of reduced folate
carrier protein (RCF1));
. genotype of a SNP locus at rs8007267 (position 27 of SEQ ID NO. 18), wherein the
SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence of GTP
cyclohydrolase 1 (GCH1);
xi. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO. 19), wherein the
SEQ ID NO. 19 is a portion of a genomic nucleic acid sequence of choline-
phosphate cytidylyltransferase A (PCYTlA);
xii. genotype of a SNP locus at rs6275 ion 27 of SEQ ID NO. 20), wherein the SEQ
ID NO. 20 is a portion of a genomic nucleic acid ce of dopamine receptor
D2 (DRD2);
xiii. genotype of a SNP locus at rs1079596 (position 27 of SEQ ID NO. 21), wherein the
SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 (DRD2);
xiV. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22), n the
SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence of dopamine
receptor D2 ;
XV. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23), wherein the SEQ
ID NO. 23 is a portion of a genomic nucleic acid sequence of catechol-O-
methyltransferase (COMT);
xvi. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24), wherein the SEQ
ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-O-
methyltransferase (COMT);
xvii. pe of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25), wherein the
SEQ ID NO. 25 is a n of a c c acid ce of solute carrier
family 6 (neurotransmitted transported, dopamine), member 3 (SLC6A3);
xviii. genotype of a SNP locus at rs2277820 (position 27 of SEQ ID NO. 26), n the
SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of
formiminotransferase cyclodeaminase (FTCD);
xix. genotype of a SNP locus at rs2236225 (position 27 of SEQ ID NO. 27), wherein the
SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) l l);
xx. sions of SAM and SAH;
xxi. sion of 4-HNE; and
xxii. expression of hsCRP.
90. The method of paragraph 89 further comprising determining the presence of at least one of
the following conditions or any combinations thereof:
i. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8)
comprising at least one alanine “A” allele;
ii. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising at
least one guanine "G" ;
iii. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one e
“A” allele;
iV. a SNP at rsl883729 (position 27 of SEQ ID NO. 12) comprising at least one alanine
“A” allele;
V. a SNP at rs7l63862 (position 27 of SEQ ID NO. 13) comprising at least one thymine
“T” allele;
Vi. a SNP at rsl2659 (position 27 of SEQ ID NO. 14) comprising at least one e “T”
allele;
Vii. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine
“G” allele;
Viii. a SNP at rs229729l (position 27 of SEQ ID NO. 16) comprising at least one alanine
“A” ;
ix. a SNP at rs1051266 (position 27 of SEQ ID NO. 17) comprising at least one alanine
“A” allele;
x. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine
“T” allele;
xi. a SNP at 752 ion 27 of SEQ ID NO. 19) comprising at least one alanine
“A” allele;
xii. a SNP at rs6275 (position 27 of SEQ ID NO. 20) sing at least one thymine “T”
allele;
xiii. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one thymine
“T” ;
xiv. a SNP at rs11240594 (position 27 of SEQ ID NO. 22) comprising at least one alanine
“A” allele;
xv. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C”
allele;
xvi. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G”
allele;
xvii. a SNP at rs250682 (position 27 of SEQ ID NO. 25) comprising at least one cytosine
“C” allele;
xviii. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine
“T” allele; and
xix. a SNP at rs2236225 (position 27 of SEQ ID NO. 27) comprising at least one alanine
“A” allele;
xx. an expression ratio of SAM to SAH smaller than a pre-determined reference ratio;
xxi. an expression of 4-HNE greater than a pre-determined reference value; and
xxii. an expression of hsCRP r than about 2.3 mg per liter of plasma as measured in a
plasma sample.
91. The method of any of the preceding paragraphs, wherein the predetermined nce value is
about 3.0 mg per liter as measured in a plasma .
92. The method of any of the preceding paragraphs, wherein the predetermined reference value is
about 3.2 mg per liter as measured in a plasma sample.
93. The method of any of the preceding aphs, wherein the step (b) further comprises
optionally packing and shipping the test sample to a test facility.
94. The method of paragraph 93, wherein the test facility is a third-party CLIA-certified service
provider.
95. The method of any of the preceding paragraphs, wherein the step (d) is med by a non-
human machine.
96. The method of any of the preceding aphs, further comprising determining an obesity
indicator (e.g., measuring a BMI value) of the subject.
97. The method of any of the preceding paragraphs, wherein at least three of the foregoing
biomarker parameters are determined.
98. The method of any of the preceding paragraphs, wherein the depression is major depressive
disorder.
99. A folate-comprising composition for use in the ent of depression in a human subject
who carries at least one of the following single nucleotide polymorphisms or a combination thereof:
a. at least one thymine “T” allele at SNP677, wherein the SNP677 is at position 677 of
SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133), wherein
the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic
nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR); and
b. at least one e “G” allele at SNP2756, n the SNP2756 is at position 2756
of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein
the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a portion of a genomic
nucleic acid sequence of methionine se (MTR).
100. A folate-comprising composition for use in the treatment of depression in a human t
who carries at least one of the ing conditions or any combination thereof:
a. at least one thymine "T" allele at SNP locus at position 677 of SEQ ID NO. 1 or
on 27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each ndently a portion of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase );
b. at least one alanine "A" allele at SNP locus at rs2274976 (position 1793 of SEQ ID
NO. 1 or position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO.
8 are each independently a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
c. at least one guanine "G" allele at SNP locus at position 2756 of SEQ ID NO. 2 or
position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase (MTR);
d. at least one guanine "G" allele at SNP locus at position 66 of SEQ ID NO. 3 or
on 27 of SEQ ID NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3
and SEQ ID NO. 10 are each independently a n of a genomic nucleic acid
sequence of methionine synthase ase (MTRR);
e. at least one alanine "A" allele at SNP locus at rs1006737 (position 27 of SEQ ID NO.
11, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of
m channel, voltage-dependent, L type, alpha 1C subunit (CACNAlC));
f. at least one alanine "A" allele at SNP locus at rs1883729 (position 27 of SEQ ID NO.
12, wherein the SEQ ID NO. 12 is a n of a genomic nucleic acid sequence of
DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B));
g. at least one thymine "T" allele at SNP locus at rs7163862 (position 27 of SEQ ID
NO. 13, n the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)) ;
h. at least one thymine "T" allele at SNP locus at rs12659 (position 27 of SEQ ID NO.
14, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF2));
i. at least one guanine "G" allele at SNP locus at rs202676 (position 27 of SEQ ID NO.
, n the SEQ ID NO. 15 is a portion of a c nucleic acid sequence of
folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1));
j. at least one alanine "A" allele at SNP locus at rs2297291 (position 27 of SEQ ID NO.
16, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid ce of
reduced folate carrier protein (RCF1)) ;
k. at least one alanine "A" allele at SNP locus at rs1051266 (position 27 of SEQ ID NO.
17), wherein the SEQ ID NO. 17 is a portion of a genomic c acid sequence of
reduced folate carrier protein (RCFl);
l. at least one thymine "T" allele at SNP locus at rs8007267 (position 27 of SEQ ID
NO. 18, wherein the SEQ ID NO. 18 is a n of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 (GCH1));
m. at least one alanine "A" allele at SNP locus at rs7639752 (position 27 of SEQ ID NO.
19, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid sequence of
choline-phosphate cytidylyltransferase A (PCYT1A));
n. at least one e "T" allele at SNP locus at rs6275 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 20 is a portion of a genomic c acid sequence of
dopamine receptor D2 (DRD2));
0. at least one thymine "T" allele at SNP locus at rs1079596 (position 27 of SEQ ID
NO. 21), wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
p. at least one alanine "A" allele at SNP locus at rs11240594 (position 27 of SEQ ID
NO. 22), wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
q. at least one cytosine "C" allele at SNP locus at rs4633 (position 27 of SEQ ID NO.
23, wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid ce of
catechol-O-methyltransferase (COMT));
r. at least one e "G" allele at SNP locus at rs4680 (position 27 of SEQ ID NO.
24), wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT);
s. at least one ne "C" allele at SNP locus at rs250682 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of
solute r family 6 (neurotransmitted transported, dopamine), member 3
(SLC6A3));
t. at least one thymine "T" allele at SNP locus at rs2277820 (position 27 of SEQ ID
NO. 26, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence
of formiminotransferase cyclodeaminase (FTCD)); and
u. at least one alanine "A" allele at SNP locus at rs2236225 (position 27 of SEQ ID NO.
27, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1));
V. obesity (e. g., defined by BMI value of at least 30 kg/m2 or r);
w. an sion level ratio of SAM to SAH smaller than a termined reference
ratio;
x. an expression level of 4-HNE greater than a pre-determined nce value; and
y. an expression of hsCRP greater than about 2.3 mg per liter of plasma as ed in
a plasma sample.
101. A folate-comprising composition in combination with an anti-depressant for use in the
treatment of depression in a human t who carries at least one of the following single
nucleotide polymorphisms or a combination thereof:
a. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7
(identified by rs1801133) comprising at least one thymine “T” allele; and
b. a SNP2756 at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9
comprising at least one guanine “G” allele.
102. A folate-comprising ition in combination with an anti-depressant for use in the
treatment of depression in a human subject who carries at least one of the following conditions or
any ation thereof:
a. at least one thymine "T" allele at SNP locus at position 677 of SEQ ID NO. 1 or
position 27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1
and SEQ ID NO. 7 are each independently a n of a genomic nucleic acid
sequence of methylenetetrahydrofolate reductase (MTHFR);
at least one alanine "A" allele at SNP locus at rs2274976 (position 1793 of SEQ ID
NO. 1 or on 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO.
8 are each independently a n of a genomic nucleic acid sequence of
methylenetetrahydrofolate reductase (MTHFR);
at least one guanine "G" allele at SNP locus at position 2756 of SEQ ID N02 or
position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2
and SEQ ID NO. 9 are each independently a n of a genomic nucleic acid
sequence of methionine synthase (MTR);
at least one guanine "G" allele at SNP locus at position 66 of SEQ ID NO. 3 or
position 27 of SEQ ID NO. 10 (identified by rs1801394), n the SEQ ID NO. 3
and SEQ ID NO. 10 are each independently a portion of a genomic nucleic acid
sequence of methionine synthase reductase (MTRR);
at least one alanine "A" allele at SNP locus at rs1006737 (position 27 of SEQ ID NO.
11, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of
calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNAlC));
at least one alanine "A" allele at SNP locus at rs1883729 (position 27 of SEQ ID NO.
12, n the SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of
DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B));
at least one thymine "T" allele at SNP locus at rs7l63862 (position 27 of SEQ ID
NO. 13, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence
of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)) ;
at least one e "T" allele at SNP locus at rsl2659 (position 27 of SEQ ID NO.
14, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF2));
i. at least one guanine "G" allele at SNP locus at rs202676 (position 27 of SEQ ID NO.
, n the SEQ ID NO. 15 is a portion of a genomic nucleic acid sequence of
folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1));
at least one alanine "A" allele at SNP locus at rs2297291 (position 27 of SEQ ID NO.
16, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCF1)) ;
at least one alanine "A" allele at SNP locus at rs1051266 (position 27 of SEQ ID NO.
17), wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid sequence of
reduced folate carrier protein (RCFl);
at least one thymine "T" allele at SNP locus at 267 (position 27 of SEQ ID
NO. 18, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence
of GTP ydrolase 1 (GCH1));
at least one alanine "A" allele at SNP locus at rs7639752 (position 27 of SEQ ID NO.
19, wherein the SEQ ID NO. 19 is a n of a genomic nucleic acid sequence of
choline-phosphate cytidylyltransferase A (PCYT1A));
at least one thymine "T" allele at SNP locus at rs6275 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence of
ne receptor D2 );
at least one thymine "T" allele at SNP locus at 596 (position 27 of SEQ ID
NO. 21), wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
at least one alanine "A" allele at SNP locus at 0594 (position 27 of SEQ ID
NO. 22), wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence
of dopamine receptor D2 (DRD2);
at least one cytosine "C" allele at SNP locus at rs4633 (position 27 of SEQ ID NO.
23, wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of
catechol-O-methyltransferase (COMT));
at least one guanine "G" allele at SNP locus at rs4680 (position 27 of SEQ ID NO.
24), wherein the SEQ ID NO. 24 is a n of a genomic nucleic acid ce of
catechol-O-methyltransferase (COMT);
at least one ne "C" allele at SNP locus at rs250682 (position 27 of SEQ ID NO.
, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of
solute carrier family 6 transmitted transported, dopamine), member 3
(SLC6A3));
t. at least one thymine "T" allele at SNP locus at rs2277820 (position 27 of SEQ ID
NO. 26, wherein the SEQ ID NO. 26 is a n of a genomic nucleic acid sequence
of formiminotransferase cyclodeaminase (FTCD)); and
u. at least one alanine "A" allele at SNP locus at rs2236225 (position 27 of SEQ ID NO.
27, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1));
V. obsesity (e. g., defined by BMI value of at least 30 kg/m2 or greater);
W. an expression level ratio of SAM to SAH r than a pre-determined reference
ratio;
x. an expression level of 4-HNE greater than a pre-determined reference value; and
y. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in
a plasma sample.
103. The composition of any one of the ing paragraphs, n the folate-comprising
composition comprises at least about 5mg of folate.
104. The composition of any one of the preceding paragraphs, wherein the folate-comprising
composition comprises about 75-50 mg of folate.
105. The composition of any one of the preceding paragraphs, wherein the -comprising
composition further comprises a pre-determined release profile.
106. The ition of paragraph 105, wherein the pre-determined release profile comprises a
sustained release profile.
107. The composition of paragraph 106, wherein the ned release is a steady-state release.
108. The composition of paragraph 105, wherein the pre-determined release profile comprises a
pulsatile release profile.
109. The ition of paragraph 105, wherein the pre-determined release profile comprises a
chrono-controlled release profile.
110. The composition of any of paragraphs 105-109, wherein the -comprising composition is
formulated to release at least 30% of the folate-containing nd over a period of at least about
3-6 hours, upon the administration of the ition.
111. The composition of any of the preceding paragraphs, wherein the depression is a major
depressive disorder.
Some Selected Definitions
For convenience, certain terms employed in the entire application (including the
specification, examples, and appended claims) are collected here. Unless defined otherwise, all
technical and scientific terms used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs.
It should be understood that this invention is not limited to the particular
ology, protocols, and reagents, etc., described herein and as such may vary. The terminology
used herein is for the e of describing particular ments only, and is not intended to limit
the scope of the present invention, which is d solely by the claims.
Other than in the operating examples, or where otherwise ted, all numbers
expressing quantities of ingredients or reaction conditions used herein should be understood as
modified in all instances by the term “about.” The term “about” when used to described the present
invention, in connection with percentages means 11%.
In one aspect, the t invention relates to the herein described compositions,
methods, and respective component(s) thereof, as ial to the invention, yet open to the inclusion
of unspecified elements, essential or not (“comprising”). In some ments, other elements to be
included in the description of the composition, method or respective component thereof are limited to
those that do not materially affect the basic and novel characteristic(s) of the invention (“consisting
essentially of”). This applies equally to steps within a described method as well as compositions and
ents therein. In other embodiments, the inventions, compositions, methods, and respective
components thereof, described herein are intended to be exclusive of any element not deemed an
essential element to the ent, composition or method (“consisting of”).
All patents, patent ations, and publications identified are sly incorporated
herein by reference for the purpose of describing and disclosing, for example, the methodologies
described in such ations that might be used in connection with the present ion. These
publications are provided solely for their sure prior to the filing date of the present application.
Nothing in this regard should be construed as an admission that the inventors are not entitled to
antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the
date or entation as to the contents of these documents is based on the information available to
the applicants and does not tute any admission as to the correctness of the dates or contents of
these documents.
The term “adjuvant” as used herein generally refers to any agent or entity which
increases the effect of another agent or entity. In certain embodiments, the term “adjuvant” is used
herein in reference to a -containing compound as an adjuvant to increase or enhance the effect
(e.g., efficacy and/or therapeutic effect) of an antidepressant drug.
] As used herein, the term “polyglutamates” refers to folates that have at least two or
more glutamate .
] The term “derivative" as used herein refers to a chemical substance related
structurally to another, i.e., an "original" substance, which can be referred to as a "parent" nd.
A "derivative" can be made from the structurally-related parent compound in one or more steps. In
some embodiments, the general physical and chemical properties of a derivative can be similar to or
different from the parent nd.
As used here in the term “isomer" refers to compounds having the same molecular
formula but differing in structure. Isomers which differ only in configuration and/or conformation are
referred to as “stereoisomers." The term “isomer" is also used to refer to an enantiomer.
The term iomer" is used to describe one of a pair of molecular isomers which
are mirror images of each other and non-superimposable. Other terms used to designate or refer to
enantiomers include “stereoisomers" (because of the different arrangement or stereochemistry around
the chiral center; although all enantiomers are stereoisomers, not all stereoisomers are omers) or
“optical isomers" (because of the optical activity of pure enantiomers, which is the ability of different
pure enantiomers to rotate plane polarized light in different directions). Enantiomers generally have
identical physical ties, such as melting points and boiling points, and also have cal
spectroscopic properties. Enantiomers can differ from each other with respect to their ction with
plane polarized light and with t to biological activity.
The designations “R " and “ S " are used to denote the absolute configuration of the
molecule about its chiral (s). The designations may appear as a prefix or as a suffix; they may or
may not be separated from the isomer by a hyphen; they may or may not be hyphenated; and they may
or may not be surrounded by parentheses. The designations or prefixes “(+) and (-)" are employed to
designate the sign of rotation of plane-polarized light by the compound, with (-) g that the
compound is levorotatory (rotates to the left). A nd prefixed with (+) is dextrorotatory (rotates
to the right).
The term “racemic mixture" refers to a mixture of the two omers of one
compound, in any ratio. An ideal racemic mixture is one wherein there is a 50:50 mixture of both
enantiomers of a compound such that the optical rotation of the (+) enantiomer cancels out the optical
rotation of the (-) enantiomer.
The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will
generally refer to a molecule (i.e., strand) of DNA, RNA or a derivative or analog f, comprising
a nucleobase. A nucleobase includes, for e, a naturally occurring purine or pyrimidine base
found in DNA (e.g. an adenine "A," a guanine "G" a thymine "T" or a cytosine "C") or RNA (e.g. an
A, a G. an uracil "U" or a C). The term "nucleic acid" encompasses the terms "oligonucleotide" and
"polynucleotide," each as a subgenus of the term "nucleic acid." The term "oligonucleotide" refers to a
le of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to
at least one molecule of greater than about 100 nucleobases in length.
The term "nucleic acid sequence" refers to a single or -stranded polymer of
deoxyribonucleotide or ribonucleotide bases read from the 5'—to the 3'—end. It includes chromosomal
DNA, self-replicating plasmids, infectious polymers of DNA or RNA and DNA or RNA that
performs a primarily structural role. "Nucleic acid sequence" also refers to a consecutive list of
abbreviations, s, characters or words, which represent nucleotides. In one embodiment, a nucleic
acid can be a "probe" which is a vely short nucleic acid, usually less than 100 nucleotides in
length.
The term "oligonucleotide," as used herein refers to s and probes bed
herein, and is defined as a nucleic acid molecule comprised of at least two or more ribo- or
ibonucleotides. The exact size of the oligonucleotide will depend on s factors and on the
particular application and use of the ucleotide. The term "probe" as used herein refers to an
oligonucleotide, polynucleotide or nucleic acid, either RNA or DNA, whether occurring naturally as
in a purified restriction enzyme digest or produced synthetically, which is capable of annealing with
or specifically hybridizing to a nucleic acid with sequences complementary to the probe. A probe
may be either single-stranded or double-stranded. The exact length of the probe will depend upon
many factors, including temperature, source of probe and the method used. For example, for
diagnostic applications, depending on the complexity of the target sequence, an oligonucleotide probe
typically ns 15-25 or more tides, although it may n fewer nucleotides. The probes
as disclosed herein are selected to be substantially complementary to different strands of a particular
target nucleic acid sequence. This means that the probes must be sufficiently complementary so as to
be able to "specifically hybridize" or anneal with their respective target strands. Therefore, the probe
sequence need not reflect the exact complementary sequence of the target. For example, a non-
complementary nucleotide fragment may be attached to the 5' or 3' end of the probe, with the
remainder of the probe sequence being complementary to the target . Alternatively, non-
complementary bases or longer sequences can be interspersed into the probe, provided that the probe
sequence has sufficient complementarily with the sequence of the target nucleic acid to anneal
therewith specifically.
In the context of some embodiments of various aspects described herein, the term
" refers to a molecule which can detectably distinguish between target molecules differing in
structure (e. g. nucleic acid or protein sequence). ion can be accomplished in a variety of
different ways depending on the type of probe used and the type of target molecule. Thus, for
example, detection may be based on discrimination on detection of specific binding. es of
such specific binding include antibody binding and nucleic acid, antibody binding to protein, c
acid binding to nucleic acid, or aptamer binding to protein or nucleic acid. Thus, for example, probes
can include enzyme substrates, antibodies and dy fragments, and preferably nucleic acid
hybridization probes.
The term "specifically hybridize" refers to the association between two singlestranded
nucleic acid molecules of ient mentary sequence to permit such hybridization
under pre-determined ions generally used in the art (sometimes the sequences are referred to as
"substantially complementary"). In particular, the term ically hybridize also refers to
hybridization of an oligonucleotide with a substantially complementary sequence as ed to non-
mentary sequence.
The term “specifically” as used herein with reference to a probe which is used to
specifically detect a sequence difference, refers to a probe that identifies a particular ce
ence based on exclusive hybridization to the sequence difference under stringent ization
conditions and/or on exclusive amplification or replication of the sequence difference.
In its broadest sense, the term "substantially” as used herein in respect to
“substantially complementary", or when used herein with respect to a nucleotide sequence in relation
to a reference or target nucleotide sequence, means a nucleotide sequence having a percentage of
identity between the substantially complementary nucleotide sequence and the exact complementary
sequence of the reference or target nucleotide sequence of at least 60%, at least 70%, at least 80% or
85%, at least 90%, at least 93%, at least 95% or 96%, at least 97% or 98%, at least 99% or 100% (the
later being equivalent to the term "identical" in this t). For example, identity is assessed over a
length of at least 10 nucleotides, or at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or up to 50
nucleotides of the entire length of the nucleic acid sequence to the reference sequence (if not specified
otherwise below). Sequence comparisons can be carried out using default GAP analysis with the
University of Wisconsin GCG, SEQWEB application of GAP, based on the algorithm of Needleman
and Wunsch (Needleman and Wunsch (1970) J Mol. Biol. 48: 443-453; as defined above). A
nucleotide ce "substantially complementary" to a reference nucleotide sequence izes to
the reference nucleotide sequence under low stringency conditions, preferably medium stringency
conditions, most preferably high stringency conditions.
In its broadest sense, the term antially identical", when used herein with respect
to a nucleotide sequence, means a nucleotide sequence corresponding to a reference or target
nucleotide sequence, wherein the percentage of identity n the substantially identical nucleotide
ce and the reference or target nucleotide sequence is at least 60%, at least 70%, at least 80% or
85%, at least 90%, at least 93%, at least 95% or 96%, at least 97% or 98%, at least 99% or 100% (the
later being equivalent to the term "identical" in this context). For example, ty is assessed over a
length of 10-22 nucleotides, such as at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22 or up to
50 nucleotides of a nucleic acid sequence to the nce sequence (if not specified otherwise below).
Sequence comparisons are carried out using default GAP analysis with the University of Wisconsin
GCG, SEQWEB application of GAP, based on the algorithm of Needleman and Wunsch (Needleman
and Wunsch (1970) J Mol. Biol. 48: 443-453; as d . A nucleotide sequence "substantially
identical" to a reference nucleotide sequence hybridizes to the exact complementary sequence of the
reference nucleotide sequence (i.e. its corresponding strand in a double-stranded molecule) under low
stringency conditions, preferably medium stringency conditions, most preferably high stringency
conditions (as defined above). Homologues of a specific nucleotide sequence include nucleotide
sequences that encode an amino acid sequence that is at least 24% identical, at least 35% identical, at
least 50% identical, at least 65% cal to the reference amino acid sequence, as measured using the
parameters described above, wherein the amino acid sequence d by the homolog has the same
biological activity as the protein encoded by the specific nucleotide. The term “substantially non-
identical” refers to a nucleotide ce that does not hybridize to the nucleic acid ce under
stringent conditions. The term "substantially identical", when used herein with respect to a
ptide, means a n corresponding to a reference polypeptide, wherein the polypeptide has
ntially the same structure and function as the reference protein, e.g. where only changes in
amino acids sequence not affecting the polypeptide function occur. When used for a polypeptide or an
amino acid sequence, the percentage of identity between the substantially similar and the reference
polypeptide or amino acid sequence is at least 24%, at least 30%, at least 45%, at least 60%, at least
75%, at least 90%, at least 95%, at least 99%, using default GAP analysis parameters as bed
above. gues are amino acid ces that are at least 24% identical, more preferably at least
% identical, yet more preferably at least 50% identical, yet more preferably at least 65% identical to
the reference polypeptide or amino acid sequence, as measured using the parameters described above,
wherein the amino acid sequence encoded by the homolog has the same biological activity as the
reference polypeptide.
The term "primer" as used herein refers to an oligonucleotide, either RNA or DNA,
either single-stranded or double-stranded, either derived from a biological system, generated by
restriction enzyme digestion, or produced synthetically which, when placed in the proper
environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis.
When presented with an riate nucleic acid template, suitable nucleoside triphosphate precursors
of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as a suitable
temperature and pH, the primer may be extended at its 3' terminus by the addition of nucleotides by
the action of a polymerase or similar activity to yield a primer ion product. The primer may
vary in length depending on the ular conditions and requirement of the application. For example,
in stic applications, the oligonucleotide primer is typically 15-25 or more tides in length.
The primer must be of sufficient complementarity to the desired template to prime the synthesis of the
desired extension product, that is, to be able to anneal with the desired template strand in a manner
sufficient to provide the 3' hydroxyl moiety of the primer in riate juxtaposition for use in the
initiation of synthesis by a polymerase or similar . It is not required that the primer sequence
represent an exact complement of the desired template. For example, a mplementary nucleotide
ce may be attached to the 5' end of an otherwise complementary . Alternatively, non-
complementary bases may be interspersed within the oligonucleotide primer sequence, provided that
the primer sequence has sufficient mentarity with the sequence of the desired template strand
to functionally provide a template-primer complex for the synthesis of the extension product.
The term "complementary" or “complement” as used herein refers to the broad
concept of sequence complementarity n regions of two nucleic acid strands or between two
regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid
region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second
nucleic acid region which is anti-parallel to the first region if the residue is thymine or uracil.
Similarly, it is known that a cytosine residue of a first c acid strand is capable of base pairing
with a residue of a second nucleic acid strand which is anti-parallel to the first strand if the residue is
guanine. A first region of a nucleic acid is complementary to a second region of the same or a
different nucleic acid if, when the two regions are arranged in an anti-parallel fashion, at least one
nucleotide e of the first region is capable of base pairing with a residue of the second region.
Preferably, the first region comprises a first portion and the second region comprises a second portion,
whereby, when the first and second portions are ed in an anti-parallel fashion, such that at least
about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% or at least
100% of the tide residues of the first portion are capable of base pairing with nucleotide
residues in the second portion. More preferably, all tide residues of the first portion are capable
of base pairing with nucleotide residues in the second n.
The terms “variant”, “variance”, “mutation” or “polymorphism” are used
interchangeably herein, and refer to a difference in nucleic acid sequence among members if a
population of individuals. Polymorphisms can sometimes be referred to as e nucleotide
polymorphism” or “SNP” when they vary at a single tide. In some embodiments,
polymorphisms can be mous or nonsynonymous. Synonymous polymorphisms when present in
the coding region or non-coding region typically do not result in an amino acid change, but can result
in altered mRNA stability or altered alternative splice sites. Nonsynonymous polymorphism, when
present in the coding , can result in the alteration of one or more codons resulting in an amino
acid replacement in the amino acid chain. Such mutations and polymorphisms may be either
heterozygous or homozygous within an dual. gous individuals have identical alleles at
one or more corresponding loci on gous chromosomes, while heterozygous individuals have
two different alleles at one or more corresponding loci on homologous chromosomes. A
polymorphism is thus said to be ic," in that, due to the existence of the polymorphism, some
members of a species carry a gene with one sequence (e. g., the normal or wild-type "allele"), whereas
other members may have an altered sequence (e. g., the variant or, mutant "allele").
] The term "genotype" refers to the specific allelic composition of an entire cell or a
certain gene, whereas the term "phenotype” refers to the detectable outward manifestations of a
specific genotype.
The term "allele", as used herein, refers to one member of a pair of different forms of
a gene. As used herein alleles refer to coding and to non-coding ces. Alleles occupy the same
locus or position on homologous chromosomes. When a subject has two identical alleles of a gene,
the t is said to be homozygous for the gene or allele. When a t has two different alleles of
a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from
each other in a single nucleotide, or l nucleotides, and can include substitutions, deletions and
insertions of nucleotides. An allele of a gene can also be a form of a gene containing a mutation.
As used herein, the term “administer" refers to the ent of a composition into a
subject by a method or route which results in at least l localization of the composition at a
desired site such that desired effect is produced. Routes of administration suitable for the methods
described herein can include both local and systemic administration. Generally, local administration
results in a higher amount of an antidepressant (e.g., SSRI) and/or a folate-containing compound
being delivered to a ic location (e.g., serotonin receptors in the central and/or eral nervous
systems) as compared to the entire body of the subject, whereas, ic administration results in
delivery of an pressant (e.g., SSRI) and/or a folate-containing compound to essentially the
entire body of the subject. In some ments, the compositions described herein are stered
to subjects with depression orally. In other embodiments, the compositions described herein can be
administered to subjects with depression by injection.
EXAMPLES
The es ted herein, in part, relate to the use of a folate-containing
compound, e.g., 6(S)MTHF, alone or as an adjunct to an antidepressant drug for treating a patient
with depression, e.g., major depressive disorder (MDD). The examples presented herein also relate to
methods to identify genetic polymorphisms, peripheral biomarkers and clinical features involved in
selecting patients with depression for receiving a folate-containing compound, e.g., as an adjunctive
treatment to an antidepressant drug, e.g., a ive serotonin reuptake inhibitor (SSRI). Throughout
this application, various publications are referenced. The sures of all of the publications and
those nces cited within those publications in their entireties are hereby incorporated by reference
into this application in order to more fully describe the state of the art to which this invention pertains.
The following examples are not intended to limit the scope of the paragraphs to the invention, but are
rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods
which occur to the skilled artisan are intended to fall within the scope of the present invention.
Example I. A -blind, placebo controlled study of a folate-containing compound among SSRI—
resistant outpatients with major depressive er (MDD)
Exemplary Study Design
Using the sequential parallel design [51] (see, for example, Figs. 1A-1B, and 2), the
60-day, double-blind treatment, either administration with a folate-containing nd (e. g., a 6(S)-
) or a placebo as an adjunct to an SSRI, can be divided into two phases of 30 days each, with
assessments performed every 10 days. During the first phase of the double-blind treatment, eligible
patients can be ized to 30 days of treatment with either 6(S)MTHF (15 mg/day) (n=19) or
placebo , with a 2:33 ratio for random assignment to the treatment sequences drug/drug
(referring to 6(S)MTHF), placebo/placebo, and placebo/drug. By way of example only, if there is a
% ut rate during the first phase, 50 patients on placebo would te the first 30-day
phase, 17 patients on 15 mg/day -MTHF would complete the first phase. Patients randomly
assigned to the drug/drug sequence stay on the same 6(S)MTHF dose (15 mg/day) during the
second phase, regardless of whether patients have responded during the first phase or have not. For
those ly assigned to the placebo/placebo sequence, both responders and non-responders to
placebo during the first phase (n=25) remain on placebo during the second phase. On the other hand,
for those randomly assigned to the placebo/drug ce, both responders and non-responders to
placebo during the first phase (n=25) go on to receive 15 mg/day 6(S)MTHF during the second
phase. In some embodiments, some of the placebo-treated patients (e. g., about 27% of the placebo-
treated patients) can respond during the first phase, and that a portion of the remaining placebo non-
responders (e. g., about 9% of the placebo non-responders) during the first phase can go on to respond
during the second phase, while a larger portion of 6(S)MTHF-treated patients (e.g., about 48% of
the 6(S)-5 -MTHF-treated patients) can respond during the first phase, and that a portion of the
placebo non-responders (e.g., about 35% of placebo non-responders) during the first phase can go on
to respond to 15 mg/day 6(S)MTHF during the second phase. Data from the previous -
blind, placebo-controlled study (Trial 1) can be pooled into the instant study (Trial 2) to provide a
more te estimate of the placebo effect size, with a ed average from the two Phases 1 (one
from Trial 1 and one from Trial 2) and two Phases 2 (one from Trial 1 and one from Trial 2). With
148 patients randomized to placebo during phase 1 or to stay on placebo during phase 2 following
non-response to placebo in Trial 1; and with patients randomized to placebo during phase 1 (n=56) or
to stay on placebo during phase 2 following non-response to placebo in Trial 2 (n=18) in Trial 2, and
a weighted average response rate of approximately 19% across Trials 1 and 2 (total n=222); and
patients randomized to 15 mg/day 6(S)MTHF during phase 1 (n=19) or to 15 mg/day 6(S)
MTHF during phase 2 following non-response to placebo (n=18) and a weighted average response
rate of approximately 41.5% (total n=37) in Trial 2, the statistical power to show a drug-placebo
difference in response rates is greater than 0.8.
Subject Selection
Inclusion Criteria: (1) Age 18-65; (2) Written informed consent; (3) Meet DSM-IV
criteria (by Structured Clinical Interview for DSM-IV - /P) for MDD, t patients; (4)
Quick Inventory of Depressive Symptomatology — Self-Rated (QIDS-SR) [52] score of at least 12 at
both screen and baseline visits; (5) Patients treated with an SSRI at adequate doses, e. g., as shown in
Table 1 (defined as 20mg/day or more of fluoxetine, citalopram, or paroxetine, 10 mg/day or more of
escitalopram, and ay or more of sertraline) during the current episode for at least 8 weeks; and
(6) During the baseline visit, patients must be on a stable dose of SSRI for the past 4 weeks.
In some embodiments, 40% of patients ed for Trial 2 study were on starting
doses. In some embodiments, 90% of patients ed for Trial 2 study had not been maximized in
therapeutic dose range.
Table I. Mean doses of SSRIS at baseline — Trial 2
_Dose (number of patients)
mg (6) 40 mg (10) 60 mg (2) 35.5 mg
mg (3) 40 mg (8) 60 mg (2) 38.5 mg
mg (2) 30 mg (1) 40 mg (1) 27.5 mg
mg (4) 20 mg (7) 30 mg (1) 17.5 mg
50 mg (4) 100 mg (9) 200 mg (1) 92.9 mg
Exclusion Criteria: (1) Pregnant women or women of child bearing potential who are
not using a medically accepted means of ception (to include oral contraceptive or implant,
condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy); (2)
Patients who no longer meet DSM-IV criteria for MDD during the baseline visit; (3) Patients who
demonstrate a greater than 25% decrease in depressive symptoms as reflected by the QIDS-SR total
score - screen to baseline; (4) Patients with serious suicide or homicide risk, as assessed by ting
clinician; (5) Patients with unstable medical illness including cardiovascular, hepatic, renal,
respiratory, endocrine, neurological, or logical disease; (6) Patients with the following DSM-
IV diagnoses: nce use disorders active within the last six months, any bipolar disorder nt
or past), any psychotic disorder (current or past); (7) ts with a history of a seizure disorder or
clinical evidence of untreated hypothyroidism; (8) Patients requiring excluded medications (see Table
2 for details); (9) Patients with psychotic features in the current episode or a history of psychotic
features, as assessed by SCID; (10) Patients with prior course of MTHF augmentation, or rance
to MTHF at any dose; (1 1) Patients with any investigational psychotropic drug within the last 3
months; (12) Patients who have failed more than 2 adequate antidepressant trials during the current
Major sive Episode. Some es of te dosage of an antidepressant trial include
either greater than 150 mg of imipramine (or its tricyclic equivalent), greater than 60 mg of
phenelzine (or its monoamine oxidase inhibitor equivalent), greater than 20 mg of fluoxetine (or its
SSRI-equivalent), greater than 150mg of bupropion, greater than 300mg of trazodone (or
nefazodone), or greater than 150 mg of venlafaxine. A trial of adequate duration was defined as one
during which the patient was on any given antidepressant at an adequate dose for a minimum of 6
weeks; and (13) Patients with a history of antidepressant-induced nia.
] Human Subjects Involvement and Characteristics: A total of 75 individuals age 18-
65 with MDD are involved. Subjects must be medically stable as defined in the protocol bed
herein. Patients excluded from the study include ts at acute risk for suicide, active substance
abuse or dependence, with mild depression, inadequately treated with SSRIs or who have failed more
than 2 , who have received MTHF for depression in the past, and those with psychosis or bipolar
illness. Patients below the age of 18 or over the age of 65 are also excluded.
Drugs allowed or excluded as concomitant medications during the study
Drugs that may be given to the patient include any iption or OTC medication
such as aspirin, acetaminophen and cold ations not specifically excluded by the protocol.
Patients ing concomitant drug therapy with excluded drugs are discontinued from the study.
Table 2 shows a list of drugs allowed (Y) and not allowed (N) as concomitant medications. Some of
the drug classes in Table 2 have a numeric value within parentheses, referring to additional notes
shown below.
Table 2.‘ Concomitant drug therapy
K VliSt'KrK‘K'iii‘ Kw Chm-n in: K31:
‘ IsiII'IHI-airteuté cf} ‘21?
nix-KKK: Emma}mum K ‘I. I
‘ a}
I Innmfhian HI: Iilcnmux 5in N
(l) Benzodiazepine anxiolytics and non-benzodiazepine ve-hypnotics noted above are
allowed only if subjects are on a stable regimen for at least 2 weeks prior to baseline at doses no
greater than the ing or their equivalent: clonazepam 1.0 qd and zolpidem 10 mg qhs.
(2) Patients must have been treated prior to study entry with adequate doses of SSRIs (e. g.
minimum doses: fluoxetine/paroxetine/citalopram 20mg/day, escitalopram lOmg/day, sertraline 50
mg/day) for at least 8 weeks with only non-response. They must be on an SSRI at the time of study
enrollment and they must have been at the current dose for at least 4 weeks at the ne Visit.
Patients must also agree to continue to take their SSRI medication at the same dose while being
treated with 6(S)MTHF. If patients are on other tropic drugs as well, they must have been at
the current dose of the psychotropic drug for at least 4 weeks, and they must also agree to continue to
take their medication at the same dose while being treated with 6(S)MTHF.
(3) Propranolol, metoprolol, acebutolol, ine, clonidine and aldomet are excluded.
(4) Adequate thyroid replacement which has been stable for 6 months or more is able as is
estrogen replacement for post-menopausal women or the use of oral contraceptives, the initiation of
which does not coincide with the onset or exacerbation of depression.
(5) Standard multivitamins with or without minerals are allowed (with no more than 400 mcg
folate and 6 mcg B 12) if initiated at least 12 weeks prior to Baseline. Dietary supplements with
putative CNS activity are excluded including SAMe, St. John's Wort, DHEA, Inositol, Ginko biloba
and Omegafatty acids including DHA and Flax Seed Oil.
Subject Enrollment
] Seventy-five subjects enter double-blind treatment over 12 months (Trial 2, total
ment Trials 1 and 2 is 225). This trial is conducted according to the FDA guidelines. Written
informed consent is obtained from all patients before protocol-specified procedures are d out.
The subjects are drawn primarily from an outpatient sample of patients with MDD, diagnosed by the
use of the Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P).
At study entry, subjects must meet SCID ia for a depressive episode, and have a QIDS-SR score
of at least 12 at both the screen and ne visits. In addition, their current major depressive e
(MDE) must be considered resistant to SSRIs: during the current MDE, all patients must have
received at least one prior trial of an SSRI at an adequate dose and duration, as defined by the MGH
Antidepressant Treatment Response Questionnaire (MGH-ATR) [53]. The MGH-ATR defines an
te trial of SSRIs as 10 mg or more of escitalopram, 20mg or more of fluoxetine, citalopram, or
paroxetine, 50mg or more of sertraline for a minimum of 6 weeks. In addition, during the baseline
visit, patients must be on a stable dose of SSRI for the past 4 weeks or more.
Study Procedures
Once patients agree to participate in the study by signing the informed consent
document, a full medical and psychiatric history is taken and a physical ation is performed.
Screen rating scales are performed. Screened and eligible ts are asked to return two weeks later
for a baseline visit when they are randomized to double-blind treatment with placebo or 6(S)MTHF
mg/day with the study design outlined above. The double-blind treatment lasts 60 days, during
which patients are seen every 10 days (Visits 1 to 6 of Phase 1 — See Table 4 below). Subjects are
ed randomization numbers in consecutive order. The randomization list is provided by a
computer-generated random-number list and is ined by the research pharmacist. In addition, the
presence of any side effect or adverse event is carefully documented with the SAFTEE-SI [54].
Reasons for premature tinuation, including rable side effects, are ed.
All concomitant medications taken during the study is recorded in the case report
form, along with dosage information and start and stop dates. Patients requiring excluded drugs (see
Table 2 for details) are discontinued from the study. Medication ment and clinical ratings are
performed by the study clinicians.
For patients randomly assigned to the drug/drug sequence, the dose of 6(S)MTHF
is 15 mg/day during both phases of the study. For patients randomly assigned to the placebo/drug
sequence, the dose of 6(S)MTHF is 15 mg/day during the second phase of the study as well. All
patients are asked to take one tablet of blinded study medication in the morning, in addition to their
stable dose of g SSRI treatment. Each study medication tablet is either 15 mg of 6(S)MTHF
or matching placebo. Therefore, for patients randomly assigned to the placebo/placebo ce, the
tablets of study medication are placebo during both phases of the study. For ts randomly
assigned to the drug/drug sequence, the tablets are 15 mg of 6(S)MTHF during both phases of the
study. For patients randomly assigned to the placebo/drug sequence, the tablets are placebo during the
first phase of the study, while the tablets are 15 mg of -MTHF during the second phase of the
study.
Subjects unable to tolerate the study tions are withdrawn from the study.
ts need to comply with the dosage regimen and to take all medications as instructed. All
patients are instructed to return any excess medication at each Visit. A pill count is done to
corroborate the study drug record. Protocol Violation is defined as less than 80% compliance by pill
count
Specimen collection procedure
Blood samples should be taken from subjects after overnight fasting. The following
specimens as shown in Table 3 are included for metabolic testing.
Table 3: Specimens and metabolic tests
Specimen M etabntie Test m vnlume
E’Ezmmu hiJEEIOCySmEH e, has-CREE, 3:13. We, .:=\Ej}i‘~v"E..»“=i. 2.5 mi
mm, $2153 WMA
Scrum it BEEP. {£1de 1 {BE
WhoEe bEuuiE hemoEysztte Reel ecEE finite: i mE
Who Ee h E0 :11d E‘sfii'EEilE-‘R and RES yping E mE
Specimen Collection Instructions
Plasma: About 5 ml of blood is withdrawn into a sodium n vacutainer tube.
Specimens should be centrifuged within one hour of collection at ~2000g for ~10 minutes. About 2ml
of plasma are aliquoted into 2 plastic storage Vials (~1ml in each). The Vials are labeled and frozen at
—80°C.
Serum: About 5 ml of blood is withdrawn into a vacutainer tube (plain red top),
which contains no additive. The blood-containing tube is left to stand at room temperature for 20
about minutes and allowed to clot. The sample is then centrifuge at ~2000g for ~10 minutes.
Approximately 2ml of plasma is aliquoted into 2 plastic e Vials (~1ml in each). The Vials are
labeled and frozen at —20°C or -80°C.
Whole blood Hemolysate: 100 [1L of fully suspended heparinized blood is accurately
pipetted into a test tube with a pre-made solution, followed by vortexing and freezing at —20°C or -
80°C.
Whole Blood: About 5 mls of blood is awn into a EDTA vacutainer tube
(lavender top). About 4 ml of whole blood is aliquoted into 2 plastic storage vials (~2 ml each). The
vials are labeled and frozen at —20°C or -80°C.
Efficacy Measures
] Any neuropsychological tests can be used to measure efficacy response of a patient
treated with a o or 6(S)MTHF in conjunction with an SSRI. The primary efficacy measure
can e the change in l7—item on Rating Scale for Depression (HAM-D-l7) [55] score. In
this study, a response is, for example, d as a 50% or greater reduction in HAM-D-l7 score from
ne. A remission is, for example, defined as a HAM-D-l7 score less than 8 at endpoint.
Secondary measures of efficacy can include change in CGI-severity, with “clinical response defined”
as CGI-S of l or 2 at endpoint. Patients with a CGI-I score greater than 5 at any post baseline visit or
a 50 percent or greater worsening of depressive symptoms from baseline to that visit are discontinued
from the study. Subjects are also discontinued from the study with any emergence of suicidality,
homicidality, mania, or psychosis. Additional exemplary instruments that can be administered
according to the study schedule include the following:
(1) Structured Clinical Interview for DSM-IV: The SCID-I/P, administered by the clinician, proceeds
by modules to diagnose the different Axis I disorders. Questions are asked exactly as written,
and each is based on the individual criteria from DSM-IV. Answers are lly rated on a
scale of 1-3 (1: doubtful, 2: probable, 3: te), and, based on the number of positive
answers, a diagnosis is ined by a clinician. While the entire SCID-I/P is administered at
screen, the mood module is administered at each follow up visit.
(2) The MGH pressant Treatment History Questionnaire (MGH-ATR) [53]: The MGH-ATR
es specific criteria for the adequate dose and adequate length of a trial for it to be
considered a failure, thus allowing clinicians to systematically collect data aimed at assessing
the degree of treatment-resistance of the current major depressive episode.
(3) The 28-item Hamilton Depression Scale (HAM-D-28) [55]: This version allows scoring of the
l7, 21-, 25-, and 28-item scales. This instrument is completed by the clinician by using
a structured interview and defined anchor points, and aims to quantify the degree of depression
over the past 7 days. The HAM-D is the most widely studied instrument for depression, and its
ility and validity are high.
(4) Clinical Global Impressions - ty and Improvement (CGI-S, CGI-I): These two instruments
are scored 1-7 by the clinician based on ment of the t's clinical status. They
measure, based on history and scores on other instruments: a) Depressive severity (CGI-S) and
b) Clinical Improvement (CGI-I). Patient rated versions of both scales are also utilized (the
PGI-S/I).
WO 74676 2012/065084
(5) QIDS-SR [52]: This is a brief (l6-item) self-report inventory of core depressive symptoms such as
sleep, depressed mood, appetite, concentration, suicidal ideation, interest, energy, psychomotor
retardation or agitation.
(6) The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire: This is a
brief (7-item) eport inventory to assess rates of significant cognitive symptoms, sleepiness,
and fatigue.
(7) The Massachusetts General Hospital Sexual Functioning Questionnaire [56]: This is a self-rating
scale that es common symptoms of sexual dysfunction, such as reduced libido and
orgasm ulties.
(8) The Visual Analog Scale [57]: This is a brief (8-item) eport scale to measure painful
symptoms of depression during treatment with the study medication (6(S)MTHF) or placebo.
Safety Measurements
Once the patient has agreed to participate in the study by signing the informed
consent document, vital signs (weight, and ng and supine pulse and blood pressure) are recorded
at each visit and a physical exam is performed at screen and visit 6 (Day 60, or Phase I endpoint).
Consumptive habits (e. g., smoking, alcohol, and nated beverages) are recorded at baseline, Day
, Day 60, Day 150, Day 240, Day 330, and Day 420 (or endpoint)(See Tables 4 & 5 below). A
urine pregnancy test (for women of childbearing ial) is also administered at the screen visit and
visit 3 (day 30). Pregnant women may not enroll in this study.
onally, baseline blood samples are collected for the assessment of genetic
polymorphism for (i) T677C allele for the methylenetetrahydrofolate reductase (MTHFR), (ii)
A1298C allele for the MTHFR gene, (iii) A66G allele for the methionine synthase reductase gene,
and (iv) A2746G allele for the methionine synthase gene.
Further, baseline, Day 30, Day 60, and Day 420 (or endpoint) blood samples are
collected for the measurement of plasma folate, RBC folate, plasma homocysteine, vitamin B 12,
MMA (methylmalonic acid), SAMe, asymmetrical dimethylarginine (ADMA), ialdehyde
(MDA), 4-hydroxynonenal ), F2-Isoprostanes, and high-sensitivity C-Reactive Protein (hs-
CRP).
e side effects or events
] Documentation of the presence of any side effect or adverse event is completed at
every visit using the SAFTEE-SI. Subjects can contact a clinician at any time between visits
concerning adverse events or worsening of symptoms. Suicidal on is assessed at each visit.
Subjects who are felt by the study clinician to be at high risk for suicide are discontinued from the
study and referred for hospitalization and further treatment if clinically indicated (See Tables 4 & 5
below).
Table 4. Schedule of ian/Subject Ratings & Plasma Tests — Double Blind Phase
1.,.._1 .3. a 1 1»3f0 “LWa» n 1.1f
Emlym‘sm 1.
"ham-‘- ‘1 .HE
.11 .\
i. J1 1 31.3.11
. 1511111111 12
T,I.,1». NM :1. H.11 v. XXRXXKXKX\R
Table 5. Schedule of Clinician/Subject Ratings & Plasma Tests — Follow Up Phase
E's-lesi‘xitwettient'
, ”.1 Elwin].
. £338-
at“ a” IA: ./
{:3 HISLLIEH up{ 1%. .1.
.1»;
Groslairies \
Termination
Acceptable reasons for early tinuation include the following: 1) request of
patient, 2) on of physician, 3) serious adverse event, 4) protocol violation, 5) worsening of
depression or al deterioration ing hospitalization.
ary Data Management
Clinical data at each visit are recorded using a standardized clinician assessment form
and a set of patient rating scales. Edited and corrected data are added to a database that is ready to be
used as input to statistical software (e. g., STATA) for data pment and analysis. All data are
stored in locked file cabinets. No identifiers other than study ID’s are included in the data. Study staff
and subjects may have the option to enter clinical data into the database directly, using DatStat
IllumeTM, a platform for electronic data capture that streamlines data collection and management,
and ensures data integrity, resulting in improved data quality. Subjects and/or ch staff enter
survey responses into electronic assessment forms, and the ses are then transmitted securely via
encrypted connection and stored in a secured database.
Exemplary Statistical es
General considerations: Data are entered and error-checked at each clinical site
involved in the study. Study staff and subjects may have the option to enter self-evaluations into the
system directly using DatStat IllumeTM. The process of data entry is supervised by the DCRP staff.
2012/065084
Once the data set is entered and checked, analyses are conducted. Both a completer analysis of all
patients finishing the trial and an intent-to-treat analysis examining all patients enrolled into the trial
are used to define the severity of depression at endpoint. Examination of both study completers and
all ts randomized can provide the broadest assessment of the s of treatment in trials of
such kind. The data from Trial 2 can be pooled with those from Trial 1 with the sequential parallel
comparison design, to provide an estimate of the placebo se based on a larger sample size.
According to the sequential parallel comparison design analytical plan, the effect of the active
treatment is assessed using a e. Under the null hypothesis of no drug-placebo difference, the Z
score has a mean of 0. Let pl, ql be the response rates to the first administration of drug and placebo
respectively and let p2, q2 be the responses rates to the second ent. To analyze these data, a
tic based on h = w(pl - ql) + (l - w)(p2 - q2) is used. The weight (W) and the randomization
fraction (a) are chosen to maximize the power of the test, based on the ative hypothesis. The
randomization fraction (a) can be involved in calculation of pl, ql, p2, and/or q2. For example,
multiplying the total sample size by the randomization fraction (a) to obtain the denominator of the
response rates, e. g., pl. The standard error for h requires a special formula because some of the same
patients who are included in the estimation of p2, q2 are included in the estimation of pl, ql. The
computation is facilitated by considering a table of outcomes, where in this case pl, p2, ql, q2 are the
theoretical probabilities rather than the observed relative ncies. A more detailed description of
the analyses is described in the Fava et al nce on the sequential el ison design [51].
Analysis ofStudy Attrition: A detailed analysis of the number and timing of study
dropouts is calculated. ial differences between treatment groups in ts are examined with
a Fisher's Exact test; if even weak trends (p < 0.05) indicative of differential dropout are detected, a
more detailed al analysis is completed to illustrate the timing and magnitude of these
differences. These t analyses can be used to better understand the outcomes depicted by the
following analyses.
Analyses of the magnitude ofresponses: The ude of response between the two
treatment groups can be measured by a decrease in baseline HAM-D-l7 scores. One-way analysis of
covariance (adjusting for baseline HAM-D-l7 scores) can be used to assess differences in HAM-D-l7
scores at endpoint, pooling data from Trials 1 and 2 and from both phases by using the sequential
parallel design.
Analyses ofpercentage onders and remitters: An exemplary statistical test for
analysis of differences in proportion of responders in the treatment conditions is a Fisher's Exact test,
pooling data from Trials 1 and 2 and from both phases by using the sequential parallel design.
Logistic regression is can also be carried out, with response or non-response and remission or
non-remissions as the dependent variables, with the baseline HAM-D score, gender, and age, as the
independent variables. Exploratory covariate analysis can be carried out to investigate any differences
in remission rates seen with gender, age, and other variables.
] Analyses of the number ofadverse events: One-way analysis of variance can be used
to assess differences in total number of SAFTEE-SI AEs between baseline and nt.
Analyses ofpredictors ofa greater 6(S)MTHF/placebo difierence in response
rates: Folate levels are classified as either low (<=2.5 ng/ml) or normal; and homocysteine levels as
either normal or elevated (>=13.2mmol/liter). The presence or absence of at least one T677C allele
for the MTHFR gene are entered as a dichotomous le (present or absent). A 2X2 Analysis of
Variance (ANOVA) can be used to test whether the presence of a low folate level predicts a
r drug/placebo difference in response. Using folate as an example predicator, the presence or
absence of a low serum-folate level along with treatment assignment can be entered in a 2x2, factorial
ANOVA, using depression improvement scores (baseline minus endpoint HAM-D-17 scores) as the
dependant variable. The effect of the predictor can be indicated by the interaction term, reflecting the
potential differential effect of 6(S)MTHF on individuals with low vs. normal folate. Similar
es (i.e. separate 2X2 ANOVA's) can be performed substituting the presence of low folate levels
for the presence of other predictors as described herein. Similarly, the effect of other predictors can
be indicated by the interaction term representing the potential modulating influence of those variables.
Example 2. Evaluation of the efiicacy 0f 6(S)MTHF as an augmentation strategy in MDD patients
(Trial 1)
Using the study design and sequential el design as described in Example 1, a
60-day, multi-center, double-blind, placebo-controlled study (Trial 1) on the efficacy of oral 6(S)
MTHF augmentation of selective serotonin reuptake inhibitors (SSRIs) has been completed in 148
ts with major depressive disorder (MDD) resistant to treatment with SSRIs. The study
involved the enrollment of a total of 148 patients with MDD over the course of 12 months across 10
medical centers or hospitals in the United States. Outpatients suffering from MDD were treated with
either 7.5 mg/day of 6(S)MTHF or with placebo as an adjuvant to SSRIs for 60 days using the
sequential parallel comparison design [51]. In accordance with the sequential parallel design [51], the
60-day, double-blind treatment was divided into two phases of 30 days each, with assessments
performed every 10 days. As shown in Fig. 1A, during the first phase of double-blind treatment, 148
eligible patients were ized to 30 days of treatment with either 7.5 mg/day of 6(S)MTHF
(“drug”) or placebo, with a 2:33 ratio for random assignment to the ent sequences drug/drug,
placebo/placebo, and placebo/drug. Patients randomly ed to the drug/drug sequence had their
-MTHF dose increased from 7.5 mg/day to 15 mg/day during the second phase, regardless of
whether patients had responded during the first phase (n=12) or had not (n=20). For those ly
assigned to the o/placebo sequence, both ders and non-responders to placebo during the
first phase remained on o during the second phase. On the other hand, for those ly
assigned to the placebo/drug sequence, both responders and non-responders to placebo during the first
phase went on to receive 7.5 mg/day of 6(S)MTHF during the second phase.
The findings from Trial 1, as shown in Tables 6-7, te that the 7.5 mg/day 6(8)-
-MTHF is not effective to act as an adjunct to the SSRIs. While 6(S)MTHF does not appear to
cause any adverse side effect when administered with an SSRI, there was no significant difference in
efficacy e (as measured by various parameters such as HDRS-l7, QIDS-SR and CGI-S)
between MDD patients d with an SSRI in combination with either 7.5 mg/day 6(S)MTHF or
placebo.
Table 6: Eflieaey results ofMDD patients having 7.5 mg/day 6(S)MTHF or placebo as an adjunct
\\ \
\ “ \: \_-\\ 'm.\:
\‘n\\fl\ \ ~~
'\\\\\\\\\\\\\
3. * :43:-
.w J
Table 7. Adverse side- efieets of an SSRI administered with or without 6(S)MTHF
‘- '
- \- rm; - ‘
\u u:«\\\\ v. \ - -
- ~
aaslrsnx-mzarxs 2‘ wt: 1 s °"‘\} a -
Afiimei: mums f$ -_’.‘ ‘
' «‘2 Mamba a '34-
\\\ \x\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\~
However, an increase in dose of 6(S)MTHF from 7.5 mg/day to 15 mg/day in the
ts assigned to the drug/drug sequence during the second phase demonstrated an significant
increase in the se and remission rate, e. g., an increase by at least 2-fold, as compared to the
group taking placebo with the SSRIs (24% vs 9%, p = 0.1: Such result is not included in Table 6).
Accordingly, a higher dose of oral 6(S)MTHF augmentation, 15 mg/day, was determined to be
used in Trial 2.
Example 3. tion of the efiieaey of 6(S)MTHF as an tation strategy in MDD patients
(Trial 2)
Using the study design and sequential parallel design as described in Example 1, this
Example 3 shows a 60-day, multi-center, double-blind, placebo-controlled pilot study (Trial 2) on the
efficacy of a higher dose (15 mg qd) oral 6(S)MTHF augmentation of selective serotonin reuptake
inhibitors (SSRIs) in 75 patients with major depressive disorder (MDD) resistant to ent with
SSRIs. The design of Trial 2 (as shown in Fig. 1B) was identical to that of Trial 1, with the exception
of the dosing of -MTHF, which was 15 mg/day throughout the trial for those patients assigned
to the placebo-drug group and to the drug-drug group.
The critical clinical purpose of this study was to determine whether the use of a
higher dose of oral 6(S)MTHF as an adjunct to SSRIs would be more effective than placebo as an
adjunct to SSRIs in reducing depressive symptoms in outpatients with MDD with l or no
response to SSRI treatment. An additional aim of the study was to demonstrate the safety and
tolerability of 6(S)MTHF 15 mg/day augmentation. The study involves the enrollment of a total of
75 patients with MDD over the course of 12 months across 6 different medical centers or hospitals
across the United . Outpatients ing from MDD were treated with either 6(S)MTHF 15
mg/day or with placebo for 60 days using the sequential parallel comparison design [51]. Fig. 2 shows
the actual number of completers in each group by the end of the study.
Fig. 3A shows that there is a statistically significant difference in the percentage of
responders (50% or greater reduction in 17 at endpoint) in the two treatment conditions (i.e.,
SSRI + 15 mg/day of 6(S)MTHF vs. SSRI + placebo) after 30 days. Using the sequential parallel
comparison design [51], it was ined that the se rate is higher for the 6(S)MTHF group
than the placebo group, with the response rate on placebo estimated from Trials 1 and 2.
Fig. 3B shows that there is a statistically significant difference between the two
treatment conditions (i.e., SSRI + 15 mg/day of 6(S)MTHF vs. SSRI + placebo) after 30 days in
the degree of improvement, as measured by the change in the 17-item Hamilton Depression Rating
Scale (HAM-D-17) score from baseline to nt, QID-SR, or Clinical Global Impressions —
Severity (CGI-S), using the sequential el ison design [51]. Using the sequential parallel
comparison design [51], it was determined that there is a greater degree of reduction in the scores of
HAM-D-17, QIDS-SR and CGI-S, tively, in the 6(S)MTHF group than in the placebo group,
with the change on placebo estimated from Trials 1 and 2.
Figs. 3C-3D show that there is no significant difference in the percentage of remitters
(HAM-D-17 score < 8 at end point or QIDS-SR score S 5 at end point) in the two treatment
conditions (i.e., SSRI + 15 mg/day of 6(S)MTHF vs. SSRI + placebo) after 30 days.
The results of Figs. 3A-3D are summarized in Table 8 below.
Table 8. Eflicacy results ofMDD patients having 15 mg/day 6(S)MTHF or placebo as an adjunct
; 5:333.filth:-F1~F€=Sfrh¥ffi$$2f9
Table 9 shows that there are no significant differences in the number of e
, as measured by the SAFTEE-SI between the two treatment groups (i.e., SSRI + 15 mg/day of
6(S)MTHF vs. SSRI + placebo).
Table 9. Adverse side- eflects of an SSRI administered with 15 mg/day of 6(S)MTHF or placebo
“‘aaimi Mast 332523 3 {WWW I i7 85?“:3}
mime. manna 5 {‘c .B‘Xfi . a:
.. a: giam‘m {3.34
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\V
“ r: :a E'.»S:S::?".i 'fafift'J‘EEE numb: "55': 15:3! receévexi simian:- w isnwtiws‘uikfie 35:23; a: some paint Mme. the 31:55:.
] As shown in Fig. 3E, there is no difference in discontinuation from the study due to
overall adverse side-effects or exclusion events. The patient administered with 6(S)MTHF as an
adjunct to his/her SSRI was removed from the trial due to mood elevation. The medical y of the
patient indicated bipolar disorder which was not detected at the baseline visit.
Follow-up Study
At the end of the double-blind study, both responders and non-responders who have
completed the double-blind phase have the option of ing free, open-label adjunctive treatment
with 15 mg/day of 6(S)MTHF for 12 months. Subjects who agree to receive open-label treatment
with 6(S)MTHF for 12 months are assessed every three (3) months until the end of the follow-up
phase. During each visit, patients are stered the 28, the CGI, the QIDS-SR, the
SAFTEE-SI, the MGH-CPFQ, and the MGH-SFQ (See, e.g., Table 10 below). The dose of their
concomitant SSRI can be adjusted during the 12 months of follow-up, as can the dose of 6(S)
MTHF (e.g., up to 15 mg twice a day). Subjects are also allowed to change their antidepressant
during the course of the follow-up, if deemed appropriate. For patients who refuse the 12 months of
free -up care, a referral to a psychiatrist is offered.
Table 10 shows that remitters at the end of double-blind phase who received
adjunctive treatment with 15 mg/day of 6(S)MTHF did not have a relapse during a 12-month
maintenance phase.
Table 10. Follow-up s on remitters during the 12-month maintenance phase
ers at end of double-blind Relapsers (HAM-D-17 > 15) during 12-month
phase -17 < 8) entering nance phase, administered with 15
maintenance phase mg/day 6(S)MTHF as an adjuvant
(1 subject had not relapsed at 9-month visit but did
not return for 12-month visit)
Example 4. Identification of biomarkersfor selecting patients with depressionfor a treatment
comprising afolate-containing compound in combination with an SSRI
A double-blind, placebo-controlled study of 6(S)MTHF among SSRI resistant
outpatients with major depressive disorder (MDD) is performed, as described in Examples 1-3, to
identify genetic polymorphisms, peripheral biomarkers and/or clinical features that are associated
with a greater efficacy response when a patient is stered with a folate-containing compound
(e. g., 6(S)MTHF) in addition to an antidepressant drug, e. g., an SSRI.
Figs. 4A-4B show the effect of the single genetic polymorphism (SNP) at the
MTHFR gene (MTHFR C677T) on the cy of the treatment sing a folate-containing
compound (e.g., 6(S)MTHF) and an SSRI in a patient with depression, as measured by HDRS-28
(28-item Hamilton Depression Rating Scale) and CGI-S (Clinical Global Impression-Severity),
respectively. The findings of Figs. 4A-4B indicate that patients having at least one T allele (e. g., CT
or TT) at the on 677 of the SEQ ID NO: 1, corresponding to a portion of the genomic sequence
of the MTHFR gene, demonstrate a greater degree of improvement in the HDRS-28 or CGI-S test
when they are treated with a folate-containing compound in combination with an SSRI, as compared
to patients with no T allele ed at the position 677 of the SEQ ID NO: 1.
] Figs. SA-SB show the effect of obesity (i.e., BMI is at least 30 kg/m2 or above) on the
efficacy of the treatment comprising a folate-containing compound (e. g., 6(S)MTHF) and an SSRI
in a patient with depression, as measured by HAMD-28 (28-item Hamilton Depression Rating Scale)
and CGI-S (Clinical Global Impression-Severity), respectively. The findings of Figs. SA-SB indicate
that obese patients (i.e., with a BMI at least 30 kg/m2 or above) demonstrate a greater degree of
improvement in the 8 or CGI-S test when they are treated with a folate-containing
compound in combination with an SSRI, as compared to non-obese patients.
] Some exemplary predictors for greater efficacy response rates in ts receiving
6(S)MTHF in combination with their respective SSRIs in combination with SSRIs, can include low
plasma and/or RBC folate levels, low plasma B12 and SAM levels, low ratios of SAM/SAH levels, an
elevated plasma homocysteine level, presence of folate receptor autoantibodies (FRAs), trical
dimethylarginine (ADMA), malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), high-sensitivity
C-Reactive Protein (hs-CRP), prostanes (8-OH-Dg), brain d neutropic factor (BDNF)
levels, and the following genetic polymorphisms: a) T677C allele for the methylenetetrahydrofolate
reductase (MTHFR); b) A1298C allele for the MTHFR gene; c) A66G allele for the methionine
synthase reductase gene; and d) A2746G allele for the nine synthase gene.
Various combinations of genetic and biomarkers were assessed for their effects on the
efficacy of the treatment comprising a folate-containing compound (e. g., 6(S)MTHF) and an SSRI
in ts with depression. Particularly, specific c and biomarkers that were assessed include
the following:
(a) BMI calculation of at least about 30 kg/mz;
(b) an expression ratio of SAM/SAH smaller than 2.8 (e. g., 2.71) as measured in a plasma
sample;
(c) a level of 4-HNE no less than 3.28 ug/mL (as measured in a plasma sample);
(d) presence of rare variants CT or TT at position 677 of SEQ ID NO: 1 ponding to a
portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase( MTHFR)
(abbreviated as “MTHFR 677” below);
(e) presence of rare ts AG or GG at position 2756 of SEQ ID NO: 2 corresponding to a
portion of genomic nucleic acid sequence of methionine synthase (MTR) (abbreviated as
“MTR 2756” below); and
(f) presence of rare variants AG or GG at position 66 of SEQ ID NO: 3 corresponding to a
n of genomic nucleic acid sequence of nine synthase reductase (MTRR)
(abbreviated as “MTRR 66” below).
The s of how various combinations of the above conditions (a)-(f) affect the
degree in improvement, as measured by 7 and HAMD-28 scores, when patients are treated
with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI, are shown in Tables 11-36
below. The efficacy effect is determined by measuring the mean change in the HAMD-17 score and
HAMD-28 score by the end of Phase I and Phase II, as compared to the baseline.
Table 11. Effect of at least one rare variant on both MTHFR 677 and MTR 2756, as
opposed to fully normal on both, in MDD patients on the change in HAMD-17 and HAMD-28 scores,
when the patients are treated with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
MTHFR 677 CC and . 0.817 -0.571 0.866 0.722 (-2.694, 4.138) 0.679
MTR 2756 AA (29,13)*
MTHFR 677 CT or TT . 0.006 -10.33 0.223 -18.71 (-24.33, -13.08) <0.001
and MTR 2756 AG or
GG (8,4)*
MTHFR 677 CC and -0.192 0 960 0.048 0.990 0.711 (-3.121, 4.543)
MTR 2756 AA
MTHFR 677 CT or TT -18.00 0.008 -13.00 0.167 -23.29 (-32.08, -14.50) <0.001
and MTR 2756 AG or
* The numeric values within the parentheses correspond to the number of patients having the
indicated condition
Table 12. Effect of at least one rare variant on both MTR 2756 and MTRR 66 and
baseline BMI of at least 30 kg/mz, as opposed to fully normal on both genes and ne BMI less
than 30 kg/mz, in MDD patients on the change in HAMD-17 and HAMD-28 scores, when the patients
are treated with a -containing compound (e.g., 6(S)MTHF) and an SSRI.
””17 -------
MTR 2756 AA and All non-treated All non-treated
MTRR 66 AA and BMI <
kg/m2 (7,4)
MTR 2756 AG or GG -13.667 0.029 -11.000 0.064 40.972 (—17.377, —
and MTRR 66 AG or GG
and BMI >= 30 kg/m2
(8,4)
HAMD-28
MTR 2756 AA and
MTRR 66 AA and BMI <
kg/m2
MTR 2756 AG or GG -18.833 0.014 -12.000 0.115 -15.347 (-22.967,-
and MTRR 66 AG or GG
and BMI >= 30 kg/m2
Table 13. Effect of at least one rare variant on MTR 2756 and baseline BMI of at
least 30 kg/mz, as opposed to fully normal on the gene and baseline BMI less than 30 kg/mz, in MDD
patients on the change in HAMD-17 and HAMD-28 scores, when the patients are treated with a
folate-containing compound (e.g., 6(S)MTHF) and an SSRI.
Phase I Phase II Pooled phases
95% CI p-
HAMD-17
MTR 2756 AA and BMI 3.196 6, 8.298) 0.220
< 30 kg/m2 (17,7)
MTR 2756 AG or GG -11.714 (-15.859, -7.569)
and BMI >= 30 kg/m2
(10,5)
HAMD-28
MTR 2756 AA and BMI 3.352 (-2.692, 9.395)
< 30 kg/m2
MTR 2756 AG or GG 3 (-19.453, -9.414)
and BMI >= 30 kg/m2
Table 14. Effect of at least one rare variant on MTR 2756 and ne H
smaller than a pre-determined reference ratio (e.g., the median ratio of a reference group), as d
to fully normal on the gene and the baseline SAM/SAH no less than the pre-determined reference
ratio, in MDD patients on the change in HAMD-17 and HAMD-28 scores, when the patients are
treated with a folate-containing compound (e.g., -MTHF) and an SSRI.
Phase I Phase II Pooled phases
Effect Effect p-Value Effect 95% CI e
MTR 2756 AA and -1.556 0.510 (-3.764, 3.873)
SAM/SAH
>=median(24,12)
MTR 2756 AG or GG and -9.800 0.007 (-12.163, 0.998)
SAM/SAH < median (10,4)
MTR 2756 AA and -1.278 0.662 9, 3.747)
SAM/SAH >= median
MTR 2756 AG or GG and 3 0.003 (-17.836, -5.530)
SAM/SAH < median=2.71
(as measured in a plasma
sample)
] Table 15. Effect of at least one rare variant on both MTR 2756 and MTRR 66 in
combination with baseline SAM/SAH smaller than a pre-determined reference ratio (e.g., the median
ratio of a reference group), as opposed to fully normal on both genes in combination with the baseline
SAM/SAH no less than the pre-determined reference ratio, in MDD patients on the change in HAMD-
17 and HAMD-28 scores, when the patients are treated with a folate-containing compound (e. g., 6(S)-
-MTHF) and an SSRI.
Phase II Pooled phases
p-Value
--—-—
MTR 2756 AA and -0.400 0.962 -7.000 0.154 -3.98* (-8.03, 0.064)
MTRR 66 AA and
SAM/SAH >= median
(63)
MTR 2756 AG or GG -9.000 0.037 -6.500 0.084 -7.64* (-11.93, -3.34)
and MTRR 66 AG or GG
and SAM/SAH < median
(83)
HAMD-28
MTR 2756 AA and -1.000 0.916 -7.500 0.333 -3.74* (-8.60, 1.12)
MTRR 66 AA and
SAM/SAH >= median
MTR 2756 AG or GG 1 0.019 -10.500 0.052 -11.62* (-16.14,-7.10)
and MTRR 66 AG or GG
and SAM/SAH <
median=2.71 (as
measured in a plasma
Table 16. Effect of at least one rare variant on both MTR 2756 and MTRR 66 in
ation with baseline HNE-His (or 4-HNE) no less than a predetermined level (e. g., a median
level of a reference group), as opposed to fully normal on both genes in combination with the baseline
HNE-His smaller than the predetermined level, in MDD patients on the change in HAMD-17 and
HAMD-28 , when the patients are treated with a folate-containing compound (e. g., 6(S)
MTHF) and an SSRI.
Phase I Phase II Pooled phases
Effect p-value Effect p-value Effect 95% CI p-value
HAMD-17
MTR 2756 AA and 3.000 0.750 -8.667 0.532 0.466 (-14.699, 15.630) 0.952
MTRR 66 AA and HNE-
His < median (6,4)
-7.200 0.131 -11.000 0.064 -7.942 (-14.328, -1.556) 0.015
MTR 2756 AG or GG
and MTRR 66 AG or GG
and HNE-His >=median
(10,4)
HAMD-28
MTR 2756 AA and 4.200 0.735 -9.000 0.500 -2.221 90, 17.549) 0.826
MTRR 66 AA and HNE-
His < median=3.28 (as
measured in a plasma
sample)
MTR 2756 AG or GG -9.800 0.072 -12.000 0.115 -10.241 (-17.365, -3.117) 0.005
and MTRR 66 AG or GG
and HNE-His >= median
Table 17. Effect of at least one rare variant on both MTHFR 677 and baseline BMI of
at least about 30 kg/mz, as opposed to fully normal on the gene and the baseline BMI less than 30
kg/mz, in MDD patients on the change in HAMD-17 and HAMD-28 , when the patients are
treated with a folate-containing compound (e.g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
Effect e Effect p-value 95% CI p-
value
HAMD-17
MTHFR 677 CC and 4.500 0.360 -2.267 0.480 1.356 (4.388, 7.100) 0644
BMI < 30 kg/m2 (17,8)
MTHFR 677 CT or TT -8.738 0.009 -7.333 0.129 -8.090 (-13.622, -2.558)
and BMI >= 30 kg/m2
(13,6)
HAMD-28
MTHFR 677 CC and 2.769 0.663 -3.000 0 415 -0.234 7, 6.750)
BMI < 30 kg/m2
MTHFR 677 CT or TT -9.857 0.035 -8.667 0.077 -9.884 (-15.794, -3.974)
and BMI >= 30 kg/m2
Table 18. Effect of at least one rare variant on both MTHFR 677 and baseline HNEHis
(or 4-HNE) no less than a predetermined level (e.g., a median level of a reference group), as
opposed to fully normal on the gene and the ne HNE-His smaller than the predetermined level,
in MDD patients on the change in HAMD-17 and HAMD-28 scores, when the patients are d
with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI.
Phase I Phase II Pooled phases
Effect
HAMD-17
MTHFR 677 CC and —1.471 0.695 -1.050 (-5.914, 3.814)
HNE-His < median
(20,1 1)
MTHFR 677 CT or TT -7.143 0.050 0.215 -9.446 (-15.920, -
and HNE-His >= median 2.972)
(1 1,6)
HAMD-28
MTHFR 677 CC and -2.821 0.559 -0.536 0.908 -1.340 (-6.933, 4.253)
s < median=3.28
(as measured in a plasma
sample)
MTHFR 677 CT or TT -6.929 0.090 -7.500 0.223 -9.865 (-16.200, -
and HNE-His >= median 3.529)
Table 19. Effect of at least one rare variant on both MTR 2756 and baseline HNE-His
(or 4-HNE) no less than a predetermined level (e.g., a median level of a nce group), as opposed
to fully normal on the gene and the baseline HNE-His smaller than the ermined level, in MDD
patients on the change in 7 and HAMD-28 scores, when the patients are treated with a
-containing compound (e.g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
e Effect p-value 95% CI p-value
MTR 2756 AA and HNE- 0.897 0.300 0.936 1.319 (-2.257, 4.895)
His < median (26,13)
MTR 2756 AG or GG 0.061 -8.417 0.048 -8.072 (-12.314, -
and HNE-His >= median 3.831)
(137)
MTR 2756 AA and HNE- 0.835 -0 125 0.975 2.085 (-2.142, 6.312)
His < median
MTR 2756 AG or GG 0.026 -9.500 0.037 -9.508 (-13.855, -
and HNE-His >= 5.161)
median=3.28 (as
measured in a plasma
sample)
Table 20. Effect of baseline H ratio smaller than a pre-determined reference
ratio (e.g., a median ratio of a reference group) and baseline HNE-His (or 4-HNE) level no less than a
predetermined level (e. g., a median level of a reference group), as opposed to the baseline SAM/SAH
ratio no less than the pre-determined reference ratio and the baseline HNE-His level smaller than the
predetermined level, in MDD patients on the change in HAMD-17 and HAMD-28 scores, when the
patients are treated with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI.
Effect p-Value Effect 95% CI e
HAMD-17
SAM/SAH >= median -0.250 0.920 4.000 0.380 2.107 (-2.851, 7.064)
and HNE-His < median
(18,8)
SAM/SAH < median -3.670 0.139 -9.000 0.031 -9.898 (-14.436, —
and HNE-His >= median 5.361)
(19,7)
SAM/SAH >= median -0.750 0.822 4.500 0.388 2.413 (-3.079, 7.906)
and HNE-His < median
SAM/SAH < median -4.227 0.230 -12.000 0.004 -9.500 (-13.164, -
and HNE-His >= median 5.830)
Table 21. Effect of at least one rare variant on MTR 2756 and MTRR 66, as opposed
to fully normal on both genes, in MDD patients on the change in HAMD-17 and HAMD-28 scores,
when the patients are treated with a folate-containing nd (e. g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
Effect p-Value Effect p-Value 95% CI p-Value
HAMD-17
MTR 2756 AA and 3.125 0.555 -8.000 0.451 (-10.45, 7.705)
MTRR 66 AA (11,5)
MTR 2756 AG or GG -6.900 0.091 -4.667 0.338 (-11.32, -2.638)
and MTRR 66 AG or GG
(15,7)
HAMD-28
MTR 2756 AA and 5.000 0.454 -8.000 0 439 -3.032 (-13.50, 7.431)
MTRR 66 AA
MTR 2756 AG or GG -9.996 0.039 -6.583 0.263 -9.348 (-13.01, )
and MTRR 66 AG or GG
Table 22. Effect of at least one rare variant on MTR 2756, as opposed to fully normal
on the gene, in MDD patients on the change in HAMD-17 and 8 scores, when the patients
are treated with a folate-containing compound (e.g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
Effect p-Value 95% CI p-Value
MTR 2756 AA (45,21) ---0 621 -0.427 0869 0590 (3418,2238) 0.683
MTR 2756 AG/GG 6 600 0.273 (-9.422, -1.932)
(20,11)
HAMD-28
MTR 2756 AA 0.409 0.859 -0.446 0869 (-2.974, 2.879) 0.975
MTR 2756 AG/GG -10.926 -5.300 0.160 -8.243 (-12.549, -
3.938)
Table 23. Effect of baseline BMI of at least 30 kg/m2 and baseline SAM/SAH ratio
smaller than a pre-determined reference ratio (e.g., a median ratio of a reference group), as opposed to
the baseline BMI smaller than 30 kg/m2 and the baseline SAM/SAH ratio no less than the pre-
determined reference ratio, in MDD patients on the change in HAMD-17 and HAMD-28 scores, when
the patients are treated with a folate-containing compound (e.g., 6(S)MTHF) and an SSRI.
Phase I Phase II Pooled phases
Effect p-Value Effect p-Value 95% CI p-Value
HAMD-17
BMI < 30 kg/m2 and 0.120 1.500 0.699 2.583 (-2.224, 7.389)
SAM/SAH >= median
(16,8)
BMI >= 30 kg/m2 and -5.611 0.011 -9.200 0.005 (-10.404, —
SAM/SAH < median 4.201)
(21,9)
BMI < 30 kg/m2 and 4.333 0.215 2.500 0.596 2.906 8, 8.970)
SAM/SAH >= median
BMI >= 30 kg/m2 and -6.306 0.049 0 0.005 -7.572 (-10.871, —
SAM/SAH < 4.274)
median=2.71 (as
measured in a plasma
sample)
Table 24. Effect of at least one rare variant on MTRR 66 and baseline HNE-His (or 4-
HNE) level no less than a predetermined level (e. g., a median level of a reference group), as opposed
to fully normal on the gene and the baseline HNE-His level smaller than the predetermined level, in
MDD patients on the change in HAMD-17 and HAMD-28 scores, when the patients are d with a
folate-containing compound (e.g., 6(S)MTHF) and an SSRI.
Phase I Phase II Pooled phases
Effect p-value Effect p-value Effect 95% CI p-value
MTRR 66 AA and HNE- -1.167 0.844 -1.667 0.866 2.575 (-11.15, 16.30)
His < median (8,5)
MTRR 66 AG or GG and -5.958 0.018 -3.500 0.322 -4.850 (-9.033, -0.667)
HNE-His >= median
(24,11)
MTRR 66 AA and HNE- -4.167 0.625 -2.000 0.835 -2.626 (-17.80, 12.55)
His < median=3.28 (as
measured in a plasma
MTRR 66 AG or GG and -6.975 0.017 -4.071 0.335 -6.582 (-10.895, -
HNE-His >= median 2.269)
Table 25. Effect of at least one rare variant on MTRR 66 and baseline SAM/SAH
smaller than a termined reference ratio (e.g., a median ratio determined from a nce group),
as d to fully normal on the gene and the baseline SAM/SAH ratio no less than the pre-
determined reference ratio, in MDD patients on the change in 7 and HAMD-28 scores, when
the patients are treated with a folate-containing nd (e.g., 6(S)MTHF) and an SSRI.
Phase I Phase II Pooled phases
Effect p-value Effect p-value 95% CI p-value
MTRR 66 AA and -0.125 0.984 -3.000 0.554 -2.978 (-8.884, 2.928)
SAM/SAH >= median
(9,6)
MTRR 66 AG or GG and -5.062 0.028 -6.190 0.042 -5.879 (-9.272, -2.487)
SAM/SAH < median
(24,10)
MTRR 66 AA and 0.500 0.945 -3.333 0.523 -1.221 3, 4.581)
SAM/SAH >= median
MTRR 66 AG or GG and -6.498 0.031 -7.381 0.022 -6.579 (-10.257, -
H < 2.901)
median=2.71 (as
measured in a plasma
sample)
Table 26. Effect of baseline BMI of at least about 30 kg/m2 and baseline s (or
4-HNE) level no less than a predetermined level (e. g., a median level determined from a nce
group), as opposed to the baseline BMI smaller than 30 kg/m2 and the baseline HNE-His level smaller
than the predetermined level, in MDD ts on the change in HAMD-17 and HAMD-28 scores,
when the patients are treated with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
Effect p-value Effect p-value Effect 95% CI p-value
BMI < 30 kg/m2 and 0.307 3.667 0.382 4.738 (-0.935, 10.412)
HNE-His < median
(199)
BMI >= 30 kg/m2 and -6.569 0.012 -4.233 0.242 -5.420 (-9.107, -1.732)
HNE-His >= median
(23,11)
BMI < 30 kg/m2 and 4.606 0.335 1.833 0.708 4.253 (-2.634, 11.139)
HNE-His < median
BMI >= 30 kg/m2 and -6.510 0.055 -4.933 0.253 -5.996 (-9.831, )
HNE-His >= median
Table 27. Effect of baseline BMI of at least about 30 kg/mz, as opposed to the
baseline BMI smaller than 30 kg/mz, in MDD patients on the change in HAMD-17 and HAMD-28
scores, when the patients are treated with a folate-containing compound (e.g., 6(S)MTHF) and an
SSRI. The phrase “BMI>*< treat” as used in Table 27 refers to interaction of BMI with the treatment.
HAMD-17
BMI < 25 (14,7) 1.576 0.666 -1.400 0.761 -1.248 (-8.854, 6.359)
=< BMI < 30 kg/m2 2.600 0.473 2.000 0.559 3.331 (-1.345, 8.001)
(18,10)
BMI >= 30 kg/m2 (40,21 ) 0.231 -4.600 (-7.219, -1.981)
BMI*treat 0.619 -0.233 2, 0.036)
BMI < 25 (14,7) 0.681 -1.018 (-8.587, 6.552)
=< BMI < 30 kg/m2 1.000 2.054 (-3.884, 7.992)
(18,10)
BMI >= 30 kg/m2 (40,21) 0.262 -4.660 (-7.449, -1.871)
BMI*treat 0.757 -0.270 (-0.581, 0.040)
Table 28. Effect of ne SAM/SAH ratio smaller than a pre-determined reference
ratio (e.g., a median ratio determined from a reference group), as opposed to the baseline SAM/SAH
ratio no less than the pre-determined reference ratio, in MDD patients on the change in HAMD-17
and HAMD-28 scores, when the patients are treated with a -containing compound (e. g., 6(S)
MTHF) and an SSRI. The phrases “baseHAMD-17* treat” and “SAM/SAH*treat” as used in Table
28 refer to interaction of base 7 and SAM/SAH, respectively, with the treatment.
Phase II Pooled phases
p-Value Effect p-Value Effect 95% CI p-Value
baseHAMD-17*treat 0.165 0.722 -0.249 0.566 -0.025 (-0.553, 0.504) 0.927
SAM/SAH>=med -0.946 0.675 0.564 0.816 -0.202 (-3.111, 2.708) 0.892
SAM/SAH < med (-6.730, -0.514)
(37,18)
SAM/SAH*treat 0.495 0.755 1.483 0.298 0.882 (-0.913, 2.677) 0.335
H*treat 0.495 0.755 1.483 0.298 0.882 (-0.913, 2.677) 0.335
SAM/SAH >=med=2.71 -1.148 0.681 1.355 0.634 0.073 (-3.333, 3.480) 0.966
(as measured in a plasma
WO 74676
—-------
H< med -4.523 0.113 -7.325 0.014 -4.572 (-7.732, -1.413) 0.005
SAM/SAH*treat 0.972 0.636 1.806 0.271 1.112 (-0.927, 3.151) 0.285
Table 29. Effect of baseline HNE-his (or 4-HNE) no less than a predetermined level
(e. g., a median level determined from a reference , as opposed to the baseline HNE-his smaller
than the predetermined level, in MDD patients on the change in 7 and HAMD-28 scores,
when the patients are treated with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI.
The phrase “HNE-his*treat” as used in Table 29 refers to interaction of HNE-his with the treatment.
Phase I Phase II Pooled phases
Effect p-value Effect Effect 95% CI p-value
HAMD-17
HNE-his >=med (37,20) 0.048 -4.030 0.086 -4.175 (-6.891, -1.459)
HNE-his < med (36,19) . 0.532 0.631 0.824 0.260 (-2.900, 3.421)
HNE-his >*‘treat . 0.754 2.027 0.188 .626 (- 1. 197, 2.449)
HAMD-28
HNE-his >=med=3.28 (as (-7. 610, -1.499)
measured in a plasma
HNE-his < med . . . 0.961 -0.107 (-3.670, 3.457)
HNE-his at . . . 0.184 0.685 (-1.440, 2.810)
Table 30. Effect of at least one rare variant on MTHFR 677 and MTR 2756 in
combination with baseline s (or 4-HNE) no less than a predetermined level (e. g., a median
level determined from a reference group), as opposed to fully normal on both genes in combination
with the baseline HNE-His smaller than the predetermined level, in MDD patients on the change in
HAMD-17 and HAMD-28 scores, when the patients are treated with a -containing compound
(e. g., 6(S)MTHF) and an SSRI.
Effect p-value Effect p-value E—ffect95% CI
value
””17 -----_-
MTHFR 677 CC and (-5.972, 5.688)
MTR 2756 AA and
HNE-His < median
(17,9)
MTHFR 677 CT or TT
and MTR 2756 AG or
GG and HNE-His >
median (4,2)
MTHFR 677 CC and -2.333 .687 -0.053
MTR 2756 AA and
HNE-His < median
MTHFR 677 CT or TT -17.0 NA Not enough data
and MTR 2756 AG or
GG and HNE-His >
median
Table 31. Effect of at least one rare variant on MTHFR 677 and MTR 2756 in
combination with baseline SAM/SAH ratio smaller than a pre-determined reference ratio (e.g., a
median ratio determined from a nce , as opposed to fully normal on both genes in
combination with the baseline SAM/SAH ratio no less than the pre-determined reference ratio, in
MDD patients on the change in HAMD-17 and HAMD-28 scores, when the patients are treated with a
folate-containing nd (e.g., 6(S)MTHF) and an SSRI.
Pooled phases
Effect p-Value Effect e Effect 95% CI p-
value
MTHFR 677 CC and -6.429 0.284 4.000 0.346 -0.830 (-5.190, 3.530) 0.709
MTR 2756 AA and
SAM/SAH >= median
(15,8)
MTHFR 677 CT or TT -12.667 0.070 Not enough data
and MTR 2756 AG or
GG and SAM/SAH <
median (4,1)
MTHFR 677 CC and -12.643 0.084 4.500 0.349 -4.472 (-10.619, 1.676) 0.154
MTR 2756 AA and
-----—-
MTHFR 677 CT or TT -18.000 0.070 Not enough data
and MTR 2756 AG or
GG and SAM/SAH <
median
] Table 32. Effect of at least one rare variant on MTHFR 677 and MTR 2756 in
combination with baseline BMI of at least about 30 kg/mz, as opposed to fully normal on both genes
in combination with the baseline BMI smaller than 30 kg/mz, in MDD ts on the change in
HAMD-l7 and HAMD-28 scores, when the patients are treated with a folate-containing compound
(e. g., -MTHF) and an SSRI.
Phase II Pooled phases
HAMD-17
MTHFR 677 CC and
MTR 2756 AA and BMI
< 30 kg/m2 (10,5)
MTHFR 677 CT or TT
and MTR 2756 AG or
GG and BMI >= 30
kg/m2 (5,2)
HAMD-28
MTHFR 677 CC and . . All non-treated
MTR 2756 AA and BMI
< 30 kg/m2
MTHFR 677 CT or TT -23.500 0.021 -l7.0 NA Not enough data
and MTR 2756 AG or
GG and BMI >= 30
kg/m2
Table 33. Effect of at least one rare variant on MTRR 66 in combination with
baseline BMI of at least about 30 kg/mz, as d to fully normal on the gene in combination with
the baseline BMI smaller than 30 kg/mz, in MDD patients on the change in HAMD-l7 and HAMD-28
scores, when the patients are treated with a folate-containing compound (e.g., 6(S)MTHF) and an
SSRI.
HAMD-17
MTRR 66 AA and BMI
< 30 kg/m2
(10,7)
MTRR 66 AG or GG
and BMI >= 30 kg/m2
(29,16)
MTRR 66 AA and BMI
< 30 kg/m2
MTRR 66 AG or GG
and BMI >= 30 kg/m2
Table 34. Effect of at least one rare variant on MTHFR 677 and baseline SAM/SAH
ratio smaller than a pre-determined reference ratio (e. g., a median ratio determined from a reference
group), as opposed to fully normal on the MTHFR 677 and the baseline SAM/SAH ratio no less than
the pre-determined reference ratio, in MDD patients on the change in HAMD-17 and HAMD-28
scores, when the ts are treated with a folate-containing compound (e.g., 6(S)MTHF) and an
SSRI.
Phase II Pooled phases
p-Value Effect p-Value 95% CI p-Value
MTHFR 677 CC and 0.827 2.333 0.443 1.075 (-3.250, 5.400)
SAM/SAH >= median
(21,12)
MTHFR 677 CT or TT 0.059 2.333 0.751 -2.041 (-11.186, 7.104)
and SAM/SAH <
median (11,5)
MTHFR 677 CC and 0.666 2.833 0.428 -0.764 0, 3.791)
SAM/SAH >= median
MTHFR 677 CT or TT 0.078 0.000 1.000 -3.533 (-11.408, 4.341) 0.379
and SAM/SAH <
media“ -
Table 35. Effect of at least one rare variant on both MTHFR 677 and MTRR 66, as
opposed to fully normal on both, in MDD patients on the change in HAMD-17 and HAMD-28 scores,
when the patients are treated with a folate-containing compound (e. g., 6(S)MTHF) and an SSRI.
Phase II Pooled phases
Effect p-value Effect p-value Effect 95% CI p-
value
MTHFR 677 CC and 3.750 0.579 -12.25 0.116 -8.281 (-18.82, 2.262) 0.124
MTRR 66 AA (10,5)
MTHFR 677 CT or TT -5.550 0.053 -5.250 0.069 -5.648 (-9.477, -1.818) 0.004
and MTRR 66 AG or
GG (18,8)
MTHFR 677 CC and 5.500 0 521 -13.00 0.047 -9.379 (-21.55, 2.789) 0.131
MTRR 66 AA
MTHFR 677 CT or TT -5.275 0.141 -7.500 0.025 -6.264 (-10.36, -2.167) 0.003
and MTRR 66 AG or
Table 36. l results combining all conditions from (a)-(f), when ts are
treated with a folate-containing compound (e.g., 6(S)MTHF) and an SSRI.
All Patients (-4.292, -0.236)
All Patients -3.632 0.069 (-4.995,-0.482)
2012/065084
Table 37. y of s from Tables 11-19 and 36.
‘33 T'riai 2 Cs: mbinations of
(2on Variable Pamsmgun Trial 2 Population
Priority Combinations fl 1 2 3 4 5 6 T B 9
Variable L‘omba‘natians OVERALL D35 A+E+F {ME E+E E+E+F O+JE+F {3+5 {1er {3+5
N273 N24 «=4 :.— N28 M25 was N23 N: «=9
A EM5330 533% NA NA 553153 5 5‘3”: NA N:3 5N A ‘3 5“va NA NA
E Lam-‘3 autism Ram; 53% NA. NA N33. NA 5333» .J “.2 “-5.: NA NA Nfi. N“.
C'- HESH NHNE 533%: NA NA NS}. NA N53. N31. 53 “ NA 5 14 '13; 53"};
D MTHFR 6?? C ’12??? 43%: NA 43% NA Nsb‘. NA Nix EN P4 4 :75; 41:3 NA
.53: ('4. 8. 3e, 3. 8.
E MTR 2755 @5036 34% NA 534% 34% 343.“: 34% fin-337:: 34% NA NA. 34%
F MTRR 66 MEGS ‘34‘3’3 NA NA ?:;3 NA NA Fifi: 73% NR Nr-K. NA
COMB!NflTEON ‘35.. 100% TV}; 14% $333 3 '31-‘51 ‘I 3% it 3% 2m 25% 1 1’33
Fuuiefi Street 31cm iMMD-EE 12.3133 $3.298 235.34?" 44.433 41.683 -1 i .1523 43.343 -9.3=34 3.8535 3.5%
wicked gm: \1: HAMBvEfi mm “£3,331 <1). (131: 8:31.36! 23.081 «mm 0.305 {1.9M 0.302 20.081
P‘uokm Eiiaci 352 * MAR-1&1 ? 3.263 48.719 -‘ifl..§?2 #13314 - 5.533 I? .540 3?.342 $.35“): $.44?) 43.6172
Fatima parasite iiiAMD-i? 6.029 30.001 0.051 «10.031 {3,096 20.001 5.611135 6.004 61.604 «0.801%
Table 3 8. Summary of results from Tables 20-29.
“A Trial 2 Combinations of
Code Variable anflafion Trial 2 Population
Priority Combinaiians 1G 11 12 13 1.4 15 15 17’ 18 19
Variable: Combinations 8+3: £3}: E n+5 C+F EH? R“: A E C
N231 N29 N231 M213 N215 M211 N212 M223 N213 N221
A 8ME230 52““.3 NR N33. NR ‘1‘ 5'33 NR N .553, 55% “J5% NA. NA.
{3 Law 5:433:1an RAP-O 5 5‘: '23; NA NA 55 :33 NA 55 333 NA NA 5? ‘3 N91.
(2 HEGH ANNE 53°23 5:33: NA NA NA 53% NA {33% NA Ms! 5W.
3‘} MTHFR '57? CTI'TT 49% NA Nzfi. NA NA NA NA NA NA NA. NA
E MTR 2355 AGNES 34% NA 34% 343$} NA NA NA NA MR NA N3“
F MTRR 55 AEGIS T433 Nit. Fisk NA NA 3:73; Fifi NA NA M3. M53.
CflMBENATEON “1% 233% 253?. 31:32. 233?. 3fi'33 3-533. 2333 55% 5133 5153
gamed Efimi sue HAM 0328‘ 3.599 .3343 412-13 -~?.§?2 - 6.552 -6 .5133 .5_ 896 4.530 «4. 5.?2 «4.554
93mm p-w ism HAM{123 20.0631 (.EMIIEN 20.881 1 {1.003 film“! £1,062 3.9m 3.605 3
Passed iii-“set Size HEMEM? 3 26.9?6 255?? - ‘3362 4.85:} 25 RS: 25.42!) 24.696 23. S22 «M 7’5
PeuSed g-vaiue HAN!EMT 63.301 (L003 0.833 <0. cm: 8.323 {3.051 8.904 0.061 8,922 8.583
In addition to using HAMD- l 7 or HAMD-28 scales to evaluate the effects, other
scales such as social functioning questionnaire (SFQ), visual analogue scale (VAS), cognitive and
physical function questionnaire (CPFQ), Maier, and HAMD-7 subscales of HAMD were also used to
analyze the effects and the results are shown in Figs. 9A-9C and Figs. lOA-lOE.
Additional SNP biomarkers were also evaluated for their effects on change in
HAMD-28 in MDD ts with at least one rare variant as indicated below as opposed to fully
2012/065084
normal on the gene, when they were treated with a folate-containing compound (e.g., 6(S)MTHF)
and an SSRI. While Table 39 lists dual SNP biomarkers in an order of their decreasing effects in
MDD patients (i.e., a SNP marker with a greater reduction in HAMD-28 is listed earlier in the table),
it should not be construed as one SNP biomarker is more preferable than another one for use in the
, methods, systems, and kits described herein, as all these SNP kers have indicated a
significant change in HAMD-28 when a MDD patient carrying at least one indicated rare variant was
treated with a folate-containing compound, as compared to a MDD patient carrying normal alleles on
the gene. In some embodiments, a certain combination of any SNP markers dually with low
effect priority can produce a synergistic effect and/or even yield a better tive power than a
single SNP marker with higher effect priority.
Table 39, as shown on the next page, indicates effects of the presence of at least one
rare variant in an indicated SNP biomarker, as opposed to fully normal on the gene, in MDD patients
on the change in HAMD-28 score, when the patients were treated with a folate-containing compound
(e.g., 6(S)MTHF) and an SSRI.
EC" ‘ PHASE 1 PHASE H (’00 LE!) (“BASES
(“R1050 Y ‘ : EC'i p-V‘aim‘. (i FFECI -'
p - 8" :2km - ram- 95°74) {11 p- Value
I (GMT (_ ‘v'al 358 Met?
”4588 {CG} . l 2.0.70 40.1% (HMS? 40.880 (463.770., 4.990 3 3,000
la) CGMT (Va! 358}
(”343653 {CC} ~ ll} ,0? '3 ~:() Hi} RUM '9 45.21“} mum. mm 3 film
RC F1 (in SLCI‘SIA i :3
! 266 ( AA) “Mil 3,6) — 3 «mm (LDSl .7351; (— RAMS, 3,690) LUNGS:
DRD2 {HXIJH}
136275 (T'E') mum; -l(\ 5'39 :3 244 i: 7‘28 47.62 7
’1! filifl’l {Taq l 81‘)
”1(179595 (TE) - H;- .640 433318 ~fi.903 (£12613.
AHJE) - 3 0,510
s OH; 43.905 (—5 0,
6 DNM‘I‘ES
[81883739 (AG) 1103,87 (-1.811
-6tNS
$360
PCYT I A
r-i'7639752 1' rL-X) {I (13‘?) ~ HE 40¢) GEEK} {mm 9.5%) 45.1316
Gt?“ 1
r8800726? (TC) +2 21:0.- $739 (I ,963 .5437 {MM —6.654 iL‘GGl
MTHFR {$1793A
m2} ?4976 (GA) 4:015; u v; (2 703
l0 Rt: Fl ANS“
(822557291 (AA) ~83“ ”F51 .043) 4.400 (2 («37 3.0.30
1}. GCP (I or FOLHI
173202676 (AG) Gil-15 44 130“} 43,545 —:“,.402 33329
DJH' (§l.('6.~\3)
1'5250632 (CU) «4.996 (-81:63, 4.921)) [LC-:3}
GCHFR
(37163862 (IL-U {3 (>03 n‘l, 5:1 2 «1.863 (asm, 4,913; E1031
14 RCFZ (in SLCi‘l-U j
1312658" {T'I'j 0. 1,30 -1 .4013 13.66? "4.861) :, . 41.3571"
CA(3NA 1C
r51 3? (AG) 13(‘3 LU)? - Sjlim '1: {107' -2. "167’ 4.633 {18,52'Ltifl)‘ £3,946}
l6 i; DRC
1‘52277329i1‘t’7) 23739,; 5: -,1 63-1 v{t:32 {2 OP} '5 «U?! 7 :7 mamas;
1'? URDZ murmur}
r51. i 2 4ll59—l (3‘ij 33(36QO; =5.0ES G. W9 {4:124 l. «a w 4358 Cr—fiSSl. éiijjfl Gill}:
l8 'M'THF!) i GWSBA (R653Q)
132236225 (AG) [1 ‘32:: -3, 76‘} 0.253 «3.496 {1 03'?
Example 5. Exemplary methods of selecting patientsforfolate-containing augmentation therapy (with
an SSRI) and personalized prognosis ofMDD patients subjected to such therapy
Based upon the double-blind placebo controlled multi-site study on augmentation of
MDD treatment with a folate-containing compound, e.g., DEPLIN®15, in which 36 ts ed
a folate-containing compound, e.g., DEPLIN® 15, that had a reduction in their HAMD-28 from the
ne measurement, the ts sed with at least one of the conditions as described in the
Panel of Tests (PT) with the corresponding “Values” (as shown in detail later), generally responded in
accordance with the expected HAMDreduction as shown in Table 40 below.
Accordingly, methods of treating a MMD t and/or determining or improving
the effectiveness of an anti-depressant drug taken by the MMD patient are also provided herein. For
example, in some embodiments, the method can include (1) screening for a treatment resistant MDD
patient (see, e.g., Step 1 for details below); and (2) performing the Panel of Tests (PT) on a test
sample of the MDD patient (see, e.g., Step 2 for details below). In some embodiments, if the PT
results show at least one of the Code grouping as shown in Table 40 below, the patient can be
recommended for a treatment regimen comprising an anti-depressant drug and a folate-containing
compound (e.g., DEPLIN®15). In some embodiments, if the PT results show at least one of the Code
grouping as shown in Table 40 below, it can be expected that the corresponding reduction in HAMD-
28 from the Baseline value (e.g., the value measured at the Baseline visit) would be achievable with a
minimum of 4 weeks of treatment with a folate-containing compound (e. g., DEPLIN®15) in
combination with an antidepressant drug (e.g., an SSRI).
Step 1: Treatment-resistant MDD ts are screened to determine (a) if they meet
DSM-IV criteria for MDD; and (b) if they are on an adequate dose of an SSRI and have not
adequately responded to one or more courses of an SSRI. Should the patient meet both of the screen
criteria (a) and (b) then it is recommended that the physician order the panel of test (PT) as described
below.
Step 2: An e of a panel of test (PT) as shown below can be performed.
Code Panel Of Tests Sat—mm Value Decision
A BMI ation Height & Weight 2 30 kg/m2 Y N
B SAM/SAH Ratio Plasma (nmol/L) <2.7l Y N
C 4-HNE Plasma Z 3.28 ug/mL Y N
D MTHFR 677 CT/TT Whole Blood Yes/No Y N
E MTR 2756 AG/GG Whole Blood Yes/No Y N
F MTRR 66 AG/GG Whole Blood Yes/No Y N
The panel of test (PT) as shown above can be modified to delete or add at least one or
any combinations of the biomarkers as shown in Tables B enclosed herein.
Step 3: Based on the test results of the ions listed in PT of step (2), any of the
PTs (items A through F) tested positive (i.e., with a decision Y) are fied, and then recorded in
alphabetical order of the “Codes” the st number of Codes that are represented in Table 40
below. Once the Code grouping has been selected for a given patient’s PT, the corresponding “95%
CI” (95% ence als) for that Code grouping can be reviewed from Table 40. In some
embodiments, if the upper end of the CI is below zero, the HAMD-28 reduction from the Baseline
value is likely to be significant. In other embodiments, if the upper end of the CI is above zero, then
the HAMD-28 reduction from the Baseline value should be interpreted with caution.
Step 4: The expected reduction in HAMD-28 from ne can be determined, for
example, as follows:
(a) If a patient has only a single hit of the PT (i.e., one condition is positive), then the HAMD-28
reduction from Baseline can be based upon the Code “All”; or
(b) If a patient has a double hit of the PT (i.e., two conditions are positive), then the HAMD-28
reduction from ne can be based upon the highest response (i.e., greatest change in
HAM-D-28) obtained from either A, B, C, E or “ALL” as shown in Table 40. In some
embodiments, if the double hit is “D+F,” then the reduction can be based upon Code “All”;
(c) If a patient has a triple hit of the PT (i.e., three conditions are positive), then the HAMD-28
reduction from Baseline can be based upon the highest se (i.e., greatest change in
HAM-D-28) obtained from the best ation (i.e., the best of 2-code combinations) as
shown in Table 40. By way of example only, if a patient has a triple hit on A, C and E of the
PT, possible 2-code combinations are A+C, A+E and C+E. Among these combinations, as the
combination “A+E” corresponds to the greatest HAMD-28 reduction as shown in Table 40,
the combination “A+E” is considered as the best combination that corresponds to the greatest
HAMD-28 reduction. However, if the triple hit contains “D+F,” then the HAM-D-28
reduction should be based upon the highest response obtained from the single Codes of A, B,
C, E or “ALL”;
(d) The negative HAMDA numbers in Table 40 reflect the potential reduction from Trial 2
Baseline HAMD-28 7). The HAMDA number represents the expected reduction in a
HAMD-28 scale a patient can obtain in response to Deplin®15 augmentation therapy (with an
SSRI) in as little as 4 weeks. In some embodiments, the actual ion can fall re
within the 95% as shown in Table 40 below.
Table 40: The expected 8 redaction based upon Trial 2’s mean Baseline of 24.47 per various
Code combinations.
95% CI HAMDA
(-203, 7.2) .
023.0, 8.2) . _
025.3, 6.7) .
(40.2, 7.5) . _
028.3, 7.6) _
, 7.8) .
A+C 12 (40.3.7.2) -6.6 D+E
A+D 9 (60.2.6.9) -11.7 E+F_
(-35.7, 0.5)
References
1. V. Herbert, Experimental nutritional folate deficiency in man. Trans Assoc Am Phys 75 ,
p. 307.
2. M.W.P. , Serum folate values in 423 psychiatric patients. Br Med J 4 (1967), p. 512.
3. EH. Reynolds, J.M. Preece, J. Bailey and A. , Folate deficiency in sive illness. Br
J Psychiatry 117 (1970), p. 287.
4. SD. Shorvon, M.W.P. Carney, I. Chanarin and EH. Reynolds, The neuropsychiatry of
megaloblastic anaemia. Br Med J 281 (1980), p. 1036.
. MRC Vitamin Study Research Group, Prevention of neural tube defects: results of the l
Research Council Vitamin Study. Lancet 338 (1991), p. 131.
6. EB. Rimm, W.C. Willett, F.B. Hu et al., Folate and vitamin B6 from diet and supplements in
relation to risk of coronary heart disease among women. JAMA 279 (1998), p. 359.
7. D. Mischoulon, Herbal es for mental illness. Psychiatr Clin North Am Annu Drug Ther 6
(1999), p. 1.
8. A. Fugh-Berman and J.M. Cott, y supplements and natural products as psychotherapeutic
agents. Psychosom Med 61 (1999), p. 712.
9. American atric Association. Diagnostic and statistical manual of mental disorders, 4th ed.
Washington, DC: American Psychiatric Association, 1994.
. T. Bottiglieri, Folate, vitamin B 12, and neuropsychiatric disorders. Nutr Rev 54 (1997), p. 382.
11. J.E. Alpert and M. Fava, Nutrition and depression: the role of folate. Nutr Rev 55 (1997), p.
145.
12. BR. Hutto, Folate and cobalamin in psychiatric illness. Compr Psychiatry 38 (1997), p. 305.
13. MI. Botez, T. Botez, J. Leveille, P. nn and M. Cadotte, Neurological correlates of folic
acid deficiency: facts and eses. In: M.I. Botez and EH. Reynolds, Editors, Folic acid in
neurology, psychiatry and internal medicine, Raven Press, New York (1979), p. 435.
14. E.H. Reynolds, nvulsant drugs, folate metabolism and mental symptoms. In: M. Dam, L.
Gram and J.K. Penry, Editors, es in epileptology. XIIth Epilepsy International
Symposium, Raven Press, New York (1981), p. 621.
. J. Edeh and BK. Toone, Antiepileptic therapy, folate deficiency, and psychiatric morbidity: a
general practice survey. Epilepsia 26 (1985), p. 434.
16. SD. Shorvon, M.W.P. Carney, I. Chanarin and EH. Reynolds, The neuropsychiatry of
megaloblastic anemia. Br Med J 281 (1980), p. 1036.
17. SN. Young and M. Ghadirian, Folic acid and psychopathology. Prog Neuropsychopharmacol
Biol Psychiatry 13 (1989), p. 841.
18. R. n, T. Bottiglieri and EH. ds, Folates and psychiatric disorders: clinical potential.
Drugs 45 (1993), p. 623.
19. A.M. Ghadirian, J. Anath and F. Engelsmann, Folic acid deficiency in depression.
Psychosomatics 21 (1980), p. 926.
. M.W.P. Carney, T.K.N. Chary, M. Laundy et al., Red cell folate concentrations in psychiatric
patients. J Affect Dis 19 (1990), p. 207.
21. T. Bottiglieri, K. Hyland, M. Laundy et al., Folate deficiency, biopterin and ine
lism in depression. l Med 22 (1992), p. 871.
22. A. Wilkinson, D. Anderson, M. Abou-Saleh et al., 5-Methyltetrahydrofolate level in the serum
of depressed subjects and its relationship to the outcome of ECT. J Affect Disord 32 (1994), p.
163.
23. M.T. Abou-Saleh and A. , Serum and red blood cell folate in sion. Acta Psychiatr
Scand 80 (1989), p. 78.
24. E.H. Reynolds, J.M. Preece, J. Bailey and A. Coppen, Folate deficiency in depressive illness. Br
J Psychiatry 117 (1970), p. 287.
. V.A. Wesson, A.J. Levitt and RT. Joffe, Change in folate status with antidepressant treatment.
Psychiatry Res 53 (1994), p. 313.
26. A. Levitt and R. Joffee, Folate, B12, and life course of depressive illness. Biol Psychiatry 25
(1989), p. 867.
27. IR. Bell, J .S. Edman, D.W. Marby et al., Vitamin B 12 and folate status in acute geropsychiatric
inpatients: affective and cognitive characteristics of a vitamin nondeficient population. Biol
Psychiatry 27 (1990), p. 125.
28. M. Fava, J .S. Borus, J.E. Alpert et al., Folate, B 12, and homocysteine in major depressive
disorder. Am J Psychiatry 154 (1997), p. 426.
29. Alpert M, Silva R, Pouget E. Folate as a predictor of response to sertraline or nortriptyline in
geriatric depression. Presented at the 36th Annual g of the NCDEU. Boca Raton, FL,
May 28—3 1 , 1996.
. M. Fava and K.G. Davidson, Definition and epidemiology of treatment-resistant depression.
Psychiatr Clin North Am 119 (1996), p. 176.
31. P.S.A. Godfrey, B.K. Toone, M.W.P. Carney et al., ement of recovery from psychiatric
illness by methylfolate. Lancet 336 (1990), p. 392.
32. M.W.P. Carney and BF. eld, Associations of mal serum folate and vitamin B 12
values and effects of ement therapy. J Nerv Ment Dis 150 (1970), p. 404.
33. S. Lee, Y.K. Wing and S. Fong, A controlled study of folate levels in Chinese inpatients with
major depression in Hong Kong. J Affect Disord 49 (1998), p. 73.
34. PF. Jacques, J. Selhub, A.G. Bostom, P.W.F. Wilson and I.H. Rosenberg, The effect of folic
acid fortification on plasma folate and total homocysteine trations. N Engl J Med 340
(1999), p. 1449.
. M.T. Abou-Saleh and A. Coppen, The biology of folate in depression: implications for
nutritional hypotheses of psychoses. J Psychiatr Res 20 (1986), p. 91.
36. W.E. Thorton and B.P. Thornton, Folic acid, mental function and dietary habits. J Clin
Psychiatry 39 (1978), p. 315.
37. A. Coppen, S. Chaudry and C. Swade, Folic acid enhances lithium prophylaxis. J Affect Disord
(1986), p. 9.
38. M. Passeri, S. Ventura, G. Abate, D. Cucinotta and P. LaGreca, Oral 5-methyltetrahydrofolate
(MTHF) in depression association with Senile Organic Mental Disorders (OMDs): a double-
blind, multicenter study vs. trazodone (TRZ). Eur J Clin Invest 21 (1993), p. 24.
39. G. Guaraldi, M. Fava, F. Maui and P. LaGreca, An open trial of methyltetrahydrofolate
(MTHF) in elderly depressed patients. Ann Clin Psychiatry 5 (1993), p. 101.
40. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid
(Leucovorin) as an adjunctive treatment for efractory depression. Ann Clin Psychiatry.
2002 Mar;14(1):33-8.
41. M. Spillman and M. Fava, S-adenosyl-methionine in psychiatric disorders: historical
perspective and current status. CNS Drugs 6 (1996), p. 416.
42. A. Ruck, S. Kramer, J. Metz and M. Brennan, Methyltetrahydrofolate is a potent and selective
agonist for kainic acid receptors. Nature 287 , p. 852.
43. RA. SchatZ, T.E. Wilens and 0.2. Sellinger, sed in vivo protein and olipid
methylation after in vivo elevation of brain S-adenosylhomocysteine. Biochem Biophys Res
Commun 98 (1981), p. 1097.
44. P.J. Shaw, tory amino acid receptors, excitotoxicity and the human nervous system. Curr
Opin Neurol Neurosurg 6 , p. 414.
45. MB. , Jr and EH. Reynolds, Cerebrospinal fluid folate and acid monoamine
lites. Lancet 2 (1972), p. 137.
46. M.I. Botez and SN. Young, Effects of anticonvulsants and low levels of folate and thiamine on
amine metabolites in cerebrospinal fluid. Brain 114 (1991), p. 333.
47. M.I. Botez, S.N. Young, J. Bachevalier and S. er, Folate deficiency and decreased brain
oxytryptamine synthesis in man and rat. Nature 278 (1979), p. 182.
48. R. Surtees, S. Heales and A. Bowron, Association of cerebrospinal fluid deficiency of 5-
methyltetrahydrofolate, but not S-adenosylmethionine, with reduced concentrations of the acid
metabolites of 5-hydroxytryptamine and dopamine. Clin Sci 986 , p. 697.
49. Alpert JE, Mischoulon D, berg AA, Fava M. Nutrition and depression: focus on .
Nutrition. 2000 Jul-Aug;16(7-8):544-6
50. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression.
Psychiatr Clin North Am. 1996 Jun;19(2):179-200.
2012/065084
51. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical
trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach.
Psychother Psychosom. 2003 n;72(3): 1 15-27.
52. Trivedi MH, Rush AJ, Ibrahim HM et al. The Inventory of Depressive Symptomatology,
ian Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive
Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector
ts with mood disorders: a psychometric evaluation. Psychol Med 2004; 34(1):73-82.
53. Fava M. Diagnosis and tion of treatment-resistant depression. Biol Psychiatry. 2003 Apr
l5;53(8):649-59.
54. Levine J, Schooler NR. General versus specific inquiry with SAFTEE. J Clin Psychopharmacol
1992; 12(6):448.
55. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.
56. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral
sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom.
7(6):328-31.
57. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate
postoperative : intrasubject variability and correlation with a numeric scale. Anesth
Analg. l998;86(l):102-6.
SEQUENCE LISTING:
S EQ ID NO: 1————human MTHFR (NM_005957.4 CDS plus 12 nucleotides in the
beginning of the sequence) C6771 and A1298C
1 aggaacccag ccatggtgaa cgaagccaga ggaaacagca gcctcaaccc ctgcttggag
61 ggcagtgcca gcag tgagagctcc aaagatagt: cgagatgttc caccccgggc
121 ctggaccccg agcggcatga gagactccgg gagaagatga gatt ggaatctggt
181 gacaagtggt tgga attcttccct actg ctgagggagc tgtcaatctc
241 atctcaaggt ttgaccggat ggcagcaggt ggccccctc: acatagacgt gacctggcac
301 ccagcaggtg gctc agacaaggag acctcctcca tgatgatcgc cagcaccgcc
361 gtgaactact tgga gaccatcctg cacatgacc: gctgccgtca gcgcctggag
421 gagatcacgg gccatctgca caaagctaag cagctgggcc tgaagaacat catggcgctg
481 cggggagacc caataggtga ccagtgggaa gaggaggagg gaggcttcaa ctacgcagtg
541 gacctggtga tccg aagtgagttt ggtgactac: tctg tgtggcaggt
601 taccccaaag gccaccccga agcagggagc tttgaggctg acctgaagca cttgaaggag
661 aaggtgtctg acga tttcatcatc acgcagctt: tctttgaggc tgacacattc
721 ttccgctttg tgaaggcatg caccgacatg ggcatcact: gccccatcgt ccccgggatc
781 atcc agggctacca ctcccttcgg cagcttgtga agctgtccaa gctggaggtg
841 ccacaggaga tcaaggacgt gattgagcca atcaaagaca ctgc catccgcaac
901 tatggcatcg agctggccgt gagcctgtgc caggagcttc gtgg gcca
961 ggcctccact tctacaccct caaccgcgag atggctacca cagaggtgct gaagcgcctg
1021 gggatgtgga ctgaggaccc caggcgtccc ctaccctggg ctctcagcgc ccaccccaag
1081 gagg aagatgtacg tcccatcttc tcca gaccaaagag ttacatctac
1141 cgtacccagg agtgggacga gttccctaac ggccgctggg gcaattcctc ttcccctgcc
1201 tttggggagc :gaaggacta ctacctcttc tacctgaaga gcaagtcccc caaggaggag
1261 ctgctgaaga ggga ggagctgacc agtgaagaaa gtgtctttga agtcttcgtt
1321 ctttacctct cgggagaacc aaaccggaat ggtcacaaag gcct gccctggaac
1381 cccc :ggcggctga gaccagcctg ctgaaggagg agctgctgcg ggtgaaccgc
1441 cagggcatcc :caccatcaa ctcacagccc aacatcaacg ggaagccgtc cccc
1501 atcgtgggct ggggccccag cgggggctat gtcttccaga aggcctactt agagtttttc
1561 acttcccgcg agacagcgga agcacttctg caagtgctga agaagtacga gctccgggtt
1621 aattaccacc atgt tgaa aacatcacca atgcccctga gccg
1681 gtca cttggggcat cttccctggg cgagagatca tccagcccac cgtagtggat
1741 cccgtcagct tctg gaaggacgag gcctttgccc tgtggattga gcggtgggga
1801 tatg aggaggagtc cccgtcccgc accatcatcc agtacatcca cgacaactac
1861 ttcctggtca acctggtgga caatgacttc ccactggaca actgcctctg gcaggtggtg
1921 gaagacacat :ggagcttct caacaggccc acccagaatg cgagagaaac ggaggctcca
1981 tga
EQ ID NO 2: ----human MIR (NM_000254.2) CDS A2756G
1 atgtcacccg cgctccaaga cctgtcgcaa cccgaaggtc tgaagaaaac cctgcgggat
61 gagatcaatg ccattc:gca gaagaggatt atggtgc:gg atggagggat ggggaccatg
121 atccagcggg agaagc:aaa cgaagaacac ttccgaggtc aggaatttaa agatcatgcc
181 aggccgctga aaggcaacaa tgacatttta agtataactc agcctgatgt catttaccaa
241 atccataagg aatact:gct ggctggggca gatatca:tg aaacaaatac ttttagcagc
301 ac:agtattg cccaagctga ctatggcct: gaacact:gg cctaccggat gaacatgtgc
361 tc:gcaggag gaaa agctgccgag gaggtaactc tccagacagg aattaagagg
421 tt:gtggcag gggctc:ggg tccgactaa: aagacac:ct ctgtgtcccc atctgtggaa
481 aggccggatt ataggaacat cacatttga: g:tg aagcatacca agagcaggcc
541 aaaggacttc tggatggcgg ggttgatatc a:tg aaactatttt tgcc
601 aa:gccaagg cagcct:gtt ccaa aatcttt:tg aggagaaata tgctccccgg
661 cc:atcttta tttcagggac gatcgttga(I aaaagtgggc ggactctttc cggacagaca
721 ggagagggat ttgtca:cag cgtgtctca(I ggagaaccac tctgcattgg attaaattgt
781 gc:ttgggtg cagctgaaat gagaccttt (I attgaaa:aa ttggaaaatg tacaacagcc
841 ta:gtcctct gttatcccaa tgcaggtct(I cccaacacct ttggtgacta tgatgaaacg
901 cc:tctatga tggccaagca cctaaagga(I tttgcta:gg atggcttggt caatatagtt
961 ggaggatgct gtgggtcaac accagatca(I atcagggaaa aagc tgtgaaaaat
1021 tg:aagccta gagttccacc tgccactgc(I tttgaaggac atatgttact gtctggtcta
1081 gagcccttca ggattggacc gtacaccaac tttgttaaca :ggagagcg ctgtaatgtt
1141 gcaggatcaa ggaagtttgc taaactcatc ggaa ctatgaaga agccttg:gt
1201 gttgccaaag tgcaggtgga aatgggagcc caggtgttgg :gtcaacat ggatgatggc
1261 atgctagatg gtccaagtgc aatgaccaga ttttgcaact aattgcttc cgagccagac
1321 atcgcaaagg tacctttgtg catcgactcc tccaattttg :gtgattga agctggg:ta
1381 aagtgctgcc aagggaagtg cattgtcaat agcattagtc agg agaggacgac
1441 ttcttggaga aggccaggaa gattaaaaag tatggagctg :atggtggt catggct:tt
1501 gatgaagaag gacaggcaac agaaacagac acaaaaatca cac ccgggcc:ac
1561 catctgcttg aac: gggctttaat ccaaatgaca :atttttga ccctaatatc
1621 ctaaccattg ggactggaa: acac aacttgtatg (It—QOIILQOHOIIQJQJH cattaattt tatccatgca
1681 acaaaagtca t:aaagaaac at:acctgga gccagaataa :ggaggtct ttccaac:tg
1741 tccttctcct ggaagccatt cgagaagcaa gcatggggt tttcctt:ac
1801 catgcaatca (‘ffl'Ofl'LQOQJQJQJQJQJfl' ccgaggaa gtctggca ggacatgggg atagtgaatg c:ggaaacct ccctgtg:at
1861 gatgatatcc :aaggaac tc:gcagctc tgtgaagatc :catctggaa taaagaccct
1921 gaggccac:g ct acgttatgcc cagactcaag gagg gaagaaag:c
1981 attcagac:g :gagtggag ccct gtcgaagaac gccttgagta tgccct:g:g
2041 aagggcat:g aaaacata: ta:tgaggat actgaggaag ccaggt:aaa ccaaaaaaaa
2101 tatccccgac :ctcaata: aa:tgaagga cccctgatga atggaa:gaa aattgt:ggt
2161 gatctttt:g agctggaaa aa:gtttcta cctcaggtta taaagtcagc ccgggt:a:g
2221 aagaaggc:g :ggccacc: tttc atggaaaaag aaagagaaga aaccagag:g
2281 c:taacggca aga agaggaccct taccagggca ccatcg:gct ggccac:g:t
2341 QJQJLQFFOFFOQJLQQJLQWQJ aaggcgacg gcacgaca: aggcaagaac atagttggag tagtcc:tgg ctgcaa:aat
2401 :ccgagt:a :gatttagg gact ccatgtgata agatac:gaa agctgc:c:t
2461 accacaaag cagatataa: tggcctgtca ggactcatca ctccttccct ggatgaaa:g
2521 :ttttgt:g ccaaggaaa: ggagagatta gctataagga ttccat:gtt agga
2581 O Q) 0) O O 0) O :t caaaaaccca cacagcagtt aaaatagctc cgagatacag tgcacc:g:a
2641 :ccatgtcc tggacgcgtc caagagtgtg gtggtgtgtt cccagc:gtt agatgaaaat
2701 :aaagga:g aatact:tga ggaaatcatg gaagaatatg aagata:tag acaggaccat
2761 atgagtc:c tcaaggagag gagatactta agtc aagccagaaa aagtgg:t:c
2821 aaatgga:t ggctgtctga acctcaccca gtgaagccca cgttta:tgg gacccagg:c
2881 :tgaagact atgacc:gca gaagctggtg gactacattg actggaagcc :gat
2941 :ctggcagc tccggggcaa gaat cgaggctttc ccaaga:att taacgacaaa
3001 O 0) L0 fl. 0) LO LO :g gagaggccag gaaggtctac gatgatgccc acaata:gct gaacacac:g
3061 :tagtcaaa agaaac:ccg ggcccggggt gtggttgggt cagc acagag:a:c
3121 caagacgaca ttcacc:gta cgcagaggct gctgtgcccc aggctgcaga agcc
3181 accttcta:g ggttaaggca acaggctgag tctg cgga gccatactac
3241 tgcctctcag acttca:cgc tcccttgcat tctggcatcc gtgactacct gggcctgt:t
3301 gccgttgcct gctttggggt agaagagctg agcaaggcct atgaggatga tggtgacgac
3361 tacagcagca tcatgg:caa gggg gaccggctgg cagaggcctt tgcagaagag
3421 ctccatgaaa gagttcgccg agaactgtgg gcctactgtg gcagtgagca gctggacg:c
3481 gcagacctgc :gcg gtacaagggc atccgcccgg ctcctggcta ccccagccag
3541 caca ccgagaagct caccatgtgg gcag acatcgagca gtctacaggc
3601 attaggttaa cagaatcatt agcaatggca cctgcttcag cagtctcagg cctctact:c
3661 tccaatttga agtccaaata ttttgctgtg gggaagattt ccaaggatca ggat
3721 tatgcattga ggaagaacat atctgtggct gaggttgaga aatggcttgg tt:g
3781 ggatatgata cagactaa
EQ ID NO: 3 uman MTRR (NM_002454.2) A66G
atgaggaggt ttctgttact taca ggac aggc catcgcagaa
61 gaaatatgtg agcaagctgt ggtacatgga ttttctgcag atcttcactg tattagtgaa
121 tccgataagt atgacctaaa aaccgaaaca gctcctcttg ttgttgtggt ttctaccacg
181 ggcaccggag acccacccga cacagcccgc aagtttgtta aggaaataca gaaccaaaca
241 ctgccggttg atttctttgc tcacctgcgg tatgggttac tcgg tgattcagaa
301 tacacctact tttgcaatgg ggggaagata attgataaac gacttcaaga gcttggagcc
361 cggcatttct atgacactgg acatgcagat gactgtgtag gtttagaact tgtggttgag
421 ccgtggattg ctggactctg gccagccctc agaaagcatt ttaggtcaag cagaggacaa
481 gaggagataa gtggcgcact cccggtggca tcacctgcat cctcgaggac agaccttgtg
541 aagtcagagc tgctacacat tgaatctcaa cttc tcga tgattcagga
601 agaaaggatt ctgaggtttt gaagcaaaat gcagtgaaca gcaaccaatc caatgttgta
661 attgaagact :tgagtcctc acttacccgt tcggtacccc cactctcaca agcctctctg
721 aatattcctg gtt:accccc agaatattta caggtacatc tgcaggagtc tcttggccag
781 gaggaaagcc aag:atctgt gacttcagca gttt ttcaag:gcc aatttcaaag
841 gcagttcaac :tactacgaa tgatgccata aaaaccactc tgctgg:aga attggacatt
901 tcaaatacag act:ttccta tcagcctgga gatgccttca gcgtga:ctg ccctaacagt
961 gattctgagg :acaaagcct actccaaaga ctgcagcttg aagataaaag agagcactgc
1021 g:ccttttga aaa:aaaggc agacacaaag aagaaaggag :acc ccagcatata
1081 gttctctcca gttcattttt acctggtgtc ttgaaa:ccg agcaattcct
1141 OOQJQJQJQJWOQJWOWOQJO ctgcgggat aaaaggcat :tt:gcgagc ggac tataccagtg acagtgctga aaagcgcagg
1201 :acaggagc :gtgcagtaa acaaggggca gccgattata gccgct:tgt acgagatgcc
1261 gtgcctgct :gt:ggatct cctcctcgct ttcccttctt gccagccacc actcagtctc
1321 :gctcgaac atc:tcctaa acttcaaccc agaccatatt caag ctcaagttta
1381 cag gaaagctcca ttttgtcttc aacattgtgg aatttc:gtc tactgccaca
1441 cagaggttc :gcggaaggg agtatgtaca ggctggctgg ccttgt:ggt tgcttcagtt
1501 :tcagccaa atgc atcccatgaa gacagcggga aagccc:ggc tcctaagata
1561 ctc ctcgaacaac aaattctttc ccag atgacccctc catc
1621 :aatggtgg gtccaggaac cggcatagcc ccgtttattg ggttcc:aca acatagagag
1681 aactccaag aacaacaccc agatggaaat tttggagcaa :gtt ttttggctgc
1741 ggcataagg atta tctattcaga aaagagctca gacatt:cct taagcatggg
1801 :cttaactc atctaaaggt ttccttctca agagatgctc ctgttgggga ggaggaagcc
1861 cagcaaagt aaga ccag cttcatggcc agcagg:ggc gagaatcctc
1921 :ccaggaga acggccatat ttatgtgtgt ggagatgcaa agaata:ggc caaggatgta
1981 catgatgccc ttgtgcaaat aataagcaaa gaggttggag ttgaaaaact agaagcaatg
2041 aaaaccctgg ccactttaaa agaagaaaaa cgctaccttc aggata:ttg gtcataa
S EQ ID NO: 4 ————MTHFR human amino acid sequence 5948.3) A222V &
E429A
1 mvneargnss 1npc1egsas kdss rcstpgldpe rherlrekmr rrlesgdkwf
61 sleffpprta isrf drmaaggply pagd pgsdketssm miastavnyc
121 g1etilhmtc crqr1eeitg hthaqugl knima1rgdp igdqweeeeg gfnyavdlvk
181 gdyf dicvagypkg fead 1kh1kekvsa gadfiitqlf feadtffrfv
241 kactdmgitc inpgifpiq gyhs1rq1vk 1sk1equei ikdn daairnygie
301 1avs1cqe11 asg1vog1hf thnrematt ev1kr1gmwt edprrplpwa lsahpkrree
361 dvrpifwasr pksyiyrtqe wdefpngrwg nssspafgel kdyylfylks kspkeellkm
421 wgeeltsees vfevalyls gepnrnghkv tclpwndepl aaetsllkee 11rvnrqgil
481 tinsqpning kpssdoivgw quk aylefftsre qv1k kyelrvnyhl
541 vnvkgenitn navt wgifpgreii qotvvdpvsf mfwkdeafal wierwgklye
601 eespsrtiiq yihdnyflvn 1vdndfp1dn c1quvedt1 e11nrptqna reteap
EQ ID NO: 5 ————MTR huna 1 amino acid seque ice (NP_00 0245.2) D91 9G
1 dlsq peg1<kt1rd uri nv1dggmgtm iqreklneeh frgqefkdha
61 rp1kgn1d11 Si:qodviyq ihkey11aga diietntfss tsiaqadygl eh1ayrmnmc
121 sagvar<aae ev:1qtgikr fvagalgptn {tlsvspsve rpdyrnitfd e1veayqeqa
181 <g11dggvdi 111e ' nakaa1fa1q q1feekyapr tivd ksgr:1sgqt
241 gegfvisvsq geolciglnc a1gaaemrpf ieiigkctta yvlcypnagl pntfgdydet
301 osmmakqlkd fandglvniv ggccgstpdh ireiaeavkn ckprvppata feghnllsgl
361 epfrigoytq quigercnv agsr<fakli nagnyeealc vakquemga qvldvnmddg
421 nldgpsamtr fcqliasepd iakvolcids snfavieagl kccqgkcivn gedd
481 f1ekar<ik< ygaamvvmaf deegqatetd :kirvctray h11vkk1gfn pndiifdpni
541 1tigtgnee1 n1yainfiha tkvi<et1pg arisgglsnl sfsfrgmeai reamqgvfly
601 naiksgndmg ivqagnlpvy ddih<e11q1 cedliwnkdp eatekllrya qtqg:ggkkv
661 iqtdewrngo yalv kgie<hiied nqkk yprplniieg plmngmkivg
721 d1fgag<mf1 pqviksarvm kkavghlipf etrv 1ngtveeedp ngtivlatv
781 {gdvhdigkq ivgvvlgcnn frvidlgvmt ocdkilkaal dhkadiigls glitosldem
841 nerl airiplligg atts<thtav {iaprysapv ihvldasksv lden
901 1kdeyfeein eeyedirqdh yesl<erry1 Olsqarksgf qmdwlsephp vkptfigtqv
961 fedydlqklv dyidwkpffd qulrgkypn rgfpkifndk tvggearkvy ddahqmlntl
1021 isqkklrarg vvgpraqsi qddiquaea aquaaepia tfygquqae kdsastepyy
1081 clsdfiaplq sgirdylglf avacfgveel skayeddgdd yssimvkalg drlaeafaee
WO 74676
1141 1hervrre1w qldv adlrrlrykg irpapgypsq pdhtekltmw qstg
1201 irlteslama pasavsglyf snlkskyfav gkiskdqved yalrknisva evekwlgpil
1261 gydtd
SEQ ID NO: 6 RR human amino acid sequence (NP_002445.2) 122M
nrrf111yat qngakaiae eiceqavvhg fsadlhcise sdkydlktet ap1vvvvstt
61 dtar kkaeiqnqt 1pvdffah1r ygllglgdse ytyfcnggki idkrlqelga
121 rhfydtghad dcvg1e1vve pwiaglwpal r<hfrssrgq eeisgalpva spassrtdlv
181 <se11hiesq ve11rfddsg lkqn vnansnvv iedfessltr svpplsqasl
241 qipglppeyl qvhlqeslgq eesquvtsa oquvpisk avqlttndai kttllveldi
301 sntdfsyqu dafsvicpns llqr HKLQqledkrehc v11kikadtk kkgatlpqhi
361 oagcsquif twc1eiraip kkaflralvd HL< krr 1qe1cskqga adysrfvrda
421 cac11d111a fpscqpplsl 11eh1pk1qp oyscasssl fhpgklhfvf niveflstat
481 :evlrkgvct gw1a11vasv 1qpnihashe Qsgkalapki sisprttnsf h1pddpsipi
541 imvgpgtgia pfigflthe k1qethdgn elm gamwlffgc rhkdrdylfr ke1rhf1khg
601 ilthlkvsfs rdapvgeeea pakyquniq agquaril 1qenghiyvc gdaknmakdv
661 adalvqiisk evgvekleam kt1at1keek Hqudiws
SEQ ID NO: 28 ———COMT human amino acid sequence (NP_000745.1) V158M
mpeappllla av11g1v11v Vlllllrhwg wglcligwne filqpihnll mgdtkeqril
61 nhv1qhaepg eaid tyceqkewam nvgdkkgkiv daviqehqps v11e1gaycg
121 ysavrmarll spgarlitie inpdcaaitq rmvdfagvkd kvtlvvgasq diipqlkkky
181 dvdtldmvfl dhwkdrylpd t111eecg11 rkgtvlladn pdfl ahvrgsscfe
241 cthyqsfley revvdgleka iykgpgseag p
It is understood that the foregoing detailed ption and examples are illustrative
only and are not to be taken as limitations upon the scope of the invention. Various changes and
cations to the sed embodiments, which will be apparent to those of skill in the art, may be
made Without departing from the spirit and scope of the present invention. Further, all patents and
other publications identified are expressly incorporated herein by reference for the purpose of
describing and sing, for e, the methodologies described in such publications that might
be used in connection with the present invention. These publications are provided solely for their
disclosure prior to the filing date of the present ation. Nothing in this regard should be construed
as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior
invention or for any other reason. All statements as to the date or entation as to the contents of
these documents is based on the information available to the applicants and does not constitute any
admission as to the correctness of the dates or contents of these documents.
Claims (17)
1. An assay for selecting a treatment regimen for a human subject with depression, comprising: (a) subjecting a test sample previously obtained from a human subject, who is diagnosed as having depression or having a risk for depression, to at least one genotyping assay adapted to determine the genotypes of at least two loci, wherein said at least two loci are: i. position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate ase (MTHFR); ii.position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a n of a genomic nucleic acid sequence of nine synthase (MTR); and (b) ing from the genotypes of said at least two loci the presence of a single tide polymorphism (SNP) selected from the following: i. a SNP677 at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 comprising at least one thymine “T” ; ii. a SNP2756 at position 2756 of SEQ ID NO.2 or position 27 of SEQ ID NO. 9 comprising at least one guanine “G” allele; and iii. a combination of at least one SNP677 T allele and at least one SNP2756 G allele; and if at least one of T allele at position SNP677 or at least one G allele at position SNP2756 or both at least one T allele at position SNP677 and at least one G allele at on SNP2756 is detected, then selecting a treatment regimen comprising an effective amount of a folate-containing compound.
2. An assay for ing a treatment regimen for a human t having depression and currently taking an antidepressant, comprising: (a) subjecting a test sample of the human subject, who is diagnosed as having depression or having a risk for depression, to at least one analysis to determine parameters of at least two biomarkers from: i. genotype of a SNP locus at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR); otype of a SNP locus at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO. 8 are each independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR); iii. genotype of a SNP locus at position 2756 of SEQ ID NO. 2 or position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid ce of methionine synthase (MTR); iv. genotype of a SNP locus at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 (identified by rs1801394), wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are each independently a n of a genomic nucleic acid sequence of methionine synthase reductase (MTRR); v. pe of a SNP locus at rs1006737 (position 27 of SEQ ID NO. 11, wherein the SEQ ID NO. 11 is a portion of a c c acid sequence of calcium channel, e-dependent, L type, alpha 1C subunit (CACNA1C)); vi. genotype of a SNP locus at rs1883729 (position 27 of SEQ ID NO. 12, wherein the SEQ ID NO. 12 is a portion of a c nucleic acid sequence of DNA ine-5)-methyltransferase 3 beta (DNMT3B)); vii. genotype of a SNP locus at rs7163862 (position 27 of SEQ ID NO. 13, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)) ; viii. genotype of a SNP locus at rs12659 (position 27 of SEQ ID NO. 14, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of reduced folate carrier protein (RCF2)); ix. genotype of a SNP locus at rs202676 (position 27 of SEQ ID NO. 15, wherein the SEQ ID NO. 15 is a portion of a genomic c acid sequence of folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1)); x. genotype of a SNP locus at 291 (position 27 of SEQ ID NO. 16, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of reduced folate carrier protein (RCF1)); xi. genotype of a SNP locus at rs1051266 (position 27 of SEQ ID NO. 17, wherein the SEQ ID NO. 17 is a n of a genomic nucleic acid sequence of reduced folate carrier protein (RCF1)); xii. genotype of a SNP locus at 267 (position 27 of SEQ ID NO. 18, wherein the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence of GTP cyclohydrolase 1 (GCH1)); xiii. genotype of a SNP locus at rs7639752 (position 27 of SEQ ID NO. 19, n the SEQ ID NO. 19 is a n of a genomic nucleic acid sequence of choline-phosphate cytidylyltransferase A A)); xiv. pe of a SNP locus at rs6275 (position 27 of SEQ ID NO. 20, wherein the SEQ ID NO. 20 is a portion of a genomic nucleic acid sequence of dopamine receptor D2 (DRD2)); xv. genotype of a SNP locus at rs1079596 (position 27 of SEQ ID NO. 21), wherein the SEQ ID NO. 21 is a portion of a genomic c acid sequence of dopamine receptor D2 (DRD2); xvi. genotype of a SNP locus at rs11240594 (position 27 of SEQ ID NO. 22), wherein the SEQ ID NO. 22 is a portion of a genomic nucleic acid sequence of dopamine receptor D2 (DRD2); xvii. genotype of a SNP locus at rs4633 (position 27 of SEQ ID NO. 23, wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of catechol-O-methyltransferase (COMT)); xviii. genotype of a SNP locus at rs4680 (position 27 of SEQ ID NO. 24), n the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-O-methyltransferase (COMT); xix. genotype of a SNP locus at rs250682 (position 27 of SEQ ID NO. 25, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of solute r family 6 (neurotransmitter transporter, dopamine), member 3 (SLC6A3)); xx. genotype of a SNP locus at rs2277820 ion 27 of SEQ ID NO. 26, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of formiminotransferase cyclodeaminase ); and xxi. genotype of a SNP locus at rs2236225 (position 27 of SEQ ID NO. 27, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1)); xxii. level of expression of SAM and SAH; xxiii. level of expression of 4-HNE; xxiv. level of expression of hsCRP; and any combinations thereof; (b) detecting from the parameters of said at least two biomarkers, the ce of at least one ion selected from the following: i. a SNP at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 comprising at least one thymine “T” allele; ii. a SNP at rs2274976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8) comprising at least one alanine “A” allele; iii. a SNP at on 2756 of SEQ ID NO. 2 or on 27 of SEQ ID NO. 9 comprising at least one guanine “G” allele; iv. a SNP at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 comprising at least one guanine "G" allele; v. a SNP at rs1006737 (position 27 of SEQ ID NO. 11) comprising at least one alanine “A” allele; vi. a SNP at rs1883729 (position 27 of SEQ ID NO. 12) comprising at least one alanine “A” allele; vii. a SNP at 862 (position 27 of SEQ ID NO. 13) comprising at least one thymine “T” allele; viii. a SNP at rs12659 (position 27 of SEQ ID NO. 14) comprising at least one thymine “T” ; ix. a SNP at rs202676 (position 27 of SEQ ID NO. 15) comprising at least one guanine “G” allele; x. a SNP at rs2297291 (position 27 of SEQ ID NO. 16) comprising at least one alanine “A” allele; xi. a SNP at 266 (position 27 of SEQ ID NO. 17) comprising at least one alanine “A” allele; xii. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine “T” allele; xiii. a SNP at rs7639752 (position 27 of SEQ ID NO. 19 ) comprising at least one alanine “A” allele; xiv. a SNP at rs6275 (position 27 of SEQ ID NO. 20) sing at least one thymine “T” allele; xv. a SNP at rs1079596 (position 27 of SEQ ID NO. 21) comprising at least one thymine “T” allele; xvi. a SNP at rs11240594 ion 27 of SEQ ID NO. 22) comprising at least one alanine “A” allele; xvii. a SNP at rs4633 (position 27 of SEQ ID NO. 23) comprising at least one cytosine “C” allele; xviii. a SNP at rs4680 (position 27 of SEQ ID NO. 24) comprising at least one guanine “G” allele; xix. a SNP at 82 (position 27 of SEQ ID NO. 25) sing at least one cytosine “C” allele; xx. a SNP at rs2277820 (position 27 of SEQ ID NO. 26) comprising at least one thymine “T” allele; xxi. a SNP at rs2236225 (position 1958 of SEQ ID NO. 27) comprising at least one alanine “A” allele; xxii. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or r); xxiii. an expression level ratio of SAM to SAH smaller than a termined reference ratio; xxiv. an expression level of 4-HNE greater than a pre-determined reference value; xxv. an expression of hsCRP greater than about 2.3 mg per liter of plasma as measured in a plasma sample; and any combinations thereof, and if at least one of said conditions is detected, then selecting a treatment regimen comprising an effective amount of a folate-containing nd.
3. The assay of claim 2, wherein the at least one condition is: a. a SNP at rs8007267 (position 27 of SEQ ID NO. 18) comprising at least one thymine “T” allele, n the SEQ ID NO. 18 is a genomic nucleic acid sequence of GTP cyclohydrolase 1 (GCH1); and b. a SNP at rs4680 ion 27 of SEQ ID NO. 24) comprising at least one guanine “G” allele, wherein the SEQ ID NO. 24 is a genomic nucleic acid sequence of catechol-O-methyltransferase (COMT).
4. The assay of any one of the ing claims, wherein the test sample is selected from the group consisting of a blood sample, a urine sample, a buccal sample, and a saliva sample.
5. The assay of any one of the preceding claims, n the genotyping comprises the step of ying the test sample with a set of primers flanking any one of the SNPs.
6. The assay of claim 5, wherein at least two sets of primers amplifying at least two of the SNPs are used in a multiplex amplification assay.
7. The assay of claim 1, wherein the treatment regimen further comprises selecting an antidepressant drug.
8. The assay of claim 7, wherein the anti-depressant drug comprises a selective serotonin reuptake inhibitor.
9. The assay of any one of the preceding claims, n the sion is major depressive disorder.
10. Use of a folate-comprising composition in combination with an anti-depressant in the preparation of a medicament for use in the treatment of depression in a human subject who s at least the following single nucleotide polymorphisms: a. a SNP677 at on 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133) comprising at least one e “T” allele; and b. a SNP2756 at position 2756 of SEQ ID NO. 2 or on 27 of SEQ ID NO. 9 comprising at least one guanine “G” allele.
11. Use of a folate-comprising composition in combination with an anti-depressant in the preparation of a medicament for use in the treatment of depression in a human subject who carries at least two of the following conditions or any combination thereof: a. at least one thymine "T" allele at SNP locus at position 677 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 7 (identified by rs1801133), wherein the SEQ ID NO. 1 and SEQ ID NO. 7 are each independently a portion of a genomic nucleic acid ce of methylenetetrahydrofolate reductase (MTHFR); b. at least one e "A" allele at SNP locus at 976 (position 1793 of SEQ ID NO. 1 or position 27 of SEQ ID NO. 8), wherein the SEQ ID NO. 1 and SEQ ID NO. 8 are each independently a portion of a genomic nucleic acid sequence of methylenetetrahydrofolate reductase (MTHFR); c. at least one e "G" allele at SNP locus at position 2756 of SEQ ID NO.2 or position 27 of SEQ ID NO. 9 (identified by rs1805087), wherein the SEQ ID NO. 2 and SEQ ID NO. 9 are each independently a portion of a genomic nucleic acid sequence of methionine se (MTR); d. at least one guanine "G" allele at SNP locus at position 66 of SEQ ID NO. 3 or position 27 of SEQ ID NO. 10 ified by rs1801394), wherein the SEQ ID NO. 3 and SEQ ID NO. 10 are each independently a portion of a genomic nucleic acid sequence of methionine synthase reductase (MTRR); e. at least one alanine "A" allele at SNP locus at rs1006737 (position 27 of SEQ ID NO. 11, wherein the SEQ ID NO. 11 is a portion of a genomic nucleic acid sequence of calcium channel, voltage-dependent, L type, alpha 1C subunit 1C)); f. at least one alanine "A" allele at SNP locus at rs1883729 (position 27 of SEQ ID NO. 12, wherein the SEQ ID NO. 12 is a portion of a genomic nucleic acid sequence of DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B)); g. at least one thymine "T" allele at SNP locus at 862 (position 27 of SEQ ID NO. 13, wherein the SEQ ID NO. 13 is a portion of a genomic nucleic acid sequence of GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)); h. at least one thymine "T" allele at SNP locus at 9 (position 27 of SEQ ID NO. 14, wherein the SEQ ID NO. 14 is a portion of a genomic nucleic acid sequence of reduced folate carrier protein ); i. at least one guanine "G" allele at SNP locus at rs202676 (position 27 of SEQ ID NO. 15, wherein the SEQ ID NO. 15 is a portion of a genomic nucleic acid ce of folate ase (prostate-specific membrane antigen) 1 (FOLH1)); j. at least one alanine "A" allele at SNP locus at rs2297291 (position 27 of SEQ ID NO. 16, wherein the SEQ ID NO. 16 is a portion of a genomic nucleic acid sequence of reduced folate carrier protein (RCF1)); k. at least one alanine "A" allele at SNP locus at rs1051266 (position 27 of SEQ ID NO. 17), wherein the SEQ ID NO. 17 is a portion of a genomic nucleic acid sequence of reduced folate carrier protein (RCF1); l. at least one thymine "T" allele at SNP locus at rs8007267 (position 27 of SEQ ID NO. 18, n the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence of GTP cyclohydrolase 1 (GCH1)); m. at least one alanine "A" allele at SNP locus at rs7639752 (position 27 of SEQ ID NO. 19, wherein the SEQ ID NO. 19 is a portion of a genomic nucleic acid sequence of choline-phosphate cytidylyltransferase A (PCYT1A)); n. at least one thymine "T" allele at SNP locus at rs6275 (position 27 of SEQ ID NO. 20, wherein the SEQ ID NO. 20 is a n of a genomic nucleic acid sequence of dopamine receptor D2 (DRD2)); o. at least one thymine "T" allele at SNP locus at rs1079596 (position 27 of SEQ ID NO. 21), wherein the SEQ ID NO. 21 is a portion of a genomic nucleic acid sequence of dopamine receptor D2 (DRD2); p. at least one alanine "A" allele at SNP locus at rs11240594 (position 27 of SEQ ID NO. 22), n the SEQ ID NO. 22 is a n of a genomic nucleic acid sequence of dopamine receptor D2 ; q. at least one cytosine "C" allele at SNP locus at rs4633 (position 27 of SEQ ID NO. 23, wherein the SEQ ID NO. 23 is a portion of a genomic nucleic acid sequence of catechol-O-methyltransferase (COMT)); r. at least one guanine "G" allele at SNP locus at rs4680 (position 27 of SEQ ID NO. 24), wherein the SEQ ID NO. 24 is a portion of a c c acid sequence of catechol-O-methyltransferase (COMT); s. at least one ne "C" allele at SNP locus at rs250682 (position 27 of SEQ ID NO. 25, wherein the SEQ ID NO. 25 is a portion of a genomic nucleic acid sequence of solute carrier family 6 (neurotransmitter orter, ne), member 3 (SLC6A3)); t. at least one thymine "T" allele at SNP locus at rs2277820 (position 27 of SEQ ID NO. 26, wherein the SEQ ID NO. 26 is a portion of a genomic nucleic acid sequence of formiminotransferase cyclodeaminase (FTCD)); and u. at least one e "A" allele at SNP locus at rs2236225 (position 27 of SEQ ID NO. 27, wherein the SEQ ID NO. 27 is a portion of a genomic nucleic acid ce of methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1)); v. obesity (e.g., defined by a BMI value of at least 30 kg/m2 or greater); w. an expression level ratio of SAM to SAH r than a pre-determined reference ratio; x. an expression level of 4-HNE greater than a pre-determined reference value; and y. an expression of hsCRP r than about 2.3 mg per liter of plasma as measured in a plasma .
12. The use of claim 11, n the at least two conditions are: a. at least one thymine “T” allele at SNP locus at rs8007267 (position 27 of SEQ ID NO. 18), n the SEQ ID NO. 18 is a portion of a genomic nucleic acid sequence of GTP cyclohydrolase 1 (GCH1); and b. at least one guanine “G” allele at SNP locus at rs4680 (position 27 of SEQ ID NO. 24), wherein the SEQ ID NO. 24 is a portion of a genomic nucleic acid sequence of catechol-O-methyltransferase (COMT).
13. The use of any one of claims 10 to 12, wherein the folate-comprising composition comprises at least about 5 mg of folate or about 7.5-50 mg of folate.
14. The use of any one of claims 10 to 13, wherein the depression is a major depressive disorder.
15. The use of any one of claims 10 to 14, wherein the folate-comprising composition includes an antidepressant.
16. An assay according to any one of claims 1 to 9, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
17. Use of a folate-comprising composition according to any one of claims 10 to 15, substantially as herein described with reference to any one or more of the es but excluding comparative examples.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161559541P | 2011-11-14 | 2011-11-14 | |
US61/559,541 | 2011-11-14 | ||
PCT/US2012/065084 WO2013074676A2 (en) | 2011-11-14 | 2012-11-14 | Assays and methods for selecting a treatment regimen for a subject with depression |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624231A NZ624231A (en) | 2016-10-28 |
NZ624231B2 true NZ624231B2 (en) | 2017-01-31 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9540691B2 (en) | Assays and methods for selecting a treatment regimen for a subject with depression | |
Claes et al. | The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes | |
Myint et al. | Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene | |
TW201437635A (en) | Assays and methods for selecting a treatment regimen for a subject with depression | |
Serretti et al. | A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression | |
US20090191568A1 (en) | Methods and compositions for predicting compliance with an antidepressant treatment regimen | |
Borilova Linhartova et al. | Genetic determinants and postorthodontic external apical root resorption in Czech children | |
JP2008509674A (en) | Compositions and methods for determining and predicting treatment responses for depression and anxiety | |
US20180275149A1 (en) | Method for predicting a subject's response to valproic acid therapy | |
Dhingra et al. | Serotonin receptor 1A C (-1019) G polymorphism associated with premenstrual dysphoric disorder | |
US8178299B2 (en) | Method to determine the risk for side effects of an SSRI treatment in a person | |
WO2015136446A1 (en) | Methods for selecting antidepressant drug therapy to treat depression | |
US20110118133A1 (en) | Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication | |
Moreno et al. | Association study of genotype by depressive response during acute tryptophan depletion in subjects recovered from major depression | |
NZ624231B2 (en) | Assays and methods for selecting a treatment regimen for a subject with depression | |
US20160058766A1 (en) | Assays and methods for selecting a treatment regimen for a subject with depression | |
WO2015083685A1 (en) | Dlg1/SAP97 GENE SPLICING VARIANT, AND DETECTION OF SCHIZOPHRENIA USING SPLICING VARIANT |